<SEC-DOCUMENT>0001193125-18-124895.txt : 20180420
<SEC-HEADER>0001193125-18-124895.hdr.sgml : 20180420
<ACCEPTANCE-DATETIME>20180420161334
ACCESSION NUMBER:		0001193125-18-124895
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20180531
FILED AS OF DATE:		20180420
DATE AS OF CHANGE:		20180420
EFFECTIVENESS DATE:		20180420

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			DYNAVAX TECHNOLOGIES CORP
		CENTRAL INDEX KEY:			0001029142
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				330728374
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-34207
		FILM NUMBER:		18766817

	BUSINESS ADDRESS:	
		STREET 1:		2929 SEVENTH STREET
		STREET 2:		SUITE 100
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
		BUSINESS PHONE:		5108485100

	MAIL ADDRESS:	
		STREET 1:		2929 SEVENTH STREET
		STREET 2:		SUITE 100
		CITY:			BERKELEY
		STATE:			CA
		ZIP:			94710
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d563018ddef14a.htm
<DESCRIPTION>DEFINITIVE PROXY STATEMENT
<TEXT>
<HTML><HEAD>
<TITLE>Definitive Proxy Statement</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section&nbsp;14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>(Amendment No. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Filed by a Party other than
the Registrant&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Preliminary Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>Confidential, for Use of the Commission Only (as permitted by Rule <FONT STYLE="white-space:nowrap">14a-6(e)(2))</FONT></B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Definitive Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Definitive Additional Materials</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3">Soliciting Material under <FONT STYLE="white-space:nowrap">&#167;240.14a-12</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="5"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>DYNAVAX TECHNOLOGIES
CORPORATION</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="5" VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center"><FONT STYLE="font-size:8pt"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant)</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="32" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="5">Payment of Filing Fee (Check the appropriate box):</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">No fee required.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee computed on table below per Exchange Act Rules <FONT STYLE="white-space:nowrap">14a-6(i)(1)</FONT> and <FONT STYLE="white-space:nowrap">0-11.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title of each class of securities to which transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate number of securities to which transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule <FONT STYLE="white-space:nowrap">0-11</FONT>
(set forth the amount on which the filing fee is calculated and state how it was determined):</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proposed maximum aggregate value of transaction:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">5.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Total fee paid:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee paid previously with preliminary materials.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Check box if any part of the fee is offset as provided by Exchange Act Rule <FONT STYLE="white-space:nowrap">0-11(a)(2)</FONT> and identify the filing for which the offsetting fee was paid previously. Identify the
previous filing by registration statement number, or the Form or Schedule and the date of its filing.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">1.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amount Previously Paid:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">2.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form, Schedule or Registration Statement No.:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">3.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing Party:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">4.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date Filed:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DYNAVAX TECHNOLOGIES CORPORATION </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2929 Seventh Street, Suite 100 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Berkeley, California 94710 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NOTICE OF 2018 ANNUAL MEETING OF STOCKHOLDERS
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>May&nbsp;31, 2018 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dear Stockholder: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You are cordially invited to attend the 2018 Annual Meeting of
Stockholders of Dynavax Technologies Corporation, a Delaware corporation, or the Company. The meeting will be held on May&nbsp;31, 2018, at 9:00 a.m. Pacific Time, at the Company&#146;s executive offices at 2929 Seventh Street, Suite 100, Berkeley,
California 94710 for the following purposes: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To elect our nominees for Class&nbsp;III directors to hold office until the 2021 Annual Meeting of Stockholders or until their respective successors are duly elected
and qualified. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To approve the Dynavax Technologies Corporation 2018 Equity Incentive Plan. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To amend and restate the Dynavax Technologies Corporation 2014 Employee Stock Purchase Plan to, among other things, increase the aggregate number of shares of common
stock authorized for issuance under the plan by 600,000. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To approve, on an advisory basis, the compensation of the Company&#146;s named executive officers, as disclosed in the Proxy Statement accompanying this Notice.
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To ratify the selection of Ernst&nbsp;&amp; Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December&nbsp;31,
2018. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To conduct any other business properly brought before the meeting or any adjournment(s) thereof. </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">These items of business are more fully described in the Proxy Statement accompanying this Notice. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The record date for the 2018 Annual Meeting is April&nbsp;9, 2018. Only stockholders of record at the close of business on that date may
vote at the meeting or any adjournment thereof. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1pt;background-color:;;padding-top:2px;padding-bottom:3px">
<P STYLE="margin-top:0px;margin-bottom:0px;padding-top:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Important Notice Regarding the Availability of Proxy Materials for the Stockholders&#146; Meeting to Be Held at 9:00
a.m., Pacific Time, on May&nbsp;31, 2018 at 2929 Seventh Street, Suite 100, Berkeley, California 94710. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The proxy
statement and annual report to stockholders </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>are available at <U>http://investors.dynavax.com/annuals-proxies.cfm</U>.
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The Board of Directors recommends that you vote FOR the proposals identified above.
</B></FONT></P></div> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By Order of the Board of Directors</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Steven N. Gersten</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven N. Gersten</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Secretary</FONT></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Berkeley, California </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;20, 2018 </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1pt;background-color:;;padding-top:2px;padding-bottom:3px">
<P STYLE="margin-top:0px;margin-bottom:0px;padding-top:0px; margin-left:2%;margin-right:2%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Your vote is very important, regardless of the number of shares you own. Whether or not
you expect to attend the meeting, please complete, date, sign and return the enclosed proxy as promptly as possible in order to ensure your representation at the meeting. A return envelope (which is postage prepaid if mailed in the United States) is
enclosed for your convenience. Even if you have voted by proxy, you may still vote in person if you attend the meeting. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the
meeting, you must obtain a proxy issued in your name from that record holder. </B></FONT></P></div>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DYNAVAX TECHNOLOGIES CORPORATION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2929 Seventh Street, Suite 100 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Berkeley, California 94710 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROXY STATEMENT </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>FOR THE 2018 ANNUAL MEETING OF STOCKHOLDERS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">May&nbsp;31, 2018 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>QUESTIONS AND ANSWERS ABOUT THIS PROXY MATERIAL AND VOTING
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Why am I receiving these materials? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have sent you this proxy statement and the enclosed proxy card because the Board of Directors, or Board, of Dynavax Technologies Corporation, or the Company or Dynavax, or we or us, is soliciting your
proxy to vote at the 2018 Annual Meeting of Stockholders, or Annual Meeting. You are invited to attend the Annual Meeting to vote on the proposals described in this proxy statement. However, you do not need to attend the Annual Meeting to vote your
shares. Instead, you may simply complete, sign and return the enclosed proxy card. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We intend to mail this proxy statement and
accompanying proxy card on or about April&nbsp;26, 2018, to all stockholders of record entitled to vote at the Annual Meeting. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>How do I
attend the Annual Meeting? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Annual Meeting will be held on May&nbsp;31, 2018 at 9:00 a.m. Pacific Time, at our
executive offices at 2929 Seventh Street, Suite 100, Berkeley, California 94710. Directions to the Annual Meeting may be found at <U>http://www.dynavax.com/contact</U>. Information on how to vote in person at the Annual Meeting is discussed below.
For admission to the Annual Meeting, stockholders may be asked to present proof of identification and a statement from their bank, broker or other nominee reflecting their beneficial ownership of our common stock as of April&nbsp;9, 2018, as well as
a proxy from the record holder to the stockholder. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Who can vote at the Annual Meeting? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Only stockholders of record at the close of business on April&nbsp;9, 2018, will be entitled to vote at the Annual Meeting. On this record
date, there were 62,255,860 shares of common stock outstanding and entitled to vote. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stockholder of Record: Shares
Registered in Your Name </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If on April&nbsp;9, 2018, your shares were registered directly in your name with our transfer
agent, then you are a stockholder of record. As a stockholder of record, you may vote in person at the Annual Meeting or vote by proxy. Whether or not you plan to attend the Annual Meeting, we urge you to fill out and return the enclosed proxy card
to ensure your vote is counted. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Beneficial Owner: Shares Registered in the Name of a Broker or Bank </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If on April&nbsp;9, 2018, your shares were held, not in your name, but rather in an account at a brokerage firm, bank, dealer or other
similar organization, then you are the beneficial owner of shares held in &#147;street name&#148; and these proxy materials are being forwarded to you by that organization. The organization holding your account is considered to be the stockholder of
record for purposes of voting at the Annual Meeting. As a beneficial owner, you have the right to direct your broker or other agent regarding how to vote the shares in your account. You are also invited to attend the Annual Meeting. However, since
you are not the stockholder of record, you may not vote your shares in person at the Annual Meeting unless you request and obtain a valid proxy from your broker or other agent. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">1 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What am I voting on? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are asking you to vote on five&nbsp;proposals: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To elect our nominees for Class&nbsp;III directors to hold office until the 2021 Annual Meeting of Stockholders or until their respective successors are duly elected
and qualified. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To approve the Dynavax Technologies Corporation 2018 Equity Incentive Plan (the &#147;2018 EIP&#148;). </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To amend and restate the Dynavax Technologies Corporation 2014 Employee Stock Purchase Plan (the &#147;2014 ESPP&#148;) to, among other things, increase the aggregate
number of shares of common stock authorized for issuance under the plan by 600,000. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To approve, on an advisory basis, the compensation of the Company&#146;s named executive officers, as disclosed in this proxy statement. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To ratify the selection of Ernst&nbsp;&amp; Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December&nbsp;31,
2018. </FONT></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What if another matter is properly brought before the Annual Meeting? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly
brought before the Annual Meeting, it is the intention of the persons named in the accompanying proxy to vote on those matters in accordance with her or his best judgment. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>How do I vote? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may either vote &#147;For&#148; all the nominees to the
Board or you may &#147;Withhold&#148; your vote for any nominee you specify. For each of the other matters to be voted on, you may vote &#147;For&#148; or &#147;Against&#148; or abstain from voting. The procedures for voting are fairly simple:
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stockholder of Record: Shares Registered in Your Name </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you are a stockholder of record, you may vote in person at the Annual Meeting or vote by proxy using the enclosed proxy card. Whether
or not you plan to attend the Annual Meeting, we urge you to vote by proxy to ensure your vote is counted. You may still attend the Annual Meeting and vote in person even if you have already voted by proxy. </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To vote in person, come to the Annual Meeting and we will give you a ballot when you arrive. Directions to the Annual Meeting may be found at
<U>http://www.dynavax.com/contact</U>. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To vote using the proxy card, simply complete, sign and date the enclosed proxy card and return it promptly in the envelope provided. If you return
your signed proxy card to us before the Annual Meeting, we will vote your shares as you direct. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To vote using the telephone, simply follow the instructions on the enclosed proxy card. Voting by telephone has the same effect as voting by mail. You
may vote by telephone until 11:59 p.m., Eastern Time, May&nbsp;30, 2018. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To vote using the internet, simply follow the instructions on the enclosed proxy card. You may vote by using the internet until 11:59 p.m., Eastern
Time, May&nbsp;30, 2018. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Beneficial Owner: Shares Registered in the Name of Broker or Bank
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should have
received a proxy card and voting instructions with these proxy materials from that organization rather than from Dynavax. Simply complete and mail the proxy card to ensure that your vote is counted. To vote in person at
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the Annual Meeting, you must obtain a valid proxy from your broker, bank or other agent. Follow the instructions from your broker, bank or other agent included with these proxy materials, or
contact your broker, bank or other agent to request a proxy form. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><div style="max-width:100%;margin-left:0%; margin-right:0%;border:solid 1pt;background-color:;;padding-top:2px;padding-bottom:3px">
<P STYLE="margin-top:0px;margin-bottom:0px;padding-top:0px; margin-left:2%;margin-right:2%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We provide internet proxy voting to allow you to vote your shares online, with
procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and
telephone companies. </B></FONT></P></div> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>How many votes do I have? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">On each matter to be voted upon, you have one vote for each share of common stock you own as of April&nbsp;9, 2018. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>What happens if I do not vote? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Stockholder of Record: Shares
Registered in Your Name </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you are a stockholder of record and do not vote by completing your proxy card, by
telephone, through the internet or in person at the Annual Meeting, your shares will not be voted. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Beneficial Owner:
Shares Registered in the Name of Broker or Bank </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you are a beneficial owner and do not instruct your broker, bank,
or other agent how to vote your shares, the question of whether your broker or nominee will still be able to vote your shares depends on whether the applicable stock exchange deems the particular proposal to be a &#147;routine&#148; matter. Brokers
and nominees can use their discretion to vote &#147;uninstructed&#148; shares with respect to matters that are considered to be &#147;routine,&#148; but not with respect to <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters.
Under the rules and interpretations of the NYSE, <FONT STYLE="white-space:nowrap">&#147;non-routine&#148;</FONT> matters are matters that may substantially affect the rights or privileges of stockholders, such as mergers, stockholder proposals,
elections of directors (even if not contested), executive compensation (including any advisory stockholder votes on executive compensation and on the frequency of stockholder votes on executive compensation), and certain corporate governance
proposals, even if management-supported. Accordingly, your broker or nominee may not vote your shares on Proposals 1, 2, 3 or 4 without your instructions, but may vote your shares on Proposal 5. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What if I return a proxy card but do not make specific choices? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If you return a signed and dated proxy card without marking any voting selections, your shares will be voted: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 1: &#147;For&#148; election of our nominees for Class&nbsp;III directors. </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 2: &#147;For&#148; approval of the 2018 EIP; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 3: &#147;For&#148; approval of the amendment and restatement of the 2014 ESPP to, among other things, increase the aggregate number of shares of common stock
authorized for issuance under the plan by 600,000; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 4: &#147;For&#148; advisory approval of executive compensation; and </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 5: &#147;For&#148; ratification of the selection of Ernst&nbsp;&amp; Young LLP as the independent registered public accounting firm of the Company for its
fiscal year ending December&nbsp;31, 2018. </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If any other matter is properly presented at the Annual Meeting,
your proxyholder (one of the individuals named on your proxy card) will vote your shares using his or her best judgment. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Who is paying for this proxy solicitation? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will pay for the entire cost of soliciting proxies. In addition to mailing these proxy materials, our directors and employees may also
solicit proxies in person, by telephone, or by other means of communication. Directors and employees will not be paid any additional compensation for soliciting proxies. We may also reimburse brokerage firms, banks and other agents for the cost of
forwarding proxy materials to beneficial owners. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What does it mean if I receive more than one proxy card? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you receive more than one proxy card, your shares are registered in more than one name or are registered in different accounts. Please
complete, sign and return each proxy card to ensure that all of your shares are voted. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Can I change my vote after submitting my proxy?
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Yes. You can revoke your proxy at any time before the final vote at the Annual Meeting. If you are the record holder of
your shares, you may revoke your proxy in any one of three ways: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may submit another properly completed proxy card with a later date. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may send a timely written notice that you are revoking your proxy to Dynavax Technologies Corporation, Attention: Corporate Secretary, 2929 Seventh
Street, Suite 100, Berkeley, California 94710. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">You may attend the Annual Meeting and vote in person. Simply attending the Annual Meeting will not, by itself, revoke your proxy.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Your proxy card with the most recent date is the one that will be counted. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If your shares are held by your broker or bank as a nominee or agent, you should follow the instructions provided by your broker or bank.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>When are stockholder proposals due for next year&#146;s Annual Meeting? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To be considered for inclusion in next year&#146;s proxy materials, your proposal must be submitted in writing by December&nbsp;27, 2018
to Dynavax Technologies Corporation, Attention: Corporate Secretary, 2929 Seventh Street, Suite 100, Berkeley, California 94710. However, if our 2019 Annual Meeting of Stockholders is not held between May&nbsp;1, 2019, and June&nbsp;30, 2019, then
the deadline will be a reasonable time before we begin to print and send our proxy materials. If you wish to submit a proposal (including a director nomination) that is not to be included in next year&#146;s proxy materials or nominate a director,
you must do so no later than April&nbsp;1, 2019, and no earlier than March&nbsp;2, 2019. However, if our 2018 Annual Meeting of Stockholders is not held between May&nbsp;1, 2018, and June&nbsp;30, 2018, then you must submit your proposal (or
director nomination) not less than 60 days nor more than 90 days prior to the time we send our proxy materials. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>How many votes are needed
to approve each proposal? </B></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 1, to elect our nominees for Class&nbsp;III directors, the three nominees receiving the most &#147;For&#148; votes from the holders of shares
present (either in person or represented by proxy) and cast for the election of directors will be elected. Only votes &#147;For&#148; will affect the outcome of the vote; &#147;Withhold&#148; votes will have no effect on the outcome of the vote.
However, if a nominee receives a greater number of &#147;Withhold&#148; votes than &#147;For&#148; votes, such nominee will submit his or her offer of resignation for consideration by our Nominating and Corporate Governance Committee in accordance
with our Majority Vote Policy discussed in more detail on page 63 of this proxy statement. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 2, to approve the 2018 EIP, must receive &#147;For&#148; votes from the holders of a majority of shares present (either in person or by proxy)
and cast at the meeting (i.e., representing the majority voting power). If you return your proxy and select &#147;Abstain,&#148; it will have the same effect as an &#147;Against&#148; vote. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT>
will have no effect. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 3, to approve the amendment and restatement of the 2014 ESPP to, among other things, increase the aggregate number of shares of common stock
authorized for issuance under the plan by 600,000, must receive &#147;For&#148; votes from the holders of a majority of shares present (either in person or by proxy) and cast at the meeting (i.e., representing the majority voting power). If you
return your proxy and select &#147;Abstain,&#148; it will have the same effect as an &#147;Against&#148; vote. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 4, advisory approval of the compensation of the Company&#146;s named executive officers, will be considered to be approved if it receives
&#147;For&#148; votes from the holders of a majority of shares present (either in person or by proxy) and cast at the meeting (i.e., representing the majority voting power). If you return your proxy and select &#147;Abstain&#148; from voting, it
will have the same effect as an &#147;Against&#148; vote. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proposal 5, to ratify the selection of Ernst&nbsp;&amp; Young LLP as the Company&#146;s independent registered public accounting firm for our fiscal
year ending December&nbsp;31, 2018, must receive &#147;For&#148; votes from the holders of a majority of shares present (either in person or by proxy) and cast at the meeting (i.e., representing the majority voting power). If you return your proxy
and select &#147;Abstain&#148; from voting, it will have the same effect as an &#147;Against&#148; vote. As Proposal 5 is considered a &#147;routine&#148; matter, we do not expect to receive any broker
<FONT STYLE="white-space:nowrap">non-votes.</FONT> </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What is the quorum requirement? </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A quorum of stockholders is necessary to hold a valid Annual Meeting. A quorum will be present if stockholders holding at least a majority
of the outstanding shares entitled to vote are present at the Annual Meeting in person or represented by proxy. On the record date, there were 62,255,860 shares outstanding and entitled to vote. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank
or other nominee) or if you vote in person at the Annual Meeting. Abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will be counted towards the quorum requirement. If there is no quorum, the holders of a majority of shares
present at the Annual Meeting in person or represented by proxy may adjourn the Annual Meeting to another date. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>How can I find out the
results of the voting at the Annual Meeting? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preliminary voting results will be announced at the Annual Meeting. Final
voting results will be published in a current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> within four business days following the voting. If we are unable to obtain final results in that time, we will announce the preliminary results
and subsequently file a second current report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> with the final results. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>What proxy
materials are available on the internet? </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 2018 proxy statement and 2017 Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> are available at <U>http://investors.dynavax.com/annuals-proxies.cfm</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Householding of Proxy
Materials </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Securities and Exchange Commission, or SEC, has adopted rules that permit companies and intermediaries
(e.g., brokers) to satisfy the delivery requirements for Annual Meeting materials with respect to two or more stockholders sharing the same address by delivering a single set of Annual Meeting materials addressed to those stockholders. This process,
which is commonly referred to as &#147;householding,&#148; potentially means extra convenience for stockholders and cost savings for companies. A number of brokers with account holders who are Dynavax stockholders will be &#147;householding&#148;
our proxy materials. A single set of Annual Meeting materials will be delivered to multiple stockholders sharing an address unless contrary instructions have been received from the affected stockholders. Once you have received notice from your
broker that they will be &#147;householding&#148; communications to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
your address, &#147;householding&#148; will continue until you are notified otherwise or until you revoke your consent. If, at any time, you no longer wish to participate in
&#147;householding&#148; and would prefer to receive a separate set of Annual Meeting materials, please notify your broker and we will promptly deliver to you a separate set of our Annual Meeting materials. Direct your written request to Dynavax
Technologies Corporation, Attention: Corporate Secretary, 2929 Seventh Street, Suite 100, Berkeley, California 94710, <FONT STYLE="white-space:nowrap">(510)&nbsp;848-5100.</FONT> Stockholders who currently receive multiple copies of the Annual
Meeting materials at their addresses and would like to request &#147;householding&#148; of their communications should contact their brokers. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROPOSAL 1 </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ELECTION OF DIRECTORS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our Board is divided into three classes, and each class has a three-year term. Vacancies on the Board may be filled only by persons elected by a majority of the remaining directors. A director elected by
the Board to fill a vacancy in a class, including vacancies created by an increase in the number of directors, shall serve for the remainder of the full term of that class and until the director&#146;s successor is elected and qualified. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board presently has nine members. However, one of our Class&nbsp;III directors, Dr.&nbsp;Plotkin, has advised the Board of his
decision to retire effective as of the date of the Annual Meeting. The Board has no current plans to fill the vacancy upon the effective date of Dr.&nbsp;Plotkin&#146;s resignation. There are three directors in the class whose term of office expires
in 2018: Arnold L. Oronsky, Ph.D., Francis R. Cano, Ph.D. and Peggy V. Phillips, each of whom is a nominee for director and currently a director of the Company. Drs. Oronsky and Cano and Ms.&nbsp;Phillips were previously elected by the stockholders
in 2015. If each nominee is elected at the Annual Meeting, each of these nominees will serve until the 2021 Annual Meeting and until his or her successor is elected and has qualified, or, if sooner, until the director&#146;s death, resignation or
removal. There were six directors in attendance at our 2017 Annual Meeting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Directors are elected by a plurality of the votes
of the holders of shares present in person or represented by proxy and entitled to vote on the election of directors. The three nominees receiving the highest number of affirmative votes will be elected. Shares represented by executed proxies will
be voted, if authority to do so is not withheld, for the election of the nominees named below. Although the election of directors at the Annual Meeting is uncontested and directors are elected by a plurality of votes cast, and we therefore
anticipate that each of the named nominees for director will be elected at the Annual Meeting, under our Corporate Governance Guidelines, any nominee for director is required to submit an offer of resignation for consideration by the Nominating and
Corporate Governance Committee if such nominee for director (in an uncontested election) receives a greater number of &#147;Withhold&#148; votes than &#147;For&#148; votes. In such case, the Nominating and Corporate Governance Committee will then
consider all of the relevant facts and circumstances and recommend to the Board the action to be taken with respect to such offer of resignation. For more information on this policy see the section entitled &#147;Corporate Governance.&#148; If any
nominee becomes unavailable for election as a result of an unexpected occurrence, your shares will be voted for the election of a substitute nominee proposed by our Board. Each person nominated for election has agreed to serve if elected. Our Board
has no reason to believe that any nominee will be unable to serve. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL>
O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> R<SMALL>ECOMMENDS</SMALL> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A V<SMALL>OTE</SMALL> I<SMALL>N</SMALL>
F<SMALL>AVOR</SMALL> O<SMALL>F</SMALL> E<SMALL>ACH</SMALL> N<SMALL>AMED</SMALL> N<SMALL>OMINEE</SMALL>. </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Set forth below
is certain biographical information as of April&nbsp;9, 2018, for the nominees and each person whose term as a director will continue after the Annual Meeting. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt ; display:inline;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Age</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:27pt ; display:inline;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Position</B></FONT></P></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnold L. Oronsky, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chairperson of the Board</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Francis R. Cano, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">73</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dennis A. Carson, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Laura Brege</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer (&#147;CEO&#148;) and Director</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Daniel L. Kisner, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peggy V. Phillips</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Natale Ricciardi</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">69</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Director</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>LASS</SMALL> III D<SMALL>IRECTORS</SMALL> N<SMALL>OMINEES</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Arnold L. Oronsky, Ph.D. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dr. Oronsky has been a member of our Board since November 1996 and became Chairperson of the Board in February 2006. Dr.&nbsp;Oronsky has been a managing director with InterWest Partners, a venture
capital firm, since 2009. Prior to joining InterWest Partners in 1994, Dr.&nbsp;Oronsky was Vice President of Discovery Research for the Lederle Laboratories division of American Cyanamid, a pharmaceutical company. From 1973 until 1976,
Dr.&nbsp;Oronsky was head of the inflammation, allergy and immunology research program at Ciba-Geigy Pharmaceutical Company. Dr.&nbsp;Oronsky also serves as a senior lecturer in the Department of Medicine at The Johns Hopkins Medical School.
Dr.&nbsp;Oronsky has won numerous grants and awards and has published over 125 scientific articles. Dr.&nbsp;Oronsky currently serves on the boards of directors of Tesaro, Inc., an oncology-focused biopharmaceutical company, and KalVista
Pharmaceuticals, Inc., a biotechnology company.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">
</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Oronsky also served on the board of directors of MacroGenics, Inc., a biopharmaceutical company, from 2000 to 2014, and Applied Genetic Technologies Corporation, a
biotechnology company, from November 2003 until August 2017. The Board believes that Dr.&nbsp;Oronsky&#146;s significant experience in growing and developing life sciences companies, particularly in the immunology area, provides significant
leadership and insights for the Board in defining the strategy of the Company and qualifies him to be nominated as a director. He received his Ph.D. from Columbia University, College of Physicians and Surgeons and his A.B. from New York University.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Francis R. Cano, Ph.D. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Cano was appointed to our Board in November 2009. Dr.&nbsp;Cano has been President and Founder of Cano Biotech Corp., a consulting firm focusing on the vaccine business, since 1996 and also
serves on the board of Biomerica, Inc., a developer and manufacturer of diagnostic products. Previously, Dr.&nbsp;Cano served on the board of Arbor Vita Corporation, a biopharmaceutical company. From 1993 to 1996, Dr.&nbsp;Cano was President and
Chief Operating Officer for Aviron, a biopharmaceutical company, which was later acquired by MedImmune in 2001. As a <FONT STYLE="white-space:nowrap">Co-Founder</FONT> of Aviron, he completed two rounds of venture financing, a licensing agreement
with SmithKline Biologicals and <FONT STYLE="white-space:nowrap">in-licensed</FONT> <FONT STYLE="white-space:nowrap">Flu-Mist</FONT> influenza vaccine from the National Institutes of Health. For 21 years, Dr.&nbsp;Cano worked with the Lederle
Laboratories Division of American Cyanamid, including as its Vice President and General Manager of the Biologicals unit. The Board believes that Dr.&nbsp;Cano&#146;s experience as a founder of and advisor to established vaccine businesses provides
significant insights for the strategy of the Company with respect to key technical and operational issues in vaccine development and qualifies him to be nominated as a director. He earned a Ph.D. in Microbiology from Pennsylvania State University,
served as a Research Associate at Rutgers Institute of Microbiology, and holds a M.S. in Microbiology and a B.S. in Biology from St. John&#146;s University. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Peggy V. Phillips </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Phillips has been a member
of our Board since August 2006. Ms.&nbsp;Phillips served on the board of directors of several biopharmaceutical companies: PhaseRx, Inc. from 2016 to 2018, Tekmira Pharmaceuticals from 2014 to 2015, Portola Pharmaceuticals from 2006 to 2013, as well
as the Naval Academy Foundation from 2003 to 2011. From 1996 until 2002, she served on the board of directors of Immunex Corporation, a biotechnology company, and, from 1999, she served as its Chief Operating Officer until the company was acquired
by Amgen in 2002. During her career at Immunex, she held positions of increasing responsibility in research, development, manufacturing, sales and marketing. As Senior Vice President for Pharmaceutical Development and General Manager for Enbrel <FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> from 1994 until 1998, she was responsible for clinical development and regulatory affairs as well as the launch,
sales and marketing of the product. Prior to joining Immunex, Ms.&nbsp;Phillips worked at Miles Laboratories. The Board believes that Ms.&nbsp;Phillips provides significant experience in development and commercialization of biotechnology products.
Her background and experience with larger, complex organizations provides significant operational and strategic insights in assessing the strategy of the Company and qualifies her to be nominated as a director. Ms.&nbsp;Phillips holds a B.S. and a
M.S. in microbiology from the University of Idaho. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>LASS</SMALL> I D<SMALL>IRECTORS</SMALL> C<SMALL>ONTINUING</SMALL> <SMALL>IN</SMALL>
O<SMALL>FFICE</SMALL> U<SMALL>NTIL</SMALL> <SMALL>THE</SMALL> 2019 A<SMALL>NNUAL</SMALL> M<SMALL>EETING</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dennis A. Carson, M.D.
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Carson has been a member of our Board since December 1997. Dr.&nbsp;Carson is a noted researcher in the fields of
autoimmune and immunodeficiency diseases and is <FONT STYLE="white-space:nowrap">co-discoverer</FONT> with Dr.&nbsp;Eyal Raz of the immunostimulatory sequences (ISS) that form the basis of our technology. He has played key roles in the founding of
Vical, Inc., a gene therapy company, IDEC Pharmaceuticals, a biopharmaceutical company, and Triangle Pharmaceuticals, a pharmaceutical company. Dr.&nbsp;Carson is former director of the Rebecca and John Moores Cancer Center at the University of
California, San Diego and has been a professor in the Department of Medicine at the University of California, San Diego since 1990. The Board believes that Dr.&nbsp;Carson&#146;s significant experience in research and development provides important
insights for the strategy of the Company, particularly with regard to scientific opportunities for development by the Company, and qualifies Dr.&nbsp;Carson to serve as a director. He is a member of the National Academy of Sciences, the American
Academy of Arts and Sciences, and the Institute of Medicine, as well as the American Association for Cancer Research, the American Society for Clinical Investigation, the American Society of Hematology and the Association of American Physicians. He
received his M.D. from Columbia University and his B.A. from Haverford College. Dr.&nbsp;Carson completed his residency in internal medicine and a postdoctoral fellowship at the University of California, San Diego. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eddie Gray &#150; CEO and Director </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Gray joined Dynavax as Chief Executive Officer and was appointed to our Board in May 2013. Most recently, Mr.&nbsp;Gray served as the President of Pharmaceuticals Europe and a member of the
corporate executive team at GlaxoSmithKline plc (GSK) from 2008 until 2013 and as Senior Vice President and General Manager of Pharmaceuticals UK from 2001 through 2007. Prior to the formation of GSK, Mr.&nbsp;Gray was with SmithKline Beecham from
1988 through 2000 serving in various positions of increasing responsibility, including Vice President and Director of Anti-Infectives Marketing in the U.S., Vice President and Director of the Vaccines Business Unit in the U.S., and Vice President
and General Manager of Pharmaceuticals in Canada. Our Board believes that Mr.&nbsp;Gray&#146;s more than 30 years of pharmaceutical industry experience, including, most recently, as the President of Pharmaceuticals Europe at GSK, a leading
pharmaceutical company, and other senior management roles at GSK and its predecessor, where he was responsible for the launch, commercialization and strategic development of vaccines and other products, enables him to provide commercial and
strategic leadership to the Company and qualifies Mr.&nbsp;Gray to serve as a director. Mr.&nbsp;Gray received a Bachelor of Science degree in Chemistry and Management Studies from the University of London and an MBA from the Cranfield School of
Management in the UK. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Laura Brege </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Brege has been a member of our Board since February 2015. Since September 2015, she has served as managing director of Cervantes Life Science Partners, LLC, a consulting firm providing integrated
business solutions to life sciences companies. She has over 20 years of executive management experience in the pharmaceutical, biotechnology and venture capital industries. From September 2012 to July 2015, Ms.&nbsp;Brege was President and Chief
Executive Officer of Nodality Inc., a life sciences company focused on innovative personalized medicine. Prior to joining Nodality in 2012, Ms.&nbsp;Brege held several senior-level positions at Onyx Pharmaceuticals, Inc., a biopharmaceutical and
biotherapeutics company, from 2006 until 2012, including positions as Executive Vice President and Chief Operating Officer. While at Onyx she led multiple functions, including commercialization, strategic planning, corporate development, and
medical, scientific and government affairs. Prior to Onyx, Ms.&nbsp;Brege was a General Partner at Red Rock Capital Management, a venture capital firm specializing in early stage financing for technology companies. Previously Ms.&nbsp;Brege was
Senior Vice President and Chief Financial Officer at COR Therapeutics, where she helped build the company from an early stage R&amp;D company through commercial launch of a successful cardiovascular product. Earlier in her career, she served as
Chief Financial Officer at Flextronics, Inc. and Treasurer of The Cooper Companies. She serves on the board of directors of the following public pharmaceutical companies: Acadia Pharmaceuticals, Inc., Aratana Therapeutics, Inc., Pacira
Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc. During the past five years, Ms.&nbsp;Brege also served on the boards of directors of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Angiotech Pharmaceuticals, Inc., a biotechnology company, and Delcath Systems, Inc., a pharmaceutical company. Our Board believes that Ms.&nbsp;Brege&#146;s background in finance and management
of biotechnology companies and her participation as a member of the audit committees of other public companies provides important strategic insights for the Board in setting strategy and reviewing the operations of the Company, as well as qualifies
Ms.&nbsp;Brege to serve on the Company&#146;s Audit Committee. Ms.&nbsp;Brege attended all Board and Audit Committee meetings of the Company and all meetings of the boards and committees on which she sits at other companies during the past year.
Ms.&nbsp;Brege earned her undergraduate degrees from Ohio University (Honors Tutorial College) and her MBA degree from the University of Chicago. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>LASS</SMALL> II D<SMALL>IRECTORS</SMALL> C<SMALL>ONTINUING</SMALL> <SMALL>IN</SMALL> O<SMALL>FFICE</SMALL> U<SMALL>NTIL</SMALL> <SMALL>THE</SMALL> 2020 A<SMALL>NNUAL</SMALL>
M<SMALL>EETING</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Daniel L. Kisner, M.D. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Kisner has been a member of our Board since July 2010. From 2003 to 2010, Dr.&nbsp;Kisner served as a partner at Aberdare Ventures and prior to that as President and CEO of Caliper Technologies,
leading its evolution from a <FONT STYLE="white-space:nowrap">start-up</FONT> focused on microfluidic <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">lab-on-chip</FONT></FONT> technology to a publicly traded, commercial
organization. Prior to Caliper, he was the President and Chief Operating Officer of Isis Pharmaceuticals, Inc., a biomedical pharmaceutical company. Previously, Dr.&nbsp;Kisner was Division Vice President of Pharmaceutical Development for Abbott
Laboratories and Vice President of Clinical Research and Development at SmithKline Beecham Pharmaceuticals. In addition, he held a tenured position in the Division of Oncology at the University of Texas, San Antonio School of Medicine and is
certified by the American Board of Internal Medicine in Internal Medicine and Medical Oncology. Additionally, he is currently serving on the boards of Conatus Pharmaceuticals, Inc., a biotechnology company, Nativis Inc., a medical device company,
and Zynerba Pharmaceuticals, a biotechnology company. Dr.&nbsp;Kisner previously served as Chairman of the board for Tekmira Pharmaceuticals, a biopharmaceutical company, until March 2015. Our Board believes that Dr.&nbsp;Kisner&#146;s background
with larger, complex technology-based organizations as well as his significant experience with corporate transactions, including investing in venture-backed life science companies provides the Board with insights for setting strategy of the Company
and qualifies him to serve as a director. He holds a B.A. from Rutgers University and an M.D. from Georgetown University. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Natale
(&#147;Nat&#148;) Ricciardi </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Ricciardi has been a member of our Board since June 2013. Mr.&nbsp;Ricciardi spent
his entire <FONT STYLE="white-space:nowrap">39-year</FONT> career at Pfizer Inc., a biopharmaceutical company, retiring in 2011 as a member of the Pfizer Executive Leadership Team. While holding the positions of President, Pfizer Global
Manufacturing, and Senior Vice President of Pfizer Inc. from 2004 until 2011, Mr.&nbsp;Ricciardi was directly responsible for all of Pfizer&#146;s internal and external supply organization, a global enterprise that grew to more than 100
manufacturing facilities supplying small and large molecule pharmaceuticals, vaccines, consumer, nutrition and animal health products. Mr.&nbsp;Ricciardi maintained responsibility for global manufacturing activities from 2004 through 2011.
Previously, from 1999 to 2004, he had oversight for Pfizer&#146;s U.S. manufacturing operations and from 1995 to 1999 was Vice President of Manufacturing for Pfizer&#146;s Animal Health Group. Mr.&nbsp;Ricciardi is currently a member of the board of
directors of Asterias Biotherapeutics, Inc., a biotechnology company, Rapid Micro Biosystems, Inc., a healthcare environmental technology company, and Prestige Brands Holdings, Inc., a healthcare and household product company. Mr.&nbsp;Ricciardi
also serves as a member of the board of directors of the 21st Century Foundation of The City College of New York and as a member of the Advisory Board of HealthCare Royalty Partners. Our Board believes Mr.&nbsp;Ricciardi&#146;s <FONT
STYLE="white-space:nowrap">39-year</FONT> career at Pfizer Inc., a leading pharmaceutical company, including as a member of the Pfizer Executive Leadership Team and direct responsibility for all of Pfizer&#146;s internal supply organization,
including global manufacturing, provides the Board with insights for reviewing the operations of the Company and qualifies him to serve as a director. Mr.&nbsp;Ricciardi earned a degree in Chemical Engineering from The City College of New York and
an MBA in Finance and International Business from Fordham University. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">10 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROPOSAL 2 </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>APPROVAL OF THE 2018 EQUITY INCENTIVE PLAN </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Board is requesting stockholder approval of the Dynavax Technologies Corporation 2018 Equity Incentive Plan (the &#147;2018 EIP&#148;). The 2018 EIP is intended to be the successor to the Dynavax
Technologies Corporation 2011 Equity Incentive Plan (the &#147;2011 EIP&#148;). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Why We Are Asking Our Stockholders to Approve the 2018 EIP
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Currently, we maintain the 2011 EIP to grant stock options and restricted stock unit awards to our employees and
directors. In addition, we maintain the Dynavax Technologies Corporation 2017 Inducement Award Plan (the &#147;2017 Inducement Plan&#148;) to grant stock options and restricted stock unit awards to our new hires. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are seeking stockholder approval of the 2018 EIP to increase the number of shares available for the grant of stock options, restricted
stock unit awards and other awards, which will enable us to have a competitive equity incentive program to compete with our peer group for key talent. If the 2018 EIP is approved by our stockholders, no additional awards will be granted under the
2011 EIP or the 2017 Inducement Plan. We also have awards outstanding under the Dynavax Technologies Corporation 2004 Stock Incentive Plan and the Dynavax Technologies Corporation 2010 Employment Inducement Award Plan, but no additional awards may
be granted under such plans. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approval of the 2018 EIP by our stockholders will allow us to grant stock options, restricted
stock unit awards and other awards at levels determined appropriate by the Board or Compensation Committee. The 2018 EIP will also allow us to utilize a broad array of equity incentives in order to secure and retain the services of our employees and
directors, and to provide long-term incentives that align the interests of our employees and directors with the interests of our stockholders. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Requested Shares </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If
this Proposal 2 is approved by our stockholders, then subject to adjustment for certain changes in our capitalization, the aggregate number of shares of our common stock that may be issued under the 2018 EIP will not exceed the sum of (i) 5,000,000
new shares, (ii)&nbsp;the number of unallocated shares remaining available for grant under the 2011 EIP as of the effective date of the 2018 EIP, and (iii)&nbsp;certain shares subject to outstanding stock awards granted under the 2011 EIP and the
2017 Inducement Plan (together, the &#147;Prior Plans&#148;) that may become available for issuance under the 2018 EIP as such shares become available from time to time (as further described below in &#147;Description of the 2018 Equity Incentive
Plan &#150; Shares Available for Awards&#148;). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stockholder Approval </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If this Proposal 2 is approved by our stockholders, the 2018 EIP will become effective as of the date of the Annual Meeting and no
additional awards will be granted under the 2011 EIP or the 2017 Inducement Plan. In the event that our stockholders do not approve this Proposal 2, the 2018 EIP will not become effective, and the 2011 EIP and the 2017 Inducement Plan will continue
to be effective in accordance with their terms. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Why You Should Vote for the 2018 EIP </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The 2018 EIP Combines Compensation and Governance Best Practices </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The 2018 EIP includes provisions that are designed to protect our stockholders&#146; interests and to reflect corporate governance best practices including: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Stockholder approval is required for additional shares</I>.&nbsp;&nbsp;&nbsp;&nbsp;The 2018 EIP does not contain an annual &#147;evergreen&#148;
provision. The 2018 EIP authorizes a fixed number of shares, so that stockholder approval is required to issue any additional shares. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">11 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Repricing is not allowed</I>.&nbsp;&nbsp;&nbsp;&nbsp;The 2018 EIP prohibits the repricing of stock options and stock appreciation rights without
prior stockholder approval. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>No discounted stock options or stock appreciation rights.</I>&nbsp;&nbsp;&nbsp;&nbsp;All stock options and stock appreciation rights granted under
the 2018 EIP must have an exercise price equal to or greater than the fair market value of our common stock on the date the stock option or stock appreciation right is granted. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Reasonable share counting provisions.</I>&nbsp;&nbsp;&nbsp;&nbsp;In general, when awards granted under the 2018 EIP lapse or are canceled, the
shares reserved for those awards will be returned to the share reserve and be available for future awards. However, any shares received from the exercise of stock options or withheld for taxes will not be returned to our share reserve.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Minimum vesting requirements.</I>&nbsp;&nbsp;&nbsp;&nbsp;The 2018 EIP provides that no award may vest until at least 12 months following the date of
grant of such award, except that up to 5% of the share reserve of the 2018 EIP may be subject to awards that do not meet such vesting requirements. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Limit on <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation.</I>&nbsp;&nbsp;&nbsp;&nbsp;The aggregate value of all cash and
equity-based compensation granted or paid by us to any individual for service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director of the Board with respect to any fiscal year of the Company will not exceed (i)&nbsp;a total of $200,000
with respect to any such cash compensation and (ii)&nbsp;$800,000 in total value with respect to any such equity-based compensation (including awards granted under the 2018 EIP and any other equity-based awards), calculating the value of any such
awards based on the grant date fair value of such awards for financial reporting purposes. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Awards subject to forfeiture/clawback.</I>&nbsp;&nbsp;&nbsp;&nbsp;Awards granted under the 2018 EIP will be subject to recoupment in accordance with
any clawback policy that we are required to adopt pursuant to the listing standards of any national securities exchange or association on which our securities are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer
Protection Act or other applicable law. In addition, the Board may impose other clawback, recovery or recoupment provisions in an award agreement, including a reacquisition right in respect of previously acquired shares or other cash or property
upon the occurrence of cause. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Restrictions on dividends.</I>&nbsp;&nbsp;&nbsp;&nbsp;The 2018 EIP provides that (i)&nbsp;no dividends or dividend equivalents may be paid with
respect to any shares of our common stock subject to an award before the date such shares have vested, (ii)&nbsp;any dividends or dividend equivalents that are credited with respect to any such shares will be subject to all of the terms and
conditions applicable to such shares under the terms of the applicable award agreement (including any vesting conditions), and (iii)&nbsp;any dividends or dividend equivalents that are credited with respect to any such shares will be forfeited to us
on the date such shares are forfeited to or repurchased by us due to a failure to vest. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Overhang </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table provides certain information regarding our equity incentive program. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;of&nbsp;March&nbsp;15,&nbsp;2018</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total number of shares of common stock
subject to outstanding stock options</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,972,623</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted-average exercise price of
outstanding stock options</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.46</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted-average remaining term of
outstanding stock options</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.18&nbsp;years</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total number of shares of common stock
subject to outstanding full value awards</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,194,591</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total number of shares of common stock
available for grant under the 2011 EIP (1)</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">343,956</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="81%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;of&nbsp;April&nbsp;9,&nbsp;2018</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total number of shares of common stock
outstanding</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,255,860</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">Per-share</FONT> closing price of common stock as reported on NASDAQ Capital Market</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.60</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Although there were 848,200 shares available for grant under the 2017 Inducement Plan as of March&nbsp;15, 2018, no additional awards will be granted
under the 2017 Inducement Plan if the 2018 EIP is approved by our stockholders. As of March&nbsp;15, 2018, there were no shares of common stock available for grant under any of our equity incentive plans, other than the 2011 EIP and the 2017
Inducement Plan, as described in this table. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>We Manage Our Equity Incentive Award Use Carefully and Dilution Is
Reasonable </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We continue to believe that equity incentive awards such as stock options and restricted stock unit awards are
a vital part of our overall compensation program. Our compensation philosophy reflects broad-based eligibility for equity incentive awards, and we grant awards to substantially all of our employees. However, we recognize that equity incentive awards
dilute existing stockholders, and, therefore, we must responsibly manage the growth of our equity compensation program. We are committed to effectively monitoring our equity compensation share reserve, including our &#147;burn rate,&#148; to ensure
that we maximize stockholders&#146; value by granting the appropriate number of equity incentive awards necessary to attract, reward, and retain employees. In addition, the vesting of some of our equity awards granted to our named executive officers
are contingent on meeting <FONT STYLE="white-space:nowrap">pre-defined</FONT> performance criteria, thereby ensuring alignment with value creation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table shows our responsible historical dilution and burn rate percentages. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:64pt ; display:inline;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As of December&nbsp;31</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2017</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2015</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Full Dilution</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14.92</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11.88</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gross Burn Rate</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.90</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Full Dilution is calculated as (shares available for grant + shares subject to outstanding equity incentive awards)/(weighted average common stock
outstanding + shares available for grant + shares subject to outstanding equity incentive awards). </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Gross Burn Rate is calculated as (shares subject to options granted + shares subject to other equity incentive awards granted)/weighted average common
stock outstanding. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The Size of Our Share Reserve Request Is Reasonable </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If this Proposal 2 is approved by our stockholders, we will have 5,000,000 new shares available for grant after our Annual Meeting, and
absent any unforeseen circumstances, we anticipate returning to stockholders for additional shares in 2019. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Burn Rate </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table provides detailed information regarding the activity related to our equity incentive plans for fiscal years 2017, 2016
and 2015. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8px">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fiscal&nbsp;Year&nbsp;2017</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fiscal&nbsp;Year&nbsp;2016</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fiscal&nbsp;Year&nbsp;2015</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total
number of shares of common stock subject to stock options granted</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">535,497</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,414,262</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,338,661</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total number of shares of common stock subject to full value awards
granted</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,217,303</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">856,258</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">36,986</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px">
<P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Weighted-average number of shares of common stock outstanding</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52,613,215</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">38,505,856</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">32,881,333</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Burn Rate</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.23</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.90</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4.18</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">%</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">13 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Description of the 2018 Equity Incentive Plan </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A summary of the principal features of the 2018 EIP follows below. The summary is qualified by the full text of the 2018 EIP that is
attached as Appendix A to this proxy statement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Purpose</I></B><B> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 2018 EIP is designed to secure and retain the services of our employees and directors, provide incentives for our employees and
directors to exert maximum efforts for the success of the Company and its affiliates, and provide a means by which our employees and directors may be given an opportunity to benefit from increases in the value of our common stock. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><I></I><B><I>Types of Awards</I></B><I></I><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The 2018 EIP provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance stock awards, and
other stock awards. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><I></I><B><I>Shares Available for Awards</I></B><I></I><B> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to adjustment for certain changes in our capitalization, the aggregate number of shares of our common stock that may be issued
under the 2018 EIP will not exceed the sum of (i) 5,000,000 new shares, (ii)&nbsp;the number of unallocated shares remaining available for grant under the 2011 EIP as of the effective date of the 2018 EIP, and (iii)&nbsp;the Prior Plans&#146;
Returning Shares (as defined below), as such shares become available from time to time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term &#147;Prior Plans&#146;
Returning Shares&#148; refers to the following shares of our common stock subject to any outstanding stock award granted under either of the Prior Plans: (i)&nbsp;any shares subject to such stock award that are not issued because such stock award
expires or otherwise terminates without all of the shares covered by such stock award having been issued; (ii)&nbsp;any shares subject to such stock award that are not issued because such stock award is settled in cash; and (iii)&nbsp;any shares
issued pursuant to such stock award that are forfeited back to or repurchased by us because of a failure to vest. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
following shares of our common stock (collectively, the &#147;2018 EIP Returning Shares&#148;) will also become available again for issuance under the 2018 EIP: (i)&nbsp;any shares subject to a stock award granted under the 2018 EIP that are not
issued because such stock award expires or otherwise terminates without all of the shares covered by such stock award having been issued; (ii)&nbsp;any shares subject to a stock award granted under the 2018 EIP that are not issued because such stock
award is settled in cash; and (iii)&nbsp;any shares issued pursuant to a stock award granted under the 2018 EIP that are forfeited back to or repurchased by us because of a failure to vest. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following shares of our common stock will not become available again for issuance under the 2018 EIP: (i)&nbsp;any shares that are
reacquired or withheld (or not issued) by us to satisfy the exercise, strike or purchase price of a stock award granted under the 2018 EIP or any Prior Plan (including any shares subject to such award that are not delivered because such award is
exercised through a reduction of shares subject to such award); (ii)&nbsp;any shares that are reacquired or withheld (or not issued) by us to satisfy a tax withholding obligation in connection with a stock award granted under the 2018 EIP or any
Prior Plan; (iii)&nbsp;any shares repurchased by us on the open market with the proceeds of the exercise, strike or purchase price of a stock award granted under the 2018 EIP or any Prior Plan; and (iv)&nbsp;in the event that a stock appreciation
right granted under the 2018 EIP or any Prior Plan is settled in shares, the gross number of shares subject to such award. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of shares of our common stock available for issuance under the 2018 EIP will be reduced by: (i)&nbsp;one share for each share
issued pursuant to a stock option or stock appreciation right with an exercise price that is at least 100% of the fair market value of our common stock on the date of grant (an &#147;Appreciation Award&#148;) granted under the 2018 EIP; and
(ii)&nbsp;1.28 shares for each share issued pursuant to a stock award that is not an Appreciation Award (a &#147;Full Value Award&#148;) granted under the 2018 EIP. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">14 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of shares of our common stock available for issuance under the 2018 EIP will
be increased by: (i)&nbsp;one share for each Prior Plans&#146; Returning Share or 2018 EIP Returning Share subject to an Appreciation Award; and (ii)&nbsp;1.28 shares for each Prior Plans&#146; Returning Share or 2018 EIP Returning Share subject to
a Full Value Award. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Eligibility</I></B><B> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">All of our (including our affiliates&#146;) employees and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors are eligible to
participate in the 2018 EIP and may receive all types of awards other than incentive stock options. Incentive stock options may be granted under the 2018 EIP only to our (including our affiliates&#146;) employees. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of April&nbsp;9, 2018, we (including our affiliates) had approximately 213 employees and eight
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Limit</I></B><B> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The aggregate value of all cash and equity-based compensation granted or paid by us to any individual for service as a <FONT
STYLE="white-space:nowrap">non-employee</FONT> director of the Board with respect to any fiscal year of the Company will not exceed (i)&nbsp;a total of $200,000 with respect to any such cash compensation and (ii)&nbsp;$800,000 in total value with
respect to any such equity-based compensation (including awards granted under the 2018 EIP and any other equity-based awards), calculating the value of any such awards based on the grant date fair value of such awards for financial reporting
purposes. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Administration</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The 2018 EIP will be administered by our Board, which may in turn delegate authority to administer the 2018 EIP to a committee. Our Board has delegated concurrent authority to administer the 2018 EIP to
our Compensation Committee, but may, at any time, revest in itself some or all of the power delegated to our Compensation Committee. Our Board and Compensation Committee are each considered to be a Plan Administrator for purposes of this Proposal 2.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the terms of the 2018 EIP, the Plan Administrator may determine the recipients, the types of awards to be granted,
the number of shares of our common subject to or the cash value of awards, and the terms and conditions of awards granted under the 2018 EIP, including the period of their exercisability and vesting. The Plan Administrator also has the authority to
provide for accelerated exercisability and vesting of awards. Subject to the limitations set forth below, the Plan Administrator also determines the fair market value applicable to a stock award and the exercise or strike price of stock options and
stock appreciation rights granted under the 2018 EIP. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Plan Administrator may also delegate to one or more officers the
authority to designate employees who are not officers to be recipients of certain stock awards and the number of shares of our common stock subject to such stock awards. Under any such delegation, the Plan Administrator will specify the total number
of shares of our common stock that may be subject to the stock awards granted by such officer. The officer may not grant a stock award to himself or herself. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Repricing; Cancellation and <FONT STYLE="white-space:nowrap">Re-Grant</FONT> of Stock Awards</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under the 2018 EIP, the Plan Administrator does not have the authority to reprice any outstanding stock option or stock appreciation right by reducing the exercise or strike price of the stock option or
stock appreciation right or to cancel any outstanding stock option or stock appreciation right that has an exercise or strike price greater than the then-current fair market value of our common stock in exchange for cash or other stock awards
without obtaining the approval of our stockholders. Such approval must be obtained within 12 months prior to such an event. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">15 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Minimum Vesting Requirements</I></B><B> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under the 2018 EIP, no award may vest until at least 12 months following the date of grant of such award, except that up to 5% of the
share reserve of the 2018 EIP may be subject to awards that do not meet such vesting requirements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Dividends and
Dividend Equivalents</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 2018 EIP provides that dividends or dividend equivalents may be paid or credited with
respect to any shares of our common stock subject to an award, as determined by the Plan Administrator and contained in the applicable award agreement;<I>&nbsp;provided, however</I>, that (i)&nbsp;no dividends or dividend equivalents may be paid
with respect to any such shares before the date such shares have vested, (ii)&nbsp;any dividends or dividend equivalents that are credited with respect to any such shares will be subject to all of the terms and conditions applicable to such shares
under the terms of the applicable award agreement (including any vesting conditions), and (iii)&nbsp;any dividends or dividend equivalents that are credited with respect to any such shares will be forfeited to us on the date such shares are
forfeited to or repurchased by us due to a failure to vest. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Stock Options</I></B><B> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock options may be granted under the 2018 EIP pursuant to stock option agreements. The 2018 EIP permits the grant of stock options that
are intended to qualify as incentive stock options, or ISOs, and nonstatutory stock options, or NSOs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The exercise price of a
stock option granted under the 2018 EIP may not be less than 100% of the fair market value of our common stock on the date of grant and, in some cases (see &#147;Limitations on Incentive Stock Options&#148; below), may not be less than 110% of such
fair market value. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The term of stock options granted under the 2018 EIP may not exceed seven years and, in some cases (see
&#147;Limitations on Incentive Stock Options&#148; below), may not exceed five years. Except as otherwise provided in a participant&#146;s stock option agreement or other written agreement with us or one of our affiliates, if a participant&#146;s
service relationship with us or any of our affiliates (referred to in this Proposal 2 as &#147;continuous service&#148;) terminates (other than for cause and other than upon the participant&#146;s death or disability), the participant may exercise
any vested stock options for up to three months following the participant&#146;s termination of continuous service. Except as otherwise provided in a participant&#146;s stock option agreement or other written agreement with us or one of our
affiliates, if a participant&#146;s continuous service terminates due to the participant&#146;s disability or death (or the participant dies within a specified period, if any, following termination of continuous service), the participant, or his or
her beneficiary, as applicable, may exercise any vested stock options for up to 12 months following the participant&#146;s termination due to the participant&#146;s disability or for up to 18 months following the participant&#146;s death. Except as
explicitly provided otherwise in a participant&#146;s stock option agreement or other written agreement with us or one of our affiliates, if a participant&#146;s continuous service is terminated for cause (as defined in the 2018 EIP), all stock
options held by the participant will terminate upon the participant&#146;s termination of continuous service and the participant will be prohibited from exercising any stock option from and after such termination date. Except as otherwise provided
in a participant&#146;s stock option agreement or other written agreement with us or one of our affiliates, the term of a stock option may be extended if the exercise of the stock option following the participant&#146;s termination of continuous
service (other than for cause and other than upon the participant&#146;s death or disability) would be prohibited by applicable securities laws or if the sale of any common stock received upon exercise of the stock option following the
participant&#146;s termination of continuous service (other than for cause) would violate our insider trading policy. In no event, however, may a stock option be exercised after its original expiration date. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Acceptable forms of consideration for the purchase of our common stock pursuant to the exercise of a stock option under the 2018 EIP will
be determined by the Plan Administrator and may include payment: (i)&nbsp;by cash, check, bank draft or money order payable to us; (ii)&nbsp;pursuant to a program developed under Regulation T as
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">16 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
promulgated by the Federal Reserve Board; (iii)&nbsp;by delivery to us of shares of our common stock (either by actual delivery or attestation); (iv)&nbsp;by a net exercise arrangement (for NSOs
only); or (v)&nbsp;in other legal consideration approved by the Plan Administrator. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock options granted under the 2018 EIP
may vest and become exercisable in cumulative increments, as determined by the Plan Administrator at the rate specified in the stock option agreement (subject to the limitations described in &#147;Minimum Vesting Requirements&#148; above). Shares
covered by different stock options granted under the 2018 EIP may be subject to different vesting schedules as the Plan Administrator may determine. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Plan Administrator may impose limitations on the transferability of stock options granted under the 2018 EIP in its discretion. Generally, a participant may not transfer a stock option granted under
the 2018 EIP other than by will or the laws of descent and distribution or, subject to approval by the Plan Administrator, pursuant to a domestic relations order or an official marital settlement agreement. However, the Plan Administrator may permit
transfer of a stock option in a manner that is not prohibited by applicable tax and securities laws. In addition, subject to approval by the Plan Administrator, a participant may designate a beneficiary who may exercise the stock option following
the participant&#146;s death. Notwithstanding the foregoing, no option may be transferred to any financial institution without prior stockholder approval. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Limitations on Incentive Stock Options</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The aggregate
fair market value, determined at the time of grant, of shares of our common stock with respect to ISOs that are exercisable for the first time by a participant during any calendar year under all of our stock plans may not exceed $100,000. The stock
options or portions of stock options that exceed this limit or otherwise fail to qualify as ISOs are treated as NSOs. No ISO may be granted to any person who, at the time of grant, owns or is deemed to own stock possessing more than 10% of our total
combined voting power or that of any affiliate unless the following conditions are satisfied: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the exercise price of the ISO must be at least 110% of the fair market value of our common stock on the date of grant; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the term of the ISO must not exceed five years from the date of grant. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to adjustment for certain changes in our capitalization, the aggregate maximum number of shares of our common stock that may be
issued pursuant to the exercise of ISOs under the 2018 EIP is 10,000,000 shares. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Stock Appreciation
Rights</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock appreciation rights may be granted under the 2018 EIP pursuant to stock appreciation right
agreements. Each stock appreciation right is denominated in common stock share equivalents. The strike price of each stock appreciation right will be determined by the Plan Administrator, but will in no event be less than 100% of the fair market
value of our common stock on the date of grant. The Plan Administrator may also impose restrictions or conditions upon the vesting of stock appreciation rights that it deems appropriate. The appreciation distribution payable upon exercise of a stock
appreciation right may be paid in shares of our common stock, in cash, in a combination of cash and stock, or in any other form of consideration determined by the Plan Administrator and set forth in the stock appreciation right agreement. Stock
appreciation rights will be subject to the same conditions upon termination of continuous service and restrictions on transfer as stock options under the 2018 EIP. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Restricted Stock Awards</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock awards may
be granted under the 2018 EIP pursuant to restricted stock award agreements. A restricted stock award may be granted in consideration for cash, check, bank draft or money order payable to us, the participant&#146;s services performed for us or any
of our affiliates, or any other form of legal consideration acceptable to the Plan Administrator. Shares of our common stock acquired under a restricted stock award may be subject to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">17 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
forfeiture to or repurchase by us in accordance with a vesting schedule to be determined by the Plan Administrator (subject to the limitations described in &#147;Minimum Vesting
Requirements&#148; above). Rights to acquire shares of our common stock under a restricted stock award may be transferred only upon such terms and conditions as are set forth in the restricted stock award agreement;<I>&nbsp;provided, however</I>,
that no restricted stock award may be transferred to any financial institution without prior stockholder approval. Upon a participant&#146;s termination of continuous service for any reason, any shares subject to restricted stock awards held by the
participant that have not vested as of such termination date may be forfeited to or repurchased by us. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Restricted Stock Unit Awards</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Restricted stock unit awards may be granted under the 2018 EIP pursuant to restricted stock unit award agreements. Payment of any purchase price may be made in any form of legal consideration acceptable
to the Plan Administrator. A restricted stock unit award may be settled by the delivery of shares of our common stock, in cash, in a combination of cash and stock, or in any other form of consideration determined by the Plan Administrator and set
forth in the restricted stock unit award agreement. Restricted stock unit awards may be subject to vesting in accordance with a vesting schedule to be determined by the Plan Administrator (subject to the limitations described in &#147;Minimum
Vesting Requirements&#148; above). Except as otherwise provided in a participant&#146;s restricted stock unit award agreement or other written agreement with us or one of our affiliates, restricted stock units that have not vested will be forfeited
upon the participant&#146;s termination of continuous service for any reason. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Performance Stock
Awards</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A performance stock award is a stock award that is payable (including that may be granted, may vest, or
may be exercised) contingent upon the attainment of <FONT STYLE="white-space:nowrap">pre-determined</FONT> performance goals during a performance period. A performance stock award may require the completion of a specified period of continuous
service. The length of any performance period, the performance goals to be achieved during the performance period, and the measure of whether and to what degree such performance goals have been attained will be determined by the Plan Administrator
(subject to the limitations described in &#147;Minimum Vesting Requirements&#148; above). In addition, to the extent permitted by applicable law and the performance stock award agreement, the Plan Administrator may determine that cash may be used in
payment of performance stock awards. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Performance goals under the 2018 EIP will be based on any one or more of the following
performance criteria: (i)&nbsp;earnings (including earnings per share and net earnings); (ii) earnings before interest, taxes and depreciation; (iii)&nbsp;earnings before interest, taxes, depreciation and amortization (EBITDA); (iv) total
stockholder return; (v)&nbsp;return on equity or average stockholder&#146;s equity; (vi)&nbsp;return on assets, investment, or capital employed; (vii)&nbsp;stock price or stock price performance; (viii)&nbsp;margin (including gross margin); (ix) net
income (before or after taxes); (x) operating income; (xi)&nbsp;operating income after taxes; <FONT STYLE="white-space:nowrap">(xii)&nbsp;pre-tax</FONT> profit; (xiii)&nbsp;operating cash flow; (xiv)&nbsp;sales or revenue targets;
(xv)&nbsp;increases in revenue or product revenue; (xvi)&nbsp;expenses and cost reduction goals; (xvii)&nbsp;improvement in or attainment of working capital levels; (xviii)&nbsp;economic value added (or an equivalent metric); (xix) market share;
(xx)&nbsp;cash flow; (xxi)&nbsp;cash flow per share; (xxii)&nbsp;share price performance; (xxiii)&nbsp;debt reduction; (xxiv)&nbsp;implementation or completion of projects or processes; (xxv)&nbsp;customer satisfaction;
(xxvi)&nbsp;stockholders&#146; equity; (xxvii)&nbsp;capital expenditures; (xxviii)&nbsp;debt levels; (xxix)&nbsp;operating profit or net operating profit; (xxx)&nbsp;workforce diversity; (xxxi)&nbsp;growth of net income or operating income;
(xxxii)&nbsp;billings; (xxxiii) submission to, or approval by, a regulatory body (including but not limited to the U.S. Food and Drug Administration) of an applicable filing for a product candidate or other product development milestones;
(xxxiv)&nbsp;acquisitions, divestitures, joint ventures, strategic alliances, licenses or collaborations; (xxxv)&nbsp;spin-offs, <FONT STYLE="white-space:nowrap">split-ups,</FONT> reorganizations, recapitalizations, restructurings, financings (debt
or equity) or refinancings; (xxxvi)&nbsp;manufacturing or process development, clinical trial, regulatory, intellectual property, compliance or research objectives; and (xxxvii)&nbsp;any other measures of performance selected by the Plan
Administrator. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Performance goals may be based on a company-wide basis, with respect to one or more business units, divisions,
affiliates or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the performance of one or more relevant indices. The Plan Administrator is authorized to
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">18 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
make appropriate adjustments in the method of calculating the attainment of performance goals for a performance period as follows: (i)&nbsp;to exclude restructuring and/or other nonrecurring
charges; (ii)&nbsp;to exclude exchange rate effects, as applicable, for <FONT STYLE="white-space:nowrap">non-U.S.</FONT> dollar denominated performance goals; (iii)&nbsp;to exclude the effects of changes to generally accepted accounting principles;
(iv)&nbsp;to exclude the effects of any statutory adjustments to corporate tax rates; (v)&nbsp;to exclude the effects of items that are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as determined under generally accepted accounting
principles; (vi)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (vii)&nbsp;to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a performance period
following such divestiture; (viii)&nbsp;to exclude the effect of any change in the outstanding shares of our common stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, <FONT
STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change, or any distributions to common shareholders other than regular cash dividends; (ix)&nbsp;to exclude the effects of stock based
compensation and/or the award of an annual cash incentive under our Annual Incentive Program; (x)&nbsp;to exclude the effect of any other unusual, <FONT STYLE="white-space:nowrap">non-recurring</FONT> gain or loss or other extraordinary item; and
(xi)&nbsp;to make other appropriate adjustments selected by the Plan Administrator. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, the Plan Administrator
retains the discretion to reduce or eliminate the compensation or economic benefit due upon the attainment of any performance goals and to define the manner of calculating the performance criteria it selects to use for a performance period.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Other Stock Awards</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Other forms of stock awards valued in whole or in part by reference to, or otherwise based on, our common stock may be granted either alone or in addition to other stock awards under the 2018 EIP. Subject
to the terms of the 2018 EIP (including the limitations described in &#147;Minimum Vesting Requirements&#148; above), the Plan Administrator will have sole and complete authority to determine the persons to whom and the time or times at which such
other stock awards will be granted, the number of shares of our common stock to be granted and all other terms and conditions of such other stock awards. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Clawback Policy</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Awards granted under the 2018 EIP
will be subject to recoupment in accordance with any clawback policy that we are required to adopt pursuant to the listing standards of any national securities exchange or association on which our securities are listed or as is otherwise required by
the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Plan Administrator may impose other clawback, recovery or recoupment provisions in an award agreement, including a reacquisition right in respect
of previously acquired shares or other cash or property upon the occurrence of cause. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Changes to Capital
Structure</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event of certain capitalization adjustments, the Plan Administrator will appropriately adjust:
(i)&nbsp;the class(es) and maximum number of securities subject to the 2018 EIP; (ii)&nbsp;the class(es) and maximum number of securities that may be issued pursuant to the exercise of ISOs; and (iii)&nbsp;the class(es) and number of securities and
price per share of stock subject to outstanding stock awards. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Corporate Transaction and Change in
Control</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following provisions will apply to outstanding awards under the 2018 EIP and any Prior Plan in the
event of a corporate transaction (as defined in the 2018 EIP and described below) or a change in control (as defined in the 2018 EIP and described below) unless otherwise provided in the instrument evidencing the award, in any other written
agreement between us or one of our affiliates and the participant, or in our director compensation policy, or unless otherwise provided by the Plan Administrator at the time of grant of the award. For purposes of this Proposal&nbsp;2, the term
&#147;Transaction&#148; will mean such corporate transaction or change in control. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">19 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event of a Transaction, any surviving or acquiring corporation (or its parent
company) may assume or continue any or all outstanding awards under the 2018 EIP and/or any Prior Plan, or may substitute similar stock awards for such outstanding awards (including, but not limited to, awards to acquire the same consideration paid
to the stockholders of the Company pursuant to the Transaction), and any reacquisition or repurchase rights held by the Company in respect of shares issued pursuant to any outstanding awards under the 2018 EIP and/or any Prior Plan may be assigned
by the Company to the surviving or acquiring corporation (or its parent company). The terms of any such assumption, continuation or substitution will be set by the Plan Administrator. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event of a Transaction in which the surviving or acquiring corporation (or its parent company) does not assume or continue
outstanding awards under the 2018 EIP and/or any Prior Plan, or substitute similar stock awards for such outstanding awards, then with respect to any such awards that have not been assumed, continued or substituted and that are held by participants
whose continuous service has not terminated prior to the effective time of the Transaction (the &#147;Current Participants&#148;), the vesting (and exercisability, if applicable) of such awards will be accelerated in full to a date prior to the
effective time of the Transaction (contingent upon the closing or completion of the Transaction) as the Plan Administrator will determine (or, if the Plan Administrator does not determine such a date, to the date that is five days prior to the
effective time of the Transaction), and such awards will terminate if not exercised (if applicable) prior to the effective time of the Transaction in accordance with the exercise procedures determined by the Plan Administrator, and any reacquisition
or repurchase rights held by the Company with respect to such awards will lapse (contingent upon the closing or completion of the Transaction). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the event of a Transaction in which the surviving or acquiring corporation (or its parent company) does not assume or continue outstanding awards under the 2018 EIP and/or any Prior Plan, or substitute
similar stock awards for such outstanding awards, then with respect to any such awards that have not been assumed, continued or substituted and that are held by participants other than the Current Participants, such awards will terminate if not
exercised (if applicable) prior to the effective time of the Transaction in accordance with the exercise procedures determined by the Plan Administrator; <I>provided, however</I>, that any reacquisition or repurchase rights held by the Company with
respect to such awards will not terminate and may continue to be exercised notwithstanding the Transaction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding
the foregoing, in the event any outstanding award under the 2018 EIP and/or any Prior Plan held by a participant will terminate if not exercised prior to the effective time of a Transaction, the Plan Administrator may provide, in its sole
discretion, that the participant may not exercise such award but instead will receive a payment, in such form as may be determined by the Plan Administrator, equal in value to the excess, if any, of (i)&nbsp;the value of the property the participant
would have received upon the exercise of such award immediately prior to the effective time of the Transaction (including, at the discretion of the Plan Administrator, any unvested portion of such award), over (ii)&nbsp;any exercise price payable by
the participant in connection with such exercise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Outstanding awards under the 2018 EIP and any Prior Plan may be subject to
additional acceleration of vesting and exercisability upon or after a change in control as may be provided in the participant&#146;s award agreement, in any other written agreement with us or one of our affiliates, or in our director compensation
policy, but in the absence of such provision, no such acceleration will occur. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of the 2018 EIP, a corporate
transaction generally will be deemed to occur in the event of the consummation of: (i)&nbsp;a sale or other disposition of all or substantially all of our consolidated assets; (ii)&nbsp;a sale or other disposition of at least 90% of our outstanding
securities; (iii)&nbsp;a merger, consolidation or similar transaction following which we are not the surviving corporation; or (iv)&nbsp;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares
of our common stock outstanding immediately prior to the transaction are converted or exchanged into other property by virtue of the transaction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For purposes of the 2018 EIP, a change in control generally will be deemed to occur in the event: (i)&nbsp;a person, entity or group acquires, directly or indirectly, our securities representing more than
50% of the combined voting </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">20 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
power of our then outstanding securities, other than by virtue of a merger, consolidation, or similar transaction; (ii)&nbsp;there is consummated a merger, consolidation, or similar transaction
and, immediately after the consummation of such transaction, our stockholders immediately prior thereto do not own, directly or indirectly, more than 50% of the combined outstanding voting power of the surviving entity or the parent of the surviving
entity in substantially the same proportions as their ownership of our outstanding voting securities immediately prior to such transaction; (iii)&nbsp;there is consummated a sale or other disposition of all or substantially all of our consolidated
assets, other than a sale or other disposition to an entity in which more than 50% of the entity&#146;s combined voting power is owned by our stockholders in substantially the same proportions as their ownership of our outstanding voting securities
immediately prior to such sale or other disposition; or (iv)&nbsp;over a period of 12 months or less, a majority of our Board becomes comprised of individuals whose nomination, appointment, or election was not approved by a majority of the Board
members or their approved successors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Plan Amendments and Termination</I></B><B> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board (or a committee of one or more directors delegated by the Board) will have the authority to amend or terminate the 2018 EIP at
any time. However, except as otherwise provided in the 2018 EIP or an award agreement, no amendment or termination of the 2018 EIP may materially impair a participant&#146;s rights under his or her outstanding awards without the participant&#146;s
consent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We will obtain stockholder approval of any amendment to the 2018 EIP as required by applicable law and listing
requirements. No incentive stock options may be granted under the 2018 EIP after the tenth anniversary of the date the 2018 EIP was adopted by the Board. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>U.S. Federal Income Tax Consequences </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following is a summary of the
principal United States federal income tax consequences to participants and us with respect to participation in the 2018 EIP. This summary is not intended to be exhaustive and does not discuss the income tax laws of any local, state or foreign
jurisdiction in which a participant may reside. The information is based upon current federal income tax rules and therefore is subject to change when those rules change. Because the tax consequences to any participant may depend on his or her
particular situation, each participant should consult the participant&#146;s tax adviser regarding the federal, state, local and other tax consequences of the grant or exercise of an award or the disposition of stock acquired the 2018 EIP. The 2018
EIP is not qualified under the provisions of Section&nbsp;401(a) of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), and is not subject to any of the provisions of the Employee Retirement Income Security Act of 1974. Our ability
to realize the benefit of any tax deductions described below depends on our generation of taxable income as well as the requirement of reasonableness, the provisions of Section&nbsp;162(m) of the Code and the satisfaction of our tax reporting
obligations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Nonstatutory Stock Options </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Generally, there is no taxation upon the grant of an NSO if the stock option is granted with an exercise price equal to the fair market value of the underlying stock on the grant date. Upon exercise, a
participant will recognize ordinary income equal to the excess, if any, of the fair market value of the underlying stock on the date of exercise of the stock option over the exercise price. If the participant is employed by us or one of our
affiliates, that income will be subject to withholding taxes. The participant&#146;s tax basis in those shares will be equal to their fair market value on the date of exercise of the stock option, and the participant&#146;s capital gain holding
period for those shares will begin on that date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the requirement of reasonableness, the provisions of
Section&nbsp;162(m) of the Code and the satisfaction of our tax reporting obligation, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the participant. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">21 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Incentive Stock Options</I></B><B> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 2018 EIP provides for the grant of stock options that are intended to qualify as &#147;incentive stock options,&#148; as defined in
Section&nbsp;422 of the Code. Under the Code, a participant generally is not subject to ordinary income tax upon the grant or exercise of an ISO. If the participant holds a share received upon exercise of an ISO for more than two years from the date
the stock option was granted and more than one year from the date the stock option was exercised, which is referred to as the required holding period, the difference, if any, between the amount realized on a sale or other taxable disposition of that
share and the participant&#146;s tax basis in that share will be long-term capital gain or loss. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If, however, a participant
disposes of a share acquired upon exercise of an ISO before the end of the required holding period, which is referred to as a disqualifying disposition, the participant generally will recognize ordinary income in the year of the disqualifying
disposition equal to the excess, if any, of the fair market value of the share on the date of exercise of the stock option over the exercise price. However, if the sales proceeds are less than the fair market value of the share on the date of
exercise of the stock option, the amount of ordinary income recognized by the participant will not exceed the gain, if any, realized on the sale. If the amount realized on a disqualifying disposition exceeds the fair market value of the share on the
date of exercise of the stock option, that excess will be short-term or long-term capital gain, depending on whether the holding period for the share exceeds one year. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">For purposes of the alternative minimum tax, the amount by which the fair market value of a share of stock acquired upon exercise of an ISO exceeds the exercise price of the stock option generally will be
an adjustment included in the participant&#146;s alternative minimum taxable income for the year in which the stock option is exercised. If, however, there is a disqualifying disposition of the share in the year in which the stock option is
exercised, there will be no adjustment for alternative minimum tax purposes with respect to that share. In computing alternative minimum taxable income, the tax basis of a share acquired upon exercise of an ISO is increased by the amount of the
adjustment taken into account with respect to that share for alternative minimum tax purposes in the year the stock option is exercised. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are not allowed a tax deduction with respect to the grant or exercise of an ISO or the disposition of a share acquired upon exercise of an ISO after the required holding period. If there is a
disqualifying disposition of a share, however, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the participant, subject to the requirement of reasonableness and the provisions of Section&nbsp;162(m)
of the Code, and provided that either the employee includes that amount in income or we timely satisfy our reporting requirements with respect to that amount. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Restricted Stock Awards</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Generally, the recipient of a
restricted stock award will recognize ordinary income at the time the stock is received equal to the excess, if any, of the fair market value of the stock received over any amount paid by the recipient in exchange for the stock. If, however, the
stock is not vested when it is received (for example, if the employee is required to work for a period of time in order to have the right to sell the stock), the recipient generally will not recognize income until the stock becomes vested, at which
time the recipient will recognize ordinary income equal to the excess, if any, of the fair market value of the stock on the date it becomes vested over any amount paid by the recipient in exchange for the stock. A recipient may, however, file an
election with the Internal Revenue Service, within 30 days following his or her receipt of the stock award, to recognize ordinary income, as of the date the recipient receives the award, equal to the excess, if any, of the fair market value of the
stock on the date the award is granted over any amount paid by the recipient for the stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The recipient&#146;s basis for
the determination of gain or loss upon the subsequent disposition of shares acquired from a restricted stock award will be the amount paid for such shares plus any ordinary income recognized either when the stock is received or when the stock
becomes vested. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">22 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the requirement of reasonableness, the provisions of Section&nbsp;162(m) of
the Code and the satisfaction of our tax reporting obligation, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the restricted stock award. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Restricted Stock Unit Awards</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Generally, the recipient of a restricted stock unit award structured to comply with the requirements of Section&nbsp;409A of the Code or an exemption to Section&nbsp;409A of the Code will recognize
ordinary income at the time the stock is delivered equal to the excess, if any, of the fair market value of the stock received over any amount paid by the recipient in exchange for the stock. To comply with the requirements of Section&nbsp;409A of
the Code, the stock subject to a restricted stock unit award may generally only be delivered upon one of the following events: a fixed calendar date (or dates), separation from service, death, disability or a change in control. If delivery occurs on
another date, unless the restricted stock unit award otherwise complies with or qualifies for an exemption to the requirements of Section&nbsp;409A of the Code, in addition to the tax treatment described above, the recipient will owe an additional
20% federal tax and interest on any taxes owed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The recipient&#146;s basis for the determination of gain or loss upon the
subsequent disposition of shares acquired from a restricted stock unit award will be the amount paid for such shares plus any ordinary income recognized when the stock is delivered. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the requirement of reasonableness, the provisions of Section&nbsp;162(m) of the Code and the satisfaction of our tax reporting
obligation, we will generally be entitled to a tax deduction equal to the taxable ordinary income realized by the recipient of the restricted stock unit award. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Stock Appreciation Rights</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Generally, if a stock
appreciation right is granted with an exercise price equal to the fair market value of the underlying stock on the grant date, the recipient will recognize ordinary income equal to the fair market value of the stock or cash received upon such
exercise. Subject to the requirement of reasonableness, the provisions of Section&nbsp;162(m) of the Code, and the satisfaction of our tax reporting obligation, we will generally be entitled to a tax deduction equal to the taxable ordinary income
realized by the recipient of the stock appreciation right. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B><B><I>Section&nbsp;162(m) Limitations</I></B><B>
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;162(m) of the Code disallows a deduction to any publicly held corporation and its affiliates for certain
compensation paid to &#147;covered employees&#148; in a taxable year to the extent that compensation paid to a covered employee exceeds $1&nbsp;million. As a result, compensation (including compensation pursuant to awards granted under the 2018 EIP)
paid to any of our &#147;covered employees&#148; under Section&nbsp;162(m) of the Code in excess of $1&nbsp;million per taxable year generally will not be deductible. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">23 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>New Plan Benefits under 2018 EIP </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:64pt ; display:inline;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">CEO and Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Chief Financial Officer and Chief Business Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President and Chief Scientific Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Operations and Quality</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All current executive officers as a group</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All current directors who are not executive officers as a group</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">105,000&nbsp;per&nbsp;calendar&nbsp;year</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All employees, including all current officers who are not executive officers, as a group</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Awards granted under the 2018 EIP to our executive officers and other employees are discretionary and are not subject to set benefits or amounts under
the terms of the 2018 EIP, and our Board and our Compensation Committee have not granted any awards under the 2018 EIP subject to stockholder approval of this Proposal 2. Accordingly, the benefits or amounts that will be received by or allocated to
our executive officers and other employees under the 2018 EIP, as well as the benefits or amounts which would have been received by or allocated to our executive officers and other employees for fiscal year 2017 if the 2018 EIP had been in effect,
are not determinable. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Awards granted under the 2018 EIP to our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors are discretionary and are not subject to set
benefits or amounts under the terms of the 2018 EIP. However, pursuant to our current compensation program for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, each of our current <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors (except Dr.&nbsp;Plotkin, who has advised the Board of his decision to retire effective as of the date of the Annual Meeting) is eligible to receive an annual grant of a stock option to purchase 15,000 shares of our common stock. On and
after the date of the Annual Meeting, any such stock options will be granted under the 2018 EIP if this Proposal 2 is approved by our stockholders. For additional information regarding our current compensation program for <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors, please see &#147;Director Compensation&#148; below. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Vote Required </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The affirmative vote of the holders of a majority of shares present (either in person or by proxy) and cast at the Annual Meeting (i.e., representing the majority voting power) will be required to approve
this Proposal 2. Abstentions will be counted toward the tabulation of votes cast on proposals presented to the stockholders and will have the same effect as negative votes. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are counted towards
a quorum but are not counted for any purpose in determining whether this Proposal 2 has been approved. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>HE</SMALL>
B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> R<SMALL>ECOMMENDS</SMALL> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A V<SMALL>OTE</SMALL>
I<SMALL>N</SMALL> F<SMALL>AVOR</SMALL> O<SMALL>F</SMALL> P<SMALL>ROPOSAL</SMALL> 2. </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">24 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROPOSAL 3 </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>APPROVAL OF AN AMENDMENT AND RESTATEMENT OF THE 2014 EMPLOYEE STOCK PURCHASE PLAN </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board is requesting stockholder approval of an amendment and restatement of the Dynavax Technologies Corporation 2014 Employee Stock
Purchase Plan (the &#147;2014 ESPP&#148;). We refer to such amendment and restatement of the 2014 ESPP in this proxy statement as the &#147;Amended 2014 ESPP&#148;. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Amended 2014 ESPP contains the following material change from the 2014 ESPP: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to adjustment for certain changes in our capitalization, the maximum number of shares of our common stock that may be issued under the Amended
2014 ESPP will be 850,000 shares, which is an increase of 600,000 shares over the maximum number of shares of our common stock that may be issued under the 2014 ESPP. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approval of the Amended 2014 ESPP will allow us to continue to provide our employees with the opportunity to acquire an ownership
interest in the Company through their participation in the Amended 2014 ESPP, thereby encouraging them to remain in our service and more closely aligning their interests with those of our stockholders. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If this Proposal 3 is approved by our stockholders, an additional 600,000 shares of our common stock will be available for issuance under
the Amended 2014 ESPP. As of April&nbsp;9, 2018, a total of 40,439 shares of our common stock remained available for issuance under the 2014 ESPP. We do not maintain any other employee stock purchase plans. As of April&nbsp;9, 2018, a total of
62,255,860 shares of our common stock were outstanding. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Summary of the Amended 2014 ESPP </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A summary of the principal features of the Amended 2014 ESPP follows below. The summary is qualified by the full text of the Amended 2014
ESPP that is attached as Appendix B to this proxy statement. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Purpose </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The purpose of the Amended 2014 ESPP is to provide a means by which our employees may be given an opportunity to purchase shares of our
common stock, to assist us in retaining the services of our employees, to secure and retain the services of new employees and to provide incentives for such persons to exert maximum efforts for our success. The rights to purchase common stock
granted under the Amended 2014 ESPP are intended to qualify as options issued under an &#147;employee stock purchase plan&#148; as that term is defined in Section&nbsp;423(b) of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;).
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Administration </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Board has the power to administer the Amended 2014 ESPP and may also delegate administration of the Amended 2014 ESPP to a committee comprised of one or more members of the Board. The Board has
delegated administration of the Amended 2014 ESPP to the Compensation Committee, but may, at any time, revest in itself some or all of the powers previously delegated to the Compensation Committee. Each of the Board and the Compensation Committee is
considered to be a Plan Administrator for purposes of this Proposal 3. The Plan Administrator has the power to construe and interpret both the Amended 2014 ESPP and the rights granted under it. The Plan Administrator has the power, subject to the
provisions of the Amended 2014 ESPP, to determine when and how rights to purchase our common stock will be granted, the provisions of each offering of such rights (which need not be identical), and whether employees of any of our parent or
subsidiary companies will be eligible to participate in the Amended 2014 ESPP. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">25 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Stock Subject to Amended 2014 ESPP </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to adjustment for certain changes in our capitalization, the maximum number of shares of our common stock that may be issued under
the Amended 2014 ESPP is 850,000 shares, which is equal to the sum of (i) 50,000 shares that were approved at our 2014 annual meeting of stockholders, (ii)&nbsp;an additional 200,000 shares that were approved at our 2016 annual meeting of
stockholders, and (iii)&nbsp;an additional 600,000 shares that are subject to approval by our stockholders under this Proposal 3. If any rights granted under the Amended 2014 ESPP terminate without being exercised in full, the shares of common stock
not purchased under such rights again become available for issuance under the Amended 2014 ESPP. The shares of common stock purchasable under the Amended 2014 ESPP will be shares of authorized but unissued or reacquired common stock, including
shares repurchased by us on the open market. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Offerings </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Amended 2014 ESPP will be implemented by offerings of rights to purchase our common stock to all eligible employees. The Plan
Administrator will determine the duration of each offering period, provided that in no event may an offering period exceed 27 months. The Plan Administrator may establish separate offerings which vary in terms (although not inconsistent with the
provisions of the Amended 2014 ESPP or the requirements of applicable laws). Each offering period will have one or more purchase dates, as determined by the Plan Administrator prior to the commencement of the offering period. The Plan Administrator
has the authority to alter the terms of an offering prior to the commencement of the offering period, including the duration of subsequent offering periods. When an eligible employee elects to join an offering period, he or she is granted a right to
purchase shares of our common stock on each purchase date within the offering period. On the purchase date, all contributions collected from the participant are automatically applied to the purchase of our common stock, subject to certain
limitations (which are described further below under &#147;Eligibility&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Plan Administrator has the discretion to
structure an offering so that if the fair market value of our common stock on the first trading day of a new purchase period within the offering period is less than or equal to the fair market value of our common stock on the first day of the
offering period, then that offering will terminate immediately as of that first trading day, and the participants in such terminated offering will be automatically enrolled in a new offering beginning on the first trading day of such new purchase
period. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Eligibility </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Any individual who is employed by us (or by any of our parent or subsidiary companies if such company is designated by the Plan Administrator as eligible to participate in the Amended 2014 ESPP) may
participate in offerings under the Amended 2014 ESPP, provided such individual has been employed by us (or our parent or subsidiary, if applicable) for such continuous period preceding the first day of the offering period as the Plan Administrator
may require, but in no event may the required period of continuous employment be equal to or greater than two years. In addition, the Plan Administrator may provide that an employee will not be eligible to be granted purchase rights under the
Amended 2014 ESPP unless such employee is customarily employed for more than 20 hours per week and more than five months per calendar year. The Plan Administrator may also provide in any offering that certain of our employees who are &#147;highly
compensated&#148; as defined in the Code are not eligible to participate in the Amended 2014 ESPP. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">No employee will be
eligible to participate in the Amended 2014 ESPP if, immediately after the grant of purchase rights, the employee would own, directly or indirectly, stock possessing 5% or more of the total combined voting power or value of all classes of our stock
or of any of our parent or subsidiary companies, including any stock which such employee may purchase under all outstanding purchase rights and options. In addition, no employee may purchase more than $25,000 worth of our common stock (determined
based on the fair market value of the shares at the time such rights are granted) under all our employee stock purchase plans and any employee stock purchase plans of our parent or subsidiary companies for each calendar year during which such rights
are outstanding. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of April&nbsp;9, 2018, we had approximately 213 employees. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">26 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Participation in the Amended 2014 ESPP </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">An eligible employee may enroll in the Amended 2014 ESPP by delivering to us, within the time specified in the offering, an enrollment
form authorizing contributions as specified by the Plan Administrator, which may be up to 10% of such employee&#146;s earnings during the offering period. Each participant will be granted a separate purchase right for each offering in which he or
she participates. Unless an employee&#146;s participation is discontinued, his or her purchase right will be exercised automatically at the end of each purchase period at the applicable purchase price. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Purchase Price </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The purchase price per share at which shares of our common stock are acquired pursuant to purchase rights on each purchase date during an offering period will not be less than the lower of (i)&nbsp;85% of
the fair market value of a share of our common stock on the first day of the offering period or (ii)&nbsp;85% of the fair market value of a share of our common stock on the applicable purchase date. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As of April&nbsp;9, 2018, the closing price of our common stock as reported on the Nasdaq Capital Market was $18.60 per share.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Payment of Purchase Price; Payroll Deductions </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The purchase of shares during an offering period generally will be funded by a participant&#146;s payroll deductions accumulated during the offering period. A participant may change his or her rate of
contributions, if and as permitted in the offering. All contributions made for a participant are credited to his or her account under the Amended 2014 ESPP and deposited with our general funds. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Purchase Limits </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with each offering made under the Amended 2014 ESPP, the Plan Administrator may specify (i)&nbsp;a maximum number of shares of our common stock that may be purchased by any participant
pursuant to such offering, (ii)&nbsp;a maximum number of shares of our common stock that may be purchased by any participant on any purchase date pursuant to such offering, (iii)&nbsp;a maximum aggregate number of shares of our common stock that may
be purchased by all participants pursuant to such offering, and/or (iv)&nbsp;a maximum aggregate number of shares of our common stock that may be purchased by all participants on any purchase date pursuant to such offering. If the aggregate purchase
of shares of our common stock issuable upon exercise of purchase rights granted under such offering would exceed any such maximum aggregate number, then, in the absence of any action by the Plan Administrator otherwise, a pro rata allocation of
available shares of our common stock will be made in as nearly a uniform manner as will be practicable and equitable. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Withdrawal </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Participants may withdraw from a given offering by delivering a withdrawal form to us and terminating their contributions. Such withdrawal may be elected at any time prior to the end of an offering,
except as otherwise provided by the Plan Administrator. Upon such withdrawal, we will distribute to the employee his or her accumulated but unused contributions without interest, and such employee&#146;s right to participate in that offering will
terminate. However, an employee&#146;s withdrawal from an offering does not affect such employee&#146;s eligibility to participate in subsequent offerings under the Amended 2014 ESPP. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Termination of Employment </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Except as required by law, a participant&#146;s outstanding purchase rights under any offering under the Amended 2014 ESPP will terminate immediately upon either (i)&nbsp;termination of the
participant&#146;s employment with us (or any of our parent or subsidiary companies if such company is designated by the Plan Administrator as eligible to </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">27 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
participate in the Amended 2014 ESPP) or (ii)&nbsp;any other circumstance or event that causes the participant to no longer be eligible to participate in the offering. In such event, we will
distribute to the participant his or her accumulated but unused contributions without interest. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Restrictions on Transfer
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rights granted under the Amended 2014 ESPP are not transferable except by will, the laws of descent and distribution, or,
if permitted by us, by a beneficiary designation. During the lifetime of the participant, such rights may only be exercised by the participant. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Changes in Capitalization </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the event of certain changes in our
capitalization, the Plan Administrator will appropriately and proportionately adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the Amended 2014 ESPP; (ii)&nbsp;the class(es) and number of securities subject to, and the
purchase price applicable to outstanding offerings and purchase rights; and (iii)&nbsp;the class(es) and number of securities that are the subject of the purchase limits under each ongoing offering. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Effect of Certain Corporate Transactions </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In the event of a corporate transaction (as defined in the Amended 2014 ESPP and described below), each outstanding purchase right under the Amended 2014 ESPP will be assumed or continued or a similar
right will be substituted for such purchase right by the surviving or acquiring corporation (or its parent or subsidiary), unless the Plan Administrator determines to shorten any offering periods then in progress by setting a new purchase date prior
to the corporate transaction. If the Plan Administrator sets such a new purchase date, then the Plan Administrator will notify each participant in writing at least 10 business days prior to the new purchase date that the purchase date for the
participant&#146;s outstanding purchase rights has been changed to such new purchase date and that either: (i)&nbsp;the participant&#146;s outstanding purchase rights will be exercised automatically on such new purchase date, unless the participant
withdraws from the applicable offering prior to such new purchase date, and such purchase rights will terminate immediately after such exercise; or (ii)&nbsp;in lieu of such exercise, we will pay to the participant on such new purchase date an
amount in cash, cash equivalents, or property as determined by the Plan Administrator that is equal to the difference in the fair market value of the shares of common stock subject to the participant&#146;s outstanding purchase rights on such new
purchase date and the applicable exercise price due had such purchase rights been exercised automatically on such new purchase date, and such purchase rights will terminate immediately after such payment. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of the Amended 2014 ESPP, a corporate transaction generally will be deemed to occur in the event of the consummation of:
(i)&nbsp;a merger or consolidation in which we are not the surviving entity, except for a transaction the principal purpose of which is to change the state in which we are incorporated; (ii)&nbsp;the sale, transfer or other disposition of all or
substantially all of our assets (including the capital stock of our subsidiary corporations); (iii)&nbsp;our complete liquidation or dissolution; (iv)&nbsp;any reverse merger or series of related transactions culminating in a reverse merger
(including, but not limited to, a tender offer followed by a reverse merger) in which we are the surviving entity but in which securities possessing more than 40% of the total combined voting power of our outstanding securities are transferred to a
person or persons different from those who held such securities immediately prior to such merger or the initial transaction culminating in such merger but excluding any such transaction or series of related transactions that the Plan Administrator
determines will not be a corporate transaction; or (v)&nbsp;acquisition in a single or series of related transactions by any person or related group of persons (other than us or by an employee benefit plan sponsored by us) of beneficial ownership of
securities possessing more than 50% of the total combined voting power of our outstanding securities but excluding any such transaction or series of related transactions that the Plan Administrator determines will not be a corporate transaction.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">28 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Duration, Amendment and Termination </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board (or a committee of one or more directors delegated by the Board) may amend, suspend or terminate the Amended 2014 ESPP at any
time. However, except in regard to certain capitalization adjustments, any amendment must be approved by our stockholders if such approval is required by applicable law or listing requirements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any outstanding purchase rights granted before an amendment, suspension or termination of the Amended 2014 ESPP will not be materially
impaired by any such amendment, suspension or termination, except (i)&nbsp;with the consent of the employee to whom such purchase rights were granted, (ii)&nbsp;as necessary to comply with any laws, listing requirements or governmental regulations
(including Section&nbsp;423 of the Code), or (iii)&nbsp;as necessary to obtain or maintain favorable tax, listing or regulatory treatment. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Federal Income Tax Information </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following is a summary of the principal
United States federal income taxation consequences to participants and us with respect to participation in the Amended 2014 ESPP. This summary is not intended to be exhaustive and does not discuss the income tax laws of any local, state or foreign
jurisdiction in which a participant may reside. The information is based upon current federal income tax rules and therefore is subject to change when those rules change. Because the tax consequences to any participant may depend on his or her
particular situation, each participant should consult the participant&#146;s tax adviser regarding the federal, state, local, and other tax consequences of the grant or exercise of an option or the disposition of common stock acquired under the
Amended 2014 ESPP. The Amended 2014 ESPP is not qualified under the provisions of Section&nbsp;401(a) of the Code and is not subject to any of the provisions of the Employee Retirement Income Security Act of 1974, as amended. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Rights granted under the Amended 2014 ESPP are intended to qualify for favorable federal income tax treatment associated with rights
granted under an employee stock purchase plan which qualifies under the provisions of Section&nbsp;423 of the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">A
participant will be taxed on amounts withheld for the purchase of shares of our common stock as if such amounts were actually received. Otherwise, no income will be taxable to a participant as a result of the granting or exercise of a purchase right
until a sale or other disposition of the acquired shares. The taxation upon such sale or other disposition will depend upon the holding period of the acquired shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">If the shares are sold or otherwise disposed of more than two years after the beginning of the offering period and more than one year after the shares are transferred to the participant, then the lesser
of the following will be treated as ordinary income: (i)&nbsp;the excess of the fair market value of the shares at the time of such sale or other disposition over the purchase price; or (ii)&nbsp;the excess of the fair market value of the shares as
of the beginning of the offering period over the purchase price (determined as of the beginning of the offering period). Any further gain or any loss will be taxed as a long-term capital gain or loss. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the shares are sold or otherwise disposed of before the expiration of either of the holding periods described above, then the excess
of the fair market value of the shares on the purchase date over the purchase price will be treated as ordinary income at the time of such sale or other disposition. The balance of any gain will be treated as capital gain. Even if the shares are
later sold or otherwise disposed of for less than their fair market value on the purchase date, the same amount of ordinary income is attributed to the participant, and a capital loss is recognized equal to the difference between the sales price and
the fair market value of the shares on such purchase date. Any capital gain or loss will be short-term or long-term, depending on how long the shares have been held. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">There are no federal income tax consequences to us by reason of the grant or exercise of rights under the Amended 2014 ESPP. We are entitled to a deduction to the extent amounts are taxed as ordinary
income to a participant for shares sold or otherwise disposed of before the expiration of the holding periods described above (subject to the requirement of reasonableness and the satisfaction of tax reporting obligations). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">29 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Plan Benefits under 2014 ESPP </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth, for each of the individuals and various groups indicated, the total number of shares of our common stock
that have been purchased under the 2014 ESPP as of April&nbsp;9, 2018. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2014 ESPP </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:64pt ; display:inline;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">CEO and Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Chief Financial Officer and Chief Business Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President and Chief Scientific Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory
Affairs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Operations and Quality</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,171</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All current executive officers as a group</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,171</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All current directors who are not executive officers as a group</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each nominee for election as a director:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnold L. Oronsky, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Francis R. Cano, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peggy V. Phillips</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each associate of any executive officers, current directors or director nominees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each other person who received or is to receive 5% of purchase rights</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All employees, including all current officers who are not executive officers, as a group</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">208,390</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>New Plan Benefits under Amended 2014 ESPP </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Participation in the Amended 2014 ESPP is voluntary and each eligible employee will make his or her own decision regarding whether and to
what extent to participate in the Amended 2014 ESPP. In addition, we have not approved any grants of purchase rights that are conditioned on stockholder approval of this Proposal 3. Accordingly, we cannot determine the benefits or amounts that will
be received in the future by individual employees or groups of employees under the Amended 2014 ESPP. Our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors will not be eligible to participate in the Amended 2014 ESPP. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Vote Required </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The
affirmative vote of the holders of a majority of shares present (either in person or by proxy) and cast at the Annual Meeting (i.e., representing the majority voting power) will be required to approve this Proposal&nbsp;3. Abstentions will be
counted toward the tabulation of votes cast on proposals presented to the stockholders and will have the same effect as negative votes. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are counted towards a quorum but are not counted for any
purpose in determining whether this Proposal 3 has been approved. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL>
D<SMALL>IRECTORS</SMALL> R<SMALL>ECOMMENDS</SMALL> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A V<SMALL>OTE</SMALL> I<SMALL>N</SMALL> F<SMALL>AVOR</SMALL>
O<SMALL>F</SMALL> P<SMALL>ROPOSAL</SMALL> 3. </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">30 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROPOSAL 4 </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>ADVISORY VOTE ON EXECUTIVE COMPENSATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In accordance with SEC rules, Dynavax stockholders are being asked to approve, on an advisory basis, the compensation of our named executive officers as disclosed in this proxy statement, which is
commonly referred to as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay</FONT></FONT> vote.&#148; This vote is not intended to address any specific item of compensation, but rather the overall compensation of our
named executive officers, which results from our compensation philosophy, policies and practices as discussed in this proxy statement. The compensation of our named executive officers subject to the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">say-on-pay</FONT></FONT> vote is described in the Compensation Discussion and Analysis, the accompanying tables, and the related narrative disclosure contained in this proxy statement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Compensation Committee is responsible for designing and administering our executive compensation programs. Our Compensation Committee
firmly believes that Dynavax&#146;s executive compensation programs should reward our named executive officers for performance, and that when key performance objectives are not achieved, the compensation of our named executive officers should
reflect as much. We believe that the compensation of our named executive officers, as disclosed in this proxy, reflects this philosophy. In addition, our Compensation Committee believes that the compensation programs for our named executive officers
have been instrumental in helping Dynavax be able to attract, retain and motivate our executive team, thereby enabling our Company to be in a position to move forward with our business strategy. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board of Directors is now asking our stockholders to indicate their support for the compensation of our named executive officers as
described in this proxy statement by casting a <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory vote &#147;For&#148; the following resolution: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;RESOLVED, that the compensation paid to Dynavax&#146;s named executive officers, as disclosed pursuant to Item&nbsp;402 of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> including the
Compensation Discussion and Analysis, compensation tables and narrative discussion, is hereby APPROVED.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Although this
vote is advisory and the outcome is not binding on our Board of Directors, the views expressed by our stockholders, whether through this vote or otherwise, are important to us. As a result, the Board of Directors and the Compensation Committee will
carefully review the results of this vote, and they will consider these results in making future decisions about our executive compensation programs and arrangements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Unless our Board of Directors modifies its policy on the frequency of future advisory votes on the compensation of our named executive officers, the next advisory vote on the compensation of our named
executive officers will be held at the 2019 annual meeting of stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Approval of this advisory proposal requires the
affirmative vote of the holders of a majority of shares present (either in person or by proxy) and cast at the Annual Meeting (i.e., representing the majority voting power). Abstentions will be counted toward the tabulation of votes cast on
proposals presented to the stockholders and will have the same effect as negative votes. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are counted towards a quorum but are not counted for any purpose in determining whether this Proposal 4
has been approved. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL>
R<SMALL>ECOMMENDS</SMALL> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A V<SMALL>OTE</SMALL> I<SMALL>N</SMALL> F<SMALL>AVOR</SMALL> O<SMALL>F</SMALL>
P<SMALL>ROPOSAL</SMALL> 4. </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">31 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROPOSAL 5 </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>RATIFICATION OF SELECTION OF </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee has
selected Ernst&nbsp;&amp; Young LLP, or Ernst&nbsp;&amp; Young, as our independent registered public accounting firm for the fiscal year ending December&nbsp;31, 2018. Ernst&nbsp;&amp; Young has audited our financial statements since 2002.
Representatives of Ernst&nbsp;&amp; Young are expected to be present at the Annual Meeting. Ernst&nbsp;&amp; Young will have an opportunity to make a statement if it so desires and will be available to respond to appropriate questions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If the stockholders fail to ratify the selection of Ernst&nbsp;&amp; Young, the Audit Committee will reconsider whether or not to retain
that firm. Even if the selection is ratified, the Audit Committee in its discretion may direct the appointment of a different independent registered public accounting firm at any time during the year if it determines that such a change would be in
the best interests of the Company and its stockholders. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The affirmative vote of the holders of a majority of the shares
present (either in person or by proxy) and cast at the Annual Meeting (i.e., representing the majority voting power) will be required to ratify the selection of Ernst&nbsp;&amp; Young. Abstentions will be counted toward the tabulation of votes cast
on proposals presented to the stockholders and will have the same effect as negative votes. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are counted towards a quorum but are not counted for any purpose in determining whether this matter
has been approved; however, Proposal 5 is considered a &#147;routine&#148; matter, and therefore no broker <FONT STYLE="white-space:nowrap">non-votes</FONT> are expected to exist in connection with this Proposal 5. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> R<SMALL>ECOMMENDS</SMALL> </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A V<SMALL>OTE</SMALL> I<SMALL>N</SMALL> F<SMALL>AVOR</SMALL> O<SMALL>F</SMALL> P<SMALL>ROPOSAL</SMALL> 5. </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>UDIT</SMALL> F<SMALL>EES</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with the audit of our 2017 financial statements, we entered into an engagement agreement with Ernst&nbsp;&amp; Young which sets forth the terms by which Ernst&nbsp;&amp; Young will perform
audit services for us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table represents aggregate fees billed to the Company for the fiscal years ended
December&nbsp;31, 2017 and 2016 by Ernst&nbsp;&amp; Young, our principal auditors. The Audit Committee <FONT STYLE="white-space:nowrap">pre-approved</FONT> all service fees described below. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fiscal Year Ended</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2017</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2016</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit Fees</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,203,801</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,300,804</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Audit Related Fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tax Fees</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All Other Fees</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,995</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,995</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Fees</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,246,296</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,302,799</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Audit fees include fees for the audit of our consolidated financial statements and interim reviews of our quarterly financial statements, including
compliance with the provisions of Section&nbsp;404 of the Sarbanes-Oxley Act as well as fees related to registration statements, consents and other services related to SEC matters. In each of 2016 and 2017, audit fees included fees related to a
comfort letter in connection with an equity offering. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Tax fees include Section&nbsp;382 study. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">All other fees represent subscription fees for an online accounting research tool and related database. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">32 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>RE</SMALL>-<SMALL>APPROVAL</SMALL> P<SMALL>OLICIES</SMALL> A<SMALL>ND</SMALL>
P<SMALL>ROCEDURES</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Audit Committee has adopted a policy and procedures for the
<FONT STYLE="white-space:nowrap">pre-approval</FONT> of audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services rendered by our independent registered public accounting firm, Ernst&nbsp;&amp; Young. Under the policy, the Audit Committee
<FONT STYLE="white-space:nowrap">pre-approves</FONT> specified services in the defined categories of audit services, audit-related services, tax services and all other services up to specified amounts.
<FONT STYLE="white-space:nowrap">Pre-approval</FONT> may be given as part of the Audit Committee&#146;s approval of the scope of the engagement of the independent registered public accounting firm or on an interim basis by the Audit Committee Chair,
as needed and on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">case-by-case</FONT></FONT> basis before the independent registered public accounting firm is engaged to provide each service. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee has determined that services rendered by Ernst&nbsp;&amp; Young are compatible with maintaining the principal
auditors&#146; independence. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">33 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXECUTIVE OFFICERS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth certain information with respect to our executive officers as of April&nbsp;9, 2018: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="54%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt ; display:inline;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Age</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:27pt ; display:inline;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Position</B></FONT></P></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">59</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Executive Officer and Director</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">66</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Chief Financial Officer and Chief Business Officer</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">71</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President and Chief Scientific Officer</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">64</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">56</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Vice President, Operations and Quality</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Please see &#147;Class&nbsp;I Directors Continuing In Office Until the 2019 Annual Meeting&#148; in this proxy statement for more information about
Mr.&nbsp;Gray. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Michael S. Ostrach &#150; Senior Vice President, Chief Financial Officer and Chief Business Officer
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Ostrach is our Senior Vice President, Chief Financial Officer and Chief Business Officer. Mr.&nbsp;Ostrach joined
Dynavax in October 2006 as Vice President, Chief Business Officer and General Counsel, and became Principal Financial Officer in September 2013, Chief Financial Officer in March 2015 and Senior Vice President in February 2016. Mr.&nbsp;Ostrach held
the position of Dynavax&#146;s General Counsel from October 2006 to September 2015. From 2005 to 2006, he was Chief Operating Officer, Chief Financial Officer and General Counsel at Threshold Pharmaceuticals. From 1997 to 2004, Mr.&nbsp;Ostrach was
at Kosan Biosciences, most recently as President and Chief Operating Officer. Mr.&nbsp;Ostrach began his corporate career at Cetus Corporation, where he served in several capacities between 1981 and 1991, initially as General Counsel and finally as
Senior Vice President of Corporate Affairs and General Counsel. Following the acquisition of Cetus by Chiron Corporation in 1991, Mr.&nbsp;Ostrach became President of Chiron Technologies. He holds a B.A. from Brown University and a J.D. from
Stanford Law School. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Robert L. Coffman, Ph.D. &#150; Senior Vice President and Chief Scientific Officer </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Coffman was appointed Senior Vice President and Chief Scientific Officer of Dynavax in February 2014, and prior to that he was
Vice President and Chief Scientific Officer of Dynavax since December 2000. Prior to joining Dynavax in 2000, Dr.&nbsp;Coffman was a founding member of the DNAX Research Institute in Palo Alto, California. Dr.&nbsp;Coffman has authored over 200
scientific publications, is a member of the National Academy of Sciences and the American Academy of Microbiology, and has received a number of prestigious awards for his work. With colleague Dr.&nbsp;Tim Mosmann, he defined the two principal
subtypes of helper T cells, termed Th1 and Th2 cells, and demonstrated the central relationship between their differences in cytokine expression and function. Dr.&nbsp;Coffman defined basic mechanisms of
<FONT STYLE="white-space:nowrap">T-cell</FONT> regulation in asthma and infectious and parasitic diseases, and demonstrated the central role of regulatory CD4+ T cells in preventing inflammatory bowel disease. At Dynavax, Dr.&nbsp;Coffman has
pioneered the development of agonists and antagonists for Toll-Like Receptors (&#147;TLRs&#148;), key recognition receptors in innate immunity. Dr.&nbsp;Coffman received an A.B. in Microbiology from Indiana University and a Ph.D. in Immunology from
the University of California, San Diego. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Robert Janssen, M.D. &#150; Chief Medical Officer and Senior Vice President, Clinical
Development, Medical and Regulatory Affairs </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Janssen was appointed Chief Medical Officer and Senior Vice
President, Clinical Development, Medical and Regulatory Affairs in January 2018. Dr.&nbsp;Janssen was appointed Chief Medical Officer and Vice President, Clinical Development and Regulatory Affairs in July 2013. He served as Dynavax&#146;s Vice
President, Medical Affairs since November 2012 and was previously Senior Director, Clinical Development at Dynavax from 2010 through 2012, during which time he was extensively involved with Phase 3 clinical development of <FONT
STYLE="white-space:nowrap">HEPLISAV-B</FONT> and its </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">34 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
U.S. and European licensing applications. Prior to joining Dynavax, Dr.&nbsp;Janssen was Vice President, Medical Affairs at Gilead from 2008 to 2010 where he was responsible for oversight of
physician and health care provider education focused on HIV and hepatitis B therapies. Until 2008, Dr.&nbsp;Janssen spent 23 years at the U.S. Centers for Disease Control and Prevention (&#147;CDC&#148;), most recently as the Director of the
Division of HIV/AIDS Prevention from 2000 to 2008. Under his leadership, the CDC first explored HIV treatment as a mode of HIV prevention and launched several of the earliest Phase 3 trials of <FONT STYLE="white-space:nowrap">pre-exposure</FONT>
prophylaxis for HIV. Dr.&nbsp;Janssen received a Bachelor of Arts degree with Honors in Humanities from Stanford University and his M.D. degree from the University of Southern California. He is a neurologist with training in virology received at the
University of Pennsylvania. Dr.&nbsp;Janssen has been the beneficiary of numerous honors and awards during his career. He has published over 130 scientific articles in a variety of journals and has served as a reviewer for leading scientific
journals. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>David F. Novack &#150; Senior Vice President, Operations and Quality </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Novack joined Dynavax in March 2013 as Senior Vice President, Operations and Quality. Mr.&nbsp;Novack was formerly with Novartis
Vaccines&nbsp;&amp; Diagnostics where he served since 2009 as the Global Head of Technical Operations and Supply Chain for Diagnostics and previously from 2007 to 2009 as the Global Head of Vaccine Manufacturing Strategy. Prior to Novartis,
Mr.&nbsp;Novack was the Vice President, Business Development for Vaxin, Inc., a vaccine company, from 2004 to 2006. From 1993 until 2004, Mr.&nbsp;Novack worked at MedImmune, formerly Aviron, serving in several capacities including business
development, manufacturing, contract operations and most recently as Senior Director, Supply Chain Operations. Previously, from 1989 to 1993, Mr.&nbsp;Novack was with American Cyanamid Company in various roles. Mr.&nbsp;Novack received a B.S. in
Biology from State University of New York and an M.B.A. from Columbia University. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>OMPENSATION</SMALL>
D<SMALL>ISCUSSION</SMALL> A<SMALL>ND</SMALL> A<SMALL>NALYSIS</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Compensation Discussion and Analysis discusses our executive compensation philosophy and practices and provides an overview of the
Compensation Committee&#146;s 2017 decisions for the following named executive officers (&#147;NEOs&#148;) whose compensation is set forth in the Summary Compensation Table and other related tables contained in this proxy statement: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray, Chief Executive Officer and Director; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach, Senior Vice President, Chief Financial Officer and Chief Business Officer; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D., Senior Vice President and Chief Scientific Officer; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D., Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack, Senior Vice President, Operations and Quality. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We present this Compensation Discussion and Analysis in the following sections: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.</B><I>&#8195;&#8201;Executive Summary</I>.&nbsp;&nbsp;&nbsp;&nbsp;Provides an overview of our 2017 and early 2018 corporate
performance, certain governance aspects of our executive compensation program and the Compensation Committee&#146;s response to stockholder feedback.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">p.&nbsp;36</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.</B><I>&#8195;&#8201;Executive Compensation Program</I>.&nbsp;&nbsp;&nbsp;&nbsp;Describes the Company&#146;s executive
compensation philosophy and process and the material elements of our executive compensation program.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">p.&nbsp;38</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.</B><I>&#8195;&#8201;2017 Executive Compensation Decisions</I>.&nbsp;&nbsp;&nbsp;&nbsp;Provides a synopsis of the
Compensation Committee&#146;s executive compensation decisions for 2017 and certain actions taken before or after 2017 when doing so enhances the understanding of our executive compensation program.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">p.&nbsp;43</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.</B><I>&#8195;&#8201;Other Executive Compensation Matters</I>.&nbsp;&nbsp;&nbsp;&nbsp;Reviews the accounting and tax
treatment of compensation and the relationship between our compensation program and risk.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">p.&nbsp;50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">35 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Executive Summary </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Business Overview, Corporate Developments in 2017 and Early 2018 and Relationship to Executive Compensation </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">We are now a fully-integrated biopharmaceutical company focused on leveraging the power of the body&#146;s innate and
adaptive immune responses through toll-like receptor (&#147;TLR&#148;) stimulation. Our first commercial product,
<FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT><B><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></B> (Hepatitis B Vaccine (Recombinant), Adjuvanted), was approved by the United States Food and Drug Administration
(&#147;FDA&#148;) in November 2017 for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.&nbsp;We commenced commercial shipments of <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> in
January 2018. Our development efforts are primarily focused on stimulating the innate immune response to treat cancer in combination with other immunomodulatory agents. Our&nbsp;lead investigational immuno-oncology products are <FONT
STYLE="white-space:nowrap">SD-101,</FONT> currently being evaluated in Phase 2 clinical studies, and DV281, in a Phase 1 safety study. Given the nature of our Company, we believe delivery of long term value to our stockholders is the best measure of
our performance. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Heading into 2017, we had diversified our portfolio such that our focus for the year was balanced between
obtaining FDA approval of <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> and advancing our oncology program. As a result of this diversification, we viewed our success in 2017 and beyond as being based on our progress regarding <FONT
STYLE="white-space:nowrap">HEPLISAV-B</FONT> and our oncology program. Thus, we designed our 2017 executive compensation program to reward achievement of the specific related objectives we believed would advance our business strategy and create
long-term value for our stockholders. In particular, our 2017 annual incentive program was aligned with our corporate objectives by selecting corporate goals as follows: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Commercialization goals for <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> were weighted at 35%, </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Objectives specific to advancing our oncology pipeline were weighted at 55%, and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Business plan goals that supported advancing our business and portfolio strategies were weighted at 10%. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our NEOs were focused on executing our business strategy of transforming the Company into a commercial organization by obtaining FDA
approval of <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> and successfully launching it, advancing a robust pipeline of immuno-oncology clinical stage development programs and discovering other cutting edge
<FONT STYLE="white-space:nowrap">TLR-based</FONT> vaccines and immunotherapies. The positive developments in late 2016 regarding oncology coupled with the receipt of a Complete Response Letter (&#147;CRL&#148;) from the FDA regarding <FONT
STYLE="white-space:nowrap">HEPLISAV-B</FONT> led us to reshape our business strategy in early 2017 to place greater emphasis on advancing our immuno-oncology program, while maintaining sufficient resources to advance
<FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> toward FDA approval in 2017. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">2017 was a year of many positives for our
Company, including our achievement of FDA approval of <FONT STYLE="white-space:nowrap">HEPLISAV-B,</FONT> successful delivery of the corporate goals related to advancing our oncology programs and the achievement of the business plan goals that
supported advancing our business and portfolio strategies. Key events that took place for our Company in 2017 are reflected below: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;5, 2017, we announced that we were reshaping our strategy and operations to prioritize our emerging clinical and preclinical
immuno-oncology portfolio. We implemented significant organizational restructuring and cost reductions to align around our immuno-oncology business, while allowing us to advance <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> through the FDA
review process and an approval decision. To achieve these savings, we suspended manufacturing for <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> and reduced our global workforce by 38%, which resulted in approximately a 40% reduction in cash
burn. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;28, 2017, we announced that the FDA had accepted for review our responses to the CRL issued in November 2016 for the Biologics License
Application (&#147;BLA&#148;) for <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> and that the FDA had established August&nbsp;10, 2017 as the Prescription Drug User Fee Act (&#147;PDUFA&#148;) action date. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;6, 2017, we announced encouraging data in patients with metastatic melanoma in the dose escalation phase of an ongoing Phase 1b/2 study
investigating <FONT STYLE="white-space:nowrap">SD-101,</FONT> our intratumoral TLR9 agonist, in combination with
Keytruda<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (pembrolizumab), Merck&#146;s
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> treatment. The data was presented at the International Congress on Targeted Anticancer Therapies. Results evaluating 17 patients for efficacy and 22 patients
for safety were reported. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">36 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">On March&nbsp;20, 2017, we announced upcoming data presentations on the following three programs based on stimulation of the immune response using TLR9
agonists at the 2017&nbsp;American Association for Cancer Research&nbsp;Annual Meeting: (i)&nbsp;pharmacodynamic changes confirm the mechanism of action mediating <FONT STYLE="white-space:nowrap">SD-101</FONT> efficacy, in combination with
pembrolizumab, in a phase 1b/2 study in metastatic melanoma, (ii)&nbsp;development of an inhaled TLR9 agonist for the immunotherapy of lung cancer and (iii)&nbsp;intratumoral administration of a TLR9-adjuvanted nanoparticle cancer vaccine stimulates
more effective immunity in both injected and <FONT STYLE="white-space:nowrap">un-injected</FONT> tumor sites compared to subcutaneous administration. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">On April&nbsp;3, 2017, we announced that the FDA had informed the Company that the Vaccines and Related Biological Products Advisory Committee
(&#147;VRBPAC&#148;) would review <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> at its meeting scheduled for July&nbsp;28, 2017. The PDUFA date remained unchanged. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">On June&nbsp;2, 2017, we announced the presentation of updated findings in patients with metastatic melanoma in the dose escalation phase of the
ongoing Phase 1b/2 study <FONT STYLE="white-space:nowrap">investigating&nbsp;SD-101</FONT> in combination with
Keytruda<FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> (pembrolizumab). The data was presented at the 2017 American Society of Clinical Oncology Annual
Meeting. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">On July&nbsp;28, 2017, we announced that the VRBPAC voted 12 to 1 that the safety data for <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> supports
licensure for immunization against hepatitis B infection in adults 18 years of age and older. Three members of the panel abstained. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;3, 2017, we announced that the FDA had requested more detailed information about our proposed post-marketing study for <FONT
STYLE="white-space:nowrap">HEPLISAV-B</FONT> based on feedback received from the VRBPAC. The response to the information request triggered a major amendment to the BLA. The PDUFA date was updated and expected to be no later than November&nbsp;10,
2017. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;15, 2017, we announced completion of an underwritten public offering of 5,750,000 shares of our common stock for net proceeds of
approximately $80.8&nbsp;million. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">On October&nbsp;19, 2017, we announced initiation of dosing in a phase 1B dose escalation clinical trial of our investigational inhaled TLR9 agonist,
DV281, in patients with <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">On November&nbsp;9, 2017, we announced that the FDA approved <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> for prevention of infection caused by
all known subtypes of hepatitis B virus in adults&#146; age 18 years and older. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">On January&nbsp;8, 2018, we announced <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> is now available in the United States for the prevention of
hepatitis B in adults. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">From January&nbsp;3, 2017 to January&nbsp;8, 2018, our closing stock price rose from $4.05 to $17.80. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on the decisions in early 2017 to restructure the Company and to not pay NEOs their 2016 annual cash incentive bonuses as well as
not increase their base salaries, it was imperative to stabilize the business by retaining key talent, including our NEOs. Our Compensation Committee determined it was necessary to grant retention equity awards to maintain employee and management
continuity while refocusing our strategic activities to prioritize our emerging clinical and preclinical immuno-oncology portfolio while still allowing us to advance <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> through the FDA review process
and an approval decision. The provision of retention grants was consistent with feedback we received from stockholders during our outreach efforts regarding the importance of retaining key talent to support the long term success of the Company. To
that end, in February 2017, the Compensation Committee determined that it was appropriate to approve special retention grants for certain employees, including our NEOs. The retention grants vest over two years, to link vesting with individuals&#146;
leadership through a critical and transitional <FONT STYLE="white-space:nowrap">two-year</FONT> period for the Company. We view the retention grants to NEOs as an exceptional event to meet the needs of our transition and path forward as a business.
We continue to carefully evaluate our compensation arrangements to move our Company forward and ensure that our pay program aligns our executives&#146; compensation with our stockholders&#146; interests and our Company performance. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">37 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation Governance Highlights </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="44%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:40pt ; display:inline;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>What we do</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:64pt ; display:inline;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>What we do not do</B></FONT></P></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#9746;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Design executive compensation program to align pay with performance</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#9746;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No excessive change in control or severance payments (no cash severance multiplier greater than 2x base + target bonus)</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#9746;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Majority of pay is variable and not guaranteed (over 80% for our CEO in 2017)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#9746;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No repricing of underwater stock options without stockholder approval</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#9746;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Prohibit hedging and discourage pledging by executive officers and directors (no pledging in 2017)</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#9746;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No tax <FONT STYLE="white-space:nowrap">gross-ups</FONT></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#9746;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Grant equity awards with performance-based vesting</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#9746;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No perquisites</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#9746;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Conduct an annual <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> vote</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#9746;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">No guaranteed bonuses</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#9746;</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Seek input from, listen to and respond to stockholders</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Consideration of Our Prior <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Say-on-Pay</FONT></FONT>
Votes and Related Stockholder Engagement </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We held our first stockholder advisory vote on executive compensation, commonly
referred to as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;say-on-pay</FONT></FONT> vote,&#148; at our 2011 stockholder annual meeting. At that meeting, over 99% of the shares that were voted on this proposal were cast
in favor of our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> proposal. At that time, our stockholders also voted in favor of holding a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> vote once every three years and subsequently, our Board adopted a policy consistent with that preference. Accordingly, we held our second <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> vote at our 2014 stockholder annual meeting and at that meeting, over 64% of the shares that were voted on this proposal were cast in favor of our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> proposal. In the absence of a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> vote in 2015, we received feedback from our
stockholders on our executive compensation program in connection with the reelection of our Compensation Committee members, who each received support from approximately 69% of the shares cast. In February 2016, as part of a number of corporate
governance improvements made in response to feedback from our stockholders and the proxy advisory firms, our Board of Directors adopted a policy changing the frequency of our
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> vote from once every three years to every year and therefore we held a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> vote at our 2016 stockholder annual meeting and at that meeting, over 70% of the shares that were voted on this proposal were cast in favor of our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> proposal. Most recently, we held a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> vote at our 2017 stockholder annual
meeting and at that meeting, over 86% of the shares that were voted on this proposal were cast in favor of our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">say-on-pay</FONT></FONT> proposal. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Because of its importance, we continue to solicit feedback from our stockholders regarding our executive compensation program as part of
our stockholder outreach. We consider the stockholder feedback process as being a year round activity. Thus, we obtained feedback from our stockholders in the spring of 2017, and will do so again in 2018, having already received feedback from
several stockholders in 2018. As part of our annual stockholder feedback program, we contacted 17 of our largest stockholders in early spring 2018, and we spoke with 100% of the stockholders that wanted to provide us with feedback at that time.
During these discussions we solicited feedback from our stockholders on our corporate governance and executive compensation practices. None of our stockholders expressed any concerns about our corporate governance or executive compensation
practices. The bulk of the stockholders, while appreciating the outreach, did not feel a need to talk at the time. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Executive
Compensation Program </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Philosophy and Objectives </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We believe our NEOs&#146; compensation should align our executives&#146; success with that of our stockholders over the long-term through achievement of strategic corporate objectives that are fundamental
to our business model and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">38 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
that will create long-term stockholder value. Our executive compensation programs are designed to be competitive with our peer group to enable us to attract, motivate, reward, and retain
outstanding talent. Our compensation programs are based on the following key principles: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">A significant component of pay is linked with performance and the achievement of our strategic goals. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Alignment of our executives&#146; interests with those of our stockholders through equity compensation. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Overall compensation that is competitive in the industry in which we compete for executive talent. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Recognition of individual contributions, teamwork and corporate performance. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation-Setting Process </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:6%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Role of the Compensation Committee and Management </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation
Committee oversees and administers our executive compensation programs. The Compensation Committee acts pursuant to a charter adopted by our Board, which can be found at our website, <U>www.dynavax.com</U>. The Compensation Committee generally
determines the compensation to be paid to the executive officers, including our NEOs. Either the compensation committee or the independent members of our Board, upon recommendation from the Compensation Committee, approve certain compensation of our
CEO, and references in this Compensation Discussion and Analysis to our Board approving our CEO&#146;s compensation refer to the independent members of our Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee (and the Board of Directors, with respect to our CEO)&nbsp;approves our corporate goals and the individual goals of our NEOs after considering the Company&#146;s recommendations
on these matters. The Compensation Committee annually reviews the base salaries, cash incentives and equity compensation of our NEOs and periodically reviews other elements of our compensation. Compensation decisions are based primarily on the
following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Peer and Industry Data</I> &#150; The Compensation Committee uses peer and industry data provided by its consultant, Arnosti Consulting Inc.
(&#147;Arnosti&#148;), as a reference in setting base salaries and target cash compensation, determining appropriate levels and mix of equity compensation and determining the type and portion of compensation tied to performance goals.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Annual Performance Reviews</I> &#150; The Chair of the Compensation Committee conducts annual performance reviews of our CEO taking into
consideration feedback obtained during the course of the year from the independent members of our Board and the CEO&#146;s direct reports. Our CEO conducts and presents the performance reviews of the other NEOs to the Compensation Committee after
the end of each fiscal year. In reviewing and determining the compensation of each NEO, the Compensation Committee also considers individual factors, such as: potential for future contributions to Company growth, industry experience and retention
concerns. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>CEO Recommendations</I> &#150; The Compensation Committee seeks input from our CEO for setting the salary and target cash compensation levels for
the other NEOs, and also for purposes of setting annual performance metrics and target amounts under the Annual Incentive Program. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:6%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I>Role of Compensation Consultant </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnosti was engaged by the Compensation
Committee in 2010 as its independent compensation consultant. Since then, the Compensation Committee has met regularly with Arnosti, both with and without management present, depending upon the topic being discussed. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">39 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2017 and again in January 2018, the Compensation Committee reviewed whether
the work of Arnosti as a compensation consultant raised any conflict of interest, taking into consideration the following factors: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The provision of other services to the Company; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The amount of fees paid to Arnosti by the Company; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnosti&#146;s policies and procedures that are designed to prevent conflicts of interest; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any business or personal relationship of Arnosti or the individual compensation advisors employed by Arnosti with an executive officer of the Company;
and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Any Company stock owned by Arnosti or the individual compensation advisors employed by Arnosti. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on the Compensation Committee&#146;s review of this information, it determined the work of Arnosti and the individual compensation
advisors employed by Arnosti as compensation consultant to the Compensation Committee, did not create any conflict of interest. The Compensation Committee has the sole authority to direct, terminate or continue Arnosti&#146;s services, although the
Company pays the cost for Arnosti&#146;s services. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In 2017, Arnosti provided advice to the Compensation Committee on several
different aspects of its responsibilities related to our compensation programs and practices. Specifically, during 2017, Arnosti assisted the Compensation Committee as follows: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provided analyses and recommendation for NEO and VP retention; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reviewed and analyzed compensation levels of our NEOs in comparison to those of our peer companies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provided general information concerning executive compensation trends and developments; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provided recommendations to the Compensation Committee on refining our peer group; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provided an assessment of the annual meeting voting results; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provided the Board with a review of competitive data from the peer group on Board compensation; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Reviewed the Compensation Discussion and Analysis for inclusion in our proxy statement. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2017 Peer Group </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our
Compensation Committee uses a peer group for a general understanding of market compensation practices and our positioning within the peer group. Our Compensation Committee believes that over-reliance on benchmarking could result in compensation that
is unrelated to the value delivered by the NEOs because compensation benchmarking does not take the specific performance of the NEOs, or the performance of the Company, into account. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Compensation Committee does not have a specific target compensation level for the NEOs or otherwise use a formulaic approach to
setting pay at a particular positioning within the market data; rather, the Compensation Committee reviews a range of market data reference points of the Company&#146;s peer group with respect to total target cash compensation (including both base
salary and the annual target performance bonus) and equity compensation (valued based on an approximation of grant date fair value and also considered as shares as a percentage of total common shares outstanding) to support its compensation
decisions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For 2017 compensation decisions, our Compensation Committee approved a peer group of biotechnology companies at a
similar stage of product development with which we compete for executive talent that were of similar size to the Company in terms of market capitalization, product portfolio, pipeline and number of employees. To align with our strategic plan, which
included commercialization of <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> and expansion of our pipeline with early clinical development in cancer immunotherapy, our peer group included companies that were: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">both oncology and <FONT STYLE="white-space:nowrap">non-oncology</FONT> focused, </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">companies that had their own manufacturing operations, and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">approximately 40% of the companies in our 2017 peer group were commercial (italicized in chart below) companies. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The change in our peer group from 2016 to 2017 included removing five companies for
various reasons including market caps that were out of range or that the company had been acquired. As of June 2016, which was shortly before the 2017 peer group was approved, the companies in the 2017 peer group had market capitalizations between
ranging from $206&nbsp;million to $2.443&nbsp;billion and the median market capitalization of our peer group was $755&nbsp;million. At that time, our market capitalization was $557&nbsp;million. The following lists our 2017 peer group. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV STYLE="position:relative;float:left; width:48%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aduro Biotech, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Ariad Pharmaceuticals Inc.</I> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Array Biopharma, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">BioCryst Pharmaceuticals, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Celldex Therapeutics, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clovis Oncology, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Depomed Inc.</I> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Eagle Pharmaceuticals, Inc.</I> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Emergent BioSolutions, Inc.</I> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Epizyme, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Exelixis, Inc.</I> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="34"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="19" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Heron Therapeutics, Inc.
</FONT></P></TD></TR></TABLE></DIV><DIV STYLE="position:relative;float:left; margin-left:3%; width:49%;padding-right:0%;padding-bottom:8pt;overflow:hidden;padding-top:3pt">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="20" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>ImmunoGen, Inc.</I> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="20" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Kite Pharma, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="20" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">MacroGenics, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="20" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Nektar Therapeutics </FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="20" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">NewLink Genetics Corporation </FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="20" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Novavax, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="20" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Puma Biotechnology, Inc. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="20" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Repligen Corporation</I> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="20" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Sarepta Therapeutics, Inc.</I> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="20" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Supernus Pharmaceuticals, Inc.</I> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:4px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="20" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">ZioPharm Oncology, Inc.
</FONT></P></TD></TR></TABLE></div><div style="clear:both; height:0px; font-size:0px">&nbsp;</div>
 <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Elements of Executive Compensation
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our executive team continues to manage a changing and increasingly complex business. We strive to recognize these efforts
by compensating our NEOs for the demands and risks associated with our business through three primary elements that are designed to reward performance in a simple and straightforward manner&#151;base salaries, annual performance-based cash
incentives and long-term equity awards. During our annual stockholder outreach, our key stockholders expressed support for the elements of our executive compensation program, including our continued use of stock options as one portion of long-term
equity awards and continuing to grant a portion of long-term equity awards with performance-based vesting. As reflected in the chart below, we responded to the feedback from our stockholders by introducing performance-based vesting for a portion of
our 2016 and 2017 long-term equity awards. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table below summarizes the purpose and key characteristics of each of our
compensation elements. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Element</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Purpose</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Key Characteristics</B></FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Base
Salary</B></FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provides a fixed level of compensation for performing the essential
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> elements of the job; gives executives a degree of certainty in light of having a majority of their compensation at risk.</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Fixed compensation that is reviewed annually and adjusted if and when appropriate;
reflects each NEO&#146;s performance, experience, skills, level of responsibility and the breadth, scope and complexity of the position as well as the competitive marketplace for executive talent specific to our industry.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Annual Incentive Program</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Motivates executive officers to achieve corporate and individual business goals, which we believe increase stockholder value, while providing
flexibility to respond to opportunities and changing market conditions.</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"> <P STYLE="margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Annual cash
incentive based on corporate and individual performance compared to <FONT STYLE="white-space:nowrap">pre-established</FONT> goals. Our CEO&#146;s incentive is based entirely on corporate
goals.</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">41 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Element</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Purpose</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Key Characteristics</B></FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Corporate goals focus on overarching objectives for the Company, while individual objectives
represent key performance expectations at the departmental or individual level.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.50em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Corporate goals are aligned with our business strategy and weighted by relative importance so that achievement can be objectively measured.</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Long-Term Equity Incentives (Stock
Options)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Motivates executive officers to achieve our business objectives by tying incentives to the appreciation of our common stock over the long
term.</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stock options with an exercise price equal to the fair market value on the date of grant
vesting over three years; the ultimate value realized, if any, depends on the appreciation of our common stock price and if our stock price does not appreciate, there is no value realized. In determining the aggregate size of equity grants in any
given year, the Compensation Committee generally considers the same factors described above under &#147;Base Salary&#148; as well as the criticality of the executive to the long-term achievement of corporate goals.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Long-Term Equity Incentives (RSUs)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Motivates executive officers to achieve our corporate objectives by tying compensation to the performance of our common stock over the long
term and/or the achievement of business and clinical development goals over the long term; motivates our executive officers to remain with the Company by mitigating swings in incentive values during periods when market volatility weighs on our stock
price.</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Restricted stock unit awards may vest based
on continued service over a specified period of time and/or achievement of performance goals; the ultimate value realized varies with our common stock price. In March 2017, 20% of our executive officers&#146; annual grants were performance-based
restricted stock unit awards vesting upon the Compensation Committee&#146;s certification of achievement of the following equally weighted <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals:</FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Initiate and complete
enrollment in melanoma dose expansion study;</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Initiate and complete 75% enrollment in squamous cell carcinoma of the head and neck (&#147;SCCHN&#148;) dose expansion study;</FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Submit and receive
approved DV281 IND and initiate enrollment in dose escalation; and</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.50em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Complete preclinical research support and selection of third agent for SD101 immunotherapy regimen.</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">42 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Element</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Purpose</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Key Characteristics</B></FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Compensation</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our executive officers participate in the same benefits offered to all other employees, which promote employee health and welfare and assist
in attracting and retaining our executive officers.</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Indirect compensation element consisting of programs such as medical, vision, dental, life
and accidental death, long-term care and disability insurance as well as a 401(k) plan with a Company matching contribution, and other plans and programs made available to all eligible employees.</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Severance and Change in Control Benefits</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">Serves our retention objectives by helping our named executive officers maintain continued focus and dedication to their responsibilities to
maximize stockholder value, including in the event of a transaction that could result in a change in control of our Company.</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Provides protection in the event of a termination of employment under specified
circumstances, including following a change in control of our Company as described below under &#147;Potential Payments Upon Change in Control or Involuntary Termination.&#148;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>2017 Executive Compensation Decisions </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Total Target Cash Compensation &#150; Base Salaries and Target Bonus Percentages </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">When determining 2017 base salary and target bonus percentage adjustments, the Compensation Committee considered each individual&#146;s performance and Company performance, each individual&#146;s industry
experience and tenure, internal pay equity, and retention concerns. The Compensation Committee also reviewed a range of market data reference points (the 10th, 25th, 50th, 60th, 75th and 90th percentiles of peer group data) with respect to total
target cash compensation (including both base salary and the annual target performance bonus). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee
(and the board of directors, with respect to our CEO) decided that for 2017 each NEO&#146;s base salary and target bonus percentage would remain the same as in 2016 as shown in the table below. In addition, the Compensation Committee (and the Board
of Directors, with respect to our CEO) decided that no bonuses would be paid to the NEOs in 2017 because <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> was not approved in 2016, notwithstanding multiple other individual and corporate goal
achievements. In determining NEO compensation, the Compensation Committee takes into account peer group data; each NEO&#146;s industry experience, expertise, and tenure with the Company; internal pay equity and the Company&#146;s annual salary
budget. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="77%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD style="width:31pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:31pt"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD style="width:48pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:48pt"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD style="width:34pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:34pt"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt ; display:inline;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2017 Base<BR>Salary</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>%&nbsp;Increase<BR>from Prior<BR>Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2017<BR>Target<BR>Bonus</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">600,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">425,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">466,796</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">400,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">386,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">0</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In early 2018, the Compensation Committee (and the Board with respect to Mr.&nbsp;Gray) approved
increases to the base salaries of each of our NEOs to bring such base salary figures to a level at or above the 50th percentile of our peer group and, with respect to Dr.&nbsp;Janssen, to reflect his promotion to Senior Vice President. The 2018 base
salaries for our NEOs are: for Mr.&nbsp;Gray, $621,000 (3.5% increase); for Mr.&nbsp;Ostrach, $439,875 (3.5% increase); for Dr.&nbsp;Coffman, $483,134 (3.5% increase); for Dr.&nbsp;Janssen, $438,000 (9.5% increase) and for Mr.&nbsp;Novack, $401,700
(4.0% increase). There are no changes to our NEOs&#146; target annual cash incentive percentages for 2018. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">43 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Long-Term Equity Incentive Awards </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In making annual long-term equity incentive awards to NEOs in early 2017, the Compensation Committee considered each NEO&#146;s total
options outstanding as of December&nbsp;31, 2016, his performance during 2016, the potential amount that could be realized at different hypothetical stock prices upon exercise of those awards and each NEO&#146;s percentage of ownership of the
Company. The Compensation Committee also reviewed peer group data reference points (the 10th, 25th, 50th, 60th, 75th and 90th percentiles of the market data) with respect to an approximation of grant date fair value and shares as a percentage of
total common shares outstanding. The Compensation Committee made final determinations based on its judgment in accordance with our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">pay-for-performance</FONT></FONT> philosophy and the
need to retain and motivate these highly experienced and essential members of our management team. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee
(and the board of directors, with respect to our CEO) determined to grant each NEO&#146;s total long-term incentive compensation with a blend of both time-based RSUs and performance-based RSUs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2017, 80% of the 2017 annual grant was granted in the form of time-based RSUs. Subject to each individual&#146;s continuous
service, <FONT STYLE="white-space:nowrap">one-third</FONT> of the time-based RSUs subject to each annual grant vested on February&nbsp;22, 2018, one third will vest on February&nbsp;22, 2019 and the remainder will vest on February&nbsp;22, 2020.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In response to prior feedback from our stockholders, the remaining 20% of the 2017 annual grant were performance-based RSUs
granted in March 2017 and vest solely upon the Compensation Committee&#146;s certification of achievement of the following equally weighted <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initiate and complete enrollment in melanoma dose expansion study; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Initiate and complete 75% enrollment in SCCHN dose expansion study; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Submit and receive approved DV281 IND and initiate enrollment in dose escalation; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Complete preclinical research support and selection of third agent for SD101 immunotherapy regimen. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2018, the Compensation Committee (and the board of directors, with respect to our CEO) affirmed the achievement of these
performance goals and the vesting of these RSUs. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt ; display:inline;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares&nbsp;Subject</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>to&nbsp;
February</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">2017&nbsp;Time-</FONT></B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Based&nbsp;RSU<BR>Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares&nbsp;Subject</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>to
March</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">2017&nbsp;Performance-</FONT></B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Based RSU<BR>Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">111,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In early 2017, our Compensation Committee (and the board of directors, with respect to our CEO) also
approved two equity grants to certain key employees, including our NEOs, in an effort to maintain employee and management continuity while refocusing our strategic activities to prioritize our emerging clinical and preclinical immuno-oncology
portfolio while still allowing us to advance <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> through the FDA review process and an approval decision. As noted above, stockholder feedback following receipt of the FDA CRL recognized the importance
of retaining the management team and other key talent needed to continue advancing our oncology program and thereby drive long-term stockholder value. Specifically, our Compensation Committee considered the following contributions of our NEOs:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Gray is vital to the success of our shifted strategic focus given his proven leadership with the Company and his role in redeveloping our
corporate strategy to prioritize our emerging clinical and preclinical immuno-oncology portfolio. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">44 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Ostrach&#146;s experience managing our finance, accounting, business development, intellectual property and investor relations functions is
crucial to our business going forward. Our ability to execute on our business plan is contingent on the Company raising the money we need to pursue our strategic plan. Mr.&nbsp;Ostrach has a proven track record in accomplishing this.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Coffman&#146;s role in advancing <FONT STYLE="white-space:nowrap">SD-101,</FONT> DV281 and the other elements of our preclinical
immuno-oncology portfolio is critical to our ability to execute our new corporate strategy. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Janssen&#146;s experience with <FONT STYLE="white-space:nowrap">HEPLISAV-B,</FONT> running our clinical trial program, overseeing the design
and conduct of new studies for oncology and managing our regulatory team is critical to the success of our business. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Novack&#146;s role overseeing an international manufacturing, quality and supply chain organization for
<FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> and our immuno-oncology portfolio is critical to our ability to execute our corporate strategy. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We view the grants listed below as an exceptional event to meet the needs of our transition and path forward as a business. Half of the retention grants, or the Initial Retention Grants, were granted in
February 2017. Subject to each individual&#146;s continuous service, 50% of the RSUs subject to these grants vested on February&nbsp;22, 2018, and the remainder will vest on February&nbsp;22, 2019. The other half of the retention grants, or the
Contingent Retention Grants, were approved subject to stockholder approval of the amendment of the 2011 Equity Incentive Plan, or the 2011 Plan, at our 2017 stockholder annual meeting to increase the authorized shares available thereunder. The
grants were made in June 2017. Although each individual could elect to receive stock options in the amount of 1.35 times the number of RSUs, each of the grants was delivered as an RSU. Subject to each individual&#146;s continuous service, 50% of the
shares subject to each Contingent Retention Grant will vest on June&nbsp;2, 2018, and the remainder will vest on June&nbsp;2, 2019. The <FONT STYLE="white-space:nowrap">two-year</FONT> vesting schedule for the retention grants was designed to
correspond to a critical and transitional <FONT STYLE="white-space:nowrap">two-year</FONT> period during which the Company would be refocusing our strategic activities to prioritize our emerging clinical and preclinical immuno-oncology portfolio
while still allowing us to advance <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> through the FDA review process and an approval decision. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt ; display:inline;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares&nbsp;Subject</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>to 2017
RSU</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Initial</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Retention&nbsp;Grant</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Shares&nbsp;Subject</B></FONT><br><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>to 2017
RSU<BR>Contingent<BR>Retention&nbsp;Grant</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">99,609</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">99,609</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">109,405</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">109,405</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">93,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">93,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90,527</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90,527</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2018, our Board (upon the recommendation of the Compensation Committee) approved annual
long-term equity incentive awards to our NEOs in the form of (i)&nbsp;a stock option to purchase 350,000 shares of our common stock to our CEO and (ii)&nbsp;a stock option to purchase 100,000 shares of our common stock to each of our NEOs, other
than our CEO. Before determining the recommended form and size of these grants, the Compensation Committee considered each NEO&#146;s total options outstanding as of December&nbsp;31, 2017, his performance during 2017, the potential amount that
could be realized at different hypothetical stock prices upon exercise of those awards and each NEO&#146;s percentage of ownership of the Company in making these recommendations. The Compensation Committee also reviewed peer group data reference
points (the 10th, 25th, 50th, 60th, 75th and 90th percentiles of the market data) with respect to an approximation of grant date fair value and shares as a percentage of total common shares outstanding. In March 2018, Compensation Committee (and the
board of directors, with respect to our CEO) approved amending these options to provide that 20% of the shares subject to each option would vest, if at all, upon the Compensation Committee&#146;s certification of certain performance goals. The
remaining 80% of each option grant vests over three years, with <FONT STYLE="white-space:nowrap">one-third</FONT> of the shares subject to each such portion vesting 12 months after the grant date, and the remainder vesting in equal monthly
installments thereafter. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">45 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2017 Annual Incentive Program &#150; Structure, Goals and Payout Decision </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Structure</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our CEO does not have individual goals separate from the Company&#146;s corporate objectives. For
our other NEOs, their total cash incentive payout is typically based on a weighting of 50% corporate and 50% individual goals. Our CEO recommends individual goals for each NEO, which are aligned with our business strategy and linked with corporate
goals, and our Compensation Committee approves these goals. The individual goals for the NEOs are in addition to the general responsibilities each officer has for managing his respective functional or operational area. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>2017 Corporate Goals</I>.&nbsp;&nbsp;&nbsp;&nbsp;In early 2017, the Compensation Committee established the corporate and individual
goals described below. While we now are a fully-integrated biopharmaceutical company with a marketed product and robust development programs, at the time we were a clinical stage company, and so our corporate goals were directly aligned with the
specific strategic objectives, including advancing the development programs that we continue to believe will create long-term value for stockholders. In January 2018, the Compensation Committee evaluated the accomplishments and performance of the
Company against such corporate goals. We have omitted details about the 2017 goals or achievement of goals in the table below only where we believe disclosing such details would result in competitive harm. After its consideration of the
Company&#146;s performance, as more specifically described in the following chart, the Compensation Committee rated our 2017 corporate achievement at 125% of our 2017 corporate goals. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Corporate Goal</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighting</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Corporate Achievement</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Corporate<BR>Achievement<BR>Percentage</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8px"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Oncology: Advance the Pipeline</B></FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Advance oncology
programs that are in clinical studies</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Develop clinical and regulatory strategy and preclinical research support to advance early immuno-oncology programs towards clinical studies</FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Develop strategy for
efficient, scalable chemical synthesis and advancement of one TLR 7/8 agonist compound</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">55%</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee determined that we exceeded or achieved each goal in this category and
that, overall, we exceeded our goals in this category because of several factors, including:</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;The advancement of the <FONT STYLE="white-space:nowrap">on-going</FONT> Phase 1b/2 study
investigating <FONT STYLE="white-space:nowrap">SD-101</FONT> to the dose escalation phase. The early data in patients with metastatic melanoma was encouraging.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;The initiation of dosing in a phase 1B dose escalation clinical trial of our investigational
inhaled TLR9 agonist, DV281, in patients with <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;The advancement of three TLR 7/8 agonist programs.</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60.5%</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8px"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> Advancement</B></FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Complete CRL responses
and <FONT STYLE="white-space:nowrap">re-submission</FONT> of BLA to FDA</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Respond to FDA information requests and prepare for VRBPAC, to facilitate review completion</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Obtain ACIP recommendation in October 2017 or February 2018 meeting depending on timing of
approval</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">35%</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee
determined that, overall, we exceeded our goals in this category because of several factors, including:</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;The achievement of a 12:1 VRBPAC vote supporting the safety of
<FONT STYLE="white-space:nowrap">HEPLISAV-B.</FONT></FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.50em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;The attainment of FDA approval of <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> and an approved label including diabetes data.</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52.5%</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;
</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">46 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="40%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Corporate Goal</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Weighting</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Corporate Achievement</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Corporate<BR>Achievement<BR>Percentage</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8px"> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Establish distribution service agreements with at least one wholesaler and one specialty distributor</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Submit supplemental BLA for prefilled syringes and diabetes data within two months of
approval</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;In
vitro potency assay submission</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Complete design and approval of dialysis trial and submit IND</FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Develop scalable launch
plan</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;The submission of supplemental BLAs for prefilled syringe and in vitro potency assay in Q4.
Diabetes BLA supplement not required because data included in approved label.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;The completion of scalable launch plan.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The dialysis trial design and approval and IND submission in 2017 were not achieved due to the extension of the FDA&#146;s approval decision to November
2017. Unanimous ACIP recommendation was obtained in February 2018.</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8px"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Sustain the DVAX Business Plan</B></FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;At least one year of
cash at year end 2017</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Control net cash usage within budget</FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Develop and advance
Company&#146;s immuno-oncology presence and profile as measured by e.g., (i) oncology scientific meetings and presentations and (ii)&nbsp;establish scientific advisory board and develop key opinion leader relationships</FONT></P>
<P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Develop business
development strategy and, as necessary, secure appropriate partnership to further develop <FONT STYLE="white-space:nowrap">SD-101</FONT> in combination with other agents</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Enable <FONT STYLE="white-space:nowrap">pre-clinical</FONT> evaluation and validation of
double and/or triple combinations by securing access to agents consistent with scientific prioritization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10%</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee determined that we exceeded or achieved each goal in this category and
that, overall, we exceeded our goals in this category because of several factors, including:</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Financing strategy and effective budget management that resulted in greater cash balance at
year- end than we had planned ($196M).</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Our corporate communications, activities and scientific presentations and the positive news flow from our corporate achievements enabled us to develop and advance the profile of our
immuno-oncology program. We also established consulting relationships with key opinion leaders for individual consulting and service on Scientific Advisory Board.</FONT></P> <P STYLE="font-size:3px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Business development strategy for further development of
<FONT STYLE="white-space:nowrap">SD-101</FONT> in combination with other agents developed and discussions being held regarding securing access to agents.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">12%</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Total</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>100%</B></FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>125%</B></FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The terms used, but not defined above, have the following definitions: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B><I>ACIP</I></B>&#148; is the Centers for Disease Control and Prevention&#146;s Advisory Committee on Immunization Practices.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B><I>BLA</I></B>&#148;<I> </I>is an FDA Biologics License Application<I>.</I> </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B><I>CRL</I></B>&#148; is a Complete Response Letter issued by the FDA to communicate it has completed its review of a new drug application and
it will not approve the application in its present form. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B><I>IND</I></B>&#148; is an Investigational New Drug Application. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;<B><I>VRBPAC</I></B>&#148;<I> </I>is the FDA&#146;s Vaccines and Related Biological Products Advisory Committee<I>.</I>
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">47 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>2017 Individual Goals</I>. &nbsp;&nbsp;&nbsp;&nbsp;As described above, our CEO does
not have individual goals separate from the Company&#146;s corporate objectives. For our other NEOs, the total cash incentive payout for 2017 was based on a weighting of 50% corporate and 50% individual goals. Our CEO recommends individual goals for
each NEO, which are aligned with our business strategy and linked with corporate goals, and our Compensation Committee approves these goals. The 2017 individual goals for the NEOs include those listed below. These specific goals were in addition to
the general responsibilities each officer had for managing his respective functional operational area. In early 2018, based on the recommendation of our CEO, as well as the observations by Compensation Committee members of these officers and its own
assessment of each NEO&#146;s effectiveness, the Compensation Committee determined the level of achievement of each NEO&#146;s individual performance goals as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Individual Goals</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Individual Achievement</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Individual<BR>Achievement<BR>Percentage</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.&#8195;&#8201;Meet key financial objectives,
including securing adequate financing to support <FONT STYLE="white-space:nowrap">HELPLISAV-B</FONT> launch and oncology clinical development program, and optimize processes for managing financial reporting</FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.&#8195;&#8201;Develop business and
communications strategies that are implementable and target the right opportunities</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-2.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3.&#8195;&#8201;Optimize internal IP function, develop patent prosecution roadmap and file strategic patents related to vaccine and oncology assets</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Ostrach exceeded his individual goals by:</FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Managing our financing
strategy, implementing new processes and securing equity financing which resulted in greater cash balance at <FONT STYLE="white-space:nowrap">year-end</FONT> than planned;</FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Substantially
contributing to our corporate business and communication strategies; and</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.50em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Optimizing internal IP function, developing and implementing our patent strategy, and obtaining and filing key patents, including a second
<FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> use patent.</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>

<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.&#8195;&#8201;Initiate Phase I clinical trial for
DV281 for lung cancer, including completion of IND and other prerequisites.</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2.&#8195;&#8201;Advance preclinical and clinical vaccine and oncology programs</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.&#8195;&#8201;Develop and implement strategies that will continue to broaden our scientific
platform</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Coffman exceeded his individual goals by:</FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Guiding the lung cancer
project (DV281) to successful initiation of clinical studies;</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Playing critical role in gaining approval of <FONT STYLE="white-space:nowrap">HEPLISAV-B;</FONT> and</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Conducting <FONT STYLE="white-space:nowrap">in-depth</FONT> portfolio review for potential
new cancer trials leading to identification of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">up-to-date,</FONT></FONT> next steps for <FONT STYLE="white-space:nowrap">SD-101</FONT> development.</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">130</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">48 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; padding-left:8px"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Individual Goals</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Individual Achievement</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Individual<BR>Achievement<BR>Percentage</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-right:8px"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert
Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.&#8195;&#8201;Lead
regulatory efforts to obtain <FONT STYLE="white-space:nowrap">FDA-approval</FONT> of <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> and subsequent ACIP recommendation and post-marketing clinical program</FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.&#8195;&#8201;Develop and implement
clinical, regulatory and medical affairs strategies to advance immuno-oncology and vaccine programs in the clinic, including initiation of DV281 dose-escalation trial</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.&#8195;&#8201;Develop and advance Company&#146;s immuno-oncology presence and profile</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Janssen exceeded his individual goals by:</FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Leading and making
invaluable contributions to obtaining FDA approval of <FONT STYLE="white-space:nowrap">HEPLISAV-B;</FONT> Note: ACIP voted unanimously in favor of <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> recommendation on February 2018.</FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Supervising and
advancing of our oncology and vaccine pipelines, including initiation of DV281 dose-escalation trial in Q4 2017; and</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Substantially contributing to KOL meetings, discussions with potential partners and creating
various draft manuscripts for submission.</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">135</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8px"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David Novack</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.&#8195;&#8201;Deliver on all CMC related activities
related to the Company&#146;s BLA submission for commercialization of <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT></FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2.&#8195;&#8201;Develop and implement manufacturing strategies for commercialization of <FONT
STYLE="white-space:nowrap">HEPLISAV-B</FONT> and to advance our immuno-oncology programs in the clinic</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.&#8195;&#8201;Continue to implement quality assurance strategies required for a commercial
organization</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Novack exceeded his individual goals by:</FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Implementing our
Company&#146;s restructuring at our Dusseldorf manufacturing site and in Berkeley in order to maintain the viability of <FONT STYLE="white-space:nowrap">HEPLISAV-B;</FONT></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Contributing to the
achievement of the resolution of all regulatory requests related to <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> regulatory approval;</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Successfully planning and delivering clinical supply for oncology programs; and</FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2.00em; text-indent:-1.50em"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;&#8195;&#8202;Demonstrating leadership
and commitment to operational excellence methodologies and the use of metrics to monitor quality and performance.</FONT></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125</FONT></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:8px"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After making these determinations regarding levels of corporate and individual performance achieved
against the <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals, the Compensation Committee (and the Board with respect to the CEO) reviewed and approved the cash incentive payouts noted below. As noted above, for the NEOs
other than the CEO, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
the cash incentive payouts are based 50% on achievement of corporate goals and 50% on achievement of individual goals. There were no changes to the NEOs&#146; target annual cash incentive
percentages between 2016 and 2017. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="43%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2017 Target Annual<BR>Cash Incentive</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2017 Actual Annual Cash Incentive Paid</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" ROWSPAN="2" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt ; display:inline;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Achievement of<BR>Corporate Goals</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Achievement of<BR>Individual Goals</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>% of<BR>Base<BR>Salary</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>$</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>% of<BR>Target<BR>Annual<BR>Cash<BR>Incentive</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>$*</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>% of<BR>Target<BR>Annual<BR>Cash<BR>Incentive</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>$*</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total*</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">360,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">450,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">N/A</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">450,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">212,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">132,813</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">132,813</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">265,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">233,398</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">145,874</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">151,709</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">297,582</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">200,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">125,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">67.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">135,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">260,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">193,125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">120,703</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62.5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">120,703</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">241,406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Amounts are rounded to the nearest dollar </FONT></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Executive Compensation Matters </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Equity Compensation Policies </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our Compensation Committee approves equity awards for NEOs and authorizes the CEO to approve equity awards for all other employees based on approved pools for annual and new hire grants. NEO awards are
approved either at a regularly-scheduled meeting of the Compensation Committee or by unanimous written consent. The effective date of the grant is generally the date of the meeting, or the date the last person executes the unanimous written consent.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The exercise price of stock options is not less than the closing price of our common stock on the NASDAQ Capital Market on
the grant date of the stock option. We have no practice of timing grants of stock options or restricted stock awards to coordinate with the release of material <FONT STYLE="white-space:nowrap">non-public</FONT> information, and we have not timed the
release of material <FONT STYLE="white-space:nowrap">non-public</FONT> information for purposes of affecting the value of the compensation awarded to our NEOs or any other employee. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We encourage our NEOs to hold a significant equity interest in our Company, but we have not set specific stock ownership guidelines.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have a policy that prohibits our executive officers, directors and other members of management from engaging in short
sales, transactions in put or call options, hedging transactions or other inherently speculative transactions with respect to our stock. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Tax Effects of Executive Compensation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our Compensation Committee considers the impact of the deduction limitation imposed by section 162(m) of the Internal Revenue Code of 1986, as amended (the &#147;Tax Code&#148;), in establishing and
implementing compensation policies and practices. Section&nbsp;162(m) generally prohibits us from deducting any compensation over $1&nbsp;million per taxable year paid to our &#147;covered employees&#148; unless, under tax laws in effect prior to
January&nbsp;1, 2018, such compensation qualifies as &#147;performance-based compensation&#148; within the meaning of section 162(m). The exception from section 162(m)&#146;s deduction limit for &#147;performance-based compensation&#148; has been
repealed, effective for taxable years beginning after December&nbsp;31, 2017, such that compensation paid to our &#147;covered employees&#148; in excess of $1&nbsp;million per taxable year will not be deductible unless it qualifies for transition
relief applicable to certain arrangements in place as of November&nbsp;2, 2017. Because of certain ambiguities and uncertainties as to the application and interpretation of section 162(m) and the regulations issued thereunder, including the
uncertain scope </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">50 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of the transition relief under the legislation repealing section 162(m)&#146;s &#147;performance-based compensation&#148; exception from the deduction limit, no assurance can be given that
compensation intended to satisfy the requirements for the &#147;performance-based compensation&#148; exception under section 162(m) in fact will. The Compensation Committee reserves the right to modify compensation that was initially intended to
satisfy the requirements for the &#147;performance-based compensation&#148; exception under section 162(m) if it determines that such modifications are consistent with the Company&#146;s business needs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee also considers the impact of section 409A of the Tax Code, and in general, our executive plans and programs
are designed to comply with the requirements of that section so as to avoid possible adverse tax consequences that may result from <FONT STYLE="white-space:nowrap">non-compliance.</FONT> </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Accounting Considerations </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The accounting impact of our compensation
programs is one of many factors that the Compensation Committee considers in determining the structure and size of our executive compensation programs. In general, the Company accounts for equity compensation paid to our employees under the
Financial Accounting Standards Board Accounting Standards Codification Topic 718, Compensation&#151;Stock Compensation, or ASC 718, which requires us to estimate and record an expense over the service period of the equity award, and our cash
compensation is recorded as an expense at the time the obligation is accrued. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Compensation Recovery Policy </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amounts paid and awards granted under our 2011 Plan are subject to recoupment in accordance with the Dodd-Frank Wall Street Reform and
Consumer Protection Act and any applicable regulations under the Act, any clawback policy the Company adopts or as is required by applicable law. In addition, as a public company subject to the provisions of Section&nbsp;304 of the Sarbanes-Oxley
Act of 2002, if we are required as a result of misconduct to restate our financial results due to our material noncompliance with any financial reporting requirements under the federal securities laws, our chief executive officer and chief financial
officer may be legally required to reimburse us for any bonus or other incentive-based or equity-based compensation they receive. In addition, we will comply with the requirements of the Dodd-Frank Wall Street Reform and Consumer Protection Act once
the SEC final regulations on the subject become effective. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation Risk Analysis </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During fiscal 2017, our Compensation Committee reviewed our compensation policies as generally applicable to our employees in order to
determine whether any such programs were likely to present a material risk to the Company. As part of its assessment, the Compensation Committee considered, among other things, the allocation of compensation among base salary and short- and
long-term compensation, our approach to establishing Company-wide and individual financial, operational and other performance targets, and the nature of our key performance metrics. As a result of this review and analysis, the Compensation
Committee&#146;s determined that our policies and programs do not encourage excessive or inappropriate risk taking, and that the level of risk that they do encourage is not reasonably likely to have a material adverse effect on the Company.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Report of the Compensation Committee of the Board of Directors on Executive Compensation </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In early 2018, the Compensation Committee discussed with management the Compensation Discussion and Analysis, contained in this proxy
statement. Based on this review and discussion, the Compensation Committee has recommended to the Board that the Compensation Discussion and Analysis be included in this proxy statement and incorporated into our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The material in this report is
not &#147;soliciting material,&#148; is furnished to, but not deemed &#147;filed&#148; with, the SEC and is not deemed to be incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act,</I>
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">51 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
<I>other than the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> where it shall be deemed to be &#147;furnished,&#148; whether made before or after the date
hereof and irrespective of any general incorporation language in any such filing.</I> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Peggy&nbsp;V. Phillips,
Chairperson </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Francis&nbsp;R. Cano, Ph.D. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Daniel Kisner, M.D. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>S<SMALL>UMMARY</SMALL> C<SMALL>OMPENSATION</SMALL>
T<SMALL>ABLE</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows for the fiscal years ended December&nbsp;31, 2017, 2016 and 2015,
compensation awarded to or paid to, or earned by, NEOs. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD style="width:8pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:8pt"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD style="width:11pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:11pt"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD style="width:17pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:17pt"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD style="width:17pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:17pt"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD style="width:28pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:28pt"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD style="width:28pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:28pt"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD style="width:9pt"></TD>
<TD></TD>
<TD></TD>
<TD style="width:9pt"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:97pt ; display:inline;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Principal Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Salary</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock<BR>Awards<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT>
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Awards<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></B></FONT>
</TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive<BR>Compensation<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>All
Other<BR>Compensation<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="4" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">600,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,094,113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">450,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,146,113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">CEO and Director</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">600,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,345,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,947,840</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">566,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,004,616</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">370,491</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,943,607</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">425,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,126,060</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">265,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,818,685</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ROWSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Senior Vice President, Chief<BR>Financial Officer, Chief<BR>Business Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">425,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">703,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,130,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">390,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,420,353</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">228,150</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,040,503</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">466,796</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,223,041</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">297,582</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,989,419</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Senior Vice President and<BR>Chief Scientific Officer</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">466,796</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">703,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,172,548</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">453,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,300,631</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">253,792</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,009,623</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">400,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,068,056</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">260,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,730,056</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Chief Medical Officer and Senior Vice President, Clinical Development, Medical and Regulatory Affairs</FONT></P></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">400,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">670,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,072,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">369,513</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">747,816</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">206,928</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,326,257</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD>
<TD HEIGHT="5" COLSPAN="5"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">386,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,036,148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">241,406</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,665,804</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top" ROWSPAN="2"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Senior Vice President,<BR>Operations and Quality</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">386,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">536,192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">924,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">375,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,001,539</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">210,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,588,539</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>Represents the aggregate grant date fair value of RSUs granted in the fiscal
year in accordance with ASC 718. See note 14 of our &#147;Notes to Consolidated Financial Statements&#148; in our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the SEC on March&nbsp;8, 2018 for a discussion of
assumptions we made in determining the compensation costs included in this column. With regard to RSUs with performance-based vesting, the grant date fair value included in the table above assumes the highest level of achievement had been met, and
is as follows: </FONT></P></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="79%"></TD>
<TD VALIGN="bottom" WIDTH="19%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>RSUs with<BR>Performance-<BR>Based&nbsp;Vesting</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt ; display:inline;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>2017</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">165,113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">37,931</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">37,931</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">37,931</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">37,931</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">For further discussion of these performance-based RSUs, see the section entitled &#147;Compensation Discussion and Analysis &#150; 2017 Executive Compensation Decisions
&#150; Long-Term Equity Incentive Awards.&#148; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the aggregate grant date fair value of option awards granted in the fiscal year in accordance with ASC 718. See note 14 of our &#147;Notes
to Consolidated Financial Statements&#148; in our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the SEC on March&nbsp;8, 2018 for a discussion of assumptions we made in determining the compensation costs included in
this column<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">.</SUP> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the annual incentive bonuses earned pursuant to our annual incentive bonus plan for services rendered in the fiscal year. For further
discussion see the section entitled &#147;Compensation Discussion and Analysis &#150; 2017 Executive Compensation Decisions &#150; Annual Incentive Plan.&#148; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents $2,000 401(k) matching contribution for each NEO made by the Company in the fiscal year. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">52 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>G<SMALL>RANTS</SMALL> O<SMALL>F</SMALL> P<SMALL>LAN</SMALL> B<SMALL>ASED</SMALL>
A<SMALL>WARDS</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows certain information regarding grants of plan-based awards to NEOs during
the fiscal year ended December&nbsp;31, 2017. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt ; display:inline;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant&nbsp;Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Date&nbsp;of<BR>Board&nbsp;or<BR>Compensation<BR>Committee<BR>Action to<BR>Grant Award</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Estimated<BR>Future<BR>Payouts<BR>Under<BR><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive<BR>Plan
<BR>Awards<BR>Target<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP><BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Estimated<BR>Future<BR>Payouts<BR>Under<BR>Equity<BR>Incentive<BR>Plan<BR>Awards<BR>Target<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP><BR>(#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>All&nbsp;Other<BR>Stock<BR>Awards:<BR>Number&nbsp;of<BR>Shares of<BR>Stock<BR>or&nbsp;Units<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP><BR>(#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>All Other<BR>Option<BR>Awards:<BR>Number of<BR>Securities<BR>Underlying<BR>Options</B></FONT><br><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exercise<BR>or Base<BR>Price of<BR>Option<BR>Awards<BR>($/Share)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Grant&nbsp;Date<BR>Fair&nbsp;Value<BR>of&nbsp;RSU&nbsp;and<BR>Option<BR>Awards<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP>&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">360,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">600,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">111,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">444,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/31/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/31/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">165,113</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/2/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">885,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">212,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">99,609</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">398,436</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">102,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/31/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/31/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,931</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/2/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">99,609</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">587,693</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">233,398</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">109,405</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">437,620</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">102,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/31/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/31/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,931</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/2/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">109,405</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">645,490</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">200,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">93,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">375,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">102,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/31/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/31/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,931</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/2/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">93,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">553,125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">193,125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90,527</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">362,108</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">25,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">102,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/31/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3/31/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,931</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6/2/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2/22/2017</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">90,527</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">534,109</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>Represents the target cash incentive award in fiscal year 2017 as further
described under &#147;Compensation Discussion and Analysis &#150; Elements of Executive Compensation&#148;; our Annual Incentive Program does not specify minimum or maximum levels. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the number of RSUs granted in the fiscal year that are subject to performance-based vesting, as described in the &#147;Compensation
Discussion and Analysis.&#148; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the number of RSUs granted in the fiscal year that are subject to time-based vesting, as described in the &#147;Compensation Discussion and
Analysis.&#148; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the aggregate grant date fair value of RSUs granted in fiscal year 2017 in accordance with ASC 718. See Note&nbsp;14 of our &#147;Notes to
Consolidated Financial Statements&#148; in our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the SEC on March&nbsp;8, 2018 for a discussion of the assumptions we made in determining the compensation costs included in
this column. With regard to RSUs with performance-based vesting, the grant date fair value assumes the highest level of achievement had been met, is reported in the &#147;Summary Compensation Table.&#148; For further discussion of these
performance-based RSUs, see the section entitled &#147;Compensation Discussion and Analysis &#150; 2017 Executive Compensation Decisions &#150; Long-Term Equity Incentive Awards.&#148; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">53 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N<SMALL>ARRATIVE</SMALL> D<SMALL>ISCLOSURE</SMALL> <SMALL>TO</SMALL> S<SMALL>UMMARY</SMALL>
C<SMALL>OMPENSATION</SMALL> T<SMALL>ABLE</SMALL> <SMALL>AND</SMALL> G<SMALL>RANTS</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL> B<SMALL>ASED</SMALL> A<SMALL>WARDS</SMALL> T<SMALL>ABLE</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The material terms of NEOs&#146; annual compensation and the explanations of the amounts of base salary, annual cash-based incentives, and
equity-based awards in proportion to total compensation are described under &#147;Compensation Discussion and Analysis&#148; in this proxy statement. Our severance and change in control benefits are described under &#147;Summary of Change in Control
and Involuntary Termination Arrangements&#148; in this proxy statement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As discussed in the &#147;Compensation Discussion and
Analysis,&#148; the fiscal year 2017 cash incentive amounts were paid pursuant to the annual cash incentive compensation program, based on the achievement of certain corporate and individual performance goals. Equity-based awards were granted in
2017 under our 2011 Plan and represent a mix of time based and performance based RSUs, as described in the &#147;Compensation Discussion and Analysis.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>O<SMALL>UTSTANDING</SMALL> E<SMALL>QUITY</SMALL> A<SMALL>WARDS</SMALL> A<SMALL>T</SMALL> F<SMALL>ISCAL</SMALL> Y<SMALL>EAR</SMALL> E<SMALL>ND</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows certain information regarding outstanding equity awards for NEOs as of December&nbsp;31, 2017. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt ; display:inline;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Exercise<BR>Price<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Vesting<BR>Commencement<BR>Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Expiration<BR>Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of<BR>Shares or<BR>Units that<BR>Have Not<BR>Vested (#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Market&nbsp;Value<BR>of&nbsp;Stock&nbsp;that<BR>Have Not<BR>Vested ($)<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Number&nbsp;of<BR>Unearned<BR>Shares or<BR>Other<BR>Rights<BR>that
Have<BR>Not<BR>Vested (#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Market&nbsp;or<BR>Payout<BR>Value of<BR>Unearned<BR>Shares
or<BR>Other<BR>Rights&nbsp;that<BR>Have Not<BR>Vested&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Eddie&nbsp;Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">22.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">5/1/2013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">4/30/2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">73,438</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,563</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">17.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/31/2014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/30/2024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">143,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">6,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">17.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/4/2014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/3/2024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">159,374</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">65,626</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/9/2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/8/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">171,110</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">108,890</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">21.99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/4/2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/3/2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,805,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(6</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">111,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,075,700</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">27,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">518,925</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(7</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">150,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,805,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">4,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">53.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/3/2008</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/2/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">5.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3/10/2009</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3/9/2019</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,673</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">15.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/19/2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/18/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">31.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/6/2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/5/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">18,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">34.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/31/2012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/30/2022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">30.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/5/2013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/4/2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT></TD>

<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">25,875</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">17.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/4/2014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/3/2024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">47,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">19,542</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/9/2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/8/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">12,084</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">28.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">8/27/2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">8/26/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">51,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">32,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">21.99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/4/2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/3/2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">99,609</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,862,688</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(6</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">25,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">476,850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">6,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">119,213</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(7</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">99,609</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,862,688</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Robert&nbsp;L.&nbsp;Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">7,501</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">53.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/3/2008</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/2/2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">10,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">15.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/19/2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/18/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">30,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">31.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/6/2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/5/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">18,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">34.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/31/2012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/30/2022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">18,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">30.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/5/2013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/4/2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">53,124</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">21,876</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/9/2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/8/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">9,626</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">6,875</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">28.45</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">8/27/2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">8/26/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">51,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">32,667</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">21.99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/4/2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/3/2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">109,405</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,045,874</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(6</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">25,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">476,850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">6,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">119,213</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(7</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">109,405</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,045,874</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">54 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt ; display:inline;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Exercise<BR>Price<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Vesting<BR>Commencement<BR>Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Expiration<BR>Date</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of<BR>Shares or<BR>Units that<BR>Have Not<BR>Vested (#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Market&nbsp;Value<BR>of&nbsp;Stock&nbsp;that<BR>Have Not<BR>Vested ($)<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Number&nbsp;of<BR>Unearned<BR>Shares or<BR>Other<BR>Rights<BR>that
Have<BR>Not<BR>Vested (#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Equity<BR>Incentive<BR>Plan<BR>Awards:<BR>Market&nbsp;or<BR>Payout<BR>Value of<BR>Unearned<BR>Shares
or<BR>Other<BR>Rights&nbsp;that<BR>Have Not<BR>Vested&nbsp;($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">6,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">13.60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">4/7/2010</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">4/6/2020</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">31.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/6/2011</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/5/2021</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">36.80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/1/2012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1/31/2022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">15,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">41.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">10/31/2012</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">10/30/2022</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">17,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">17.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/4/2014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/3/2024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">39,666</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16,334</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/9/2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/8/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">48,889</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">31,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">21.99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/4/2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/3/2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">93,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,753,125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(6</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">25,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">476,850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">6,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">119,213</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(7</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">93,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,753,125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="1">David&nbsp;F.&nbsp;Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">30,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">21.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3/25/2013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">3/24/2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">21,084</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">17.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/4/2014</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/3/2024</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">53,124</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">21,876</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">16.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/9/2015</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/8/2025</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">39,111</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">24,889</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">21.99</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/4/2016</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">2/3/2023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">90,527</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,692,855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(6</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">25,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">476,850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">6,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">119,213</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(7</SUP></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">)</SUP>&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">90,527</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="1">1,692,855</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the aggregate fair value of RSUs in accordance with ASC 718, based on the last closing price per share as of December&nbsp;29, 2017 of
$18.70. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Options vest at the rate of 1/4th of the shares on the first anniversary of the vesting commencement date, with 1/48th of the total number of shares
vesting each month thereafter. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Options vests at the rate of 1/3rd of the shares on the first anniversary of the vesting commencement date, with 1/36th of the total number of shares
vesting each month thereafter. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">This amount represents the maximum number of shares subject to this stock award. Stock awards will be earned upon achievement of certain performance
conditions. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">RSU vested 50% on February&nbsp;22, 2018 and the remainder will vest on February&nbsp;22, 2019. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(6)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">RSU vested <FONT STYLE="white-space:nowrap">one-third</FONT> on February&nbsp;22, 2018, <FONT STYLE="white-space:nowrap">one-third</FONT> will vest on
February&nbsp;22, 2019 and the remainder will vest on February&nbsp;22, 2020. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(7)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">RSU vests 50% on June&nbsp;2, 2018 and the remainder will vest on June&nbsp;2, 2019. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>O<SMALL>PTION</SMALL> E<SMALL>XERCISES</SMALL> A<SMALL>ND</SMALL> S<SMALL>TOCK</SMALL> V<SMALL>ESTED</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table provides information on stock awards that vested, including the number of shares acquired upon vesting and the value
realized, determined as described below, for the named executive officers in the fiscal year ended December&nbsp;31, 2017. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Stock Awards</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt ; display:inline;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Shares<BR>Acquired on<BR>Exercise (#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Value&nbsp;Realized<BR>on
Exercise<BR>($)<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number&nbsp;of&nbsp;Shares<BR>Acquired on<BR>Vesting (#)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Value&nbsp;Realized<BR>on
Vesting<BR>($)<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">50,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">200,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">101,172</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">260,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">115,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">The value realized on vesting is determined by multiplying the number of shares of stock by the &#147;spread&#148; between the market value upon
exercise and exercise price. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">The value realized on vesting is determined by multiplying the number of shares of stock by the market value of the underlying shares as reported by
the Nasdaq Capital Market on the vesting date. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">55 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>ENSION</SMALL> B<SMALL>ENEFITS</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">None of the NEOs participates in or has an account balance under any pension or qualified or
<FONT STYLE="white-space:nowrap">non-qualified</FONT> defined benefit retirement plans sponsored by the Company. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N<SMALL>ON</SMALL>-Q<SMALL>UALIFIED</SMALL> D<SMALL>EFERRED</SMALL> C<SMALL>OMPENSATION</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">None of the NEOs participates in or has an account balance under any <FONT STYLE="white-space:nowrap">non-qualified</FONT> defined
contribution plans or other <FONT STYLE="white-space:nowrap">non-qualified</FONT> deferred compensation plans maintained by the Company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>OTENTIAL</SMALL> P<SMALL>AYMENTS</SMALL> U<SMALL>PON</SMALL> C<SMALL>HANGE</SMALL> <SMALL>IN</SMALL> C<SMALL>ONTROL</SMALL> <SMALL>OR</SMALL> I<SMALL>NVOLUNTARY</SMALL>
T<SMALL>ERMINATION</SMALL> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Summary of Change in Control and Involuntary Termination Arrangements. </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To promote retention of certain key executives, our Board has authorized the Company to enter into Management Continuity and Severance
Agreements with each NEO. We refer to the agreements in effect as of December&nbsp;31, 2017 as the &#147;Management Agreements.&#148; In order to be eligible to receive benefits under the Management Agreements, our NEOs and other officers must
execute a general waiver and release of claims, and such release must become effective in accordance with its terms. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Change in Control.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Management Agreement with Mr.&nbsp;Gray provides that, as of immediately prior to the effective date of a Change
in Control (as described below), all of Mr.&nbsp;Gray&#146;s then-outstanding equity awards (including stock options and RSUs) under the 2011 Plan shall automatically accelerate and fully vest, subject to Mr.&nbsp;Gray&#146;s execution and delivery
of a release. The table below outlines the potential payments and benefits payable to each current NEO in the event of a Change in Control (without termination of employment) of the Company, assuming such event had occurred on December&nbsp;31,
2017. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt ; display:inline;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Aggregate Number Of<BR>Equity&nbsp;Award&nbsp;Shares<BR>Subject&nbsp;to&nbsp;Accelerated<BR>Vesting on
CIC</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Value of<BR>Accelerated<BR>Equity<BR>Awards<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">621,079</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,393,847</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the value of stock and accelerated stock option and award vesting if the event took place on December&nbsp;31, 2017. The value for RSUs is
calculated in accordance with ASC 718, based on the closing price per share on December&nbsp;29, 2017. The value for stock option awards is calculated based on the &#147;spread&#148; between the closing price per share on December&nbsp;29, 2017 of
$18.70 and the exercise price of the vested awards, to the extent such vested awards were &#147;in the money.&#148; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Qualifying Termination in Connection with a Change in Control. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under the Management Agreements, if, on or during the <FONT STYLE="white-space:nowrap">two-year</FONT> period following a Change in Control (as described below), the NEO&#146;s employment is involuntarily
terminated, the NEO will, subject to the execution of a release of claims, be entitled to receive: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a <FONT STYLE="white-space:nowrap">lump-sum</FONT> cash payment equal to a specified number of months (24 months for Mr.&nbsp;Gray and 12 months for
our other NEOs) of the executive&#146;s then-effective annual base salary; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a <FONT STYLE="white-space:nowrap">lump-sum</FONT> cash payment equal to the NEO&#146;s target annual variable cash compensation (200% of such target
for Mr.&nbsp;Gray and 100% of such target for our other NEOs) for the year of termination; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">56 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">cash payments equal to the applicable COBRA premiums for up to the same number of months as the NEO receives in base salary, as set forth in the first
bullet (the &#147;COBRA Payment&#148;); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">acceleration of vesting of all outstanding equity awards at the time of such termination (provided, however, that Mr.&nbsp;Gray will receive
accelerated vesting for only those grants that (i)&nbsp;were issued under the 2011 Plan (or any equity plan of a successor company) and (ii)&nbsp;are subject to time-based vesting criteria if issued after the Change of Control); and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the extension of exercisability of all stock options to purchase the Company&#146;s common stock for a period of 3 years following termination of
employment (but in any event not beyond each option&#146;s expiration date). </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, if any payments
or benefits would constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Code and such payments would be subject to the excise tax imposed by Section&nbsp;4999 of the Code, then such payments will either be
(1)&nbsp;provided to the NEO in full or (2)&nbsp;reduced to such lesser amount that would result in no portion of such payments being subject to the excise tax, whichever amount after taking into account all applicable taxes, including the excise
tax, would result in the NEO&#146;s receipt, on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, of the greatest amount of such payments. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Management Agreements generally define a Change in Control to mean the occurrence of a change in the majority ownership of the voting securities of the Company; a merger that results in change in the
majority ownership of the voting securities of the Company; the sale of all or substantially all of the assets; or (for all of our NEOs except Mr.&nbsp;Gray) over a period of 12 months or less, when a majority of our Board becomes comprised of
individuals who were not serving on our Board as of a specified date, or whose nomination, appointment, or election was not approved by a majority of the directors who were serving on our Board as such specified date. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table below outlines the potential payments and benefits payable to each NEO in the event such executive&#146;s termination in
connection with a Change in Control of the Company, assuming such event had occurred on December&nbsp;31, 2017. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt ; display:inline;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Severance<BR>Payment</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Continuation<BR>of Benefits</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Value
of<BR>Accelerated<BR>Stock<BR>Awards<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,920,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47,193</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">8,393,847</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10,361,040</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">637,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28,761</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,376,003</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,042,264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">700,194</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,754</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,746,875</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">5,470,823</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">600,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23,754</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,147,614</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,771,368</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">579,375</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28,665</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,042,303</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,650,343</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>Represents the value of accelerated vesting of equity awards if the event
took place on December&nbsp;31, 2017. The value for RSUs is calculated in accordance with ASC 718, based on the closing price per share on December&nbsp;29, 2017. The value for stock option awards is calculated based on the &#147;spread&#148;
between the closing price per share on December&nbsp;29, 2017 of $18.70 and the exercise price of the vested awards, to the extent such vested awards were &#147;in the money.&#148; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Involuntary Termination. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Under the terms of the Management Agreements, upon an &#147;involuntary&#148; termination without &#147;cause&#148; or, if applicable, upon a resignation for &#147;good reason&#148; (as defined below),
the NEO will, subject to the execution of a release of claims, be entitled to receive: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a <FONT STYLE="white-space:nowrap">lump-sum</FONT> cash payment equal to the specified number of months (ranging from 6 to 24) of the executive&#146;s
then-effective annual base salary; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the COBRA Payment; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">57 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">accelerated vesting of all equity awards that are held by Mr.&nbsp;Gray on the effective date of termination and subject to time-based vesting
criteria; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">for Mr.&nbsp;Gray, the extension of exercisability of all vested stock options to purchase the Company&#146;s common stock for a period of 3 years
following termination of employment (but in any event not beyond each option&#146;s expiration date). </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under
the terms of the Management Agreements: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Mr.&nbsp;Gray will receive 24 months of base salary, 200% of his target annual cash incentive, the COBRA Payment, accelerated vesting of his
then-outstanding employee stock options and restricted stock awards, and up to 3 years to exercise the vested options; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our other NEOs will receive 6 months of base salary and the COBRA Payment. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The table below outlines the potential payments and benefits payable to each NEO in the event of such NEO&#146;s involuntary termination
had occurred on December&nbsp;31, 2017.</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="55%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt ; display:inline;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Severance<BR>Payment</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Continuation<BR>of Benefits</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Value of<BR>Accelerated<BR>Stock&nbsp;Awards<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,920,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">47,193</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7,874,922</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9,842,115</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">212,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,380</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">226,880</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">233,398</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,877</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">245,275</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">200,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,877</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">211,877</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">193,125</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">207,458</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the value of accelerated vesting of equity awards that are subject to time-based vesting criteria if the event took place on
December&nbsp;31, 2017. The value for RSUs is calculated in accordance with ASC 718, based on the closing price per share on December&nbsp;29, 2017. The value for stock option awards is calculated based on the &#147;spread&#148; between the closing
price per share on December&nbsp;29, 2017 of $18.70 and the exercise price of the vested awards, to the extent such vested awards were &#147;in the money.&#148; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of the Management Agreements, &#147;cause&#148; generally means (1)&nbsp;gross negligence or willful misconduct in the
performance of duties to the Company, where such gross negligence or willful misconduct has resulted or is likely to result in substantial and material damage to the Company or its subsidiaries; (2)&nbsp;repeated unexplained or unjustified absence
from the Company; (3)&nbsp;a material and willful violation of any federal or state law; (4)&nbsp;commission of any act of fraud with respect to the Company; or (5)&nbsp;conviction of a felony or a crime involving moral turpitude causing material
harm to the standing and reputation of the Company, in each case as determined in good faith by the Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of
the Management Agreements, &#147;good reason&#148; generally means the NEO&#146;s voluntary termination following (1)&nbsp;a material reduction or change in job duties, responsibilities, and requirements inconsistent with the NEO&#146;s position
with the Company and his or her prior duties, responsibilities, and requirements, or a material change in the level of management to which the NEO reports; (2)&nbsp;any material reduction of base compensation (other than in connection with a general
decrease in base salaries for most officers of the successor corporation); or (3)&nbsp;the refusal to relocate to a facility or location more than 35 miles from the Company&#146;s current location. The NEO must provide 90 days&#146; notice of the
event giving rise to good reason, give the Company 30 days&#146; to cure (if curable), and any resignation for good reason must occur within 180 days after the occurrence of the event giving rise to such resignation right. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>AY</SMALL> R<SMALL>ATIO</SMALL> D<SMALL>ISCLOSURE</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under SEC rules, we are required to calculate and disclose the annual total compensation of our median employee, as well as the ratio of
the annual total compensation of our median employee as compared to the annual total compensation of our CEO (&#147;CEO Pay Ratio&#148;). To identify our median employee, we used the following methodology: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To determine our total population of employees, we included all full-time, part-time, and temporary employees as of December&nbsp;31, 2017.
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">58 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To identify our median employee from our employee population, we calculated the aggregate amount of each employee&#146;s 2017 base salary (using a
reasonable estimate of the hours worked and overtime actually paid during 2017 for hourly employees and actual salary paid for our remaining employees), the target value of annual cash incentive awards, and the value of equity awards granted in 2017
using the same methodology we use for estimating the value of the equity awards granted to our named executive officers and reported in our Summary Compensation Table. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">In making this determination, we annualized the compensation elements listed above of employees who were employed by us for less than the entire
calendar year. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Compensation paid in foreign currencies was converted to U.S. dollars based on exchange rates in effect on December&nbsp;31, 2017.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Using this approach, we determined our median employee. Because the median employee we initially identified
had anomalous compensation characteristics due to the employee&#146;s commencement of employment in 2017, we substituted another employee to serve as our median employee who received substantially similar base salary and bonus payments and equity
award grants as the initial median employee during 2017. Once the median employee was identified, we then calculated the annual total compensation of this employee for 2017 in accordance with the requirements of the Summary Compensation Table.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For 2017, the median of the annual total compensation of our employees (other than our CEO) was $138,706 and the annual total
compensation of our CEO, as reported in the Summary Compensation Table included in this Proxy Statement, was $3,146,113. Based on this information, the ratio of the annual total compensation of our CEO to the median of the annual total compensation
of all employees was 23 to 1. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The CEO Pay Ratio above represents our reasonable estimate calculated in a manner consistent
with SEC rules and applicable guidance. SEC rules and guidance provide significant flexibility in how companies identify the median employee, and each company may use a different methodology and make different assumptions particular to that company.
As a result, and as explained by the SEC when it adopted these rules, in considering the pay ratio disclosure, stockholders should keep in mind that the rule was not designed to facilitate comparisons of pay ratios among different companies, even
companies within the same industry, but rather to allow stockholders to better understand and assess each particular company&#146;s compensation practices and pay ratio disclosures. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neither the Compensation Committee nor our management used our CEO Pay Ratio measure in making compensation decisions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">59 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>DIRECTOR COMPENSATION </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>N<SMALL>ON</SMALL>-E<SMALL>MPLOYEE</SMALL> D<SMALL>IRECTOR</SMALL> C<SMALL>OMPENSATION</SMALL> P<SMALL>HILOSOPHY</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation philosophy is based on the following guiding principles: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Aligning the long-term interests of stockholders and directors; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Compensating directors appropriately and adequately for their time, effort and experience </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The elements of director compensation consist of annual cash retainers and equity awards, as well as customary and usual expense
reimbursement in attending Board and committee meetings. In an effort to align the long-term interests of our stockholders and <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, the mix of cash and equity compensation has historically
been, and is currently, weighted more heavily to equity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee determines
<FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation, which the full Board reviews and approves upon recommendation from the Compensation Committee. When considering <FONT STYLE="white-space:nowrap">non-employee</FONT> director
compensation decisions, the Compensation Committee believes it is important to be informed as to current compensation practices of comparable publicly-held companies in the life sciences industry, especially to understand the demand and
competitiveness for attracting and retaining an individual with each <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s specific expertise and experience. Our compensation arrangements for our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors are set forth in our <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy (the &#147;Director Compensation Policy&#148;). The Director Compensation Policy
outlines cash and equity compensation automatically payable to <FONT STYLE="white-space:nowrap">non-employee</FONT> members of the Board, unless such <FONT STYLE="white-space:nowrap">non-employee</FONT> director declines receipt of such cash or
equity compensation by written notice to us. Every other year, the Compensation Committee reviews our <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation relative to industry practices. Based on this review, and guidance from
Arnosti, upon recommendation of the Compensation Committee, effective February&nbsp;1, 2018, the Board approved an amendment to the Director Compensation Policy to increase the size of the Subsequent Grant described below from 7,500 shares to 15,000
shares of Common Stock, and to increase the additional cash retainer paid to the members of the Audit Committee from $7,500 annually to $10,000 annually. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>ASH</SMALL> C<SMALL>OMPENSATION</SMALL> A<SMALL>RRANGEMENTS</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2017, each member of our Board who was not an employee or officer of the Company received the following cash compensation for Board
services: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">A $65,000 annual retainer for service as chairman of the Board and a $40,000 annual retainer for service as a member of the Board.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">A $20,000 annual retainer for the Chair of the Audit Committee and a $7,500 annual retainer for each additional member of the Audit Committee.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">A $15,000 annual retainer for the Chair of the Compensation Committee and a $7,000 annual retainer for each additional member of the Compensation
Committee. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">A $10,000 annual retainer for the Chair of the Nominating and Governance Committee and $5,000 annual retainer for each additional member of the
Nominating and Governance Committee. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also reimburse our
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors for their reasonable expenses incurred in attending meetings of our Board and committees of our Board. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">60 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>QUITY</SMALL> A<SMALL>WARDS</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our compensation program for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, except with regard to vesting periods as
described below, was unchanged in 2017 and provides that: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each director and the chairman of the Board automatically receives an initial equity award, or Initial Grant, consisting of a <FONT
STYLE="white-space:nowrap">non-qualified</FONT> stock option to purchase 15,000 shares and 25,000 shares, respectively, of Dynavax common stock upon the date each such person is elected or appointed to the Board. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">On the date of each annual meeting of the Company&#146;s stockholders, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director also
automatically receives a subsequent equity award, or Subsequent Grant, consisting of a <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option to purchase 7,500 shares of Dynavax common stock. However, the
<FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s first Subsequent Grant shall be reduced to 75% of the Subsequent Grant, or 5,625 shares, if the service period from the <FONT STYLE="white-space:nowrap">non-employee</FONT>
director&#146;s initial election date to the annual meeting is between 7 and 10 months, 50% of the Subsequent Grant, or 3,750 shares, if the service period from the <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s initial
election date to the annual meeting is between 4 and 7 months, and 25% of the Subsequent Grant, or 1,875 shares, if the service period from the <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s initial election date to the annual
meeting is between 1 and 4 months. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Effective as of the 2016 Annual Meeting, each Initial Grant vests in
equal annual installments over three years on the anniversary of the grant date. Each Subsequent Grant vests in full on the <FONT STYLE="white-space:nowrap">one-year</FONT> anniversary of the grant date. The exercise price per share of each Initial
Grant and Subsequent Grant shall be one hundred percent of the fair market value per share on the date of grant. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board may approve
additional cash and equity awards for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>D<SMALL>IRECTOR</SMALL>
C<SMALL>OMPENSATION</SMALL> T<SMALL>ABLE</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows for the fiscal year ended December&nbsp;31,
2017, certain information with respect to the compensation of all <FONT STYLE="white-space:nowrap">non-employee</FONT> directors of the Company: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt ; display:inline;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Fees&nbsp;Earned<BR>or Paid in<BR>Cash
<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Option<BR>Awards<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)(3)</SUP></B></FONT></TD>

<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnold L. Oronsky, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">72,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,203</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">101,703</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Laura Brege</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">60,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,203</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">89,203</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Francis R. Cano, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">52,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,203</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">81,203</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dennis A. Carson, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,203</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">69,203</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Daniel L. Kisner, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">57,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,203</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">86,203</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peggy V. Phillips</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">62,500</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,203</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">91,703</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stanley A. Plotkin, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">40,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,203</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">69,203</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Natale Ricciardi</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">45,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29,203</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">74,203</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>Consists of fees earned or paid in 2017 for Board and committee meeting
membership as described above. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">Represents the aggregate grant date fair value of stock options granted in the fiscal year in accordance with ASC 718. See note 14 of our &#147;Notes
to Consolidated Financial Statements&#148; in our annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed with the SEC on March&nbsp;8, 2018, for a discussion of assumptions we made in determining the compensation costs included in
this column. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">As of December&nbsp;31, 2017, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director held stock options to purchase the following numbers
of shares of our common stock: Dr.&nbsp;Oronsky held options to purchase 44,950 shares of our common stock; Ms.&nbsp;Brege held options to purchase 27,675 shares of our common stock; Dr.&nbsp;Cano held options to purchase 40,050 shares of our common
stock; Dr.&nbsp;Carson held options to purchase 34,750 shares of our common stock; Dr.&nbsp;Kisner held options to purchase 43,450 shares of our common stock; Ms.&nbsp;Phillips held options to purchase 44,950 shares of our common stock;
Dr.&nbsp;Plotkin held options to purchase 33,750 shares of our common stock; and Mr.&nbsp;Ricciardi held options to purchase 27,750 share of our common stock. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">61 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>QUITY</SMALL> C<SMALL>OMPENSATION</SMALL> P<SMALL>LANS</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows activity under our equity compensation plans as of the fiscal year ended December&nbsp;31, 2017. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="48%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:49pt ; display:inline;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Plan Category</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number of<BR>securities&nbsp;to<BR>be&nbsp;issued&nbsp;upon&nbsp;exercise<BR>of outstanding
options,<BR>warrants and rights</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B><FONT STYLE="white-space:nowrap">Weighted-average</FONT><BR>exercise price of<BR>outstanding<BR>options,
warrants<BR>and rights</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number<BR>of&nbsp;securities&nbsp;remaining<BR>available for future<BR>issuance
under<BR>equity&nbsp;compensation<BR>plans (excluding<BR>securities reflected in<BR>the first column)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity compensation plans approved by security holders:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2004 Stock Incentive Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">77,774</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27.76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2011 Equity Incentive Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,391,610</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19.41</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,100,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2014 Employee Stock Purchase Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">98,227</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Equity compensation plans not approved by security holders:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2010 Employment Inducement Award Plan</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">11,450</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">16.55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">2017 Inducement Award Plan</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">74,800</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">18.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1,125,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,555,634</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21.37</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,323,760</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">As of December&nbsp;31, 2017, an aggregate of 98,227 shares remained available for future issuance under the 2014 Employee Stock Purchase Plan, and as
of April&nbsp;9, 2018, up to a maximum of 40,439 shares may be purchased in the current purchase period. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">In order to induce qualified individuals to join our Company, our Board adopted the 2010 Employment Inducement Award Plan, or the 2010 Inducement Plan,
effective January&nbsp;8, 2010, which provided for the issuance of up to 150,000 shares of Company common stock to new employees of the Company. Stockholder approval of the 2010 Inducement Plan was not required under Nasdaq Marketplace Rule
5635(c)(4). Upon the effectiveness of the Amended 2011 Plan, no additional awards were granted under either the 2004 Stock Incentive Plan or the 2010 Inducement Plan. All shares currently subject to awards outstanding under the 2004 Stock Incentive
Plan or 2010 Inducement Plan, which awards expire or are forfeited, will be included in the reserve for the Amended 2011 Plan to the extent such shares would otherwise return to such plans. Awards granted under the 2010 Inducement Plan have a term
of 10 years. Exercisability, option price and other terms are determined by the plan administrator, but the option price cannot be less than 100% of fair market value of those shares on the date of grant. Stock options granted under the 2010
Inducement Plan generally vest over a period of four years, with the exception of performance based awards which will vest upon achievement of certain performance conditions. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">In order to induce qualified individuals to join our Company, on November&nbsp;28, 2017, our Board adopted the 2017 Inducement Award Plan, or the 2017
Inducement Plan, which provided for the issuance of up to 1,200,000 shares of Company common stock to new employees of the Company. Stockholder approval of the 2017 Inducement Plan was not required under Nasdaq Marketplace Rule 5635(c)(4). Upon the
effectiveness of the 2018 Equity Incentive Plan, no additional awards will be granted under the 2017 Inducement Plan. All shares currently subject to awards outstanding under the 2017 Inducement Plan, which awards expire or are forfeited, will be
included in the reserve for the 2018 Equity Incentive Plan to the extent such shares would otherwise return to such plan. Awards granted under the 2017 Inducement Plan have a term of 10 years. Exercisability, option price and other terms are
determined by the plan administrator, but the option price cannot be less than 100% of fair market value of those shares on the date of grant. Stock options granted under the 2017 Inducement Plan generally vest over a period of four years, with the
exception of performance based awards which will vest upon achievement of certain performance conditions. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">62 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CORPORATE GOVERNANCE </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>ORPORATE</SMALL> G<SMALL>OVERNANCE</SMALL> G<SMALL>UIDELINES</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In February 2016, our Board adopted Corporate Governance Guidelines that set forth key principles to guide the Board in its exercise of
responsibilities and serve the interests of the Company and our stockholders. The Corporate Governance Guidelines were reviewed and updated by the Board in February 2018. Our Corporate Governance Guidelines can be found on the Corporate Governance
page under the Investors and Media&nbsp;&#150;&nbsp;Corporate Governance section of our website at www.dynavax.com. In addition, these guidelines are available in print to any stockholder who requests a copy. Please direct all requests to our
Corporate Secretary, Dynavax Technologies Corporation, 2929 Seventh Street, Suite 100, Berkeley, California 94710. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>S<SMALL>TOCKHOLDER</SMALL> O<SMALL>UTREACH</SMALL> <SMALL>AND</SMALL> E<SMALL>NGAGEMENT</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board of Directors and management team value the views of our stockholders and we proactively engage with our major stockholders on a
regular basis. We believe our outreach efforts help ensure that our stockholders are aware of our governance initiatives and provide us with valuable feedback in order to enhance our governance practices and disclosure to stockholders. In early
spring 2018, we contacted 17 of our largest stockholders and we spoke with 100% of the stockholders that wanted to provide us with feedback at that time. The bulk of the stockholders, while appreciating the outreach, did not feel a need to talk at
the time. During these discussions we solicited feedback from our stockholders on our corporate governance and executive compensation practices and we specifically discussed our Rights Agreement that was adopted in November 2008 with a <FONT
STYLE="white-space:nowrap">ten-year</FONT> term that is scheduled to expire in November 2018 and our current intention to allow it to expire by its terms. None of the stockholders with which we discussed this matter objected to our approach.
Additionally, none of our stockholders expressed any concerns about our about our corporate governance or executive compensation practices. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>M<SMALL>AJORITY</SMALL> V<SMALL>OTE</SMALL> P<SMALL>OLICY</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our Corporate Governance Guidelines include a provision whereby any nominee for director in an uncontested election would submit an offer of resignation for consideration by the Nominating and Corporate
Governance Committee of the Board, if such nominee receives a greater number of &#147;Withhold&#148; votes than &#147;For&#148; votes. The Nominating and Corporate Governance Committee would then consider all of the relevant facts and circumstances
and recommend to the Board the action to be taken with respect to such offer of resignation. Promptly following the Board&#146;s decision, we would disclose that decision and an explanation of such decision in a filing with the SEC or a press
release. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>I<SMALL>NDEPENDENCE</SMALL> O<SMALL>F</SMALL> T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL>
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">As required under the Nasdaq Stock Market, or Nasdaq listing standards, and our Corporate Governance Guidelines, a
majority of the members of a listed company&#146;s board of directors must qualify as &#147;independent,&#148; as affirmatively determined by the board of directors. In addition, applicable Nasdaq rules require that, subject to specified exceptions,
each member of a listed company&#146;s audit, compensation and nominating committees be independent within the meaning of applicable Nasdaq rules. Audit committee members must also satisfy the independence criteria set forth in Rule <FONT
STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Consistent with these considerations, our Board undertook a
review of the independence of each director and considered whether any director has a material relationship that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. After review of all
relevant transactions or relationships between each director, or any of his or her family members, and the Company, its senior management and its independent registered public accounting firm, the Board has affirmatively determined that the
following directors are independent directors within the meaning of the applicable Nasdaq listing standards: Ms.&nbsp;Phillips, Ms.&nbsp;Brege and Mr.&nbsp;Ricciardi as well as Drs. Carson, Cano, Kisner, Oronsky and Plotkin. In making these
determinations, the Board found that none of these directors has a material or other disqualifying relationship with the Company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">63 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In determining the independence of Dr.&nbsp;Carson, the Board took into account his
role as the university-nominated representative on the evaluation committee to oversee aspects of the agreement between the Regents of the University of California and Dynavax and determined that this relationship would not interfere with
Dr.&nbsp;Carson&#146;s exercise of independent judgment in carrying out his responsibilities as a director. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">By virtue of his
employment with the Company, Eddie Gray, our Chief Executive Officer is not an independent director. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>B<SMALL>OARD</SMALL>
L<SMALL>EADERSHIP</SMALL> S<SMALL>TRUCTURE</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board is currently chaired by Dr.&nbsp;Oronsky. The duties of the
chairman include presiding over all meetings of the Board; preparing the agenda for Board meetings in consultation with the CEO and other members of our Board; calling and presiding over meetings of
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors; and managing the Board&#146;s process for annual evaluation of the CEO. Accordingly, the chairman has substantial ability to shape the work of our Board. Our Board currently believes
that separation of the positions of chairman and CEO reinforces the independence of our Board in its oversight of our business and affairs. In addition, such separation helps create an environment that is more conducive to objective evaluation and
oversight of management&#146;s performance, increasing management accountability and improving the ability of our Board to monitor whether management&#146;s actions are in the best interests of our Company and its stockholders. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board also believes there may be advantages to having an independent chairman for matters such as communications and relations
between our Board, the CEO and other senior management and in assisting our Board in reaching consensus on particular strategies and policies. Having a chairman separate from the CEO also allows the chairman to focus on assisting the CEO and other
senior management in seeking and adopting successful business strategies and risk management policies and in making successful choices in management succession. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>B<SMALL>OARD</SMALL>&#146;<SMALL>S</SMALL> R<SMALL>OLE</SMALL> I<SMALL>N</SMALL> R<SMALL>ISK</SMALL> O<SMALL>VERSIGHT</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk assessment and oversight are an integral part of our governance and management processes. Our Board encourages management to promote
a culture that incorporates risk management into our corporate strategy and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> business operations. Management discusses strategic and operational risks at
regular management meetings, and conducts specific strategic planning and review sessions during the year that include a focused discussion and analysis of the risks facing the Company. Throughout the year, senior management reviews these risks with
the Board at regular Board meetings as part of management presentations that focus on particular business functions, operations or strategies, and presents the steps taken by management to mitigate or eliminate such risks. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board does not have a standing risk management committee but rather administers this oversight function directly through our Board as
a whole as well as through various standing committees of our Board that address risks inherent in their respective areas of oversight. In particular, our Board is responsible for monitoring and assessing strategic risk exposure, including
overseeing our healthcare compliance program pertaining to healthcare laws, regulations and industry standards applicable to pharmaceutical companies. Our Audit Committee has the responsibility to oversee our major financial risk exposures and the
steps our management has taken to monitor and control these exposures as well as oversight of our enterprise risk management program. The Audit Committee also monitors compliance with legal and regulatory requirements, oversees the performance of
our internal audit function and approves or disapproves any related-persons transactions. Our Nominating and Governance Committee monitors the effectiveness of our corporate governance guidelines and manages the process for annual director
self-assessment and evaluation of the Board. Our Compensation Committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>M<SMALL>EETINGS</SMALL> O<SMALL>F</SMALL> T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board met nine times during fiscal year 2017, substantially more frequently than the five or six times per year that the Board
normally meets. Despite the substantial increase in the number of Board meetings in 2017, all </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">64 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Board members, with the exception of Dr.&nbsp;Plotkin, attended at least 75% or more of the aggregate of the meetings of the Board and of the committees, on which the member served, held during
the period of service as a director or committee member. In addition to his contribution to the Company at Board meetings, Dr.&nbsp;Plotkin made substantial contributions to the Company in 2017, including speaking at the July meeting of the
FDA&#146;s Vaccines and Related Biological Products Advisory Committee in favor of <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> approval (the Committee voted <FONT STYLE="white-space:nowrap">12-1</FONT> with 3 abstentions in favor of approval)
and meeting with management throughout the year, including pertaining to <FONT STYLE="white-space:nowrap">HEPLISAV-B</FONT> and our immuno-oncology program. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>OMMITTEES</SMALL> O<SMALL>F</SMALL> T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL> D<SMALL>IRECTORS</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Board has three standing committees: an Audit Committee, a Compensation Committee and a Nominating and Governance Committee. The
following table provides membership and meeting information for fiscal year 2017 for each of the Board committees: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:20pt ; display:inline;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Audit</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Compensation</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Nominating</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnold L. Oronsky, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Francis R. Cano, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Laura Brege</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Daniel L. Kisner, M.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peggy V. Phillips</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Natale Ricciardi</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">X</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Members</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total Meetings</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Committee Chairperson </FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Below is
a description of each committee of our Board. Each of the committees has authority to engage legal counsel or other experts or consultants as it deems appropriate to carry out its responsibilities. Our Board has determined that each member of each
committee meets the applicable Nasdaq listing standards and related rules and regulations regarding &#147;independence&#148; and that each member is free of any relationship that would impair his or her individual exercise of independent judgment
with regard to the Company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Audit Committee </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Audit Committee for 2017 was comprised of three directors: Ms.&nbsp;Brege (Chairperson), Dr.&nbsp;Oronsky and Ms.&nbsp;Phillips. In addition to determining that all members of the Audit Committee are
independent (as independence is currently defined in Rule 5605(c)(2)(A)(i) and (ii)&nbsp;of the Nasdaq listing standards), the Board determined that Ms.&nbsp;Brege qualified as an &#147;audit committee financial expert,&#148; as defined in
applicable SEC rules. The Board made a qualitative assessment of Ms.&nbsp;Brege&#146;s level of knowledge and experience based on a number of factors, including Ms.&nbsp;Brege&#146;s formal education and experience as a chief financial officer. The
Audit Committee was established by the Board in accordance with Section&nbsp;3(a)(58)(A) of the Exchange Act to oversee the Company&#146;s corporate accounting and financial reporting processes and audits of its financial statements. The Audit
Committee operates under a written charter that is available on the Company&#146;s website at <U>http://investors.dynavax.com/corporate-governance</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Among other things, the charter specifically requires our Audit Committee to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review and monitor the policies and procedures adopted by the Company to fulfill its responsibilities regarding the fair and accurate presentation of
the Company&#146;s financial statements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">appoint, compensate, and oversee the work of the Company&#146;s independent registered public accounting firm; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">65 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">approve and monitor all audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services performed by the Company&#146;s independent registered
public accounting firm; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">investigate, review and report the propriety and ethical implications of any transactions between the Company and any related persons;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">consult and discuss with management and the independent registered public accounting firm regarding the effectiveness of the Company&#146;s internal
controls over financial reporting; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">establish procedures, as required under applicable law, for the receipt, retention and treatment of complaints received by the Company regarding
accounting, internal controls or auditing matters and the confidential and anonymous submission by employees of concerns regarding questionable accounting or auditing matters; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review and evaluate the Company&#146;s accounting principles and systems of internal controls; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">review and discuss the disclosure of the Company&#146;s annual audited financial statements and quarterly financial statements, including reviewing the
Company&#146;s disclosures under &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Management is responsible for the financial reporting process, including the system of internal controls and for the preparation of consolidated financial statements in accordance with accounting
principles generally accepted in the United States. Ernst&nbsp;&amp; Young, the Company&#146;s independent registered public accounting firm, is responsible for auditing or reviewing those financial statements. The Audit Committee monitors and
reviews these processes. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Report of the Audit Committee of the Board of Directors </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">During 2017, the Audit Committee met on four occasions. During these meetings the Committee met with Ernst&nbsp;&amp; Young, without the
presence of the Company&#146;s management. During the course of these meetings, we: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">discussed with management and Ernst&nbsp;&amp; Young management&#146;s continued testing and evaluation of its system of internal control over
financial reporting. We also reviewed Ernst&nbsp;&amp; Young&#146;s Report of Independent Registered Public Accounting Firm included in the Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> or Annual Report, related to its audit of
the effectiveness of the Company&#146;s internal control over financial reporting; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewed and discussed with management and Ernst&nbsp;&amp; Young the annual audited financial statements before filing the Annual Report with the SEC,
addressing the acceptability of the Company&#146;s accounting principles and such other matters as applicable auditing standards require us to discuss; the Audit Committee has discussed with the independent registered public accounting firm the
matters required to be discussed by Auditing Standard No.&nbsp;1301, Communications with Audit Committees (&#147;AS 1301&#148;), as adopted by the Public Company Accounting Oversight Board (&#147;PCAOB&#148;) and recommended to the Board that the
financial statements should be included in the Annual Report; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewed and discussed with management and Ernst&nbsp;&amp; Young the Company&#146;s quarterly unaudited financial statements before the issuance of
its quarterly financial results press releases and the filing of its Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> with the SEC; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">discussed with management and Ernst&nbsp;&amp; Young significant financial reporting matters, including liquidity and capital requirements, and the
accounting for significant transactions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">appointed and oversaw the work and compensation of Ernst&nbsp;&amp; Young, including the review of engagement agreement terms;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewed and provided guidance with respect to the external audit and the Company&#146;s relationship with Ernst&nbsp;&amp; Young by (1)&nbsp;reviewing
Ernst&nbsp;&amp; Young&#146;s proposed audit scope, approach, compensation and independence; (2)&nbsp;obtaining written statements and disclosures from Ernst&nbsp;&amp; Young regarding relationships and services with the Company which may impact
independence as required by Ethics and </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">66 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
Independence Rule 3526, &#147;Communications with Audit Committees Concerning Independence&#148;; (3)&nbsp;discussing with Ernst&nbsp;&amp; Young the financial statements and audit findings,
including any significant adjustments, management judgments and accounting estimates, significant new accounting policies and whether there were disagreements with management; and (4)&nbsp;obtaining assurance from Ernst&nbsp;&amp; Young that the
requirements of Section&nbsp;10A of the Exchange Act have been met; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reviewed, in conjunction with the Company&#146;s legal counsel, all legal matters that could have a significant impact on the Company&#146;s financial
statements or compliance policies. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Based on our reviews and discussions as described above, and based on
the report of Ernst&nbsp;&amp; Young, we recommended to the Board, and the Board approved, that the audited financial statements be included in the Company&#146;s Annual Report for the year ended December&nbsp;31, 2017, filed with the SEC. We also
approved, subject to stockholder ratification, the selection of Ernst&nbsp;&amp; Young as the Company&#146;s independent registered public accounting firm for 2018. In making this recommendation, we considered whether Ernst&nbsp;&amp; Young&#146;s
provision of services other than audit services is compatible with maintaining independence of our independent registered public accounting firm. Although we have the sole authority to appoint the independent registered public accounting firm, we
continued the long-standing practice of recommending that the Board ask the stockholders at their Annual Meeting to ratify the appointment of Ernst&nbsp;&amp; Young as the Company&#146;s independent registered public accounting firm. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>The material in this report is not &#147;soliciting material,&#148; is not deemed &#147;filed&#148; with the SEC and is not to be
incorporated by reference in any filing of the Company under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing. </I></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Laura Brege, Chairperson </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Arnold&nbsp;L. Oronsky, Ph.D. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ms.&nbsp;Peggy&nbsp;V. Phillips </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation Committee </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Compensation Committee is composed of three directors: Ms.&nbsp;Phillips (Chairperson) and Drs. Kisner and Cano. All members of the
Compensation Committee are independent as required by Nasdaq Rule 5605(d) (as independence is currently defined in Rule 5605(a)(2) of the Nasdaq listing standards), are &#147;outside directors&#148; for purposes of Section&nbsp;162(m) of the Code
and are <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> directors&#148; for purposes of Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> under the Exchange Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Compensation Committee acts on behalf of the Board to review, recommend for adoption, and oversee the Company&#146;s compensation strategy, policies, plans and programs. The Compensation Committee
operates under a written charter that is available on the Company&#146;s website at <U>http://investors.dynavax.com/corporate-governance</U>. Among other things, the charter specifically requires our Compensation Committee to: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Annually review and approve the Company&#146;s corporate goals and objectives relevant to CEO compensation, evaluate the CEO&#146;s performance in
light of such goals and objectives, and recommend to the Board the CEO&#146;s compensation level based on this evaluation. In determining the long-term incentive component of the CEO&#146;s compensation, the Compensation Committee will consider the
Company&#146;s performance and relative stockholder return, the value of similar incentive awards to CEOs at comparable companies, and the awards given to the Company&#146;s CEO in past years; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">annually review and make recommendations to the Board with respect to incentive compensation plans and equity-based plans;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">annually review Director compensation and make recommendation to the Board; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">administer the Company&#146;s incentive-compensation plans and equity-based plans as in effect and as adopted from time to time by the Board provided
that the Board shall retain the authority to interpret such plans; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">67 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">annually review and approve for the Company&#146;s executive officers as defined in Rule <FONT STYLE="white-space:nowrap">16a-1(f)</FONT> of the
Exchange Act: i) annual base salary levels; ii) annual incentive compensation levels; iii) long-term incentive compensation levels; and iv) employment agreements, severance agreements, change of control agreements/provisions and any other
compensatory arrangements, in each case as, when and if appropriate; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">make regular reports to the Board; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">perform such other functions and have such other powers consistent with the Compensation Committee Charter, the Company&#146;s Bylaws and governing
laws as the Compensation Committee or the Board may deem appropriate. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Under its charter, our Compensation
Committee may form, and delegate authority to, subcommittees, as appropriate. Our Compensation Committee has authorized and delegated authority to our CEO to grant stock options to employees and consultants who are not officers of the Company from <FONT
STYLE="white-space:nowrap">pre-approved</FONT> pools and in accordance with guidelines designated for new hire and annual grants. The purpose of this delegation is to enhance the flexibility of option administration within the Company and to
facilitate the timely grant of options to <FONT STYLE="white-space:nowrap">non-executive</FONT> employees, particularly new employees, within specified limits and values approved by our Compensation Committee. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Compensation Committee Interlocks and Insider Participation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">During the fiscal year ended December&nbsp;31, 2017, Ms.&nbsp;Phillips and Drs. Cano and Kisner, each served as a member of the Compensation Committee. None of the members of our Compensation Committee at
any time has been one of our officers or employees or an officer or employee of one of our subsidiaries at any time during the fiscal year ended December&nbsp;31, 2017. None of our executive officers currently serve, or in the past year has served,
as a member of the board of directors or compensation committee of any entity that has one or more executive officers on our Board or Compensation Committee. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Nominating and Governance Committee </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Nominating and Governance
Committee is composed of three directors: Drs. Kisner (Chairperson) and Cano, and Mr.&nbsp;Ricciardi. All members of the Nominating and Governance Committee are independent (as independence is currently defined in Rule 5605(a)(2) of the Nasdaq
listing standards). The Nominating and Governance Committee is responsible for identifying, reviewing and evaluating candidates to serve as directors of the Company (consistent with criteria approved by the Board), reviewing and evaluating incumbent
directors and identifying with the CEO candidates for appointment or election to the Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In identifying potential director
candidates, the Nominating and Governance Committee considers Board candidates through a variety of methods and sources. These include suggestions from current Board members, senior management, stockholders, professional search firms and other
sources. At this time, the Nominating and Governance Committee does not have a policy with regard to the consideration of director candidates recommended by stockholders. While the Nominating and Governance Committee does not have such a formal
policy, it will consider such a recommendation, as reflected by its decision to recommend Mr.&nbsp;Ricciardi to the Board following a stockholder recommendation. Our Nominating and Corporate Governance Committee reviews all candidates in the same
manner regardless of the source of the recommendation. In the case of a new director candidate, the Nominating and Governance Committee also determines whether the nominee is independent based upon applicable NASDAQ listing standards, applicable SEC
rules and regulations and the advice of counsel, if necessary. Among the qualifications to be considered in the selection of candidates are broad experience in business, finance or administration, familiarity with the Company&#146;s industry, and
prominence and reputation. Since prominence and reputation in a particular profession or field of endeavor are what bring most persons to the Board&#146;s attention, there is further consideration of whether the individual has the time available to
devote to the work of the Board and one or more of its committees. In addition, our Nominating and Governance Committee will consider whether the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">68 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
candidate assists in achieving a mix of members that represents a diversity of backgrounds and experience, including with respect to age, gender, international background, race and specialized
experience. Each year, our Nominating and Governance Committee reviews its Board membership criteria and assesses the composition of the Board against the criteria. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Nominating and Governance Committee discussed committee business a number of times during the year and held two formal meetings. The Nominating and Governance Committee has adopted a written charter
that is available to stockholders on the Company&#146;s website at <U>http://investors.dynavax.com/corporate-governance</U>. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>S<SMALL>TOCKHOLDER</SMALL> C<SMALL>OMMUNICATIONS</SMALL> W<SMALL>ITH</SMALL> T<SMALL>HE</SMALL> B<SMALL>OARD</SMALL> O<SMALL>F</SMALL>
D<SMALL>IRECTORS</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders may communicate with our Board by directing comments, concerns, and questions to the
Corporate Secretary at Dynavax Technologies Corporation, 2929 Seventh Street, Suite 100, Berkeley, California 94710. Communications will be distributed to the Board, or to any individual directors as appropriate, depending on the facts and
circumstances outlined in the communication. In that regard, our Board has requested that certain items that are unrelated to the duties and responsibilities of the Board be filtered, including product complaints or inquiries, new product
suggestions, r&eacute;sum&eacute;s and other forms of job inquiries, surveys, or business solicitations or advertisements. In addition, material that is unduly hostile, threatening, illegal or similarly unsuitable will be excluded, with the
provision that any communication that is filtered out must be made available to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director upon request. Stockholders may also communicate with our Board as a group through our website at <U><FONT
STYLE="white-space:nowrap">http://investors.dynavax.com/contact-us</FONT></U>. All communications directed to the Audit Committee in accordance with our whistleblower policy that relate to questionable accounting or auditing matters involving the
Company will be promptly and directly forwarded to the chairperson of the Audit Committee. Every effort has been made to ensure that the views of stockholders are heard by the Board or individual directors, as applicable, and that appropriate
responses are provided to stockholders in a timely manner. We believe our responsiveness to stockholder communications to the Board has been excellent. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">69 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CERTAIN TRANSACTIONS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">There has not been, nor is there currently proposed, any transaction or series of similar transactions to which the Company was or is to
be a party in which the amount involved exceeds $120,000 and in which any current director, executive officer, holder of more than 5% of our common stock or any immediate family member of any of the foregoing persons had or will have a direct or
indirect material interest other than compensation arrangements, described under the sections entitled &#147;Executive Compensation&#148; and &#147; Director Compensation,&#148; other than with respect to the indemnification agreements described
below. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Related Persons Transactions and Indemnification </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Policies and Procedures for Related Person Transactions </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our Audit
Committee is responsible for reviewing and approving all related party transactions, which would include a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we and any
&#147;related person&#148; are participants involving an amount that exceeds $120,000, not including transactions involving compensation for services provided to Dynavax as an employee, director, consultant or similar capacity by a related person.
Related parties include any of our directors or executive officers, certain of our stockholders and their immediate family members. This obligation is set forth in writing in the Audit Committee charter. A copy of the Audit Committee charter is
available on the Company&#146;s website at <U>http://investors.dynavax.com/corporate-governance</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Where a transaction has
been identified as a related-person transaction, management would present information regarding the proposed related-person transaction to the Audit Committee (or, where Audit Committee approval would be inappropriate, to another independent body of
the Board) for consideration and approval or ratification. The presentation would include a description of, among other things, the material facts, the interests, direct and indirect, of the related persons, the benefits to Dynavax of the
transaction and whether any alternative transactions were available. To identify related-person transactions in advance, the Audit Committee relies on information supplied by our executive officers and directors. In considering related-person
transactions, the Audit Committee takes into account the relevant available facts and circumstances including, but not limited to (a)&nbsp;the risks, costs and benefits to Dynavax, (b)&nbsp;the impact on a director&#146;s independence in the event
the related person is a director, immediate family member of a director or an entity with which a director is affiliated, (c)&nbsp;the terms of the transaction, (d)&nbsp;the availability of other sources for comparable services or products and
(e)&nbsp;the terms available to or from, as the case may be, unrelated third parties or to or from employees generally. In the event a director has an interest in the proposed transaction, the director must recuse himself or herself from the
deliberations and approval. In determining whether to approve, ratify or reject a related-person transaction, the Audit Committee considers, in light of known circumstances, whether the transaction is in, or is not inconsistent with, the best
interests of Dynavax and our stockholders, as the Audit Committee determines in the good faith exercise of its discretion. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Transactions
With Related Persons </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have no related person transactions to report. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Indemnity Agreements </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have entered into indemnity agreements with some of our officers and directors so that they will be free from undue concern about personal liability in connection with their service to the Company. The
indemnity agreements provide, among other things, that the Company will indemnify such officer or director, under the circumstances and to the extent provided for therein, for expenses, damages, judgments, fines and settlements he or she may be
required to pay in actions or proceedings which he or she is or may be made a party by reason of his or her position as a director, officer or other agent of the Company, and otherwise to the fullest extent permitted under Delaware law. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">70 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>S<SMALL>ECTION</SMALL> 16(<SMALL>A</SMALL>) B<SMALL>ENEFICIAL</SMALL> O<SMALL>WNERSHIP</SMALL>
R<SMALL>EPORTING</SMALL> C<SMALL>OMPLIANCE</SMALL> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Section&nbsp;16(a) of the Exchange Act requires the Company&#146;s
directors and executive officers, and persons who own more than ten percent of a registered class of the Company&#146;s equity securities, to file with the SEC initial reports of ownership and reports of changes in ownership of common stock and
other equity securities of the Company. Officers, directors and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">greater-than-ten-percent</FONT></FONT> stockholders are required by SEC regulation to furnish the Company with copies
of all Section&nbsp;16(a) forms they file. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the Company&#146;s knowledge, based solely on a review of the copies of such
reports furnished to the Company and written representations that no other reports were required, during the fiscal year ended December&nbsp;31, 2017, all Section&nbsp;16(a) filing requirements applicable to its officers, directors and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">greater-than-ten-percent</FONT></FONT> beneficial owners were in compliance. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>ODE</SMALL> O<SMALL>F</SMALL> B<SMALL>USINESS</SMALL> C<SMALL>ONDUCT</SMALL> A<SMALL>ND</SMALL> E<SMALL>THICS</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have adopted the Dynavax Code of Business Conduct and Ethics that applies to all officers, directors and employees. Our Code of
Business Conduct and Ethics is available on our website at <U>http://investors.dynavax.com/corporate-governance</U> and upon written request. We will provide a written copy of the Dynavax Code of Business Conduct and Ethics to anyone without charge,
upon request written to Dynavax Technologies Corporation, Attention: Chief Compliance Officer, 2929 Seventh Street, Suite 100, Berkeley, California 94710-2753, <FONT STYLE="white-space:nowrap">(510)&nbsp;848-5100.</FONT> If we make any substantive
amendments to or grant any waiver from a provision of the Code of Business Conduct and Ethics to any executive officer or director, we will promptly disclose the nature of the amendment or waiver on our website. There have been no waivers under the
Code of Business Conduct and Ethics as of April&nbsp;9, 2018. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">71 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECURITY OWNERSHIP OF </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>CERTAIN BENEFICIAL OWNERS AND MANAGEMENT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth certain information regarding the ownership of the Company&#146;s common stock as of January&nbsp;31, 2018 by: (i)&nbsp;each director and nominee for director; (ii)&nbsp;the
NEOs; (iii)&nbsp;all executive officers and directors of the Company as a group; and (iv)&nbsp;all those known by the Company to be beneficial owners of more than five percent of its common stock. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:135pt ; display:inline;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Name and Address of Beneficial Holder</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number
of<BR>Shares<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Percent&nbsp;of&nbsp;Shares<BR>Beneficially<BR>Owned<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5% Stockholders:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">BlackRock, Inc.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,873,883</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">40 East 52nd Street</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">New York, New York 10022</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Point72 Asset Management, L.P.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3,811,437</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6.19</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">72 Cummings Point Road</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stamford, CT 06902</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">State Street Corporation</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(6)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4,580,203</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7.44</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">One Lincoln Street</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Boston, MA 02111</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:80pt ; display:inline;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>NEOs and Directors (1)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Eddie Gray</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(7)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">890,454</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1.43</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Michael S. Ostrach</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(8)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">298,079</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert L. Coffman, Ph.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(9)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">272,311</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Robert Janssen, M.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(10)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">228,636</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">David F. Novack</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(11)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">222,192</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arnold L. Oronsky, Ph.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(12)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">74,956</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Laura Brege </FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(13)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">19,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Francis R. Cano, Ph.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(14)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,550</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dennis A. Carson, M.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(15)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">34,062</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Daniel L. Kisner, M.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(16)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">37,450</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Peggy V. Phillips</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(17)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">51,252</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stanley A. Plotkin, M.D.</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(18)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">27,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Natale Ricciardi</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(19)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">20,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">All executive officers and directors as a group (13 persons)</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(20)</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">2,211,117</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">3.47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">Less than one percent. </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">The address of each of the NEOs and directors is c/o Dynavax Technologies Corporation, 2929 Seventh Street, Suite 100, Berkeley, California 94710.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>To our knowledge, except as set forth in the footnotes to this table, and
subject to applicable community property laws, each person named in this table has sole voting and investment power with respect to the shares set forth opposite such person&#146;s name. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>Beneficial ownership is determined in accordance with the rules of the SEC
and generally includes voting or investment power with respect to the securities. Shares of our common stock subject to options currently exercisable or that will become exercisable within 60 days after January&nbsp;31, 2018, are deemed outstanding
for computing the percentage of the person holding such options but are not deemed outstanding for computing the percentage of any other person. Applicable percentages are based on 61,602,148 shares of our common stock outstanding as of
January&nbsp;31, 2018, adjusted as required by the rules of the SEC. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>This information is based solely on a Schedule 13G/A filed by BlackRock,
Inc., on January&nbsp;29, 2018, with the SEC. BlackRock beneficially owns and has sole dispositive power over 3,873,883 shares of common stock, of which 3,768,756 are held with sole voting power. The address of the principal business and office of
BlackRock, Inc. and its affiliates is BlackRock Inc., 40 East 52nd Street, New York, NY 10022. The Schedule 13G/A provides information only as of December&nbsp;31, 2017, and, consequently, the beneficial ownership of the above-mentioned reporting
person may have changed between December&nbsp;31, 2017 and January&nbsp;31, 2018. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">72 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>This information is based solely on a Schedule 13G/A filed by Point72 Asset
Management, L.P. on February 14, 2018, with the SEC. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management.&nbsp;Point72 Asset Management, L.P. maintains investment and voting power with respect to the securities held by
certain investment funds it manages and beneficially owns 3,811,437 shares and has no sole dispositive or sole voting power. The address of the principal business and office of Point72 Asset Management, L.P. is, 72 Cummings Point Road, Stamford, CT
06902. The Schedule 13G/A provides information only as of December&nbsp;31, 2017, and, consequently, the beneficial ownership of the above-mentioned reporting person may have changed between December&nbsp;31, 2017 and January&nbsp;31, 2018.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(6)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>This information is based solely on a Schedule 13G filed by State Street
Corporation on February&nbsp;14, 2018, with the SEC. State Street Corp. beneficially owns 4,580,203 shares and has no sole dispositive or sole voting power. The address of the principal business and office of State Street Corp. is, One Lincoln
Street, Boston, MA 02111. The Schedule 13G provides information only as of December&nbsp;31, 2017, and, consequently, the beneficial ownership of the above-mentioned reporting person may have changed between December&nbsp;31, 2017 and
January&nbsp;31, 2018. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(7)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>Consists of 35,573 shares of common stock owned directly by Mr.&nbsp;Gray,
restricted stock awards to be converted into 112,000 shares of common stock within 60 days of January&nbsp;31, 2018 and options to purchase 742,881 shares of common stock exercisable within 60 days of January&nbsp;31, 2018.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(8)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>Consists of 14,646 shares of common stock owned directly by
Mr.&nbsp;Ostrach, restricted stock awards to be converted into 58,305 shares of common stock within 60 days of January&nbsp;31, 2018 and options to purchase 225,128 shares of common stock exercisable within 60 days of January&nbsp;31, 2018.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(9)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>Consists of 6,308 shares of common stock owned directly by Dr.&nbsp;Coffman,
restricted stock awards to be converted into 63,203 shares of common stock within 60 days of January 31, 2018 and options to purchase 202,800 shares of common stock exercisable within 60 days of January&nbsp;31, 2018. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(10)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>Consists of 30,790 shares of common stock owned directly by
Dr.&nbsp;Janssen, 948 of which were purchased through the employee stock purchase plan; restricted stock awards to be converted into 55,375 shares of common stock within 60 days of January&nbsp;31, 2018 and options to purchase 142,471 shares of
common stock exercisable within 60 days of January&nbsp;31, 2018. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(11)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>Consists of 14,174 shares of common stock owned directly by Mr.&nbsp;Novack,
1,671 of which were purchased through the employee stock purchase plan; restricted stock awards to be converted into 53,764 shares of common stock within 60 days of January&nbsp;31, 2018 and options to purchase 154,254 shares of common stock
exercisable within 60 days of January&nbsp;31, 2018. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(12)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>Consists of 37,506 shares of common stock owned directly by Dr.&nbsp;Oronsky
and options to purchase 37,450 shares of common stock exercisable within 60 days of January&nbsp;31, 2018. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(13)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>Consists of options to purchase 19,675 shares of common stock exercisable
within 60 days of January&nbsp;31, 2018. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(14)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>Consists of 2,000 shares of common stock owned directly by Dr.&nbsp;Cano and
options to purchase 32,550 shares of common stock exercisable within 60 days of January&nbsp;31, 2018. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(15)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>Consists of 6,812 shares of common stock owned directly by Dr.&nbsp;Carson
and options to purchase 27,250 shares of common stock exercisable within 60 days of January&nbsp;31, 2018. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(16)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>Consists of 1,500 shares of common stock owned directly by Dr.&nbsp;Kisner
and options to purchase 35,950 shares of common stock exercisable within 60 days of January&nbsp;31, 2018. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(17)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>Consists of 13,802 shares of common stock owned directly by
Ms.&nbsp;Phillips and options to purchase 37,450 shares of common stock exercisable within 60 days of January&nbsp;31, 2018. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(18)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>Consists of 1,000 shares of common stock owned directly by Dr.&nbsp;Plotkin
and options to purchase 26,250 shares of common stock exercisable within 60 days of January&nbsp;31, 2018. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(19)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>Consists of options to purchase 20,250 shares of common stock exercisable
within 60 days of January&nbsp;31, 2018. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(20)</SUP></FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"></SUP>Total number of shares includes 164,111 shares of common stock in aggregate
held as of January&nbsp;31, 2018, by our executive officers and directors and entities affiliated with such executive officers and directors. Also includes restricted stock awards to be converted into 342,647 shares of common stock within 60 days of
January&nbsp;31, 2018 and options to purchase 1,704,359 shares of common stock exercisable within 60 days of January&nbsp;31, 2018. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">73 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>ERFORMANCE</SMALL> G<SMALL>RAPH</SMALL> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The chart below compares total stockholder return on an investment of $100 in cash on December&nbsp;31, 2012, for: our common stock, The
Nasdaq Stock Market (U.S. companies), and the Nasdaq Pharmaceutical Preparation Index. All values assume reinvestment of the full amount of all dividends. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Note: Dynavax management cautions that the stock price performance shown in the graph below should not be considered indicative of potential future stock price performance. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g563018g83b21.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Section is not
&#147;soliciting material,&#148; is not deemed &#147;filed&#148; with the SEC and is not to be incorporated by reference in any filing of Dynavax Technologies Corporation under the Securities Act, or the Exchange Act, whether made before or after
the date hereof and irrespective of any general incorporation language in any such filing. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">74 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>OTHER MATTERS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Board knows of no other matters that will be presented for consideration at the Annual Meeting. If any other matters are properly
brought before the Annual Meeting, it is the intention of the persons named in the accompanying proxy to vote on such matters in accordance with their best judgment. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By Order of the Board of Directors</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Steven N. Gersten</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven N. Gersten</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Secretary</FONT></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">April&nbsp;20, 2018 </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>A copy of the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017, is available without charge upon written request to:
Dynavax Technologies Corporation, Attention: Corporate Secretary, 2929 Seventh Street, Suite 100, Berkeley, California 94710. </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">75 </FONT></P>


</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Appendix A </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>D<SMALL>YNAVAX</SMALL> T<SMALL>ECHNOLOGIES</SMALL> C<SMALL>ORPORATION</SMALL></B><SMALL></SMALL> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>2018 E<SMALL>QUITY</SMALL> I<SMALL>NCENTIVE</SMALL> P<SMALL>LAN</SMALL> </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>DOPTED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>:
A<SMALL>PRIL</SMALL>&nbsp;8, 2018 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>[A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL>
S<SMALL>TOCKHOLDERS</SMALL>: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018] </B></FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>G<SMALL>ENERAL</SMALL>.</B> </FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> <B>Successor to and Continuation of 2011 Plan.</B> The Plan is intended as the successor to and continuation of the Dynavax
Technologies Corporation 2011 Equity Incentive Plan (the &#147;<B><I>2011 Plan</I></B>&#148;). Following the Effective Date, no additional awards may be granted under the 2011 Plan or the Dynavax Technologies Corporation 2017 Inducement Award Plan
(the &#147;<B><I>2017 Inducement Plan</I></B>&#148;) (each of the 2011 Plan and 2017 Inducement Plan, a &#147;<B><I>Prior Plan</I></B>&#148;). Any unallocated shares remaining available for grant under the 2011 Plan as of 12:01 a.m. Pacific Time on
the Effective Date (the &#147;<B><I>2011 Plan</I></B><B><I>&#146;</I></B><B><I>s Available Reserve</I></B>&#148;) will cease to be available under the 2011 Plan at such time and will be added to the Share Reserve (as defined in Section&nbsp;3(a)(i))
and be then immediately available for grant and issuance pursuant to Awards granted under this Plan. From and after 12:01 a.m. Pacific Time on the Effective Date, except as provided in Sections 9(c), 9(d) and 9(e), all outstanding stock awards
granted under either of the Prior Plans (each, a &#147;<B><I>Prior Plan Award</I></B>&#148;) will remain subject to the terms of the applicable Prior Plan; <I>provided, however</I>, that the following shares of Common Stock subject to any
outstanding Prior Plan Award (collectively, the &#147;<B><I>Prior Plans</I></B><B><I>&#146;</I></B><B><I> Returning Shares</I></B>&#148;) will immediately be added to the Share Reserve (as defined in Section&nbsp;3(a)(i)) as and when such shares
become Prior Plans&#146; Returning Shares and will become available for grant and issuance pursuant to Awards granted under this Plan: (i)&nbsp;any shares subject to such stock award that are not issued because such stock award or any portion
thereof expires or otherwise terminates without all of the shares covered by such stock award having been issued; (ii)&nbsp;any shares subject to such stock award that are not issued because such stock award or any portion thereof is settled in
cash; and (iii)&nbsp;any shares issued pursuant to such stock award that are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares. All Awards granted on or
after 12:01 a.m. Pacific Time on the Effective Date will be subject to the terms of this Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B><B> Eligible Award
Recipients.</B> Subject to Section&nbsp;4, Employees and Directors are eligible to receive Awards. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B> <B>Available
Awards.</B> The Plan provides for the grant of the following types of Awards: (i)&nbsp;Incentive Stock Options; (ii)&nbsp;Nonstatutory Stock Options; (iii)&nbsp;Stock Appreciation Rights; (iv)&nbsp;Restricted Stock Awards; (v)&nbsp;Restricted Stock
Unit Awards; (vi)&nbsp;Performance Stock Awards; and (vii)&nbsp;Other Stock Awards. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B> <B>Purpose.</B> The Plan,
through the granting of Awards, is intended to help the Company and any Affiliate secure and retain the services of eligible award recipients, provide incentives for such persons to exert maximum efforts for the success of the Company and any
Affiliate and provide a means by which such persons may benefit from increases in value of the Common Stock. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>DMINISTRATION</SMALL>.</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> <B>Administration by Board.</B> The Board will administer the Plan. The Board may delegate administration of the Plan to a Committee or Committees, as provided in Section&nbsp;2(c). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> <B>Powers of Board.</B> The Board will have the power, subject to, and within the limitations of, the express provisions of
the Plan: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> To determine (A)&nbsp;who will be granted Awards, (B)&nbsp;when and how each Award will be granted,
(C)&nbsp;what type of Award will be granted, (D)&nbsp;the provisions of each Award (which need not be identical), including </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-1
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
when a Participant will be permitted to exercise or otherwise receive cash or Common Stock under the Award, (E)&nbsp;the number of shares of Common Stock subject to, or the cash value of, an
Award, and (F)&nbsp;the Fair Market Value applicable to an Award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> To construe and interpret the Plan and Awards
granted under it, and to establish, amend and revoke rules and regulations for administration of the Plan and Awards. The Board, in the exercise of these powers, may correct any defect, omission or inconsistency in the Plan or in any Award
Agreement, in a manner and to the extent it will deem necessary or expedient to make the Plan or Award fully effective. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)</B> To settle all controversies regarding the Plan and Awards granted under it. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv)</B> To accelerate, in whole or in part, the time at which an Award may be exercised or vest (or at which cash or shares of Common
Stock may be issued in settlement thereof). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(v)</B> To suspend or terminate the Plan at any time. Except as otherwise
provided in the Plan (including Section&nbsp;2(b)(viii)) or an Award Agreement, suspension or termination of the Plan will not materially impair a Participant&#146;s rights under an outstanding Award without his or her written consent. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(vi)</B> To amend the Plan in any respect the Board deems necessary or advisable, including, without limitation, by adopting
amendments relating to Incentive Stock Options and certain nonqualified deferred compensation under Section&nbsp;409A of the Code and/or to make the Plan or Awards granted under the Plan compliant with the requirements for Incentive Stock Options or
exempt from or compliant with the requirements for nonqualified deferred compensation under Section&nbsp;409A of the Code, subject to the limitations, if any, of applicable law. However, if required by applicable law or listing requirements, and
except as provided in Section&nbsp;9(a) relating to Capitalization Adjustments, the Company will seek stockholder approval of any amendment of the Plan that (A)&nbsp;materially increases the number of shares of Common Stock available for issuance
under the Plan, (B)&nbsp;materially expands the class of individuals eligible to receive Awards under the Plan, (C)&nbsp;materially increases the benefits accruing to Participants under the Plan, (D)&nbsp;materially reduces the price at which shares
of Common Stock may be issued or purchased under the Plan, or (E)&nbsp;materially expands the types of Awards available for issuance under the Plan. Except as otherwise provided in the Plan (including Section&nbsp;2(b)(viii)) or an Award Agreement,
no amendment of the Plan will materially impair a Participant&#146;s rights under an outstanding Award without his or her written consent. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(vii)</B> To submit any amendment to the Plan for stockholder approval, including, but not limited to, amendments to the Plan intended to satisfy the requirements of (A)&nbsp;Section&nbsp;422 of the
Code regarding incentive stock options or (B)&nbsp;Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(viii)</B> To
approve forms of Award Agreements for use under the Plan and to amend the terms of any one or more outstanding Awards, including, but not limited to, amendments to provide terms more favorable to the Participant than previously provided in the Award
Agreement, subject to any specified limits in the Plan that are not subject to Board discretion; <I>provided, however,</I> that except as otherwise provided in the Plan (including this Section&nbsp;2(b)(viii)) or an Award Agreement, no amendment of
an outstanding Award will materially impair a Participant&#146;s rights under such Award without his or her written consent. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding the foregoing or anything in the Plan to the contrary, unless prohibited by applicable law, the Board may amend the terms
of any outstanding Award or the Plan, or may suspend or terminate the Plan, without the affected Participant&#146;s consent, (A)&nbsp;to maintain the qualified status of the Award as an Incentive Stock Option under Section&nbsp;422 of the Code,
(B)&nbsp;to change the terms of an Incentive Stock Option, if such change results in impairment of the Award solely because it impairs the qualified status of the Award as an Incentive Stock Option under Section&nbsp;422 of the Code, (C)&nbsp;to
clarify the manner of exemption from, or to bring the Award or the Plan into compliance with, Section&nbsp;409A of the Code or (D)&nbsp;to comply with other applicable laws or listing requirements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-2
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ix)</B> Generally, to exercise such powers and to perform such acts as the Board
deems necessary or expedient to promote the best interests of the Company and that are not in conflict with the provisions of the Plan or Awards. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(x)</B> To adopt such procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit participation in the Plan by Employees or Directors who are foreign
nationals or employed outside the United States (provided that Board approval will not be necessary for immaterial modifications to the Plan or any Award Agreement that are required for compliance with the laws of the relevant foreign jurisdiction).
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) Delegation to Committee.</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> <B>General.</B> The Board may delegate some or all of the administration of the Plan to a Committee or Committees. If administration of the Plan is delegated to a Committee, the Committee will
have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including the power to delegate to a subcommittee of the Committee any of the administrative powers the
Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee, as applicable). Any delegation of administrative powers will be reflected in resolutions, not inconsistent with the
provisions of the Plan, adopted from time to time by the Board or Committee (as applicable). The Committee may, at any time, abolish the subcommittee and/or revest in the Committee any powers delegated to the subcommittee. The Board may retain the
authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of the powers previously delegated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> <B>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> Compliance.</B> The Committee may consist solely of two or more <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors in
accordance with Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B> <B>Delegation to an Officer.</B> The Board may
delegate to one or more Officers the authority to do one or both of the following: (i)&nbsp;designate Employees who are not Officers to be recipients of Options and SARs (and, to the extent permitted by applicable law, other Awards) and, to the
extent permitted by applicable law, the terms of such Awards; and (ii)&nbsp;determine the number of shares of Common Stock to be subject to such Awards granted to such Employees; <I>provided, however</I>, that the Board resolutions regarding such
delegation will specify the total number of shares of Common Stock that may be subject to the Awards granted by such Officer and that such Officer may not grant an Award to himself or herself. Any such Awards will be granted on the form of Award
Agreement most recently approved for use by the Committee or the Board, unless otherwise provided in the resolutions approving the delegation of authority. The Board may not delegate authority to an Officer who is acting solely in the capacity of an
Officer (and not also as a Director) to determine the Fair Market Value of the Common Stock pursuant to Section&nbsp;13(w)(iii). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(e)</B> <B>Effect of Board&#146;s Decision.</B> All determinations, interpretations and constructions made by the Board in good faith will not be subject to review by any person and will be final,
binding and conclusive on all persons. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(f)</B> <B>Cancellation and <FONT STYLE="white-space:nowrap">Re-Grant</FONT> of
Awards.</B> Neither the Board nor any Committee will have the authority to (i)&nbsp;reduce the exercise or strike price of any outstanding Option or SAR or (ii)&nbsp;cancel any outstanding Option or SAR that has an exercise or strike price (per
share) greater than the then-current Fair Market Value of the Common Stock in exchange for cash or other Awards under the Plan, unless the stockholders of the Company have approved such an action within 12 months prior to such an event. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(g)</B> <B>Minimum Vesting Requirements.</B> No Award may vest (or, if applicable, be exercisable) until at least 12 months following
the date of grant of the Award; <I>provided, however</I>, that up to 5% of the Share Reserve (as defined in Section&nbsp;3(a)(i)) may be subject to Awards that do not meet such vesting (and, if applicable, exercisability) requirements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-3
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(h)</B> <B>Dividends and Dividend Equivalents.</B> Dividends or dividend equivalents
may be paid or credited, as applicable, with respect to any shares of Common Stock subject to an Award, as determined by the Board and contained in the applicable Award Agreement; <I>provided, however</I>, that (i)&nbsp;no dividends or dividend
equivalents may be paid with respect to any such shares before the date such shares have vested under the terms of such Award Agreement, (ii)&nbsp;any dividends or dividend equivalents that are credited with respect to any such shares will be
subject to all of the terms and conditions applicable to such shares under the terms of such Award Agreement (including, but not limited to, any vesting conditions), and (iii)&nbsp;any dividends or dividend equivalents that are credited with respect
to any such shares will be forfeited to the Company on the date, if any, such shares are forfeited to or repurchased by the Company due to a failure to meet any vesting conditions under the terms of such Award Agreement. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>S<SMALL>HARES</SMALL> S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) Share Reserve.</B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> Subject to Section&nbsp;3(a)(iii) and Section&nbsp;9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards from and
after the Effective Date will not exceed (A)
[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;]</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1</SUP></FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"> shares (which number is the sum of (i)&nbsp;the number of shares ([&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;])</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> subject to the 2011 Plan&#146;s Available Reserve and (ii)&nbsp;an additional 5,000,000 new shares), <I>plus</I>
(B)&nbsp;the Prior Plans&#146; Returning Shares, if any, which become available for issuance under this Plan from time to time (such aggregate number of shares described in (A)&nbsp;and (B), the &#147;<B><I>Share Reserve</I></B>&#148;). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> Subject to Section&nbsp;3(b), the number of shares of Common Stock available for issuance under the Plan will be reduced by
(A)&nbsp;one share for each share of Common Stock issued pursuant to an Appreciation Award granted under the Plan and (B) 1.28 shares for each share of Common Stock issued pursuant to a Full Value Award granted under the Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)</B> Subject to Section&nbsp;3(b), the number of shares of Common Stock available for issuance under the Plan will be increased
by (A)&nbsp;one share for each Prior Plans&#146; Returning Share or 2018 Plan Returning Share (as defined in Section&nbsp;3(b)(i)) subject to an Appreciation Award and (B) 1.28 shares for each Prior Plans&#146; Returning Share or 2018 Plan Returning
Share subject to a Full Value Award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv)</B> For clarity, the Share Reserve in this Section&nbsp;3(a) is a limitation on
the number of shares of Common Stock that may be issued pursuant to the Plan. Accordingly, this Section&nbsp;3(a) does not limit the granting of Awards except as provided in Section&nbsp;7(a). Shares may be issued in connection with a merger or
acquisition as permitted by NASDAQ Listing Rule 5635(c) or, if applicable, NYSE Listed Company Manual Section&nbsp;303A.08, AMEX Company Guide Section&nbsp;711 or other applicable rule, and such issuance will not reduce the number of shares
available for issuance under the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) Reversion of Shares to the Share Reserve.</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> <B>Shares Available for Subsequent Issuance.</B><B> </B>The following shares of Common Stock (collectively, the
&#147;<B><I>2018 Plan</I></B> <B><I>Returning Shares</I></B>&#148;) will become available again for issuance under the Plan: (A)&nbsp;any shares subject to an Award that are not issued because such Award or any portion thereof expires or otherwise
terminates without all of the shares covered by such Award having been issued; (B)&nbsp;any shares subject to an Award that are not issued because such Award or any portion thereof is settled in cash; and (C)&nbsp;any shares issued pursuant to an
Award that are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares. </FONT></P>
<P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1</SUP>&nbsp;</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To be determined on date of 2018 Annual Meeting of Stockholders. </FONT></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">2</SUP>&nbsp;</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">To be determined on date of 2018 Annual Meeting of Stockholders. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-4
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> <B>Shares Not Available for Subsequent Issuance. </B>The following shares
of Common Stock will not become available again for issuance under the Plan: (A)&nbsp;any shares that are reacquired or withheld (or not issued) by the Company to satisfy the exercise, strike or purchase price of an Award or a Prior Plan Award
(including any shares subject to such award that are not delivered because such award is exercised through a reduction of shares subject to such award (<I>i.e</I>., &#147;net exercised&#148;)); (B) any shares that are reacquired or withheld (or not
issued) by the Company to satisfy a tax withholding obligation in connection with an Award or a Prior Plan Award; (C)&nbsp;any shares repurchased by the Company on the open market with the proceeds of the exercise, strike or purchase price of an
Award or a Prior Plan Award; and (D)&nbsp;in the event that a Stock Appreciation Right granted under the Plan or a stock appreciation right granted under either of the Prior Plans is settled in shares of Common Stock, the gross number of shares of
Common Stock subject to such award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B> <B>Incentive Stock Option Limit. </B>Subject to the Share Reserve and
Section&nbsp;9(a) relating to Capitalization Adjustments, the aggregate maximum number of shares of Common Stock that may be issued pursuant to the exercise of Incentive Stock Options will be 10,000,000 shares. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B> <B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Limit.</B> The aggregate value of all cash and
equity-based compensation granted or paid, as applicable, by the Company to any individual for service as a <FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director with respect to any fiscal year of the Company will not exceed (i)&nbsp;a total
of $200,000 with respect to any such cash compensation and (ii) $800,000 in total value with respect to any such equity-based compensation (including Awards and any other equity-based awards), calculating the value of any such awards based on the
grant date fair value of such awards for financial reporting purposes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e)</B> <B>Source of Shares.</B> The stock issuable
under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market or otherwise. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>LIGIBILITY</SMALL>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> <B>Eligibility for Specific Awards.</B> Incentive Stock Options may be granted only to employees of the Company or a &#147;parent corporation&#148; or &#147;subsidiary corporation&#148; thereof
(as such terms are defined in Sections 424(e) and 424(f) of the Code). Awards other than Incentive Stock Options may be granted to Employees and Directors; <I>provided, however</I>, that Awards may not be granted to Employees and Directors who are
providing Continuous Service only to any &#147;parent&#148; of the Company, as such term is defined in Rule 405, unless (i)&nbsp;the stock underlying such Awards is treated as &#147;service recipient stock&#148; under Section&nbsp;409A of the Code
(for example, because the Awards are granted pursuant to a corporate transaction such as a spin off transaction) or (ii)&nbsp;the Company, in consultation with its legal counsel, has determined that such Awards are otherwise exempt from or
alternatively comply with Section&nbsp;409A of the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> <B>Ten Percent Stockholders.</B> A Ten Percent
Stockholder will not be granted an Incentive Stock Option unless the exercise price (per share) of such Option is at least 110% of the Fair Market Value of the Common Stock on the date of grant of such Option and the Option is not exercisable after
the expiration of five years from the date of grant. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">5.</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>ROVISIONS</SMALL> R<SMALL>ELATING</SMALL> <SMALL>TO</SMALL> O<SMALL>PTIONS</SMALL> <SMALL>AND</SMALL> S<SMALL>TOCK</SMALL> A<SMALL>PPRECIATION</SMALL>
R<SMALL>IGHTS</SMALL>.</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Each Option or SAR Agreement will be in such form and will contain such terms and
conditions as the Board deems appropriate. All Options will be separately designated Incentive Stock Options or Nonstatutory Stock Options at the time of grant, and, if certificates are issued, a separate certificate or certificates will be issued
for shares of Common Stock purchased on exercise of each type of Option. If an Option is not specifically designated as an Incentive Stock Option, or if an Option is designated as an Incentive Stock Option but some portion or all of the Option fails
to qualify as an Incentive Stock Option under the applicable rules, then the Option (or portion thereof) will be a Nonstatutory Stock Option. The terms and conditions of separate Option or SAR Agreements need not be identical; <I>provided,
however</I>, that each Award Agreement will conform to (through incorporation of the provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following provisions: </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-5
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) Term.</B> Subject to the provisions of Section&nbsp;4(b) regarding Ten Percent
Stockholders, no Option or SAR will be exercisable after the expiration of seven years from the date of its grant or such shorter period specified in the Award Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(b) Exercise or Strike Price.</B> Subject to the provisions of Section&nbsp;4(b) regarding Ten Percent Stockholders, the exercise or strike price (per share) of each Option or SAR will be not less than
100% of the Fair Market Value of the Common Stock on the date the Award is granted. Notwithstanding the foregoing, an Option or SAR may be granted with an exercise or strike price (per share) less than 100% of the Fair Market Value of the Common
Stock on the date the Award is granted if such Award is granted pursuant to an assumption of, or substitution for, another option or stock appreciation right pursuant to a Transaction and in a manner consistent with the provisions of
Section&nbsp;409A of the Code and, if applicable, Section&nbsp;424(a) of the Code. Each SAR will be denominated in shares of Common Stock equivalents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(c) Payment of Exercise Price for Options.</B> The exercise price of an Option may be paid, to the extent permitted by applicable law and as determined by the Board in its sole discretion, by one or
more of the methods of payment set forth below that are specified in the Option Agreement. The Board has the authority to grant Options that do not permit all of the following methods of payment (or that otherwise restrict the ability to utilize
certain methods) and to grant Options that require the consent of the Company to utilize a particular method of payment. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> By cash (including electronic funds transfers), check, bank draft or money order payable to the Company; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> Pursuant to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of
the Common Stock subject to the Option, results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate exercise price to the Company from the sales proceeds; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)</B> By delivery to the Company (either by actual delivery or attestation) of shares of Common Stock; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv)</B> If an Option is a Nonstatutory Stock Option, by a &#147;net exercise&#148; arrangement pursuant to which the Company will
reduce the number of shares of Common Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; <I>provided, however</I>, that the Company will accept a cash or
other payment from the Participant to the extent of any remaining balance of the aggregate exercise price not satisfied by such reduction in the number of whole shares to be issued. Shares of Common Stock will no longer be subject to an Option and
will not be exercisable thereafter to the extent that (A)&nbsp;shares issuable upon exercise are used to pay the exercise price pursuant to the &#147;net exercise,&#148; (B) shares are delivered to the Participant as a result of such exercise, and
(C)&nbsp;shares are withheld to satisfy tax withholding obligations; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(v)</B> In any other form of legal consideration
that may be acceptable to the Board and specified in the applicable Award Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d) Exercise and Payment of a
SAR.</B> To exercise any outstanding SAR, the Participant must provide written notice of exercise to the Company in compliance with the provisions of the Award Agreement evidencing such SAR. The appreciation distribution payable on the exercise of a
SAR will be not greater than an amount equal to the excess of (A)&nbsp;the aggregate Fair Market Value (on the date of the exercise of the SAR) of a number of shares of Common Stock equal to the number of Common Stock equivalents in which the
Participant is vested under such SAR, and with respect to which the Participant is exercising the SAR on such date, over (B)&nbsp;the aggregate strike price of the number of Common Stock equivalents with respect to which the Participant is
exercising the SAR on such date. The appreciation distribution may be paid in Common Stock, in cash, in any combination of the two or in any other form of consideration, as determined by the Board and contained in the Award Agreement evidencing such
SAR. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-6
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e) Transferability of Options and SARs.</B> The Board may, in its sole discretion,
impose such limitations on the transferability of Options and SARs as the Board will determine. In the absence of such a determination by the Board to the contrary, the restrictions set forth in this Section&nbsp;5(e) on the transferability of
Options and SARs will apply. Notwithstanding the foregoing or anything in the Plan or an Award Agreement to the contrary, no Option or SAR may be transferred to any financial institution without prior stockholder approval. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(<B>i) Restrictions on Transfer.</B> An Option or SAR will not be transferable, except by will or by the laws of descent and distribution
(and pursuant to Sections 5(e)(ii) and 5(e)(iii) below), and will be exercisable during the lifetime of the Participant only by the Participant. Subject to the foregoing paragraph, the Board may, in its sole discretion, permit transfer of the Option
or SAR in a manner that is not prohibited by applicable tax and securities laws. Except as explicitly provided in the Plan, neither an Option nor a SAR may be transferred for consideration. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) Domestic Relations Orders.</B> Subject to the approval of the Board or a duly authorized Officer, an Option or SAR may be
transferred pursuant to the terms of a domestic relations order, official marital settlement agreement or other divorce or separation instrument as permitted by Treasury Regulations <FONT STYLE="white-space:nowrap">Section&nbsp;1.421-1(b)(2).</FONT>
If an Option is an Incentive Stock Option, such Option may be deemed to be a Nonstatutory Stock Option as a result of such transfer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(iii) Beneficiary Designation.</B> Subject to the approval of the Board or a duly authorized Officer, a Participant may, by delivering written notice to the Company, in a form approved by the Company
(or the designated broker), designate a third party who, upon the death of the Participant, will thereafter be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise. In the absence of
such a designation, upon the death of the Participant, the executor or administrator of the Participant&#146;s estate will be entitled to exercise the Option or SAR and receive the Common Stock or other consideration resulting from such exercise.
However, the Company may prohibit designation of a beneficiary at any time, including due to any conclusion by the Company that such designation would be inconsistent with the provisions of applicable laws. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(f) Vesting.</B> The total number of shares of Common Stock subject to an Option or SAR may vest and become exercisable in periodic
installments that may or may not be equal. The Option or SAR may be subject to such other terms and conditions on the time or times when it may or may not be exercised (which may be based on the satisfaction of Performance Goals or other criteria)
as the Board may deem appropriate. The vesting provisions of individual Options or SARs may vary. The provisions of this Section&nbsp;5(f) are subject to Section&nbsp;2(g) and any Option or SAR provisions governing the minimum number of shares of
Common Stock as to which an Option or SAR may be exercised. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(g) Termination of Continuous Service.</B> Except as otherwise
provided in the applicable Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a Participant&#146;s Continuous Service terminates (other than for Cause and other than upon the Participant&#146;s death
or Disability), the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of termination of Continuous Service), but only within such period of time ending on
the earlier of (i)&nbsp;the date that is three months following such termination of Continuous Service (or such longer or shorter period specified in the Award Agreement), and (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in
the Award Agreement. If, after such termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the applicable time period, the Option or SAR (as applicable) will terminate. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(h) Extension of Termination Date.</B> Except as otherwise provided in the applicable Award Agreement or other written agreement
between a Participant and the Company or an Affiliate,<B> </B>if the exercise of an Option or SAR following the termination of a Participant&#146;s Continuous Service (other than for Cause and other than upon the Participant&#146;s death or
Disability) would be prohibited at any time solely because the issuance of shares of Common Stock would violate the registration requirements under the Securities Act, then the Option or SAR will terminate on the earlier of (i)&nbsp;the expiration
of a total period of time (that need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#146;s Continuous Service during which the exercise
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-7
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of the Option or SAR would not be in violation of such registration requirements or (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement. In
addition, except as otherwise provided in the applicable Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if the sale of any Common Stock received upon exercise of an Option or SAR following the
termination of a Participant&#146;s Continuous Service (other than for Cause) would violate the Company&#146;s insider trading policy, then the Option or SAR will terminate on the earlier of (i)&nbsp;the expiration of a total period of time (that
need not be consecutive) equal to the applicable post-termination exercise period after the termination of the Participant&#146;s Continuous Service during which the sale of the Common Stock received upon exercise of the Option or SAR would not be
in violation of the Company&#146;s insider trading policy or (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the applicable Award Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(i) Disability of Participant.</B> Except as otherwise provided in the applicable Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if a
Participant&#146;s Continuous Service terminates as a result of the Participant&#146;s Disability, the Participant may exercise his or her Option or SAR (to the extent that the Participant was entitled to exercise such Option or SAR as of the date
of termination of Continuous Service), but only within such period of time ending on the earlier of (i)&nbsp;the date that is 12 months following such termination of Continuous Service (or such longer or shorter period specified in the Award
Agreement), and (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the Award Agreement. If, after such termination of Continuous Service, the Participant does not exercise his or her Option or SAR (as applicable) within the
applicable time period, the Option or SAR (as applicable) will terminate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(j) Death of Participant.</B> Except as
otherwise provided in the applicable Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if (i)&nbsp;a Participant&#146;s Continuous Service terminates as a result of the Participant&#146;s death, or
(ii)&nbsp;a Participant dies within the period (if any) specified in the Award Agreement for exercisability after the termination of the Participant&#146;s Continuous Service (for a reason other than death), then the Participant&#146;s Option or SAR
may be exercised (to the extent that the Participant was entitled to exercise such Option or SAR as of the date of death) by the Participant&#146;s estate, by a person who acquired the right to exercise the Option or SAR by bequest or inheritance,
or by a person designated to exercise the Option or SAR upon the Participant&#146;s death, but only within such period of time ending on the earlier of (i)&nbsp;the date that is 18 months following the date of death (or such longer or shorter period
specified in the Award Agreement), and (ii)&nbsp;the expiration of the term of the Option or SAR as set forth in the Award Agreement. If, after the Participant&#146;s death, the Option or SAR (as applicable) is not exercised within the applicable
time period, the Option or SAR (as applicable) will terminate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(k) Termination for Cause.</B> Except as explicitly
provided otherwise in the applicable Award Agreement or other individual written agreement between a Participant and the Company or an Affiliate, if a Participant&#146;s Continuous Service is terminated for Cause, the Participant&#146;s Option or
SAR will terminate immediately upon such termination of Continuous Service, and the Participant will be prohibited from exercising his or her Option or SAR from and after the time of such termination of Continuous Service. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(l) <FONT STYLE="white-space:nowrap">Non-Exempt</FONT> Employees.</B> If an Option or SAR is granted to an Employee who is a <FONT
STYLE="white-space:nowrap">non-exempt</FONT> employee for purposes of the Fair Labor Standards Act of 1938, as amended, the Option or SAR will not be first exercisable for any shares of Common Stock until at least six months following the date of
grant of the Option or SAR (although the Award may vest prior to such date). Consistent with the provisions of the Worker Economic Opportunity Act, (i)&nbsp;if such <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee dies or suffers a
Disability, (ii)&nbsp;upon a Transaction in which such Option or SAR is not assumed, continued or substituted, (iii)&nbsp;upon a Change in Control, or (iv)&nbsp;upon the Participant&#146;s retirement (as such term may be defined in the
Participant&#146;s Award Agreement, in another written agreement between the Participant and the Company or an Affiliate, or, if no such definition, in accordance with the Company&#146;s or Affiliate&#146;s then current employment policies and
guidelines), the vested portion of any Options and SARs may be exercised earlier than six months following the date of grant. The foregoing provision is intended to operate so that any income derived by a
<FONT STYLE="white-space:nowrap">non-exempt</FONT> employee in connection with the exercise or vesting of an Option or SAR will be exempt from his or her regular rate of pay. To the extent permitted and/or required for
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-8
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
compliance with the Worker Economic Opportunity Act to ensure that any income derived by a <FONT STYLE="white-space:nowrap">non-exempt</FONT> employee in connection with the exercise, vesting or
issuance of any shares under any other Award will be exempt from the employee&#146;s regular rate of pay, the provisions of this Section&nbsp;5(l) will apply to all Awards and are hereby incorporated by reference into such Award Agreements.
</FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>ROVISIONS</SMALL> <SMALL>OF</SMALL> A<SMALL>WARDS</SMALL> <SMALL>OTHER</SMALL> <SMALL>THAN</SMALL> O<SMALL>PTIONS</SMALL> <SMALL>AND</SMALL>
SAR<SMALL>S</SMALL>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) Restricted Stock Awards.</B> Each Restricted Stock Award Agreement will be in
such form and will contain such terms and conditions as the Board deems appropriate. To the extent consistent with the Company&#146;s bylaws, at the Board&#146;s election, shares of Common Stock underlying a Restricted Stock Award may be
(i)&nbsp;held in book entry form subject to the Company&#146;s instructions until any restrictions relating to the Restricted Stock Award lapse, or (ii)&nbsp;evidenced by a certificate, which certificate will be held in such form and manner as
determined by the Board. The terms and conditions of separate Restricted Stock Award Agreements need not be identical; <I>provided, however</I>, that each Restricted Stock Award Agreement will conform to (through incorporation of the provisions
hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following provisions: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)
Consideration.</B> A Restricted Stock Award may be awarded in consideration for (A)&nbsp;cash (including electronic funds transfers), check, bank draft or money order payable to the Company, (B)&nbsp;past services to the Company or an Affiliate or
(C)&nbsp;any other form of legal consideration (including future services) that may be acceptable to the Board, in its sole discretion, and permissible under applicable law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) Vesting.</B> Subject to Section&nbsp;2(g), shares of Common Stock awarded under a Restricted Stock Award Agreement may be subject to forfeiture to or repurchase by the Company in accordance with a
vesting schedule to be determined by the Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii) Termination of Continuous Service.</B> If a Participant&#146;s
Continuous Service terminates, the Company may receive through a forfeiture condition or a repurchase right any or all of the shares of Common Stock held by the Participant that have not vested as of the date of such termination under the terms of
the Participant&#146;s Restricted Stock Award Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv) Transferability.</B> Rights to acquire shares of Common
Stock under a Restricted Stock Award Agreement will be transferable by the Participant only upon such terms and conditions as are set forth in the Restricted Stock Award Agreement, as the Board will determine in its sole discretion, so long as
Common Stock awarded under the Restricted Stock Award Agreement remains subject to the terms of the Restricted Stock Award Agreement. Notwithstanding the foregoing or anything in the Plan or a Restricted Stock Award Agreement to the contrary, no
Restricted Stock Award may be transferred to any financial institution without prior stockholder approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) Restricted
Stock Unit Awards.</B> Each Restricted Stock Unit Award Agreement will be in such form and will contain such terms and conditions as the Board deems appropriate. The terms and conditions of separate Restricted Stock Unit Award Agreements need not be
identical; <I>provided, however</I>, that each Restricted Stock Unit Award Agreement will conform to (through incorporation of the provisions hereof by reference in the applicable Award Agreement or otherwise) the substance of each of the following
provisions: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i) Consideration.</B> At the time of grant of a Restricted Stock Unit Award, the Board will determine the
consideration, if any, to be paid by the Participant upon delivery of each share of Common Stock subject to the Restricted Stock Unit Award. The consideration to be paid (if any) by the Participant for each share of Common Stock subject to a
Restricted Stock Unit Award may be paid in any form of legal consideration that may be acceptable to the Board, in its sole discretion, and permissible under applicable law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) Vesting.</B> Subject to Section&nbsp;2(g), at the time of the grant of a Restricted Stock Unit Award, the Board may impose such restrictions on or conditions to the vesting of the Restricted Stock
Unit Award as it, in its sole discretion, deems appropriate. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-9
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii) Payment.</B> A Restricted Stock Unit Award may be settled by the delivery of
shares of Common Stock, their cash equivalent, any combination thereof or in any other form of consideration, as determined by the Board and contained in the Restricted Stock Unit Award Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv) Additional Restrictions.</B> At the time of the grant of a Restricted Stock Unit Award, the Board, as it deems appropriate, may
impose such restrictions or conditions that delay the delivery of the shares of Common Stock (or their cash equivalent) subject to the Restricted Stock Unit Award to a time after the vesting of the Restricted Stock Unit Award. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(v) Termination of Continuous Service.</B> Except as otherwise provided in the applicable Restricted Stock Unit Award Agreement or
other written agreement between a Participant and the Company or an Affiliate, if a Participant&#146;s Continuous Service terminates, any portion of the Participant&#146;s Restricted Stock Unit Award that has not vested as of the date of such
termination will be forfeited upon such termination. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) Performance Stock Awards.</B> </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i) General. </B>A Performance Stock Award is an Award that is payable (including that may be granted, vest or be exercised)
contingent upon the attainment during a Performance Period of specified Performance Goals. A Performance Stock Award may, but need not, require the Participant&#146;s completion of a specified period of Continuous Service. Subject to
Section&nbsp;2(g), the length of any Performance Period, the Performance Goals to be achieved during the Performance Period, and the measure of whether and to what degree such Performance Goals have been attained will be conclusively determined by
the Board, in its sole discretion. In addition, to the extent permitted by applicable law and the applicable Award Agreement, the Board may determine that cash may be used in payment of Performance Stock Awards. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii) Board Discretion.</B> With respect to any Performance Stock Award, the Board retains the discretion to (A)&nbsp;reduce or
eliminate the compensation or economic benefit due upon the attainment of any Performance Goals on the basis of any considerations as the Board, in its sole discretion, may determine and (B)&nbsp;define the manner of calculating the Performance
Criteria it selects to use for a Performance Period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d) Other Stock Awards. </B>Other forms of Awards valued in whole or
in part by reference to, or otherwise based on, Common Stock, including the appreciation in value thereof (<I>e.g</I>., options or stock appreciation rights with an exercise or strike price (per share) less than 100% of the Fair Market Value of the
Common Stock on the date of grant) may be granted either alone or in addition to Awards granted under Section&nbsp;5 and this Section&nbsp;6. Subject to the provisions of the Plan (including, but not limited to, Sections 2(g) and 2(h)), the Board
will have sole and complete authority to determine the persons to whom and the time or times at which such Other Stock Awards will be granted, the number of shares of Common Stock (or the cash equivalent thereof) to be granted pursuant to such Other
Stock Awards and all other terms and conditions of such Other Stock Awards. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL>.</B> </FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a) Availability of Shares.</B> The Company will keep available at all times the number of shares of Common Stock reasonably required
to satisfy then-outstanding Awards. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) Securities Law Compliance.</B> The Company will seek to obtain from each
regulatory commission or agency having jurisdiction over the Plan the authority required to grant Awards and to issue and sell shares of Common Stock upon exercise of the Awards; <I>provided, however</I>, that this undertaking will not require the
Company to register under the Securities Act the Plan, any Award or any Common Stock issued or issuable pursuant to any such Award. If, after reasonable efforts and at a reasonable cost, the Company is unable to obtain from any such regulatory
commission or agency the authority that counsel for the Company deems necessary for the lawful issuance and sale of Common Stock under the Plan, the Company will be relieved from any liability for failure to issue and sell Common Stock upon exercise
of such Awards unless and until such authority is obtained. A </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-10
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Participant will not be eligible for the grant of an Award or the subsequent issuance of cash or Common Stock pursuant to the Award if such grant or issuance would be in violation of any
applicable securities law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) No Obligation to Notify or Minimize Taxes.</B> The Company will have no duty or obligation
to any Participant to advise such holder as to the time or manner of exercising an Award. Furthermore, the Company will have no duty or obligation to warn or otherwise advise such holder of a pending termination or expiration of an Award or a
possible period in which the Award may not be exercised. The Company has no duty or obligation to minimize the tax consequences of an Award to the holder of such Award. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>M<SMALL>ISCELLANEOUS</SMALL>.</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a) Use of Proceeds from Sales of Common Stock.</B> Proceeds from the sale of shares of Common Stock issued pursuant to Awards will constitute general funds of the Company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b) Corporate Action Constituting Grant of Awards.</B> Corporate action constituting a grant by the Company of an Award to any
Participant will be deemed completed as of the date of such corporate action, unless otherwise determined by the Board, regardless of when the instrument, certificate or letter evidencing the Award is communicated to, or actually received or
accepted by, the Participant. In the event that the corporate records (<I>e.g</I>., Board consents, resolutions or minutes) documenting the corporate action constituting the grant contain terms (<I>e.g</I>., exercise price, vesting schedule or
number of shares) that are inconsistent with those in the Award Agreement or related grant documents as a result of a clerical error in the papering of the Award Agreement or related grant documents, the corporate records will control and the
Participant will have no legally binding right to the incorrect term in the Award Agreement or related grant documents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c) Stockholder Rights.</B> No Participant will be deemed to be the holder of, or to have any of the rights of a holder with respect
to, any shares of Common Stock subject to an Award unless and until (i)&nbsp;such Participant has satisfied all requirements for exercise of, or the issuance of shares of Common Stock under, the Award pursuant to its terms, and (ii)&nbsp;the
issuance of the Common Stock subject to such Award has been entered into the books and records of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d) No
Employment or Other Service Rights.</B> Nothing in the Plan, any Award Agreement or any other instrument executed thereunder or in connection with any Award granted pursuant thereto will confer upon any Participant any right to continue to serve the
Company or an Affiliate in the capacity in effect at the time the Award was granted or will affect the right of the Company or an Affiliate to terminate (i)&nbsp;the employment of an Employee with or without notice and with or without cause, or
(ii)&nbsp;the service of a Director pursuant to the bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated, as the case may be. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e) Change in Time Commitment.</B> In the event a Participant&#146;s regular level of time commitment in the performance of his or her
services for the Company or any Affiliate is reduced (for example, and without limitation, if the Participant is an Employee of the Company and the Employee has a change in status from a full-time Employee to a part-time Employee or takes an
extended leave of absence) after the date of grant of any Award to the Participant, the Board has the right in its sole discretion to (i)&nbsp;make a corresponding reduction in the number of shares or cash amount subject to any portion of such Award
that is scheduled to vest or become payable after the date of such change in time commitment, and (ii)&nbsp;in lieu of or in combination with such a reduction, extend the vesting or payment schedule applicable to such Award. In the event of any such
reduction, the Participant will have no right with respect to any portion of the Award that is so reduced or extended. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(f)</B> <B>Incentive Stock Option Limitation.</B> To the extent that the aggregate Fair Market Value (determined at the time of grant)
of Common Stock with respect to which Incentive Stock Options are exercisable for the first time by any Participant during any calendar year (under all plans of the Company and any Affiliates) exceeds $100,000 (or such other limit established in the
Code) or otherwise does not comply with the rules governing Incentive Stock </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-11
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
Options, the Options or portions thereof that exceed such limit (according to the order in which they were granted) or otherwise do not comply with such rules will be treated as Nonstatutory
Stock Options, notwithstanding any contrary provision of the applicable Option Agreement(s). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(g)</B> <B>Investment
Assurances.</B> The Company may require a Participant, as a condition of exercising or acquiring Common Stock under any Award, (i)&nbsp;to give written assurances satisfactory to the Company as to the Participant&#146;s knowledge and experience in
financial and business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced in financial and business matters and that he or she is capable of evaluating, alone or together
with the purchaser representative, the merits and risks of exercising the Award and (ii)&nbsp;to give written assurances satisfactory to the Company stating that the Participant is acquiring Common Stock subject to the Award for the
Participant&#146;s own account and not with any present intention of selling or otherwise distributing the Common Stock. The foregoing requirements, and any assurances given pursuant to such requirements, will be inoperative if (A)&nbsp;the issuance
of the shares upon the exercise or acquisition of Common Stock under the Award has been registered under a then currently effective registration statement under the Securities Act or (B)&nbsp;as to any particular requirement, a determination is made
by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as
such counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends restricting the transfer of the Common Stock. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(h)</B> <B>Withholding Obligations.</B> Unless prohibited by the terms of an Award Agreement, the Company may, in its sole discretion,
satisfy any federal, state, local or foreign tax withholding obligation relating to an Award by any of the following means or by a combination of such means: (i)&nbsp;causing the Participant to tender a cash payment; (ii)&nbsp;withholding shares of
Common Stock from the shares of Common Stock issued or otherwise issuable to the Participant in connection with the Award; (iii)&nbsp;withholding cash from an Award settled in cash; (iv)&nbsp;withholding payment from any amounts otherwise payable to
the Participant; or (v)&nbsp;by such other method as may be set forth in the Award Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> <B>Electronic
Delivery.</B> Any reference herein to a &#147;written&#148; agreement or document will include any agreement or document delivered electronically, filed publicly at www.sec.gov (or any successor website thereto) or posted on the Company&#146;s
intranet (or other shared electronic medium controlled by the Company to which the Participant has access). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(j)</B>
<B>Deferrals.</B> To the extent permitted by applicable law, the Board, in its sole discretion, may determine that the delivery of Common Stock or the payment of cash, upon the exercise, vesting or settlement of all or a portion of any Award may be
deferred and may establish programs and procedures for deferral elections to be made by Participants. Deferrals by Participants will be made in accordance with Section&nbsp;409A of the Code. Consistent with Section&nbsp;409A of the Code, the Board
may provide for distributions while a Participant is still an employee or otherwise providing services to the Company or an Affiliate. The Board is authorized to make deferrals of Awards and determine when, and in what annual percentages,
Participants may receive payments, including lump sum payments, following the Participant&#146;s termination of Continuous Service, and implement such other terms and conditions consistent with the provisions of the Plan and in accordance with
applicable law. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(k)</B> <B>Section 409A. </B>Unless otherwise expressly provided for in an Award Agreement, the Plan and
Award Agreements will be interpreted to the greatest extent possible in a manner that makes the Plan and the Awards granted hereunder exempt from Section&nbsp;409A of the Code, and, to the extent not so exempt, in compliance with Section&nbsp;409A
of the Code. If the Board determines that any Award granted hereunder is not exempt from and is therefore subject to Section&nbsp;409A of the Code, the Award Agreement evidencing such Award will incorporate the terms and conditions necessary to
avoid the consequences specified in Section&nbsp;409A(a)(1) of the Code, and to the extent an Award Agreement is silent on terms necessary for compliance with Section&nbsp;409A of the Code, such terms are hereby incorporated by reference into the
Award Agreement. Notwithstanding anything to the contrary in this Plan (and unless the Award Agreement specifically provides otherwise), if the shares of Common Stock are publicly </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-12
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
traded, and if a Participant holding an Award that constitutes &#147;deferred compensation&#148; under Section&nbsp;409A of the Code is a &#147;specified employee&#148; for purposes of
Section&nbsp;409A of the Code, no distribution or payment of any amount under such Award that is due because of a &#147;separation from service&#148; (as defined in Section&nbsp;409A of the Code without regard to alternative definitions thereunder)
will be issued or paid before the date that is six months and one day following the date of such Participant&#146;s &#147;separation from service&#148; or, if earlier, the date of the Participant&#146;s death, unless such distribution or payment may
be made in a manner that complies with Section&nbsp;409A of the Code, and any amounts so deferred will be paid in a lump sum on the day after such <FONT STYLE="white-space:nowrap">six-month</FONT> period elapses, with the balance paid thereafter on
the original schedule. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(l)</B> <B>Clawback/Recovery.</B> All Awards granted under the Plan will be subject to recoupment
in accordance with any clawback policy that the Company is required to adopt pursuant to the listing standards of any national securities exchange or association on which the Company&#146;s securities are listed or as is otherwise required by the
Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law. In addition, the Board may impose such other clawback, recovery or recoupment provisions in an Award Agreement as the Board determines necessary or appropriate,
including, but not limited to, a reacquisition right in respect of previously acquired shares of Common Stock or other cash or property upon the occurrence of Cause. No recovery of compensation under such a clawback policy will be an event giving
rise to a right to resign for &#147;good reason&#148; or &#147;constructive termination&#148; (or similar term) under any agreement with the Company or an Affiliate. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>DJUSTMENTS</SMALL> <SMALL>UPON</SMALL> C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; O<SMALL>THER</SMALL>
C<SMALL>ORPORATE</SMALL> E<SMALL>VENTS</SMALL>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> <B>Capitalization Adjustments.</B> In the event
of a Capitalization Adjustment, the Board will appropriately and proportionately adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the Plan pursuant to Section&nbsp;3(a); (ii) the class(es) and maximum number of securities
that may be issued pursuant to the exercise of Incentive Stock Options pursuant to Section&nbsp;3(c); and (iii)&nbsp;the class(es) and number of securities and price per share of stock subject to outstanding Awards. The Board will make such
adjustments and its determination will be final, binding and conclusive. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> <B>Dissolution or Liquidation.</B> Except
as otherwise provided in the applicable Award Agreement or other written agreement between a Participant and the Company or an Affiliate, in the event of a dissolution or liquidation of the Company, all outstanding Awards (other than Awards
consisting of vested and outstanding shares of Common Stock not subject to a forfeiture condition or the Company&#146;s right of repurchase) will terminate immediately prior to the completion of such dissolution or liquidation, and the shares of
Common Stock subject to a forfeiture condition or the Company&#146;s right of repurchase may be reacquired or repurchased by the Company notwithstanding the fact that the holder of such Award is providing Continuous Service; <I>provided,
however</I>, that the Board may, in its sole discretion, cause some or all Awards to become fully vested, exercisable and/or no longer subject to forfeiture or repurchase (to the extent such Awards have not previously expired or terminated) before
the dissolution or liquidation is completed but contingent on its completion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B> <B>Transactions.</B> In the event of
a Transaction, the provisions of this Section&nbsp;9(c) will apply to each outstanding Award and Prior Plan Award, in each case unless otherwise provided in the instrument evidencing the Award or Prior Plan Award (as applicable), in any other
written agreement between the Company or any Affiliate and the Participant, or in any director compensation policy of the Company, or unless otherwise expressly provided by the Board at the time of grant of the Award or Prior Plan Award (as
applicable). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> <B>Awards May Be Assumed.</B> In the event of a Transaction, any surviving corporation or acquiring
corporation (or the surviving or acquiring corporation&#146;s parent company) may assume or continue any or all outstanding Awards and/or Prior Plan Awards or may substitute similar stock awards for any or all outstanding Awards and/or Prior Plan
Awards (including, but not limited to, awards to acquire the same consideration paid to the stockholders of the Company pursuant to the Transaction), and any reacquisition or repurchase rights held by the Company in respect of Common Stock issued
pursuant to any outstanding Awards and/or Prior Plan Awards may be assigned by the Company to the surviving corporation or acquiring corporation (or the surviving or acquiring </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-13
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
corporation&#146;s parent company). For clarity, in the event of a Transaction, any surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#146;s parent
company) may choose to assume or continue only a portion of an outstanding Award or Prior Plan Award, to substitute a similar stock award for only a portion of an outstanding Award or Prior Plan Award, or to assume or continue, or substitute similar
stock awards for, the outstanding Awards and/or Prior Plan Awards held by some, but not all, Participants. The terms of any such assumption, continuation or substitution will be set by the Board. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> <B>Awards Held by Current Participants.</B> In the event of a Transaction in which the surviving corporation or acquiring
corporation (or the surviving or acquiring corporation&#146;s parent company) does not assume or continue outstanding Awards and/or Prior Plan Awards, or substitute similar stock awards for outstanding Awards and/or Prior Plan Awards, then with
respect to any such Awards and/or Prior Plan Awards that have not been assumed, continued or substituted and that are held by Participants whose Continuous Service has not terminated prior to the effective time of the Transaction (referred to as the
&#147;<B><I>Current Participants</I></B>&#148;), the vesting (and exercisability, if applicable) of such Awards and Prior Plan Awards will be accelerated in full to a date prior to the effective time of the Transaction (contingent upon the closing
or completion of the Transaction) as the Board will determine (or, if the Board does not determine such a date, to the date that is five days prior to the effective time of the Transaction), and such Awards and Prior Plan Awards will terminate if
not exercised (if applicable) prior to the effective time of the Transaction in accordance with the exercise procedures determined by the Board, and any reacquisition or repurchase rights held by the Company with respect to such Awards and Prior
Plan Awards will lapse (contingent upon the closing or completion of the Transaction). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)</B> <B>Awards Held by
Participants other than Current Participants.</B> In the event of a Transaction in which the surviving corporation or acquiring corporation (or the surviving or acquiring corporation&#146;s parent company) does not assume or continue outstanding
Awards and/or Prior Plan Awards, or substitute similar stock awards for outstanding Awards and/or Prior Plan Awards, then with respect to any such Awards and/or Prior Plan Awards that have not been assumed, continued or substituted and that are held
by Participants other than Current Participants, such Awards and Prior Plan Awards will terminate if not exercised (if applicable) prior to the effective time of the Transaction in accordance with the exercise procedures determined by the Board;
<I>provided</I>, <I>however</I>, that any reacquisition or repurchase rights held by the Company with respect to such Awards and Prior Plan Awards will not terminate and may continue to be exercised notwithstanding the Transaction. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv)</B> <B>Payment for Awards in Lieu of Exercise.</B> Notwithstanding the foregoing, in the event any outstanding Award or Prior
Plan Award held by a Participant will terminate if not exercised prior to the effective time of a Transaction, the Board may provide, in its sole discretion, that the Participant may not exercise such Award or Prior Plan Award but instead will
receive a payment, in such form as may be determined by the Board, equal in value to the excess, if any, of (A)&nbsp;the value of the property the Participant would have received upon the exercise of such Award or Prior Plan Award immediately prior
to the effective time of the Transaction (including, at the discretion of the Board, any unvested portion of such Award or Prior Plan Award), over (B)&nbsp;any exercise price payable by the Participant in connection with such exercise. For clarity,
such payment may be zero if the value of such property is equal to or less than the exercise price. Payments under this provision may be delayed to the same extent that payment of consideration to the holders of the Common Stock in connection with
the Transaction is delayed as a result of escrows, earn outs, holdbacks or any other contingencies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B> <B>Change in
Control.</B> An Award or Prior Plan Award may be subject to additional acceleration of vesting and exercisability upon or after a Change in Control as may be provided in the Award Agreement for such Award or award agreement for such Prior Plan Award
(as applicable), in any other written agreement between the Company or any Affiliate and the Participant, or in any director compensation policy of the Company, but in the absence of such provision, no such acceleration will occur. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e)</B> <B>Prior Plan Awards. </B>For clarity, with respect to any Prior Plan Award, the terms set forth in Sections 9(c) and 9(d)
will supersede any terms set forth in the applicable Prior Plan regarding the treatment of such Prior Plan Award in the event of a Corporate Transaction (as defined in the applicable Prior Plan) or Change in Control (as defined in the applicable
Prior Plan). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-14
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(f)</B> <B>Parachute Payments. </B>Except as otherwise provided in the applicable
Award Agreement or other written agreement between a Participant and the Company or an Affiliate, if any payment or benefit the Participant would receive pursuant to a Change in Control from the Company or otherwise
(&#147;<B><I>Payment</I></B>&#148;) would (i)&nbsp;constitute a &#147;parachute payment&#148; within the meaning of Section&nbsp;280G of the Code, and (ii)&nbsp;but for this sentence, be subject to the excise tax imposed by Section&nbsp;4999 of the
Code (the &#147;<B><I>Excise Tax</I></B>&#148;), then such Payment will be equal to the Reduced Amount. The &#147;<B><I>Reduced Amount</I></B>&#148; will be either (x)&nbsp;the largest portion of the Payment that would result in no portion of the
Payment being subject to the Excise Tax or (y)&nbsp;the largest portion, up to and including the total, of the Payment, whichever amount, after taking into account all applicable federal, state and local employment taxes, income taxes, and the
Excise Tax (all computed at the highest applicable marginal rate), results in the Participant&#146;s receipt, on an <FONT STYLE="white-space:nowrap">after-tax</FONT> basis, of the greater amount of the Payment notwithstanding that all or some
portion of the Payment may be subject to the Excise Tax. If a reduction in payments or benefits constituting &#147;parachute payments&#148; is necessary so that the Payment equals the Reduced Amount, reduction will occur in the following order:
(A)&nbsp;reduction of cash payments; (B)&nbsp;cancellation of accelerated vesting of equity awards other than stock options; (C)&nbsp;cancellation of accelerated vesting of stock options; and (D)&nbsp;reduction of other benefits paid to the
Participant. Within any such category of payments and benefits (that is, (A), (B), (C) or (D)), a reduction will occur first with respect to amounts that are not &#147;deferred compensation&#148; within the meaning of Section&nbsp;409A of the Code
and then with respect to amounts that are. In the event that acceleration of compensation from a Participant&#146;s equity awards is to be reduced, such acceleration of vesting will be canceled, subject to the immediately preceding sentence, in the
reverse order of the date of grant. The accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the Change in Control will perform the foregoing calculations. If the accounting firm so engaged
by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change in Control, the Company will appoint a nationally recognized accounting firm to make the determinations required hereunder. The Company will
bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. The accounting firm engaged to make the determinations hereunder will provide its calculations, together with detailed supporting
documentation, to the Participant and the Company within 15 calendar days after the date on which the Participant&#146;s right to a Payment is triggered (if requested at that time by the Participant or the Company) or such other time as reasonably
requested by the Participant or the Company. Any good faith determinations of the accounting firm made hereunder will be final, binding and conclusive upon the Participant and the Company. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>T<SMALL>ERMINATION</SMALL> <SMALL>OR</SMALL> S<SMALL>USPENSION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> <B>Termination or Suspension.</B> The Board may suspend or terminate the Plan at any time. No Incentive Stock Option may be
granted after<B> </B>the tenth anniversary of the earlier of (i)&nbsp;the Adoption Date or (ii)&nbsp;the date the Plan is approved by the stockholders of the Company. No Awards may be granted under the Plan while the Plan is suspended or after it is
terminated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> <B>No Impairment of Rights.</B> Suspension or termination of the Plan will not materially impair
rights and obligations under any Award granted while the Plan is in effect except with the written consent of the affected Participant or as otherwise permitted in the Plan (including Section&nbsp;2(b)(viii)) or an Award Agreement. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>FFECTIVE</SMALL> D<SMALL>ATE</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL>. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This Plan will become effective on the Effective Date. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>HOICE</SMALL> <SMALL>OF</SMALL> L<SMALL>AW</SMALL>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The laws of the State of Delaware will govern all questions concerning the construction, validity and interpretation of this Plan, without regard to that state&#146;s conflict of laws rules. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-15
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>D<SMALL>EFINITIONS</SMALL>. </B>As used in the Plan, the following definitions will apply to the capitalized terms indicated below: </FONT></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> &#147;<B><I>Adoption Date</I></B>&#148; means April&nbsp;8, 2018, which is the date the Plan was adopted by the Board.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> &#147;<B><I>Affiliate</I></B>&#148; means, at the time of determination, any &#147;parent&#148; or
&#147;subsidiary&#148; of the Company as such terms are defined in Rule 405. The Board will have the authority to determine the time or times at which &#147;parent&#148; or &#147;subsidiary&#148; status is determined within the foregoing definition.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B> &#147;<B><I>Appreciation Award</I></B>&#148; means (i)&nbsp;a stock option or stock appreciation right granted
under any of the Prior Plans or (ii)&nbsp;an Option or Stock Appreciation Right, in each case with respect to which the exercise or strike price is at least 100% of the Fair Market Value of the Common Stock subject to the stock option or stock
appreciation right, or Option or Stock Appreciation Right, as applicable, on the date of grant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B>
&#147;<B><I>Award</I></B>&#148; means an Incentive Stock Option, a Nonstatutory Stock Option, a Stock Appreciation Right, a Restricted Stock Award, a Restricted Stock Unit Award, a Performance Stock Award or any Other Stock Award. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e)</B> &#147;<B><I>Award Agreement</I></B>&#148; means a written agreement between the Company and a Participant evidencing the terms
and conditions of an Award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(f)</B> &#147;<B><I>Board</I></B>&#148; means the Board of Directors of the Company.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(g)</B> &#147;<B><I>Capitalization Adjustment</I></B>&#148; means any change that is made in, or other events that occur
with respect to, the Common Stock subject to the Plan or subject to any Award after the Adoption Date without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock
dividend, dividend in property other than cash, large nonrecurring cash dividend, stock split, reverse stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or any similar equity restructuring
transaction, as that term is used in Statement of Financial Accounting Standards No.&nbsp;123 (revised). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(h)</B> &#147;<B><I>Cause</I></B>&#148;<B><I> </I></B>will have the meaning ascribed to such term in any written agreement
between a Participant and the Company or an Affiliate defining such term and, in the absence of such agreement, such term means, with respect to a Participant, the occurrence of one or more of the following: (i)&nbsp;the Participant&#146;s theft,
dishonesty, willful misconduct, breach of fiduciary duty for personal profit, or falsification of any Company or Affiliate documents or records; (ii)&nbsp;the Participant&#146;s material failure to abide by the code of conduct or other policies
(including, without limitation, policies relating to confidentiality and reasonable workplace conduct) of the Company or an Affiliate; (iii)&nbsp;the Participant&#146;s unauthorized use, misappropriation, destruction or diversion of any tangible or
intangible asset or corporate opportunity of the Company or an Affiliate (including, without limitation, the Participant&#146;s improper use or disclosure of confidential or proprietary information of the Company or an Affiliate); (iv) any
intentional act by the Participant which has a material detrimental effect on the reputation or business of the Company or an Affiliate; (v)&nbsp;the Participant&#146;s repeated failure or inability to perform any reasonable assigned duties after
written notice from the Company or an Affiliate, and a reasonable opportunity to cure, such failure or inability; (vi)&nbsp;any material breach by the Participant of any employment or service agreement between the Participant and the Company or an
Affiliate, which breach is not cured pursuant to the terms of such agreement; or (vii)&nbsp;the Participant&#146;s conviction (including any plea of guilty or nolo contendere)&nbsp;of any criminal act involving fraud, dishonesty, misappropriation or
moral turpitude, or which impairs the Participant&#146;s ability to perform his or her duties. The determination that a termination of a Participant&#146;s Continuous Service is either for Cause or without Cause will be made by the Company, in its
sole discretion. Any determination by the Company that the Continuous Service of a Participant was terminated with or without Cause for the purposes of outstanding Awards held by the Participant will have no effect upon any determination of the
rights or obligations of the Company or the Participant for any other purpose. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-16
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> &#147;<B><I>Change in Control</I></B>&#148; means the occurrence, in a
single transaction or in a series of related transactions, of any one or more of the following events: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> any
Exchange Act Person becomes the Owner, directly or indirectly, of securities of the Company representing more than 50%&nbsp;of the combined voting power of the Company&#146;s then outstanding securities other than by virtue of a merger,
consolidation or similar transaction. Notwithstanding the foregoing, a Change in Control will not be deemed to occur (A)&nbsp;on account of the acquisition of securities of the Company directly from the Company, (B)&nbsp;on account of the
acquisition of securities of the Company by an investor, any affiliate thereof or any other Exchange Act Person that acquires the Company&#146;s securities in a transaction or series of related transactions the primary purpose of which is to obtain
financing for the Company through the issuance of equity securities, or (C)&nbsp;solely because the level of Ownership held by any Exchange Act Person (the &#147;<B><I>Subject Person</I></B>&#148;)&nbsp;exceeds the designated percentage threshold of
the outstanding voting securities as a result of a repurchase or other acquisition of voting securities by the Company reducing the number of shares outstanding, provided that if a Change in Control would occur (but for the operation of this
sentence)&nbsp;as a result of the acquisition of voting securities by the Company, and after such share acquisition, the Subject Person becomes the Owner of any additional voting securities that, assuming the repurchase or other acquisition had not
occurred, increases the percentage of the then outstanding voting securities Owned by the Subject Person over the designated percentage threshold, then a Change in Control will be deemed to occur; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> there is consummated a merger, consolidation or similar transaction involving (directly or indirectly)&nbsp;the Company and,
immediately after the consummation of such merger, consolidation or similar transaction, the stockholders of the Company immediately prior thereto do not Own, directly or indirectly, either (A)&nbsp;outstanding voting securities representing more
than 50%&nbsp;of the combined outstanding voting power of the surviving Entity in such merger, consolidation or similar transaction or (B)&nbsp;more than 50%&nbsp;of the combined outstanding voting power of the parent of the surviving Entity in such
merger, consolidation or similar transaction, in each case in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such transaction; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)</B> there is consummated a sale, lease, exclusive license or other disposition of all or substantially all of the consolidated
assets of the Company and its Subsidiaries, other than a sale, lease, license or other disposition of all or substantially all of the consolidated assets of the Company and its Subsidiaries to an Entity, more than 50%&nbsp;of the combined voting
power of the voting securities of which are Owned by stockholders of the Company in substantially the same proportions as their Ownership of the outstanding voting securities of the Company immediately prior to such sale, lease, license or other
disposition; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv)</B> over a period of 12 months or less, individuals who, on the Adoption Date, are members of the
Board (the &#147;<B><I>Incumbent Board</I></B>&#148;)&nbsp;cease for any reason to constitute at least a majority of the members of the Board; <I>provided, however</I>, that if the appointment or election (or nomination for election)&nbsp;of any new
Board member was approved or recommended by a majority vote of the members of the Incumbent Board then still in office, such new member will, for purposes of this Plan, be considered as a member of the Incumbent Board. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I>Notwithstanding the foregoing or any other provision of this Plan, (A)&nbsp;the term Change in Control will not include a sale of
assets, merger or other transaction effected exclusively for the purpose of changing the domicile of the Company, and (B)&nbsp;the definition of Change in Control (or any analogous term) in an individual written agreement between a Participant and
the Company or an Affiliate will supersede the foregoing definition with respect to Awards and/or Prior Plan Awards (as applicable) subject to such agreement; <I>provided, however</I>, that (1)&nbsp;if no definition of Change in Control (or any
analogous term) is set forth in such an individual written agreement, the foregoing definition will apply; and (2)&nbsp;no Change in Control (or any analogous term) will be deemed to occur with respect to Awards and/or Prior Plan Awards (as
applicable) subject to such an individual written agreement without a requirement that the Change in Control (or any analogous term) actually occur.<I> </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><I></I>If required for compliance with Section&nbsp;409A of the Code, in no event will an event be deemed a Change in Control if such event is not also a &#147;change in the ownership of&#148; the
Company, a &#147;change in the effective control of&#148;<I> </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-17
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>
</I>the Company or a &#147;change in the ownership of a substantial portion of the assets of&#148; the Company, each as determined under Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5)</FONT> (without regard to any alternative definition thereunder). The Board may, in its sole discretion and without a Participant&#146;s consent, amend the definition of &#147;Change in
Control&#148; to conform to the definition of a &#147;change in control event&#148; under Section&nbsp;409A of the Code and the regulations thereunder.<I> </I></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(j)</B> &#147;<B><I>Code</I></B>&#148; means the Internal Revenue Code of 1986, as amended, including any applicable regulations and guidance thereunder. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(k)</B> &#147;<B><I>Committee</I></B>&#148; means a committee of one or more Directors to whom authority has been delegated by the
Board in accordance with Section&nbsp;2(c). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(l)</B> &#147;<B><I>Common Stock</I></B>&#148; means the common stock of the
Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(m)</B> &#147;<B><I>Company</I></B>&#148; means Dynavax Technologies Corporation, a Delaware corporation.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(n)</B> &#147;<B><I>Continuous Service</I></B>&#148; means that the Participant&#146;s service with the Company or an
Affiliate, whether as an Employee or Director, is not interrupted or terminated. A change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee or Director or a change in the Entity for which the
Participant renders such service, provided that there is no interruption or termination of the Participant&#146;s service with the Company or an Affiliate, will not terminate a Participant&#146;s Continuous Service; <I>provided, however,</I> that<I>
</I>if the Entity for which a Participant is rendering services ceases to qualify as an Affiliate, as determined by the Board, in its sole discretion, such Participant&#146;s Continuous Service will be considered to have terminated on the date such
Entity ceases to qualify as an Affiliate. For example, a change in status from an Employee of the Company to a Director will not constitute an interruption of Continuous Service. To the extent permitted by law, the Board or the chief executive
officer of the Company, in that party&#146;s sole discretion, may determine whether Continuous Service will be considered interrupted in the case of (i)&nbsp;any leave of absence approved by the Board or chief executive officer, including sick
leave, military leave or any other personal leave, or (ii)&nbsp;transfers between the Company, an Affiliate or their successors. Notwithstanding the foregoing, a leave of absence will be treated as Continuous Service for purposes of vesting in an
Award only to such extent as may be provided in the Company&#146;s or Affiliate&#146;s leave of absence policy, in the written terms of any leave of absence agreement or policy applicable to the Participant, or as otherwise required by law.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(o)</B> &#147;<B><I>Corporate Transaction</I></B>&#148; means the occurrence, in a single transaction or in a series of
related transactions, of any one or more of the following events: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> the consummation of a sale<B> </B>or other
disposition of all or substantially all, as determined by the Board, in its sole discretion, of the consolidated assets of the Company and its Subsidiaries; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> the consummation of a sale or other disposition of at least 90%&nbsp;of the outstanding securities of the Company; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)</B> the consummation of a merger, consolidation or similar transaction following which the Company is not the surviving corporation; or </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv)</B> the consummation of a merger, consolidation or similar transaction following which the Company is the surviving corporation
but the shares of Common Stock outstanding immediately preceding the merger, consolidation or similar transaction are converted or exchanged by virtue of the merger, consolidation or similar transaction into other property, whether in the form of
securities, cash or otherwise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If required for compliance with Section&nbsp;409A of the Code, in no event will an event be
deemed a Corporate Transaction if such event is not also a &#147;change in the ownership of&#148; the Company, a &#147;change in the effective control </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-18
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
of&#148; the Company or a &#147;change in the ownership of a substantial portion of the assets of&#148; the Company, each as determined under Treasury Regulations
<FONT STYLE="white-space:nowrap">Section&nbsp;1.409A-3(i)(5)</FONT> (without regard to any alternative definition thereunder). The Board may, in its sole discretion and without a Participant&#146;s consent, amend the definition of &#147;Corporate
Transaction&#148; to conform to the definition of a &#147;change in control event&#148; under Section&nbsp;409A of the Code and the regulations thereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(p)</B> &#147;<B><I>Director</I></B>&#148; means a member of the Board. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(q)</B> &#147;<B><I>Disability</I></B>&#148; means, with respect to a Participant, the inability of such Participant to engage in any
substantial gainful activity by reason of any medically determinable physical or mental impairment that can be expected to result in death or that has lasted or can be expected to last for a continuous period of not less than 12 months, as provided
in Sections 22(e)(3) and 409A(a)(2)(c)(i) of the Code, and will be determined by the Board on the basis of such medical evidence as the Board deems warranted under the circumstances. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(r)</B> &#147;<B><I>Effective Date</I></B>&#148; means the effective date of this Plan, which is the date of the Annual Meeting of
Stockholders of the Company held in 2018, provided that this Plan is approved by the Company&#146;s stockholders at such meeting. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(s)</B> &#147;<B><I>Employee</I></B>&#148; means any person employed by the Company or an Affiliate. However, service solely as a Director, or payment of a fee for such services, will not cause a
Director to be considered an &#147;Employee&#148; for purposes of the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(t)</B> &#147;<B><I>Entity</I></B>&#148; means
a corporation, partnership, limited liability company or other entity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(u)</B> &#147;<B><I>Exchange Act</I></B>&#148;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(v)</B>
&#147;<B><I>Exchange Act Person</I></B>&#148;<B><I> </I></B>means any natural person, Entity or &#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act), except that &#147;Exchange Act Person&#148; will not include
(i)&nbsp;the Company or any Subsidiary of the Company, (ii)&nbsp;any employee benefit plan of the Company or any Subsidiary of the Company or any trustee or other fiduciary holding securities under an employee benefit plan of the Company or any
Subsidiary of the Company, (iii)&nbsp;an underwriter temporarily holding securities pursuant to a registered public offering of such securities, (iv)&nbsp;an Entity Owned, directly or indirectly, by the stockholders of the Company in substantially
the same proportions as their Ownership of stock of the Company, or (v)&nbsp;any natural person, Entity or &#147;group&#148; (within the meaning of Section&nbsp;13(d) or 14(d) of the Exchange Act) that, as of the Effective Date, is the Owner,
directly or indirectly, of securities of the Company representing more than fifty percent 50% of the combined voting power of the Company&#146;s then outstanding securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(w)</B> &#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value of the Common Stock determined as follows: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> Unless otherwise provided by the Board, if the Common Stock is listed on any established stock exchange or traded on any established market, then the Fair Market Value of a share of Common
Stock will be the closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) on the date of determination, as reported in a source the Board deems
reliable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the
date of determination, then the Fair Market Value of a share of Common Stock will be the closing sales price for such stock on the last preceding date for which such quotation exists. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)</B> In the absence of such markets for the Common Stock, the Fair Market Value of a share of Common Stock will be determined by
the Board in good faith and in a manner that complies with Sections 409A and 422 of the Code. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-19
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(x)</B> &#147;<B><I>Full Value Award</I></B>&#148; means (i)&nbsp;a stock award
granted under any of the Prior Plans or (ii)&nbsp;an Award, in each case that is not an Appreciation Award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(y)</B>
&#147;<B><I>Incentive Stock Option</I></B>&#148; means an option granted pursuant to Section&nbsp;5 that is intended to be, and that qualifies as, an &#147;incentive stock option&#148; within the meaning of Section&nbsp;422 of the Code. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(z)</B> &#147;<B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director</I></B>&#148;<B> </B>means a Director who either
(i)&nbsp;is not a current employee or officer of the Company or an Affiliate, does not receive compensation, either directly or indirectly, from the Company or an Affiliate for services rendered as a consultant or in any capacity other than as a
Director (except for an amount as to which disclosure would not be required under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> promulgated pursuant to the Securities Act (&#147;<B><I>Regulation
<FONT STYLE="white-space:nowrap">S-K</FONT></I></B>&#148;)), does not possess an interest in any other transaction for which disclosure would be required under Item 404(a) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> and is not engaged
in a business relationship for which disclosure would be required pursuant to Item&nbsp;404(b) of Regulation <FONT STYLE="white-space:nowrap">S-K,</FONT> or (ii)&nbsp;is otherwise considered a
<FONT STYLE="white-space:nowrap">&#147;non-employee</FONT> director&#148; for purposes of Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(aa)</B> &#147;<B><I>Nonstatutory Stock Option</I></B>&#148; means an option granted pursuant to Section&nbsp;5 that does not qualify as an Incentive Stock Option. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(bb)</B> &#147;<B><I>Officer</I></B>&#148; means a person who is an officer of the Company within the meaning of Section&nbsp;16 of
the Exchange Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(cc)</B> &#147;<B><I>Option</I></B>&#148; means an Incentive Stock Option or a Nonstatutory Stock Option
to purchase shares of Common Stock granted pursuant to the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(dd)</B> &#147;<B><I>Option Agreement</I></B>&#148; means
a written agreement between the Company and a holder of an Option evidencing the terms and conditions of an Option grant. Each Option Agreement will be subject to the terms and conditions of the Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ee)</B> &#147;<B><I>Other Stock Award</I></B>&#148; means an award based in whole or in part by reference to the Common Stock which
is granted pursuant to the terms and conditions of Section&nbsp;6(d). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ff)</B> &#147;<B><I>Other Stock Award
Agreement</I></B>&#148;<B><I> </I></B>means a written agreement between the Company and a holder of an Other Stock Award evidencing the terms and conditions of an Other Stock Award grant. Each Other Stock Award Agreement will be subject to the terms
and conditions of the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(gg)</B> &#147;<B><I>Own,</I></B>&#148;<B><I> </I></B>&#147;<B><I>Owned,</I></B>&#148;<B><I>
</I></B>&#147;<B><I>Owner,</I></B>&#148;<B><I> </I></B>&#147;<B><I>Ownership</I></B>&#148;<B> </B>A person or Entity will be deemed to &#147;Own,&#148; to have &#147;Owned,&#148; to be the &#147;Owner&#148; of, or to have acquired
&#147;Ownership&#148; of securities if such person or Entity, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise, has or shares voting power, which includes the power to vote or to direct the voting,
with respect to such securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(hh)</B> &#147;<B><I>Participant</I></B>&#148; means (i)&nbsp;with respect to any Award,
a person to whom such Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award, and (ii)&nbsp;with respect to any Prior Plan Award, a person to whom such Prior Plan Award is granted pursuant to any
Prior Plan or, if applicable, such other person who holds an outstanding Prior Plan Award. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B>
&#147;<B><I>Performance Criteria</I></B>&#148; means the one or more criteria that the Board will select for purposes of establishing the Performance Goals for a Performance Period. The Performance Criteria that will be used to establish such
Performance Goals may be based on any one of, or combination of, the following, as determined by the Board: (i)&nbsp;earnings (including earnings per share and net earnings); (ii) earnings before interest, taxes and depreciation; (iii)&nbsp;earnings
before interest, taxes, depreciation and amortization (EBITDA); (iv) total stockholder return; (v)&nbsp;return on equity or average stockholder&#146;s equity; (vi)&nbsp;return on assets, investment, or capital employed; (vii)&nbsp;stock price or
stock price performance; (viii)&nbsp;margin (including gross margin); (ix) net income (before or after </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-20
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
taxes); (x) operating income; (xi)&nbsp;operating income after taxes; <FONT STYLE="white-space:nowrap">(xii)&nbsp;pre-tax</FONT> profit; (xiii)&nbsp;operating cash flow; (xiv)&nbsp;sales or
revenue targets; (xv)&nbsp;increases in revenue or product revenue; (xvi)&nbsp;expenses and cost reduction goals; (xvii)&nbsp;improvement in or attainment of working capital levels; (xviii)&nbsp;economic value added (or an equivalent metric); (xix)
market share; (xx)&nbsp;cash flow; (xxi)&nbsp;cash flow per share; (xxii)&nbsp;share price performance; (xxiii)&nbsp;debt reduction; (xxiv)&nbsp;implementation or completion of projects or processes; (xxv)&nbsp;customer satisfaction;
(xxvi)&nbsp;stockholders&#146; equity; (xxvii)&nbsp;capital expenditures; (xxviii)&nbsp;debt levels; (xxix)&nbsp;operating profit or net operating profit; (xxx)&nbsp;workforce diversity; (xxxi)&nbsp;growth of net income or operating income;
(xxxii)&nbsp;billings; (xxxiii) submission to, or approval by, a regulatory body (including but not limited to the U.S. Food and Drug Administration) of an applicable filing for a product candidate or other product development milestones;
(xxxiv)&nbsp;acquisitions, divestitures, joint ventures, strategic alliances, licenses or collaborations; (xxxv)&nbsp;spin-offs, <FONT STYLE="white-space:nowrap">split-ups,</FONT> reorganizations, recapitalizations, restructurings, financings (debt
or equity) or refinancings; (xxxvi)&nbsp;manufacturing or process development, clinical trial, regulatory, intellectual property, compliance or research objectives; and (xxxvii)&nbsp;any other measures of performance selected by the Board. Partial
achievement of the specified criteria may result in the payment or vesting corresponding to the degree of achievement as specified in the applicable Award Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(jj)</B> &#147;<B><I>Performance Goals</I></B>&#148; means, for a Performance Period, the one or more goals established by the Board for the Performance Period based upon the Performance Criteria.
Performance Goals may be based on a Company-wide basis, with respect to one or more business units, divisions, Affiliates, or business segments, and in either absolute terms or relative to the performance of one or more comparable companies or the
performance of one or more relevant indices. The Board is authorized to make appropriate adjustments in the method of calculating the attainment of Performance Goals for a Performance Period as follows: (i)&nbsp;to exclude restructuring and/or other
nonrecurring charges; (ii)&nbsp;to exclude exchange rate effects, as applicable, for <FONT STYLE="white-space:nowrap">non-U.S.</FONT> dollar denominated Performance Goals; (iii)&nbsp;to exclude the effects of changes to generally accepted accounting
principles; (iv)&nbsp;to exclude the effects of any statutory adjustments to corporate tax rates; (v)&nbsp;to exclude the effects of items that are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as determined under generally
accepted accounting principles; (vi)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (vii)&nbsp;to assume that any business divested by the Company achieved performance objectives at targeted levels during the balance of a
Performance Period following such divestiture; (viii)&nbsp;to exclude the effect of any change in the outstanding shares of common stock of the Company by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization,
merger, consolidation, <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change, or any distributions to common shareholders other than regular cash dividends; (ix)&nbsp;to exclude the
effects of stock based compensation and/or the award of an annual cash incentive under the Company&#146;s Annual Incentive Program; (x)&nbsp;to exclude the effect of any other unusual, <FONT STYLE="white-space:nowrap">non-recurring</FONT> gain or
loss or other extraordinary item; and (xi)&nbsp;to make other appropriate adjustments selected by the Board. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(kk)</B>
&#147;<B><I>Performance Period</I></B>&#148; means the period of time selected by the Board over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant&#146;s right to and the payment of a
Performance Stock Award. Performance Periods may be of varying and overlapping duration, at the sole discretion of the Board. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ll)</B> &#147;<B><I>Performance Stock Award</I></B>&#148; means an Award granted under the terms and conditions of Section&nbsp;6(c).
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(mm)</B> &#147;<B><I>Plan</I></B>&#148; means this Dynavax Technologies Corporation 2018 Equity Incentive Plan.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(nn)</B> &#147;<B><I>Restricted Stock Award</I></B>&#148; means an award of shares of Common Stock which is granted
pursuant to the terms and conditions of Section&nbsp;6(a). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(oo)</B> &#147;<B><I>Restricted Stock Award
Agreement</I></B>&#148; means a written agreement between the Company and a holder of a Restricted Stock Award evidencing the terms and conditions of a Restricted Stock Award grant. Each Restricted Stock Award Agreement will be subject to the terms
and conditions of the Plan. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-21
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(pp)</B> &#147;<B><I>Restricted Stock Unit Award</I></B>&#148;<B><I> </I></B>means a
right to receive shares of Common Stock which is granted pursuant to the terms and conditions of Section&nbsp;6(b). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(qq)</B> &#147;<B><I>Restricted Stock Unit Award Agreement</I></B>&#148;<B><I> </I></B>means a written agreement between the Company
and a holder of a Restricted Stock Unit Award evidencing the terms and conditions of a Restricted Stock Unit Award grant. Each Restricted Stock Unit Award Agreement will be subject to the terms and conditions of the Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(rr)</B> &#147;<B><I>Rule <FONT STYLE="white-space:nowrap">16b-3</FONT></I></B>&#148; means Rule
<FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act or any successor to Rule <FONT STYLE="white-space:nowrap">16b-3,</FONT> as in effect from time to time. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ss)</B> &#147;<B><I>Rule 405</I></B>&#148; means Rule 405 promulgated under the Securities Act. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(tt)</B> &#147;<B><I>Securities Act</I></B>&#148; means the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(uu)</B> &#147;<B><I>Stock Appreciation Right</I></B>&#148; or &#147;<B><I>SAR</I></B>&#148;<B><I>
</I></B>means a right to receive the appreciation on Common Stock that is granted pursuant to the terms and conditions of Section&nbsp;5. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(vv)</B> &#147;<B><I>Stock Appreciation Right Agreement</I></B>&#148; or &#147;<B><I>SAR Agreement</I></B>&#148; means a written agreement between the Company and a holder of a Stock Appreciation Right
evidencing the terms and conditions of a Stock Appreciation Right grant. Each Stock Appreciation Right Agreement will be subject to the terms and conditions of the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(ww)</B> &#147;<B><I>Subsidiary</I></B>&#148; means, with respect to the Company, (i)&nbsp;any corporation of which more than 50% of the outstanding capital stock having ordinary voting power to elect
a majority of the board of directors of such corporation (irrespective of whether, at the time, stock of any other class or classes of such corporation will have or might have voting power by reason of the happening of any contingency) is at the
time, directly or indirectly, Owned by the Company, and (ii)&nbsp;any partnership, limited liability company or other entity in which the Company has a direct or indirect interest (whether in the form of voting or participation in profits or capital
contribution) of more than 50%. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(xx)</B> &#147;<B><I>Ten Percent Stockholder</I></B>&#148; means a person who Owns (or is
deemed to Own pursuant to Section&nbsp;424(d) of the Code) stock possessing more than 10% of the total combined voting power of all classes of stock of the Company or any Affiliate. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(yy)</B> &#147;<B><I>Transaction</I></B>&#148; means a Corporate Transaction or a Change in Control. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">A-22
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Appendix B </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>D<SMALL>YNAVAX</SMALL> T<SMALL>ECHNOLOGIES</SMALL> C<SMALL>ORPORATION</SMALL> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>2014 E<SMALL>MPLOYEE</SMALL> S<SMALL>TOCK</SMALL> P<SMALL>URCHASE</SMALL> P<SMALL>LAN</SMALL> </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>DOPTED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>: A<SMALL>PRIL</SMALL>&nbsp;10, 2014 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>: M<SMALL>AY</SMALL>&nbsp;28, 2014
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL>
B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>: A<SMALL>PRIL</SMALL>&nbsp;22, 2016 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>: M<SMALL>AY</SMALL>&nbsp;31, 2016
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL>
B<SMALL>OARD</SMALL> <SMALL>OF</SMALL> D<SMALL>IRECTORS</SMALL>: A<SMALL>PRIL</SMALL>&nbsp;8, 2018 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>[A<SMALL>PPROVED</SMALL> <SMALL>BY</SMALL> <SMALL>THE</SMALL> S<SMALL>TOCKHOLDERS</SMALL>:
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018] </B></FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>1.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>G<SMALL>ENERAL</SMALL>; P<SMALL>URPOSE</SMALL>.</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits
the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> The
Company, by means of the Plan, seeks to retain the services of such Employees, to secure and retain the services of new Employees and to provide incentives for such persons to exert maximum efforts for the success of the Company and its Related
Corporations. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>DMINISTRATION</SMALL>.</B> </FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> The Board will administer the Plan unless and until the Board delegates administration of the Plan to a Committee or Committees, as provided in Section&nbsp;2(c). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> The Board will have the power, subject to, and within the limitations of, the express provisions of the Plan: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> To determine how and when Purchase Rights will be granted and the provisions of each Offering (which need not be identical).
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> To designate from time to time which Related Corporations of the Company will be eligible to participate in the
Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)</B> To construe and interpret the Plan and Purchase Rights, and to establish, amend and revoke rules and
regulations for the administration of the Plan. The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan, in a manner and to the extent it deems necessary or expedient to make the Plan fully effective.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv)</B> To settle all controversies regarding the Plan and Purchase Rights granted under the Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(v)</B> To suspend or terminate the Plan at any time as provided in Section&nbsp;12. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(vi)</B> To amend the Plan at any time as provided in Section&nbsp;12. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(vii)</B> Generally, to exercise such powers and to perform such acts as it deems necessary or expedient to promote the best interests
of the Company and its Related Corporations and to carry out the intent that the Plan be treated as an Employee Stock Purchase Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(viii)</B> To adopt such procedures and <FONT STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit participation in the Plan by Employees who are foreign nationals or
employed outside the United States. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-1
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B> The Board may delegate some or all of the administration of the Plan to a
Committee or Committees. If administration is delegated to a Committee, the Committee will have, in connection with the administration of the Plan, the powers theretofore possessed by the Board that have been delegated to the Committee, including
the power to delegate to a subcommittee any of the administrative powers the Committee is authorized to exercise (and references in this Plan to the Board will thereafter be to the Committee or subcommittee), subject, however, to such resolutions,
not inconsistent with the provisions of the Plan, as may be adopted from time to time by the Board. The Board may retain the authority to concurrently administer the Plan with the Committee and may, at any time, revest in the Board some or all of
the powers previously delegated. Whether or not the Board has delegated administration of the Plan to a Committee, the Board will have the final power to determine all questions of policy and expediency that may arise in the administration of the
Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B> All determinations, interpretations and constructions made by the Board in good faith will not be subject to
review by any person and will be final, binding and conclusive on all persons. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>3.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>S<SMALL>HARES</SMALL> <SMALL>OF</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL> S<SMALL>UBJECT</SMALL> <SMALL>TO</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>.
</B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> Subject to the provisions of Section&nbsp;11(a) relating to Capitalization Adjustments, the
maximum number of shares of Common Stock that may be issued under the Plan will not exceed 850,000 shares of Common Stock, which number is the sum of (i) 50,000 shares that were approved at the Company&#146;s 2014 Annual Meeting of
Stockholders,</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> (ii)&nbsp;an additional 200,000 shares that
were approved at the Company&#146;s 2016 Annual Meeting of Stockholders, and (iii)&nbsp;an additional 600,000 shares that were approved at the Company&#146;s 2018 Annual Meeting of Stockholders. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> If any Purchase Right granted under the Plan terminates without having been exercised in full, the shares of Common Stock not
purchased under such Purchase Right will again become available for issuance under the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B> The stock purchasable
under the Plan will be shares of authorized but unissued or reacquired Common Stock, including shares repurchased by the Company on the open market. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>G<SMALL>RANT</SMALL> <SMALL>OF</SMALL> P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>; O<SMALL>FFERING</SMALL>. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> The Board may from time to time grant or provide for the grant of Purchase Rights to Eligible Employees under an Offering
(consisting of one or more Purchase Periods) on an Offering Date or Offering Dates selected by the Board. Each Offering will be in such form and will contain such terms and conditions as the Board will deem appropriate and will comply with the
requirement of Section&nbsp;423(b)(5) of the Code that all Employees granted Purchase Rights will have the same rights and privileges. The terms and conditions of an Offering will be incorporated by reference into the Plan and treated as part of the
Plan. The provisions of separate Offerings need not be identical, but each Offering will include (through incorporation of the provisions of this Plan by reference in the document comprising the Offering or otherwise) the period during which the
Offering will be effective, which period will not exceed 27 months beginning with the Offering Date, and the substance of the provisions contained in Sections 5 through 8, inclusive. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> If a Participant has more than one Purchase Right outstanding under the Plan, unless he or she otherwise indicates in forms
delivered to the Company: (i)&nbsp;each form will apply to all of his or her Purchase Rights under the Plan, and (ii)&nbsp;a Purchase Right with a lower exercise price (or an earlier-granted Purchase Right, if different Purchase Rights have
identical exercise prices) will be exercised to the fullest possible extent before a Purchase Right with a higher exercise price (or a later-granted Purchase Right if different Purchase Rights have identical exercise prices) will be exercised.
</FONT></P> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"></FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">1</SUP>&nbsp;</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="2"></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">The 500,000 shares approved at the Company&#146;s 2014 Annual Meeting of Stockholders were adjusted to 50,000 shares pursuant to a 1-for-10 reverse stock split
effective November 7, 2014. </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-2
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B> The Board will have the discretion to structure an Offering so that if the
Fair Market Value of a share of Common Stock on the first Trading Day of a new Purchase Period within that Offering is less than or equal to the Fair Market Value of a share of Common Stock on the Offering Date for that Offering, then (i)&nbsp;that
Offering will terminate immediately as of that first Trading Day, and (ii)&nbsp;the Participants in such terminated Offering will be automatically enrolled in a new Offering beginning on the first Trading Day of such new Purchase Period. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>5.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>LIGIBILITY</SMALL>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> Purchase Rights may be granted only to Employees of the Company or, as the Board may designate in accordance with Section&nbsp;2(b), to Employees of a Related Corporation. Except as provided in
Section&nbsp;5(b), an Employee will not be eligible to be granted Purchase Rights unless, on the Offering Date, the Employee has been in the employ of the Company or the Related Corporation, as the case may be, for such continuous period preceding
such Offering Date as the Board may require, but in no event will the required period of continuous employment be equal to or greater than two years. In addition, the Board may provide that no Employee will be eligible to be granted Purchase Rights
under the Plan unless, on the Offering Date, such Employee&#146;s customary employment with the Company or the Related Corporation is more than 20 hours per week and more than five months per calendar year or such other criteria as the Board may
determine consistent with Section&nbsp;423 of the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> The Board may provide that each person who, during the
course of an Offering, first becomes an Eligible Employee will, on a date or dates specified in the Offering which coincides with the day on which such person becomes an Eligible Employee or which occurs thereafter, receive a Purchase Right under
that Offering, which Purchase Right will thereafter be deemed to be a part of that Offering. Such Purchase Right will have the same characteristics as any Purchase Rights originally granted under that Offering, as described herein, except that:
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> the date on which such Purchase Right is granted will be the &#147;Offering Date&#148; of such Purchase Right for
all purposes, including determination of the exercise price of such Purchase Right; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> the period of the Offering
with respect to such Purchase Right will begin on its Offering Date and end coincident with the end of such Offering; and </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)</B> the Board may provide that if such person first becomes an Eligible Employee within a specified period of time before the
end of the Offering, he or she will not receive any Purchase Right under that Offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B> No Employee will be
eligible for the grant of any Purchase Rights if, immediately after any such Purchase Rights are granted, such Employee owns stock possessing 5% or more of the total combined voting power or value of all classes of stock of the Company or of any
Related Corporation. For purposes of this Section&nbsp;5(c), the rules of Section&nbsp;424(d) of the Code will apply in determining the stock ownership of any Employee, and stock which such Employee may purchase under all outstanding Purchase Rights
and options will be treated as stock owned by such Employee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B> As specified by Section&nbsp;423(b)(8) of the Code,
an Eligible Employee may be granted Purchase Rights only if such Purchase Rights, together with any other rights granted under all Employee Stock Purchase Plans of the Company and any Related Corporations, do not permit such Eligible Employee&#146;s
rights to purchase stock of the Company or any Related Corporation to accrue at a rate which exceeds $25,000 of Fair Market Value of such stock (determined at the time such rights are granted, and which, with respect to the Plan, will be determined
as of their respective Offering Dates) for each calendar year in which such rights are outstanding at any time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e)</B>
Officers of the Company and any designated Related Corporation, if they are otherwise Eligible Employees, will be eligible to participate in Offerings under the Plan. Notwithstanding the foregoing, the Board may provide in an Offering that Employees
who are highly compensated Employees within the meaning of Section&nbsp;423(b)(4)(D) of the Code will not be eligible to participate. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-3
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>6.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>; P<SMALL>URCHASE</SMALL> P<SMALL>RICE</SMALL>. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> On each Offering Date, each Eligible Employee, pursuant to an Offering made under the Plan, will be granted a Purchase Right to
purchase up to that number of shares of Common Stock purchasable either with a percentage or with a maximum dollar amount, as designated by the Board, but in either case not exceeding 10% of such Employee&#146;s earnings (as defined by the Board in
each Offering) during the period that begins on the Offering Date (or such later date as the Board determines for a particular Offering) and ends on the date stated in the Offering, which date will be no later than the end of the Offering.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> The Board will establish one or more Purchase Dates during an Offering on which Purchase Rights granted for that
Offering will be exercised and shares of Common Stock will be purchased in accordance with such Offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B> In
connection with each Offering made under the Plan, the Board may specify (i)&nbsp;a maximum number of shares of Common Stock that may be purchased by any Participant pursuant to such Offering, (ii)&nbsp;a maximum number of shares of Common Stock
that may be purchased by any Participant on any Purchase Date pursuant to such Offering, (iii)&nbsp;a maximum aggregate number of shares of Common Stock that may be purchased by all Participants pursuant to such Offering, and/or (iv)&nbsp;a maximum
aggregate number of shares of Common Stock that may be purchased by all Participants on any Purchase Date pursuant to such Offering. If the aggregate purchase of shares of Common Stock issuable upon exercise of Purchase Rights granted under such
Offering would exceed any such maximum aggregate number, then, in the absence of any Board action otherwise, a pro rata (based on each Participant&#146;s accumulated Contributions) allocation of the shares of Common Stock available will be made in
as nearly a uniform manner as will be practicable and equitable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B> The purchase price of shares of Common Stock
acquired pursuant to Purchase Rights will be not less than the lesser of: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> an amount equal to 85% of the Fair
Market Value of the shares of Common Stock on the Offering Date; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> an amount equal to 85% of the Fair Market
Value of the shares of Common Stock on the applicable Purchase Date. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>7.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>P<SMALL>ARTICIPATION</SMALL>; W<SMALL>ITHDRAWAL</SMALL>; T<SMALL>ERMINATION</SMALL>. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> An Eligible Employee may elect to authorize payroll deductions as the means of making Contributions by completing and
delivering to the Company, within the time specified in the Offering, an enrollment form provided by the Company. The enrollment form will specify the amount of Contributions not to exceed the maximum amount specified by the Board. Each
Participant&#146;s Contributions will be credited to a bookkeeping account for such Participant under the Plan and will be deposited with the general funds of the Company except where applicable law requires that Contributions be deposited with a
third party. If permitted in the Offering, a Participant may begin such Contributions with the first full payroll period beginning on the Offering Date. If permitted in the Offering, a Participant may thereafter decrease (including to zero) or
increase his or her Contributions. If specifically provided in the Offering, in addition to making Contributions by payroll deductions, a Participant may make Contributions through payment by cash or check prior to a Purchase Date. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> During an Offering, a Participant may cease making Contributions and withdraw from the Offering by delivering to the Company a
withdrawal form provided by the Company. The Company may impose a deadline before a Purchase Date for withdrawing. Upon such withdrawal, such Participant&#146;s Purchase Right in that Offering will immediately terminate and the Company will
distribute to such Participant all of his or her accumulated but unused Contributions without interest. A Participant&#146;s withdrawal from that Offering will have no effect upon his or her eligibility to participate in any other Offerings under
the Plan, but such Participant will be required to deliver a new enrollment form to participate in subsequent Offerings. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-4
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B> Upon either (i)&nbsp;termination of a Participant&#146;s employment
relationship with the Company or a Related Corporation that has been designated as eligible to participate in the Plan or (ii)&nbsp;any other circumstance or event that causes a Participant to no longer be eligible to participate in an Offering, the
Company will distribute to such individual all of his or her accumulated but unused Contributions without interest and such individual&#146;s outstanding Purchase Rights under such Offering will terminate immediately (subject to any post-employment
participation period required by law). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For purposes of the Plan, the employment relationship will be treated as continuing
intact while an individual is on military leave, sick leave or other bona fide leave of absence approved by the Company or a Related Corporation, if applicable, if the period of such leave does not exceed three months, or if longer, so long as the
individual&#146;s right to reemployment with the Company or a Related Corporation, if applicable, is provided either by statute or by contract. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B> During a Participant&#146;s lifetime, Purchase Rights will be exercisable only by such Participant. Purchase Rights are not transferable by a Participant, except by will, by the laws of descent
and distribution, or, if permitted by the Company, by a beneficiary designation as described in Section&nbsp;10. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e)</B>
Unless otherwise specified in the Offering, the Company will have no obligation to pay interest on Contributions. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>8.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>XERCISE</SMALL> <SMALL>OF</SMALL> P<SMALL>URCHASE</SMALL> R<SMALL>IGHTS</SMALL>. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> On each Purchase Date, each Participant&#146;s accumulated Contributions will be applied to the purchase of shares of Common
Stock, up to the maximum number of shares of Common Stock permitted by the Plan and the applicable Offering, at the purchase price specified in the Offering. No fractional shares will be issued unless specifically provided for in the Offering.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> If any amount of accumulated Contributions remains in a Participant&#146;s account after the purchase of shares of
Common Stock and such remaining amount is less than the amount required to purchase one share of Common Stock on the final Purchase Date of an Offering, then such remaining amount will be held in such Participant&#146;s account for the purchase of
shares of Common Stock under the next Offering under the Plan, unless such Participant withdraws from or is not eligible to participate in such Offering, in which case such amount will be distributed to such Participant after the final Purchase Date
without interest. If the amount of Contributions remaining in a Participant&#146;s account after the purchase of shares of Common Stock is at least equal to the amount required to purchase one whole share of Common Stock on the final Purchase Date
of an Offering, then such remaining amount will not roll over to the next Offering and will instead be distributed in full to such Participant after the final Purchase Date of such Offering without interest. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B> No Purchase Rights may be exercised to any extent unless the shares of Common Stock to be issued upon such exercise under the
Plan are covered by an effective registration statement pursuant to the Securities Act and the Plan is in material compliance with all applicable federal, state, foreign and other securities and other laws applicable to the Plan. If, on a Purchase
Date, the shares of Common Stock are not so registered or the Plan is not in such compliance, no Purchase Rights will be exercised on such Purchase Date, and the Purchase Date will be delayed until the shares of Common Stock are subject to such an
effective registration statement and the Plan is in material compliance, except that the Purchase Date will in no event be more than 6 months from the Offering Date. If, on the Purchase Date, as delayed to the maximum extent permissible, the shares
of Common Stock are not registered and the Plan is not in material compliance with all applicable laws, no Purchase Rights will be exercised and all accumulated but unused Contributions will be distributed to the Participants without interest.
</FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>9.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>C<SMALL>OVENANTS</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> C<SMALL>OMPANY</SMALL>. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company will seek to obtain from each federal, state, foreign or other regulatory commission or agency having jurisdiction over the
Plan such authority as may be required to grant Purchase Rights and issue and sell </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-5
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
shares of Common Stock thereunder. If, after commercially reasonable efforts, the Company is unable to obtain the authority that counsel for the Company deems necessary for the grant of Purchase
Rights or the lawful issuance and sale of Common Stock under the Plan, and at a commercially reasonable cost, the Company will be relieved from any liability for failure to grant Purchase Rights and/or to issue and sell Common Stock upon exercise of
such Purchase Rights. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>10.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>D<SMALL>ESIGNATION</SMALL> <SMALL>OF</SMALL> B<SMALL>ENEFICIARY</SMALL>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> The Company may, but is not obligated to, permit a Participant to submit a form designating a beneficiary who will receive any shares of Common Stock and/or Contributions from the
Participant&#146;s account under the Plan if the Participant dies before such shares and/or Contributions are delivered to the Participant. If a Participant is married and the designated beneficiary is not the Participant&#146;s spouse, the Company
may require spousal consent for such designation to be effective. The Company may, but is not obligated to, permit the Participant (subject to spousal consent, if applicable and required by the Company) to change such designation of beneficiary. Any
such designation and/or change must be on a form approved by the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> If a Participant dies, and in the
absence of a valid beneficiary designation, the Company will deliver any shares of Common Stock and/or Contributions to the executor or administrator of the estate of the Participant. If no executor or administrator has been appointed (to the
knowledge of the Company), the Company, in its sole discretion, may deliver such shares of Common Stock and/or Contributions to the Participant&#146;s spouse, dependents or relatives, or if no spouse, dependent or relative is known to the Company,
then to such other person as the Company may designate. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>11.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>DJUSTMENTS</SMALL> <SMALL>UPON</SMALL> C<SMALL>HANGES</SMALL> <SMALL>IN</SMALL> C<SMALL>OMMON</SMALL> S<SMALL>TOCK</SMALL>; C<SMALL>ORPORATE</SMALL>
T<SMALL>RANSACTIONS</SMALL>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> In the event of a Capitalization Adjustment, the Board will
appropriately and proportionately adjust: (i)&nbsp;the class(es) and maximum number of securities subject to the Plan pursuant to Section&nbsp;3(a); (ii) the class(es) and number of securities subject to, and the purchase price applicable to
outstanding Offerings and Purchase Rights; and (iii)&nbsp;the class(es) and number of securities that are the subject of the purchase limits under each ongoing Offering. The Board will make these adjustments, and its determination will be final,
binding and conclusive. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> In the event of a Corporate Transaction, the surviving or acquiring corporation (or the
surviving or acquiring corporation&#146;s parent or subsidiary company) will assume or continue outstanding Purchase Rights or will substitute similar rights (including a right to acquire the same consideration paid to the stockholders in the
Corporate Transaction) for outstanding Purchase Rights, unless the Board determines, in the exercise of its sole discretion and in lieu of such assumption, continuation or substitution, to shorten any Offerings then in progress by setting a new
Purchase Date prior to the Corporate Transaction (the &#147;<B><I>New Purchase Date</I></B>&#148;). If the Board sets a New Purchase Date pursuant to the preceding sentence, then the Board will notify each Participant in writing, at least ten
(10)&nbsp;business days prior to the New Purchase Date, that the Purchase Date for the Participant&#146;s outstanding Purchase Rights has been changed to the New Purchase Date and that either: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> the Participant&#146;s outstanding Purchase Rights will be exercised automatically on the New Purchase Date, unless the
Participant withdraws from the applicable Offering prior to the New Purchase Date in accordance with Section&nbsp;7(b), and such Purchase Rights will terminate immediately after such exercise; or </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> in lieu of such exercise, the Company will pay to the Participant on the New Purchase Date an amount in cash, cash
equivalents, or property as determined by the Board that is equal to the difference in the Fair Market Value of the shares of Common Stock subject to the Participant&#146;s outstanding Purchase Rights on the New Purchase Date and the applicable
exercise price due had such Purchase Rights been exercised automatically under Section&nbsp;11(b)(i) above, and such Purchase Rights will terminate immediately after such payment. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-6
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>12.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>A<SMALL>MENDMENT</SMALL>, T<SMALL>ERMINATION</SMALL> <SMALL>OR</SMALL> S<SMALL>USPENSION</SMALL> <SMALL>OF</SMALL> <SMALL>THE</SMALL> P<SMALL>LAN</SMALL>.
</B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> The Board may amend the Plan at any time in any respect the Board deems necessary or advisable.
However, except as provided in Section&nbsp;11(a) relating to Capitalization Adjustments, stockholder approval will be required for any amendment of the Plan for which stockholder approval is required by applicable law or listing requirements,
including any amendment that either (i)&nbsp;materially increases the number of shares of Common Stock available for issuance under the Plan, (ii)&nbsp;materially expands the class of individuals eligible to become Participants and receive Purchase
Rights, (iii)&nbsp;materially increases the benefits accruing to Participants under the Plan or materially reduces the price at which shares of Common Stock may be purchased under the Plan, (iv)&nbsp;materially extends the term of the Plan, or
(v)&nbsp;expands the types of awards available for issuance under the Plan, but in each of (i)&nbsp;through (v) above only to the extent stockholder approval is required by applicable law or listing requirements. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> The Board may suspend or terminate the Plan at any time. No Purchase Rights may be granted under the Plan while the Plan is
suspended or after it is terminated. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B> Any benefits, privileges, entitlements and obligations under any outstanding
Purchase Rights granted before an amendment, suspension or termination of the Plan will not be materially impaired by any such amendment, suspension or termination except (i)&nbsp;with the consent of the person to whom such Purchase Rights were
granted, (ii)&nbsp;as necessary to comply with any laws, listing requirements, or governmental regulations (including, without limitation, the provisions of Section&nbsp;423 of the Code and the regulations and other interpretive guidance issued
thereunder relating to Employee Stock Purchase Plans) including, without limitation, any such regulations or other guidance that may be issued or amended after the date the Plan is adopted by the Board, or (iii)&nbsp;as necessary to obtain or
maintain favorable tax, listing, or regulatory treatment. To be clear, the Board may amend outstanding Purchase Rights without a Participant&#146;s consent if such amendment is necessary to ensure that the Purchase Right and/or the Plan complies
with the requirements of Section&nbsp;423 of the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding anything in the Plan or any Offering Document to the
contrary, the Board will be entitled to: (i)&nbsp;establish the exchange ratio applicable to amounts withheld in a currency other than U.S. dollars; (ii)&nbsp;permit Contributions in excess of the amount designated by a Participant in order to
adjust for mistakes in the Company&#146;s processing of properly completed Contribution elections; (iii)&nbsp;establish reasonable waiting and adjustment periods and/or accounting and crediting procedures to ensure that amounts applied toward the
purchase of Common Stock for each Participant properly correspond with amounts withheld from the Participant&#146;s Contributions; (iv)&nbsp;amend any outstanding Purchase Rights or clarify any ambiguities regarding the terms of any Offering to
enable the Purchase Rights to qualify under and/or comply with Section&nbsp;423 of the Code; and (v)&nbsp;establish other limitations or procedures as the Board determines in its sole discretion advisable that are consistent with the Plan. The
actions of the Board pursuant to this paragraph will not be considered to alter or impair any Purchase Rights granted under an Offering as they are part of the initial terms of each Offering and the Purchase Rights granted under each Offering.
</FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>13.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>E<SMALL>FFECTIVE</SMALL> D<SMALL>ATE</SMALL> <SMALL>OF</SMALL> P<SMALL>LAN</SMALL>. </B></FONT></TD></TR></TABLE>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Plan will become effective on the date of the annual meeting of stockholders of the Company held in 2014, provided the Plan is
approved by the Company&#146;s stockholders at such meeting. No Purchase Rights will be exercised unless and until the Plan has been approved by the stockholders of the Company, which approval must be within 12 months before or after the date the
Plan is adopted (or if required under Section&nbsp;12(a), materially amended) by the Board. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>14.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>M<SMALL>ISCELLANEOUS</SMALL> P<SMALL>ROVISIONS</SMALL>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> Proceeds from the sale of shares of Common Stock pursuant to Purchase Rights will constitute general funds of the Company. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-7
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> A Participant will not be deemed to be the holder of, or to have any of the
rights of a holder with respect to, shares of Common Stock subject to Purchase Rights unless and until the Participant&#146;s shares of Common Stock acquired upon exercise of Purchase Rights are recorded in the books of the Company (or its transfer
agent). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B> The Plan and Offering do not constitute an employment contract. Nothing in the Plan or in the Offering
will in any way alter the at will nature of a Participant&#146;s employment or be deemed to create in any way whatsoever any obligation on the part of any Participant to continue in the employ of the Company or a Related Corporation, or on the part
of the Company or a Related Corporation to continue the employment of a Participant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B> The provisions of the Plan
will be governed by the laws of the State of California without resort to that state&#146;s conflicts of laws rules. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>15.</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>D<SMALL>EFINITIONS</SMALL>. </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">As used in the Plan, the following definitions will apply to the capitalized terms indicated below: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(a)</B> &#147;<B><I>Board</I></B>&#148;<I> </I>means the Board of Directors of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(b)</B> &#147;<B><I>Capitalization Adjustment</I></B>&#148; means any change that is made in, or other events that occur with respect to, the Common Stock subject to the Plan or subject to any Purchase
Right after the date the Plan is adopted by the Board without the receipt of consideration by the Company through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property other than cash, large
nonrecurring cash dividend, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or other similar equity restructuring transaction, as that term is used in Financial Accounting Standards Board
Accounting Standards Codification Topic 718 (or any successor thereto). Notwithstanding the foregoing, the conversion of any convertible securities of the Company will not be treated as a Capitalization Adjustment. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(c)</B> &#147;<B><I>Code</I></B>&#148;<I> </I>means the Internal Revenue Code of 1986, as amended, including any applicable
regulations and guidance thereunder<I>.</I> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(d)</B> &#147;<B><I>Committee</I></B>&#148;<I> </I>means a committee of one or
more members of the Board to whom authority has been delegated by the Board in accordance with Section&nbsp;2(c). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(e)</B>
&#147;<B><I>Common Stock</I></B>&#148; means the common stock of the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(f)</B> &#147;<B><I>Company</I></B>&#148;
means Dynavax Technologies Corporation, a Delaware corporation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(g)</B> <B><I>&#147;Contributions</I></B>&#148; means the
payroll deductions and other additional payments specifically provided for in the Offering that a Participant contributes to fund the exercise of a Purchase Right. A Participant may make additional payments into his or her account if specifically
provided for in the Offering, and then only if the Participant has not already had the maximum permitted amount withheld during the Offering through payroll deductions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(h)</B> &#147;<B><I>Corporate Transaction</I></B>&#148; means the consummation, in a single transaction or in a series of related transactions, of any one or more of the following events: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> a merger or consolidation in which the Company is not the surviving entity, except for a transaction the principal purpose of
which is to change the state in which the Company is incorporated; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> the sale, transfer or other disposition of all
or substantially all of the assets of the Company (including the capital stock of the Company&#146;s subsidiary corporations); </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-8
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iii)</B> the complete liquidation or dissolution of the Company; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(iv)</B> any reverse merger or series of related transactions culminating in a reverse merger (including, but not limited to, a tender
offer followed by a reverse merger) in which the Company is the surviving entity but in which securities possessing more than forty percent (40%) of the total combined voting power of the Company&#146;s outstanding securities are transferred to a
person or persons different from those who held such securities immediately prior to such merger or the initial transaction culminating in such merger but excluding any such transaction or series of related transactions that the Board determines
will not be a Corporate Transaction; or </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(v)</B> acquisition in a single or series of related transactions by any person or
related group of persons (other than the Company or by a Company-sponsored employee benefit plan) of beneficial ownership (within the meaning of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> of the Exchange Act) of securities possessing more
than fifty percent (50%) of the total combined voting power of the Company&#146;s outstanding securities but excluding any such transaction or series of related transactions that the Board determines will not be a Corporate Transaction. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> &#147;<B><I>Director</I></B>&#148;<I> </I>means a member of the Board. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(j)</B> &#147;<B><I>Eligible Employee</I></B>&#148;<I> </I>means an Employee who meets the requirements set forth in the document(s)
governing the Offering for eligibility to participate in the Offering, provided that such Employee also meets the requirements for eligibility to participate set forth in the Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(k)</B> &#147;<B><I>Employee</I></B>&#148;<I> </I>means any person, including an Officer or Director, who is &#147;employed&#148; for
purposes of Section&nbsp;423(b)(4) of the Code by the Company or a Related Corporation. However, service solely as a Director, or payment of a fee for such services, will not cause a Director to be considered an &#147;Employee&#148; for purposes of
the Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(l)</B> &#147;<B><I>Employee Stock Purchase Plan</I></B>&#148;<I> </I>means a plan that grants Purchase Rights
intended to be options issued under an &#147;employee stock purchase plan,&#148; as that term is defined in Section&nbsp;423(b) of the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(m)</B> &#147;<B><I>Exchange Act</I></B>&#148;<I> </I>means the Securities Exchange Act of 1934, as amended and the rules and regulations promulgated thereunder. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(n)</B> &#147;<B><I>Fair Market Value</I></B>&#148; means, as of any date, the value of the Common Stock determined as follows:
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(i)</B> If the Common Stock is listed on any established stock exchange or traded on any established market, the Fair
Market Value of a share of Common Stock will be the <B><U>closing sales price</U></B> for such stock as quoted on such exchange or market (or the exchange or market with the greatest volume of trading in the Common Stock) <B><U>on the date of
determination</U></B>, as reported in such source as the Board deems reliable. Unless otherwise provided by the Board, if there is no closing sales price for the Common Stock on the date of determination, then the Fair Market Value will be the
closing sales price on the last preceding date for which such quotation exists. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(ii)</B> In the absence of such markets
for the Common Stock, the Fair Market Value will be determined by the Board in good faith in compliance with applicable laws and in a manner that complies with Section&nbsp;409A of the Code. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(o)</B> &#147;<B><I>Offering</I></B>&#148;<I> </I>means the grant to Eligible Employees of Purchase Rights, with the exercise of those
Purchase Rights automatically occurring at the end of one or more Purchase Periods. The terms and conditions of an Offering will generally be set forth in the &#147;<B><I>Offering Document</I></B>&#148; approved by the Board for that Offering.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(p)</B> &#147;<B><I>Offering Date</I></B>&#148; means a date selected by the Board for an Offering to commence.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(q)</B> &#147;<B><I>Officer</I></B>&#148;<B> </B>means<B> </B>a person who is an officer of the Company or a Related
Corporation within the meaning of Section&nbsp;16 of the Exchange Act. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-9
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(r)</B> &#147;<B><I>Participant</I></B>&#148;<I> </I>means an Eligible Employee who
holds an outstanding Purchase Right. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(s)</B> &#147;<B><I>Plan</I></B>&#148;<I> </I>means this Dynavax Technologies
Corporation 2014 Employee Stock Purchase Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(t)</B> &#147;<B><I>Purchase Date</I></B>&#148;<I> </I>means one or more
dates during an Offering selected by the Board on which Purchase Rights will be exercised and on which purchases of shares of Common Stock will be carried out in accordance with such Offering. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(u)</B> &#147;<B><I>Purchase Period</I></B>&#148; means a period of time specified within an Offering, generally beginning on the
Offering Date or on the first Trading Day following a Purchase Date, and ending on a Purchase Date. An Offering may consist of one or more Purchase Periods. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(v)</B> &#147;<B><I>Purchase Right</I></B>&#148;<I> </I>means an option to purchase shares of Common Stock granted pursuant to the Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>(w)</B> &#147;<B><I>Related Corporation</I></B>&#148;<I> </I>means any &#147;parent corporation&#148; or &#147;subsidiary
corporation&#148; of the Company whether now or subsequently established, as those terms are defined in Sections 424(e) and (f), respectively, of the Code. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(x)</B> &#147;<B><I>Securities Act</I></B>&#148;<I> </I>means the Securities Act of 1933, as amended. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(y)</B> &#147;<B><I>Trading Day</I></B>&#148;<B> </B>means any day on which the exchange(s) or market(s) on which shares of Common Stock are listed, including but not limited to the NYSE, the Nasdaq
Global Select Market, the Nasdaq Global Market, the Nasdaq Capital Market or any successors thereto, is open for trading. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">B-10
</FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g563018g95s09.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">DYNAVAX TECHNOLOGIES CORPORATION </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">ATTN: STEVEN N.
GERSTEN </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">2929 SEVENTH STREET, SUITE 100 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">BERKELEY, CA 94710 </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">VOTE BY INTERNET - www.proxyvote.com </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Use the Internet to transmit your voting instructions and
for electronic delivery of information up until 11:59 P.M. Eastern Time the day before the <FONT STYLE="white-space:nowrap">cut-off</FONT> date or meeting date. Have your proxy card in hand when you access the web site and follow the instructions to
obtain your records and to create an electronic voting instruction form. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">ELECTRONIC DELIVERY OF FUTURE PROXY MATERIALS </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">If you would like to reduce the costs incurred by our company in mailing proxy materials, you can consent to receiving all future proxy statements, proxy cards and annual reports
electronically via <FONT STYLE="white-space:nowrap">e-mail</FONT> or the Internet. To sign up for electronic delivery, please follow the instructions above to vote using the Internet and, when prompted, indicate that you agree to receive or access
proxy materials electronically in future years. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">VOTE BY PHONE
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">-1-800-690-6903</FONT></FONT></FONT> </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Use any touch-tone
telephone to transmit your voting instructions up until 11:59 P.M. Eastern Time the day before the <FONT STYLE="white-space:nowrap">cut-off</FONT> date or meeting date. Have your proxy card in hand when you call and then follow the instructions.
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">VOTE BY MAIL </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Mark, sign and date your proxy card and return it in the
postage-paid envelope we have provided or return it to Vote Processing, c/o Broadridge, 51 Mercedes Way, Edgewood, NY 11717. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">TO VOTE, MARK BLOCKS BELOW IN BLUE OR
BLACK INK AS FOLLOWS: </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">E46043-P03322 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">KEEP THIS PORTION FOR YOUR RECORDS
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">DETACH AND RETURN THIS PORTION ONLY </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">THIS PROXY CARD IS VALID ONLY WHEN SIGNED
AND DATED. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">DYNAVAX TECHNOLOGIES CORPORATION </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">The Board of Directors recommends
a vote FOR the listed nominees: </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">1. Election of Directors </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Nominees:
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">01) Arnold L. Oronsky, Ph.D. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">02) Francis R. Cano, Ph.D. </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">03) Peggy V. Phillips </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">For All </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Withhold All </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">For All Except </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">To withhold authority to vote for any individual nominee(s), mark &#147;For All Except&#148; and write the number(s) of the nominee(s) on the line below. </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">The Board of Directors recommends a vote FOR proposals 2, 3, 4 and 5. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">2. To approve the
Dynavax Technologies Corporation 2018 Equity Incentive Plan. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">3. To amend and restate the Dynavax Technologies Corporation 2014 Employee Stock Purchase Plan to,
among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 600,000. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">4. To approve, on an advisory basis,
the compensation of the Company&#146;s named executive officers, as disclosed in the proxy statement. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">5. To ratify the selection of Ernst&nbsp;&amp; Young LLP as
the independent registered public accounting firm of the Company for its fiscal year ending </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">December&nbsp;31, 2018. </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">For </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Against </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Abstain </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">NOTE: To conduct any other business properly brought before the meeting or any
adjournment thereof. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">For address changes and/or comments, please check this box and write them on the back where indicated. </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Please sign exactly as your name(s) appear(s) hereon. When signing as attorney, executor, administrator, or other fiduciary, please give full title as such. Joint owners should
each sign personally. All holders must sign. If a corporation or partnership, please sign in full corporate or partnership name by authorized officer. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Signature
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">[PLEASE SIGN WITHIN BOX] </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Date </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Signature </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">(Joint Owners) </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Date </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g563018g70t93.jpg" ALT="LOGO">
 </P> <P STYLE="font-family:Times New Roman; font-size:0.5pt"><FONT COLOR="#FFFFFF">Important Notice Regarding the Availability of Proxy Material for the Annual Meeting: </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">The Combined <FONT STYLE="white-space:nowrap">10-K</FONT> with Proxy Statement is available at www.proxyvote.com. </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">E46044-P03322 </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">DYNAVAX TECHNOLOGIES CORPORATION </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS OF </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">DYNAVAX TECHNOLOGIES
CORPORATION </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">FOR THE 2018 ANNUAL MEETING OF STOCKHOLDERS </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">May&nbsp;31, 2018
</FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">The undersigned stockholder of DYNAVAX TECHNOLOGIES CORPORATION, a Delaware corporation (the &#147;Company&#148;), hereby acknowledges receipt of the Notice of
Annual Meeting of Stockholders and Proxy Statement, each dated April&nbsp;20, 2018, and the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, and hereby appoints Eddie Gray
and Michael Ostrach, or either of them, proxies, with full power to each of substitution, on behalf and in the name of the undersigned, to represent the undersigned at the 2018 Annual Meeting of Stockholders of the Company to be held on May&nbsp;31,
2018 at 9:00 a.m., Pacific Time, at the Company&#146;s offices at 2929 Seventh Street, Suite 100, Berkeley, California, and at any postponement or adjournment thereof, and to vote all shares of common stock of the Company which the undersigned would
be entitled to vote if then and there personally present, on the matters set on the reverse side. </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">THE PROXY WILL BE VOTED AS DIRECTED OR, IF NO CONTRARY DIRECTION
IS INDICATED, WILL BE VOTED IN FAVOR OF THE COMPANY&#146;S PROPOSALS AS LISTED ON THE REVERSE SIDE, AND AS SAID PROXIES DEEM ADVISABLE ON SUCH MATTERS AS MAY PROPERLY COME BEFORE THE MEETING. </FONT><br><FONT
STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Address Changes/Comments: </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">(If you noted any Address Changes/Comments above, please mark
corresponding box on the reverse side.) </FONT><br><FONT STYLE="font-family:Times New Roman; font-size:0.5pt" COLOR="#FFFFFF">Continued and to be signed on reverse side </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g563018g70t93.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g563018g70t93.jpg
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M$0'_Q "Z  $  @(# 0$! 0          !P@&"@0%"0," 0L! 0$! 0$
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M'@#IE"UIA&$F(NV+>W_BM-$^]NM5O(7D?\B"OI0]XM6A9/V!6E<\!)8G5I$
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M75"+W=ZYY^>S(!*>@^M(7!9[4:Q+$(0*K'9ED,4%]9CX#V\]T9T9P=E*AF@
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M@P<(8<$N8^OSVM->M(?0[^A_H_;E<KW\DS80P& P& P& P& P& P& P& P&
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M,>$V5TYI'!/M.WNASHI0;1!WI88(X\0S-DQT\WHWA@P& P& P& P& P& P&
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MD^2Z3Q:%Q2-R.P'!$[3M^88\TM#S-'5M2;0-[G*G)O2)UD@<$2(6R2CE8S3
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M>Q")%OT]"<KX+;:UK6M:UK6M:UZ:UK\FM:U_LUK7_AK6$?W 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M+:34<:R1F(/;H[2RSE$52S(<>@I 4Y1$F3H&,U08L<"S MB+Z:NV>H+ C/&
MO&NW1=-5PJL-EK,]),FF0/"AF8S5KM%'%'&V*?/T'W9+;5LAD>OBM;;8IT&#
M]0V@^(, 0#+*V;\<\@HPF*QQ;V;0B&J[DN<R1NQ]?T=,'Z"2UU1QIZ6*'B2,
M#8Q.AZ6!-R=(8MG29R(D:4+>I;0'IUPA"$2,98=CP<;G'BDJT[HC53L<1>G1
MFF,G-G4E2Q.*L,%CQLCD+N\*8S(IALM.V@/2ZT4GCD57*1B$/6]_!T &AFC
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M[RO<94=2U&778,PG*$CI9&2IHJIF^I[$=N@['4# 2-2ULU'(8^;829R:A*
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M&!K,^&?_ *LOX@C_ %)U%_OW'AU]S\-?A^S9FPY& P& P&!K,_A9O\EG4_\
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M1.&J](ZA3P$5=(>]5-?_ $\" JKUEJB5#3G?_:RU0!;]OQ0 )$_LWB\>'_\
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M;6/U%EF.I@-!6OM8.+*[Q):'W;]@6DD(=>T&\)WTN\\9]6\5E><P& P& P&
MP& P& P& P& P& P& P& P& P& P& P-9GPS_P#5E_$$?ZDZB_W[CPZ^Y^&O
MP_9LS8<C 8# 8# UF?PLW^2SJ?\ [A'0O_!*YPZ^]^7RC9FPY& P& P& P&
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M-A9(M&&AN8(W&FEN8(\PM"0E TLC(SHR6]J:&M F 6F0MK:@3EDD$EA"644
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M;3M792GC;DZ<4C'N:YASA2TFH"(($+;$J?>ZYBSC7\51MA1A+<"-1I2VF-S
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M'F-IYU.4S6[ZQ24U>'&CM+Y.4SWA&);5:BR(]*8W%4PG A%):4>4A&W5R*3
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M[C\4DG+1,"9>,[*L1B9J<%(*;812%=-VR.W=52)"W2@U.0:E]A2W0A(%8O8
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MA43C\YE%+QE@?VJ*2I4Y(F!X,=IS%8JI(<530(#B4 E$_&&@^%O6]FEAUO\
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MP!';C-NNVF)TLJGV^-/).UR%I\]0:KF:_P @*_HTY_DG""=$TF.Y/!#DW$5
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MLM6ZXO&;WZ"?$$>J>KBR7E^EDB7NBP#<V'+6^.-;M]EF=R<!_ 3N#N)"A/-
M,!9HA%F:"2:VS,[1!W4GEKX3XZM)13-W6L^H[%9XL@G4V8()5=I6INL(,Z#T
M!OF-I+JXA\G00"/JP[T8 YQ,(%LD0#?;\,PL0A--K,SLOS YW#;1A,2LBO)(
MT3&!SN.L\MATK859:]ED4;?T)#FSO#8L*WL!Z->A4@, +\F_07Y=:WZZPSVZ
M57)[[OY,CG6L7X6>KF84'54RBHIG'*F,;)(->O8=-CV]@,'("64R((G$]GCJ
MQ44A4.!2XX@K0P$B",O8C7';CR\']MWNWE&A^@Z5Y8MNW6N$WKT.$&Z=A+FQ
MRLT,R&:YGLB8@F2H&%7$VE6M>$XDJ<E>N2F*% @%EA$(P&A":[69G:.T=^TN
M:&&V;NHYVLLA):/.=+I>A;EB^XW,#3(;4"Q,N6)I>:YD1\UF>"S$S<<+Y-O4
M*U^O9Z;(UO>M;)QN,^%1G%/)IP]..0IEWA$[W:7OE6O1O!,VM%'%IYZ1M2PN
M3<U.J1SAYL6+GA*U,K=TF]$_2]FF$*2C@!$2,)FR\-N7''W)5BW8W.,TO1BY
MKC-CD.=U2:AF?IMDA08[+4QJVD']V3L;3-]/2QA3QTDI6Z*BRM(C%8'$'N]P
MDX0ZWO1.-QGPR[RJNHJ+NVT+]IFL9T5)[*Y@DD7B-Y1HMCDK8.#2&9LJF0QI
MO-<GEF;FA\VY-",P[1C:H6%%^WVF" +>@[%EDEO:L%IWN[DV_P"_;NY>J&XV
M2:7MSF<81<4!1-,F1+(B8G=0L2[075U9$# _A;'L84BL38K6!2*1A+.V 0M:
MV6Z[23:]JSN#]1479%\75S-"YT4]7=SPVP-WN&$!8Y*C-A[?9K0-]A"@Q[<&
M9)''?3VU%B-T% L5#(]/:=HL7Y,)BR2^%97=UU5GSE4L^O*Y9,"&U;6$>5RN
M<RDQM>'@MC8$.P:5+QM<?;W5Z7:*V8'^C3)CC=^OY [P26W$[H>IGNCE+H+F
MZ1==U'<#/+.=XBAGCC)['^D2=D1L*2LB%BN<&.C+(61JDR0;$D0F'" )%HPX
MKVC*T8$P&Q"ZV7C>Z!&#S!^.F3\PS'LICZ*2+N;H!8;/5,ML?5=VR24TSY^!
M'3&F/BC2B"%2]68K#+&_T/(;S4P=J-:$9K81^TUPWEXXZN=6GENX"MVO+UM:
M"W<Y+X!S7"DUB71(7>G[OB9,/AZOZI\%X CEE<,CC(M;TRJ=B(:R5J@&B]>X
MO7N![B73:7%\6#P7S:>-2RFV=/$*OY\>VRMZZ<K8EZT%#=%(R$,!:75@95S\
MA&X5.E^O^QQDZ$($S?\ -*S@';,+*$6 P0"_\]YX.KKSSG^+ZUK C570'HUS
MD$[EDKC\(9V NB>B41NI/*7!.UL+8[JW*IT;?'=KUBH&M&N!J4@L&]C&,( B
M%H7V]Y,X2/(O+QX[XESC!.MY'T6W-7/-E66]U!#+'4P.TMHG6PHXHDB5[8C6
M<J$&2-K+;SHBX^]8K1D(?:FV+1VPB!L0X;9XXZK0S'JJ@H%;- 4=*+#0(K-Z
MC2S-=0T?2-;^\)["15]'D<KEBQOD#,U.$;;DK;'W E2 Q<K2A4@,UHC9@OR8
M9Q<6^$4ZO;S,^/GGVV9)1<HMR2SBV(,/9=A0RCJAMJ]W"N3 Z]3B9VIJB&2M
MLC*Q+^71Z92>%4F$'832P"UZ8:GM[69\'H-4EK06\ZQ@EQ5B\&R"O;*B[1,8
M<]*&EX83W./OB0M:W*SV60H&M\:SC2#-;$0K3$'EB]0C '>O3#-F+BO.R\O-
M9XY.>K2F5/SV\'9SE]8JP(;=.K:I[:MB*TZK$+V&)[2F=<0J31>&J48_4*DE
M4JT>D& 0#@%C#L.C4]O:S*P%S>17B^@N?JYZHLJ]XXDY^MQYCL?K6S8JU2FQ
MF*8O$K:GEY8$3,57;#*7,\:]#'UGY=D!"4<0(DS8#O0&R37:W$G5F/*G:7.'
M;$4D\VYLG3C/(U#9(&)2)<Y0&QJ^-0OXVM$\A1 ;K(B<1<UP-MS@4/XZ<DTC
M6Q;![_>$0=$NMUZ57*[/+YP905[N7-LVM.3N]M1M7&T,\8ZTJ"V[8;:R5R\:
M$$<3V3)*YA<EC\,/<OJ1 M%K%)9A(30[-"7K>L-33:S,[,8M[S;>,ZA[/EU-
MVOT,Y1.QH/+'"#2&/FTAT"Z!!*VL>@+F=I=V6K'%CDAY6Q:]!-RE669K\H!"
MU@GM[V9DZ)&G/E>X*KGG6M>II;>I+74MSO+S'*?$=!+)!8-GR*/O*Y@=V.$U
M"=$"K3>G! [-QA1F@,^@ T(HP0M%G$C&2:;6X\8S;D7R*\B]Q*YFQ<^6><\3
MJN I#;!JR:P^95;;$,2KQ_"0N+]7%C,,9E9#0K,V$(%A:8Q)\080;,T,6@[&
MVNVO= UP^:OQTTK:4LIR071()C.:Z7[;+03TW3UP76R5:N 9LI0EL*45;!Y5
M'(RJ0FA$!42:JV>E, (!P #"(.BSV][,X6K:NWN6'B5]-0LBWV)$^\<,T7D/
M2NGUOD$<::K9)G$U<YCKF\R)_:&U@7I%T60FJQ"0*5?P @]AOL,WH&R<=NGJ
MCIA\F/%LCK?G&W&ZVUQ5>=<6RV4ASC(W:LK88BK4L5Z4+DK.V,2!Z@Z!U2L[
MJ>VJ IW=:0E:#M%"$!3L/IO8X;9L\8G"4=2T3#.BZPY.DD[*;;_N6&3"P:V@
M F*3*3I)$8"$0Y8[@?T;,HB[:%I"'>]DK%J<\W_^$ >$Q<9\%'[C\W7C9HRS
M9E5$TOAS<G^L773';;Y7M3VY:$ J%WT=M.<W698=?0B1PZ)K49X1%J2CUGQ$
MIH!%G: , @Z-3V][X+:3GN#E6NH?SU8$EN6."@_5EA0:K.?9;'$SW,X_9DXL
MI.I50EI9G2'M;XD3$/A",W85BL2="3L&]&G%[_)A)KM<^CZ]:=K<S\-0B,V-
MU%9&JSB$QF:.O8RYZB<VF)SO,7!I=WM$QIFJ!QN3N^E"EL8E1@!"("5O97L]
MWO$ (B:ZW;I&(<K^1GB;M=TD4>YEZ&A=ERV(I0+I/!0DO\2L)B0#,*)^HN,
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MUL3:RYG=TW0?!?&W5D,A-?\ 0_.-6VM$ZV3$HJ];I-'21*(.A(1I&\"")O"
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MU]S\-?A^S9FPY& P& P&!K,_A9O\EG4__<(Z%_X)7.'7WOR^4;,V'(P& P&
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M>P@#O>]:]?36O7 _> P&!K,^&?\ ZLOX@C_4G47^_<>'7W/PU^'[-F;#D8#
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M;#'HJZ-J=S+0J71.F+$A!LDL1P2P;C7_ /F+(WI4.X:"NK?F?/=@RKD:NZ+
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M"1I8ZDIS!&Z3"WO90Q.ULZ=5H>?*+'TK)+Y1]A2V4VA87/LHK3GAL:66P)S
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MP*ZA58R.0$2N2_5%L/@!DX41("1UT[;7('AO/L9V-^J)S2W$XU0$P9XAE%"
M3*+(GQQ1L2=6V2%MDODLS;[(8+7,GD[L6<S><.TQB<'D]<10Y[D\E?G%S=&6
M-0R9.2-$V&#VW$"5&'Z)^8&,T0Y56&O>)GUMZ6JRSSX1%:MKNA9I<DX@S P7
MS:ULMS@[VG%9?"1H8+64JB\1@=$1E>@G;@[NR=LTN,$X@3HDOPD(#!&FKM]N
M/&KDQ_F>FHNST8Q-,7-+:.<&IT9:F1JWIZ7DL36\0I?7SDE<=+EY_P!HRU,3
M<SDV_J'S/IL?Q/\ [9K0M&<WKZL/BG&]#QF RZK$K=,Y#44UB&X(.K9?:=C3
M.N8Y!S F?+QR 1F0RAQ;H0V("S0A0";-)SFXDD@I&804G( 66[6W/B[ZH^7Z
MEH^93*RHMN;.M@V'&X9#9I.K&LR=V1)Y%'X$XRA9"6I:[SF0/9X2V$^:KRT^
MBMEB%I1^?[Q[V+9+M;,>#M[KYUKKH%&D9[,/G:^+:0.#._PEBLF=Q&$3MA=1
MIAN,>L**QA_:F>9L:W2711J=<4:$U,8:G'[DYYQ1@EL[.JD7*E(RQ\N)YDD8
M7O"2_8PSQ>VHFLE$F%!I8"/MK8R,DC%#P.P&-FG#6QLB%&G?&\I(Z$D(4WL/
M",@L81FSY,=1\6\__9JRXS)8_)[&#;S3&V"?R2T;&G]@SIX8H4N5.T%:$4[D
MTD7RN.)(,]K37)GVV*T9C>[&C<"AA7C&I$.5=@3R)3*E(V(YFDF5LE-<<M&'
MEBN6PIG:9BV(W&BB;=/HN[;FCR[!=V)V10EO !.HT8!/LLP9?M,/.&8.593$
M.=:RA:].[-J62N3T14#-1.WR3S.4REZ65I'G5\>6AG<W5^=5RUU<4JR1*O<Y
M*!FN1X1!T:>9[=;P9J.7WA[GQ\9H2Q%L\VC"2#5&P4&D402U+*@;K(Z5C"3Y
M-EK2=.\2E#.Y3:-("AG;)TXFGJ4YBM4(DTO:M5LXO*LG>>1N?GQKF+(I@)"%
MHFT1J"$N#>P.[Y&B&1CH%>ZNM,[A&X^Y-IL"=JY=7<:IJ7,XD2M*H*(& S0B
M"M@)RK#VWA/G-O9++:36"9/*^WI3 )].YJ_VE9#Q9#C8=6)6Q'7E@MEAJY0.
M71>91$AD1A0KFM6C,3@2E%@]"@^S"\JE&/\ /5?,#I6<@.43B52:I-SL4-E,
M[L2:3:1$#LA,F12S;FZ21Z<#W8I6D1E%)RC_ '$(2P:"F 4'\F$S4GR5AB\W
M89)!96V-$ECLF87&/RN+NQ*=>WO$;D2)4U.;6\-IWO H:W= :<08 P/L-+V(
M/Y=>N$]5<8WQC0<5;YFW";IG)AS^L'2C5SI8=J6+8,A:JA>$R@M=6D-?IG)W
MEWB<;4!'\4TMO-)4*CDY!J@PT:5.(HO*K-,#(VQEB98VS$B3-$?:6YD:DXSC
M5 T[:THR4"$D1YXS#SQ%)4X0[&,0ABWKUWO>]^N$5,UP9SF=)Y/(7=GG<D:I
M=9[C<SY6DEMFS'FF%EFNKVGDBV5*J>52D5>.1XY"E+7%IEC>I1$+ !.*) :$
M(M&N56(G57PNR%]=.<N;#G%95-@H[0A!A3BX(--<T01J41%*YG%H5*<MR)+8
MIDX%?+J-&IQ".T/8-C  022X?DBJX,18TNM;3-\6:3J!0ZLI0N4JUBI"Z0N!
MO$\?HTT#95!YC05I*Y66\"-- 2$U2!5H!HA@*+" 9N,(?H'C3GKF+30"F88L
MC)$>8IU&8XF62J52--'V"RK-<+=FK6S%2-X= H$SW-EI9H] ]-@2H$20&PID
M:<HL7:WNR27<PTQ.&_H!ID<85*VWI]F:V:Y4B>0R!O*D.V6)%P=L>VW:!R3&
M1:5)(RD1IP.K9M(O#MN1&:-T:E)& 9O3T=_&Z'J^)/-9/K#'1(UE-U>X4[6A
M(G-T4M\3@;L.';<T#>W*59R/;BO*@+228X& &N$0E^'\7V&&A&,UC,DY:I.5
MVJGN9^BZA7,R7RO)4KU]>>R(T\RFI44Q0UK)Y!$R5Y<=>WV$ESA88@4J4Y@R
M5)"$_P#*<W(#$XS<89O'*KK]CLB<7-&$(D<NM1CA[3-W!N=EHF25EP8IR219
M\6,A:H;&;)4#2Z"0;= $A6J&XA*F--,)2)@%#-[.QL2LH=:C4PLLV;3G1OC4
M^KVS6<DEP7MPDTQJV9,T^A3D,UN4)C5!+9*&!*>-.9L2=0$O99H!EB$'8EPB
M2?\ *-<6!:A]SG22X89/U\2B,&>G&L;EL2N4$BB\$?I;)(HVR!DBC^W-#MIH
M=9T[" 8:3LT1:T98Q"![0Z&>F'UL+E"I;"FSC9(C;&K^>O[:U,TME=-VU9-/
M.DY:6$M02QHYS]W4GCR26FLB9482A5KBCEZ%./9*<\HK\S!F]DE(:C@K=9N[
M@3-JS=@"K5JJ,;VI>GA;\2"LT@7RA VG)%BX](>L ].9QPUHP"6&^_VC-$'6
MM8,],>##(3S735=R.&2**1Y0WOL"3WV"+&FR%\7?)$=*V<SV[<8C$BYQ/)7!
MD4_94JHH1P#/IX _ 2_!)$(O8MM80W<-<O-D<OB(IJQ3_9GI&TM73:;.*02C
M2=5:!9,;TDF,1/*>BUM<O#8Y1-"Y(C8^:VB0.Y6UR;92H0C=EY;=/1RX]QI1
MC$CLH"]OF\[>[;KIQJ*<36TK0L2S9ZLJYS(<B%4!9YC-9*]/<5BQHG8\\:5K
M-1EGK!:5'?$4@ :$<JX3)Q32K=6LCIZ0JK3LVMI(TQ1F%%K7N*R+!31U/!E1
M2Z)+80N?Y&H=H,^Q]Q2)521R:E"1P3*T2904< X@HP(Y7.?%F=4<QU94$K>;
M 8PS>5V*^Q])#UEBVM94]MN;IX8A<#'9+#&:16'(9$NCT5^K&?-GHD&TQ*U8
M$"A5HX\ # DMM^"/DG"7.S>^L;BVM$];(S&; :+5C]2-MO6FAHYEL1@EA4\9
M).TTZFEQ5?M@VJ;$%NY"%.A+:P.(-*-)?B>HMEY5V4IXKHV4(4Z4*:>Q1:AO
M68](MTB@5GSR%2ELMV?QZ3127R!OD+ _(W)*B>H[,'%(8WA'\@$I3OVE!WH.
M]$Y7Z/W+>-ZLGS RQ::RR_)+&V^*JH2_,3AT9=1358T66KG-<K:;10-\V1)I
MZ6LT[GI5!J\)AZIN'I$>,Q($).AROAA9Y.G:6!K2(DA+<RLS4D2-Z%(G+3-S
M8VH4P"D:!"D(+T2E1I2"P@***!H( AT$(=:UZ:PBNK1R14,8GAL]A9UF0(Q;
M,55@O,'@EQ6C$JF?YJXN&W9WD+Q4[+*TD /5R!V$)4ZEEH"D[NJ&,Y:6H-,,
M$,O*NOLCC&B[0ELNF;TBL".NUD-S<SVNGK6W[3JQDMQK:6O;$W);-8:]E\;:
M9><FC^_IOS:DK:XQK"%$,\20 "0EFUB4VZCJL9I;")FRQ%N9G2N*G?J/A*)H
M^*VQN/5;(W*!NKC$4$61F$QXIN HK1F G_\ +>]*0D^"5L!9A@1$S6)5?S#2
MU,NT'=H&PKVIP@%4*J,A.UTHD3P!GJXV3IYD3#TB=X=%A9R-I<6XD",0]#/2
M(4X$Q8PD T#!;;W=-9O)-+VE-W.?.FI_#YO)8XW16:OE26[9M.N-A1)E&NTT
M,T]^[261C4L3LH7924B5*PC7(25)A*=0448(&Q-K.G@S-CYVIN+NE,.D6A#=
M&-\^0V4U_437'C5;0PP^(3)%%VY^9DC$B/*:U1*A)#F\)8U!1IA.R1" ((C#
M-B&;U]755'S-2M(O2UYK6-&,[CN.GP]*6>_/3RFC<16S^:VB.+1M ZN"Q/&V
M$4NGRXX"9* H 4Q:1,'_ ,LA1E$BVWN_KKS13#\9/OG(\I&58EQU=>\Q0HY"
M^)$"NVJ>55PY0J5%(4;B4G:UA*BJH^8N)("40Y_):VK =LTW9@S7/E/.%+SA
MQN%QFD&;I7J^X)#:UM9M?CUKBRRF'0$V:'Q5L&T'J1(&TYK46 YF!5) $*MF
MFEF;,]Y!(BQFSY,6K?DBG*RE^I^@!84SG"6+N,'8)9;EM6;<+[#H6\'H5+O&
M(4OLF528R*MSR>UI1+S$?PE;E\H1I6<?H@K0!;;T==).*^<I;5E!4V_P0Y;!
M>89)4TLI-)J2R9,[PY[I03?J GAD:5V)?G9*E(;"B5J9:H4)W0GU K <'>]8
M7E<V^:4ZH@,J@A5AF2^QGRQG&<6M-Y\W&NWQB4$*BSVK3)(?7,8;S5BT#>Q1
M&,-:0D?PQ  L<AJUNRRQ*A "2HIM_C+GR]))+'RPV&1+%%A0QG@]FL+#8L\B
M$:LZ*1U0]'Q5%8<7BDC9VF5[C"E_6[0GJB1G%A/$7L8R@@+");%H7! E=&]<
MUKB_C(G%&I0+"O>,&S4JL@:=07[R]A&#XA1F]>NMZWKU_)A%4:>X?H"E%M>.
M,<;IY*%M/Q\N+5 .T[8LJU4=4,!3 7%2T5<,T\E#XQ0]3J+E_3=KD24IQ&WB
M&F$HV28, C5VM9Q&N9:PAM@R6Q(H9/8^IF#S)I/)(6UV=/TM5.DNF9!I$KEQ
MU6 D7V%+D,@,/,4JSBT( G.)@UP@;6C&H$3-LPCB0\$\TR:/1J)K8S+4,;CM
M&M/-*IGCUGV/&4<UHAA;U[<R5G8VF"4-QD\CS42[K1$?4A'G@$N5:^)[%2@)
MI>52@AYFI9OM-ON5/#BA3]LI4GGM*Y*G-V6-^ZI3NY;T5'U+ J7',2Q5I67[
M-KS4XUXDPQD;.V2,0-DY7&/5'C;PWSNP5I3M5Q5AET.8J#7OKC4SY$K+L&/S
M^)J)9]7!+P$V$W2,F8.2:7$/JHMR*6+%!:O0PB'KXA)(RR\KFWS9]6/,%)TV
MH@)];Q <;^[&'63 X40!^D3D0TQBVYU';)GJ(P+PZN W-0]3*+(U?S*H1RDG
M8! +&$!@PB);;W?VJ.:ZSI-[='.MS)VQ,[A]:VBKPVS)ZZU5%AR-Z^T3V*%U
MFZR!;#8F!8\"&:66A2$DH@G&E)0$$FF%B%MO=EMN4W7]XQ9/$;$:5;@@;9 R
M2^/.;.^/D5E,1F,:5?.QZ70Z71AP:9+%9*SJ-B^"L0JB3=E&&$CV(DTTL8EL
M[(DD/'-12A+%1.[K;^Y1$XV_0LFRFV\+68;4?X1)W<+Z^0N86(Q2QME,LBZE
MU+ <G2+5!H&TP&A(?EA>N]EY5G,?Y\K& ?4%M:Q-OB#CNE8?0[*D;#UJ5@:*
M[K<Z9K8#'$#, TQN0)F-?.W#?QRB?F#0&Z"8(>BR]!)FWNK[R/PE6O/-:4BW
M2!K526PZVH2.U&H(=9U-YW6\0-7Q>,H+625/$)DX'Q^'L$[?8^$:GY-M1&*$
M99:?V%)_5/HNVUM^;-(YPISC&D;BV)HY+'9H-K.7TU&665V;8LN9ZRJR>-Z5
MJED'J5NDDG<TM:LSNV($R46VD*906C2)TI9@$J<DD Y5D4]X_HVQC(B>_,\I
M0*(?7*RGDZJ(V'.X2KD%2N1;<%QK:9JXI(6A3+X@M,:2#1)EXCM@-T,18@;.
M/^(.5C].7']$N 8*47'7QG25]2;WSFRM\?FDN96YPI5]CR:-GP"4H4#R2GE;
M4WHT9)R QP"H4H%I?S!!H#1#$(G*NNF7&E"3\I@&K;9BR[9ZT:Z84K8!:5B0
M%7,*B90J -M=3MPA<G95,UC*(2Q5L@"\9QZ82U7\$TO2M5HTO*LC5<IT0HBE
MQ0@N$$MD1O2(,,#L1@9G-U96M5$(M TU9L#&Q)6U:E)B2%JA2(I$2%LTE]@0
M:%K\_7NPF;T6( ( P &6((RQ@"(L8!:$ 8!:UL(@BUO>A!$'?KK>O]NL(JFQ
M<A5PULE?QY6LD(D%+6S)[.HU5''Y_A;U6Z&4&O(UE?@=8Z\)3I#""D,H<6KZ
M>KT)&:QC3I#21[3 .V7-9TGYPJ)*Q0N-D1U26T5]<LBOV*IM/KYO;?:$JE4Y
MFCV^&';<-G+$JF0V,[G!1'"&B*"H"6 H("B@@&:XE8<WUC44F>))7)\Y9&UV
M62=:"ORK.GJ^I&%TES\9(I6NBM7+9$J@\94NDA-/4B C1%$I3U"CY<LGXYVA
MBVWNG_"(UM>H:[NZ)[A5F1PN0L9;LTR%M&4O=6-\CLFCZL*]@E<2E,>7-4FB
M$K8EH-&HW-L5I%R86]_#-#H0M;++9V1X1R]5>ZQF]3S)98MGPB>"3GR4JWK;
ML>QG0OZ8)&J:CF*12J3+GF('L*]N(7(E+4>B4)'$@"PLP*H 3M#-SF=W5,/'
MM'LR-W >W2^5O$BF]26%(9I.K'G4WG;Z_P!%2M#-:C(<9A)']Q>S(Y!Y"@T>
MC:0&@;?<H5"&0,:Q4(XO*LQ?.<ZDD:6RD3O'E2E/;EF5[;T\ %]?"-NT\JTJ
MLB84[$C(<"QMA#874#!H:5-LI,H^4%\4 _CG>\F:KA1O"4&A,AD<\L-,M?98
MKZCO[HIB86ZP9ZKJTB0V';$YDT G2^LE;@A@YMFQR#R%(F&MVVF;2KB?C%&&
M'E%*M%NV>GHDZ'\2\\P69QZ<Q^-24#E"GVP9%7C.X6)/W6&5HXVLB?D-C!KV
M$.,C416*(I8"3+1'ITJ0))0CO0@)0  "$<JS!'SY7<'8J<%!(=I8[\Q5Z]PJ
MAFARE[\WH6]M5PMNAQ+"[O)NGLU42X-#$C2C7K4KB>GUH1X0#,]VA$S?ZL5X
MWYV*YIIY7$E+?&VR63JS+4NNPD4/4."N*H)O;\Z>9JY,,;6.J9"X+([#4#DE
M8V\XU,DV:A;"1:3IP[T067:YJ5;;JI#;[;$HX_.1A$19K!B,[D[ 6E+/!,P0
M-R#*8Q'%YYIF@IF<J=-C6XJPZ+,^<)0;2CUHH\S>$EP5E Y;#G:VGF76(\3T
MVQ+/7S*.-ZT*E*S5Q#@1F+Q:/U[&&TUQ7ITR!"5&S'%8>7HGYYV<U:@0 ^_0
M0BI7PA@:S/AG_P"K+^((_P!2=1?[]QX=?<_#7X?LV9L.1@,!@,!@:S/X6;_)
M9U/_ -PCH7_@E<X=?>_+Y1LS8<C \:J3MB[*D<;ADZ=#6RZF7SRC3>F')A6I
MI,=93B5=%U,5>$3AHE"=[(C3 5$IQ+4P!,I[.O$X-R4\[2]*8,HG4=+)?CAR
M(%Y';2GAQ\R9*W [5E*6?IA=&DI%,7ZS*JN14BP3IZ@DPLVWWYL2U%-&*T#:
M\4HU")F&W&M#FYH4A"MRWL\X!.,[>/1U[AWMTJV-%4Q]SC]6I+8L+FK76*]O
MC-*]'VS%FF-R0+,VUS2).JO5R%\^U3S(Q.);G,U@4;8A))(TF9%HS!;"7C/#
MMEB#+T!T''9CY >FH%"(3&8Y"*GYCZ(G]4W"CE9=CN12?EQHG4TJ9*H;'-@(
MJZ5QN+MII(7)R;7DLYY'I.:@(+)-.V,3IK^NZW,5[&F\JLN,TNDC<3*L9UZ9
MED0=$XP/&TJ+F1IJ9%?;!:WR 7(2U*_.T)FL6CQ@C1[1 E+@HUHOX9.R U./
M3/A@[>[#?.:T<D705^A+\_UK4CW=<RJ0^HKHL^8OD/9E:OX!RR554J$P47'W
MY.PN:5'(9*C6H!KDP]_"V0E5""377+L5EO7%=CEU EA0ZSB5)T>^2RFY 1)F
M"3R*S[#D;753/+9FZ,KHW2^,1>MV9K/FJ1"W;5(I":X;2GJAZ3DF)PB&),>:
MG_.W9EIH?&JWWY6D1@JZ)TQ1U!U17<.G"A]03R76BPH(!"9PY64G1KB5%6Q@
MY8\%E,K:I1'/*E%\-Y/T6F5I48S5UG/%\:L5->M+_J:1V!3DP9*@F=OG23DZ
M/5!)8VWS.&5R:IZPF-EP9)JQ&-UD4SD!)%7+JB>5YYR%Q"*1)AI$Q)3<H.%L
M$3C+U\.OT<U1UK=-:7+NGK?:*P>DT3L^@6J>67!FJ2QIC/JGJ5IN"(U5)2(T
M_3"5*(1*F+H&L4[$[)E3F[HU+0ZIUI)J<P>R2J<99F,'@O<EE6A'B(PYPJ&,
M4WLV[D;;7[8 QZ$2;Q_.*ME%YQ2VW9.H<@*A3)34\/<V\_10@-Y4G"47\/98
MO@BA=9/UXJUU%WE8]<4=2-=U? %$V*H+C+BA_ED224W?%E3.XGJR*GC[ZJA$
M EU8L[A":S=6>"-^E"1:_@<M.KJJ"F$F1IB3%HV5NLS<^=3%?UQWK<\47/K8
MV5>U47%?)+S9S\G85)<D+M=2&KNV:=@TBLD^5?7=14)"ZRFA0G2QO3)HXQE]
MBS;ILX?RF"22^N+_ &9ZS=B=(/QU 6J@8J4#0M_=>2?GIOBJMLFY-M1. ,#I
M;,=:+"62?4K%%WV4REXJW9QS&6RI"V9*XA#M4N-3F>ZIQG6=<R,#JCR'=#6Y
M&03*OZ*-L8JSN?K3N:HX>RU+>\'U")#&TS.]U77EC6Y8#2WUK8ZNTXN];&!:
MP;:BB79"8B3!6D'%N!8NLG?S7LI*\%EA45*[%-FT+GTBB1TV0/6X[6L\J <;
MD44;OG5$*G=56+*))/X/,688@?/(7!42H$2<4: L!9I8A&;,7"@Z+OGI R(\
M](GUHJ5@M"_.=5G5VBX]2W1]PQ*%04]GKE'#ZK6M]6K7N3.LNDLQFQOSTI-V
MV-+.@(T44VN2C8!G1KC.OE+A96H.EKYZ3FOTB 1.&TBSU_6_/LQN)ENB*322
MV,5-KOA3?93E5C/&VZ2UH.&FP&(KBDZIX= +1GO!XT^FTL*,X1E2R3NJ"D\B
MMD6Q4,\FA]2$2>J+(YAZBL]@: 4]T3$D=:MU?P1XDE?LMMV^^)66!SMNMV+)
MSBE"B,'LYK6Z>U(C,< #TO+-<<7UREZ5]B=%1&/]361'XE2P:9XT,J4]^B[@
M7,5-A65#GGGJF+ML=)'Y"5*RF>#/T2:+#5 93%C8] >C224QI:3T&L-)QG2=
M<U/G/DEN]X[ [?CTXL:/22KX6\TTFKN&HH8^,[A$BY/6;9(O80]+9^^MYA8R
M3A_40A;2A.#@+YHO:,O7RFR7'&(MFG9-V,D8O+H=FC=7BYUY]OEZIR20IS2R
M@VY)C'J^G+=6MK6&R2Q+(DT3C;DS2=0M.9(Z>QN WM W V)Q2&+R@IR\9TGC
M8[K@*-3,N7=Q3:=NM<2.8/O7%@184JC=<.T6DBELA#)&6U@:GU[=[!FC@[Q=
MC:U!!+2UA&06UZ"HV$TW:G?PAMX3T5$*D_4TC;*452:P*\L:?(/+]=T!@2]?
M$)7%H[%(Y%8AU[%EGU="98TK<I!'HXRI1G,[.F4MQH24Q2(U>,9@EI<ZKTZ_
M_']DV2'ORU&!S8*9<FR$M]RCO*^JLDMC,M177:==E1:BXK IJ;,VBFJU<WBR
M NDJ;K;CB+;>H?\ 2)J4;7'C<5("""%)./CX,IZ3MZ:VUXD+_M>1Q>8TQ/)%
MS):_UMA)',H'*HN^-S>_QMP<HXJ=$47GD=2N9K>-P951Y"%R+0J4YP@EF_[*
M23GCPR@6P.B970[QS]7]PR.5ODSXYN6YWB<*DC@K)?;]YYCO!'8EBU!92Y(
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MT,37J[IBR8JNCL'F\3K^9U9W7R+4K],G'GNZZ\2V' KD=Z?D2-.;4]DV'%+
MAZ4O<T/;7D@]<N3OS83L2-2CVHV(B+QD^&*EZ#]W6=-+X311H@)DAK473%@\
MSNC7'J2OLV3Q\FME$IA[W>KM<1C<?294/':$//2',(1;4(&A60J,=3%83&_*
MG&8^3&ZAZQ[4M=-R>7MGYJC2GK^FYU;3&MW'K*>T].(ZY(@Z\\A];-6"T&VL
M9/$,_0Z()2JHQ] .T;HPUT"6'9@NNLSWZ,.=O)C:[Y&(*9 :Y94T[_A:1=%3
M2-:J^^[H1S*3N,UL"OF.H8$LI]C/-@8)/(*C?A%2*0!5Z2EGH !:U@A*A$0X
MSY927-.T^B6PKI2SV2"ULQT_S&[44H?83-V>9%7'-&.RJFI^TIXPB<$LE;V&
MMYA T%DG%I1*6MY)<%9(4IQ*/18U1E.,Z3QJ>>97^]'?HONAGLJQ8O+8)"+H
M@L>KJ-M$+?F!9$6YWYZI>; 1)W1RL&3(C&T14G$-62!"4-2\FJEH3"23RT1!
M+C$^#O\ L#I1VY^14VQ1=(EW+KPM(RNV=^=(%8]HLT-;66!3.S)5*5]>5.F,
MG4T/31V#GI4;>D4-X#%BLLU0L3IB3A8),JU/7<UE_<E%9"$$9KN\3TU]KU-:
MR?G#IN?.]EQ^D9$X1Q!8<(K**!CUKUW55@? 0+0OLA1J"&DIW(3["M-#H9Q>
M,SCP292/4=O]3S G53-M;US7\,KSG2;V0?83/))W+I"^7S7C!;YT*A2>/2R!
MML;;XK7\A2 T_K?JH%KLI&4%O 6C-$<2ZS7OW5ZX(MBZH+5'$,6E2&MU547O
M(;EK.,-[4FDNK'B:^(M=Q6E%I<^RE4]'QJ2():P5LO)5-1#.W&M*A6F]JU;H
M!VLD7:2V^:TE[7%>+G:]F4=23=5Z4JLN:F^ZIR[6:FDZXV7J;&>[,BL'KR(B
MC[XP$P_X@*I>%#E(E8'HM%L]& #8?[C1!J23&;YJ3Q?M9VY\Y Y+41![ALK^
M[WCSC>5VC4I%5W#84V+8YS'88PB/>+:KY6?7%'A5Q[:A4TJ90A4%.2A(9O?P
MDN]G@-<<[7XUF4FZJZ$H><]<FRV81&PD[KV;2G.]%1]+4MHN:2MSK%Y_J&P%
M+NXLL,FLVEDLCL>BRUP7GLS2WIECS(OC&!6($RW1:(F)9/@DF"=@]%6G(*TI
MZ-0R(0NR99,NA0+[3LZJ;CBE?R.J:$158J(GT#IF7O,#LC:RP'"[F)M E6/F
MTS4I;G@8%3B!,3HZ%UDZ^"4_'W(UR#DE?*K(VQQAQ;;Q[7>9T)$[C<8RQ*6O
MKF^E$C/1/:HA&8H8$(DQIA1QI90PIPZ]X0BT+65-ORQ/3^RC7$?6T0D_4D8E
M&[Q234SR$1BPID96!DQ4OIM*S*K5JB24=$4$</4?)PDR3<LK1DOI"<DD*F1Q
M8PT81'J!BPUMKT^'Z_NG:H^TNE'N \NW'9T8I,F"=3JK#B3-&(2DF0)77LLC
ME8VK:4(D#J_N4J=VF81R7LU0+R7%N(0-:EC4+DVM+%H2SA9$NLS9/!!%SWM;
MUE\IQ:77/%*H1R?HKQQ=PW"S @ 9TF.J^-*.=:BD*&'_ %!VEJULEKPXJY<<
M-P<#$"<LH!"8A(4#99ZE6622]/"QZK6 S52\<Y@-O!X,8JICT%8I=.'8<VDD
M!;43%%F=*]+5$@D$7?(^X"CQ)238UB4Q1M*J*#LLXLP&]@W6.N>G=Y<UQ&9R
M]1?E6F)RJM:-\^]1];=!3F(UU*9G.&RQF'F:,T[8-B4K2,VDBM[#/6QKE#U'
M"I2H8#UXE;<TB!'U.])TRE-HWYV=Y%\^'W!S2,O157FOCW(8K1'4MBU36KA(
MWIRDSREK\$6K^P6N,*I*]+G-\?4\$=)^M84ARY2>K+1MA1)A@ME>N&=O"^-C
M _(S%ZV<:M&J<$M@/O0<P;'BI^4XM7]I6+")$X7=*D"Q3%'F.((E*V1G;%4-
M5H]/;Q)52<SZ%'FQ6H/,^5+,*,&N<^GBKK/85);-D_7+3<]H3;[:\?<ETD;6
M4VB$VE==H([:KM6-C3B9]$(6.,/C(U+7]\F4;3$@VY$*4A*%F,1:+^74KRCS
M4N),>-2 XNLQF]V>).]7^:6 V.UK,TB2RNKT<A/9ZR3KI%Q?;UD2!>NAK64C
M)?I";)4R( #G8U>!N+;B]("THS58U)/#:?KNJK:$IE/\5$]L0)MG*ZUBG:5/
M1Q7W,@L.6M,!H!@8U4"CT[Y+,HU"^EII?&WR8HCHP[R4IG4Q4A7,SU3LI X,
MAF\+)TQXX[?Y;!N',P&!K,^&?_JR_B"/]2=1?[]QX=?<_#7X?LV9L.1@,!@,
M!@:S/X6;_)9U/_W".A?^"5SAU][\OE&S-AR,"!M<UU)IB<HY]"7_ $EVOENZ
M46D?7WKXAEMM5BLUJ(GT)_SOQBT!<T84RC: .](A%@V3LO90A!V7-^C&V/D:
MHXTIGI3"?8S7$K%16"D?:O2VG/0U.B/M52M7S]RC5=C?AQJ-+Y"YNBM7OY,D
MHA*L6*#TQ9)IYHACE?F_4IY+J*2IZR+2FSZ#/=2P7=90J7UI9DVKV:DUN).P
M)UD(>)'&'IO<9+'%1D:;U&R5^U&R%J8"H@1*CU-V.58S.N&.>+!F4UG4D:IO
MIRLY!"FBWF]MM6QFB+V_'*Z;-M,1C=H1E%)B627L#8A,- :0I)WI<4I4%*]G
MD*5!1A>5[/Q7_/S@#L*X>KY?&XM'G=VJF%\]UP7'9 O?%[O7\6E4GF[S-9<4
M>R,C:S/\I=7UO1%(4_SHTJ%B*^(L-T: I.+?MFL=Y<_&E%7T^RE]L)JEQ@K!
MKY+5=G-$8L2<0N/6E 6PV2J&&.V&R11]:4,F31U3,742(PX/QRP+SBA#&0/9
M6$FUG9V3KRA5+A8C]9B$^P8L^3,EO+L5HAUES6-0NS3FB,@AK6Y6!"FUX*C4
MB>DD6((0"7#3 5J4B1,2H,.+2IPE%Y7&&.BX=YTTR+8VEBCNV,3Q5]95))&M
MJETE;D<LC%-*8\=6#A*B4KD6%]F<.21I.A3/I_N=1-GN1FGF)M + .59Y87,
MM.6FXS]UF\;6.CA9,:J^,2):FD4A9UB9/2\NED\JYYC*YE<V]=$9;"YC-%KB
MA=VTU*X$JM$CT;ZD%>TDMC UW$5 O55W'4LG:IA+VF_R4)5O2Z56)-7JT)B)
ME3(TD8.-LE2]?:QF%#26\G;*!N4I"6DT&S4H"CC#3!EY7.?)G>N8Z6!:C!<Q
M,2TFG<7I=90# L2NCJG:FRL%CFD=/HZ:/EK L@'!&:EV2F</@?/)TAYY!9H2
M3C ")FXPPULXPI:.+J^<H6.R:^65Y7U:U4097]L6##P3&O:@),(KF-600R/Z
M0B=E1<A0H+(5+PF+]D*U! CQ$'F%"+ROBX$LX:Y\FDY-G3PTS,HY1:\'O=3$
M&BRIVRULINNO'N./\:M,^O&Q^31,<Q OBB$2H_Y7X2X96SE!9B@0CMDY57-3
MQ1(9#TG 9@&%-%;U35?14DZ,;MH.@[+GC7()8ZLM@(AK(;1#C%6"OZJ?YU()
MZ:[218!6O"29\V2A (;HK6:-<NF/'"U<)Y)K"MVV61^!OUP1.)2=F>F)OA;)
M=%E(XC7B.0.@7EP'53$"1[25VH)<M;&B$VZ)TUDC&G1:3IAB)V9NUO=FE:\_
MUS5</F<-CB>0KR+(>WJ36+(I7*G^63.=2:0,;9&')_DLK?5ZQW6./V:8T+<G
M]IA9*-"A3D)P%%$@!H6VL)?N0:=>([4# W?;Z$*J)@Q=95G+ZYLJ;06=,E>;
M:8ZS+H:MED>>43I(8^[)(DV&*4[@)4$:Q 0K#[%119P1RO\ 5VDAY<K-]L!F
MM-(XV5$)ZW,,4BKU(X+:4[BBNPHO!W!6Z19CM IL?"TMA$LZQR6;)4NA:A>$
MM<J*T?\ "4G &7E<8\'0,_&=+,#%9<+:16*CK:THI8,+>JH!:D^%5S"Q6D)8
M;-R()!C'X;'"1.9SBH$GTWEDEM>E!@$ 4Q8Q V3E?FA=AX"K]VM[H>;V44ZN
M,8LJT:DDS+"6"R)RWQ&80RIJ-I>"Q-IN:"HES;&Y>8Q3>O5ZD@A86M*5HQ$@
M5#.*$),67E<8BW3/2L(C]P3"\&74A;9G8$<88Y-$B>3OFHA(PQ</R\??G"&C
M6CCWVK:FS_R);D606J$AUHD8A!"#VDSTPC%_XTHB2SMTG+FRRC14BG$>L^75
MZAGTS;J@FMFQ03&;'K E]4HGLF$/\F;U,8;% S3D>REJMN2J599ZA.4:$<JF
MB UC#ZS%-Q1! H0;L.P)#9TI^8<%KA\[,)06WE/*\CYT\_Y%.H V$Z"G)]A!
M?MW[0Z]=^HMRBQIY.IUEEATO0H93I5N[U71;>RJ)M*%D68+==8Q-HI(I-'8Z
MJ<SFUE+E2*PG90Y(B !1*G!3\T(K1P0BT.5==)^.Z2DRAS=?D)=&I8OM=]NM
M'/(5/I=$9U'K!E,0:8%)E\<DS([)%[8S2*(LB=$N:=;&U*RP:$:G&8$ PEY5
M)$SI*"V'2K_0,V!(Y-7LI@ZFO9&%YELC<)2]1Y:W?3%HG*:*G(V4*W=8GWO9
MJT:K:H9F]CV/UPF;+F=V.6/S!25L6W4MX3N&$/=C4J@L%GA+N-:O(1F,5H1%
MSA$QC\J9$Z@MFFK"N8'E4 E(ZD*R$9J@TT@)8S3-C$VLF)V8Y5W'E(U(^MT@
MCK=,'M5&H:Y5O $=@6+.+%:*OKIY$U;=H/6K5,WUY11%@<BF% 0?I.#2@Q&@
M3)1&[2IR20"[6NEC'#/.4:BJR#G15[ET26TRKYY-8Y_,Y5-4H*5.>5;T@KT@
MQ^=5:LIFCQBOX#89HSYM E**+).#HH&]%Y7N_JGBRJUS-'F]QE]\.CY"Y LD
M,!L5SOFSU]I0,;FQ%1EV9(S8*J1&20F+/C&2$EQ;5)RE(Y&  H5 .4E%' '*
M^B;I/3\!G-4KJ6G;4KG$ =8RFBCPAEKX^/KP\-R0E.!.N<94M<#).?)"%"4I
M46Z_-Z<B5Q8%19P#P!,T3-SF=T-IN+*.^REJQ9_3SR=&75&F>%V-+["LR<36
M?O<,CACB='(DGF;\]K'MECC"H>%AZ=*A,3E?-+%"DS1BD\XX8Y7.4YSJLX?9
M"F!J9@WG.FJWGK59<82_/+$J$N8L38]-C&YN2-*<42\%LVWPQ6F(4Z,(*<"4
MZK0/C)R1@)G# [BYJJ.]U UEC,2]P5'5C9U.*U#6_/+ <OKBW@1O<XC+@-G6
M(]K$JU7#VU4G&9[C42M($U.(L>Q[$66SL_-C<T5%:TD=99-6)P<7QYCE=11P
M4IG]Z;2S66J[3(N:%IP)D"TA.48WS].!488$.C%)6O@&[$3O8,$MG9Q9_P N
M4Y9B^Q7>4LCP)[LU/4P7U]9Y5(X^^-3E1C^]2JJ))#G9E<D2Z'2B&R-^/6)U
M[>,@\9OMT;LP ?9L9L1DBX.YZ3HCU+5NR4DH76B"[!VF@M^P=6B.SC:U14\[
MRHNP-2 Q\]\DK9 !H<$FC-MZA+H(?@!V43LLO*I.JSEJE*7<8DZ5S&%K$IA$
M6M"'1[X\FDKWI.RW)9K?<-B:6F/SJYJ'9Q?[!;"UXE:H9RDO>Q@ /0!B#LEM
MO=UMC<D41:;7T$U3J,+W)!TVR0YCMW14HD32<YI8 W";8>K8ES6YHUD0=V &
MPGIUK88E4EJRBS]#^* (M";68QX/I+N1Z$FXY'M_AAHB9-5=9TVJ3-4@D,>)
M:H53<Q?; JX,7$PNC:?$Y#!9E(#7%M=FX:9Q2*24XRS@[3D[ .5=:[\AUF_Q
MF)L;Y)KF=I! I0[2^$VFLN>PQV_%7A^:1Q][)9;# ^ >TL>>&$P216S^X30I
M+WH1B81H0F:+RK*7GFZN7Y[JR3.*N>FR2HXI)H(PR#=BS(QYD4,F:5@)E49L
M1P/>#E%AM;ZLBK8N.T[;5&:7H2CP# /W;$3-="R<A45'81/*\:HVYDQ:R:+@
M_.,M1&2>0'GKJHKN%R2OXJR$+CG :M O11B6+B3%Y(P+#QF!,,,$8  M#E?J
MJ#UWPP[WVME\%A,$8XQ$+:@<*KVQ;+_B!LV/)7!BC A-A"^;<^QV+@B]K2R$
MQK8BX\H<'HHM4=L@IQ%\HC*)$:UVQUKT!MVEH'=K"S,<W2NX38M)$$SALDC$
MB>XC,H3,&M(X-R*31*61U<WO;(ZA:W96C.V6;\)6A6*$J@!J8\XH9F6SLPJ(
M<J4Q""(,%E8WDYQ@5JR*[T4C>Y9)9!*I%;$L@THKB0SB<R-Y<UKM-'AQATO5
MH=?4#3B4R<"8H@!121* H9K*[;IABM\AC \S.W(7N/&N)A*JI[<GU4J%Z9S*
M3%+T;Z="'UFT[IM@1@V2,_0CT0_<-,82,8Q"$N& MG'7/K"X5XKC<*''&ZMJ
MN?J4:XJT/;T5#))5$D"(;G![#BRA<I9[#:3' PQ;H;N6K4[7'G'B-$,\_9@Y
M5U4*XHY\A&UY8F&2S="LK9]I1H9K8L":VFRQ.GI04B)DE6PUJG;X^)&&(R!&
MT)"%Y)0=GK4J%,0>:80F(+++=K7(BW&U-1HF)H59UCSMF@3NM<X3'[5M&<V@
MQQE*XUG-J@6QQ&@F[T]A6QA77]@N: Y&MVJ >$PL9NQC)*V <JR^L^:*IJ5V
MB#U#F]_+7P&NG^HX<8]2V1R+3!6K_+VZ:?8U)];<5HS6AB<F=(F:M'"--;FQ
M*4C)&%.6$O1+;49K^#N>U,?A4;:T-A0]%":K;*-)50*V;'A#Q)Z=9S%9[=74
MZ>8S)&URE[ A4.2LQ,)88-8B&N5[3'D_-J?BEY5WKOQ7SPZ-[XWI8<MC 75=
M5#JU+(3)9!#G&!N]'Q<,+JUUK1='G% ? E<4BVA("]-VR"E"(TU.H <0<:4,
MG*NE;>$>>F>'/$0:FV=H#WFYE'0YD[3VE8.K207>NB;?"'2R6JQQR$<L0OKU
M&$ D:XL*GY)8E5*4YQ TZ@TH1>52M&>?Z_C$B1RU,KFSO,D56'T_N6R6P)?(
MI2KA2R2*96;I>]NKNH<5#SM^4#-+</?I40'02BA@++  ),U^:?YZK^E'&8R"
M-*9K(IA8 (VFF$ZLB=RFQ)F]M<-(=$T/83W^5N3BK(88N6^KA(TA/PR0GKE)
MXM#/4'&C%N4--/CZYF9S"0IX],E+:TQ^U8C"XZY6?83C%JVB5UM"MELJ,5S&
MU<B-9XDS2!$L%H):<G0D6@% 2B)*)*+ 7E4KR#E^DI8A9FF4PX,@9F.C9ASD
MF9G5T=E#8IJ.>"@@I/''%-I:#2Y0NW6S1L"X>_GDXDXA%&@$8/>R<K]75U%R
MC5-,3Z1VI&U%AR*R);"8W7,AFUE6?.K*D#C"H:\R!]BC -;,GQW^"D85TH7;
M)$6$!@]J#!G",-&88(7:WIX)1@560RM5]CN41;U"%7:]AKK3FQBAQ7+PN,S<
MHW%XFK<$Q:T\X#:G&R0Y 7I,GT60$10AZ#[QCWL9RB!=Q[2:BO*@KEM;Y9%4
M=!(=-M.RR'3N61BQ8(A&S"CK@B:YVU.J>0*F]]8Q?+.*16:I2+P@+$>4,PDD
M98Y7.?-UA/#O-(& ,64P(]VCVJTLZJ]M;_)Y0_@-8[K?M2:WY J6/#NM<EMC
M66^@ I>),<<8^JC"P[VJUZB]PY7OXL=J;FA;'^JK&Z2E3.UM[@GI*O>9*R6%
MS)ZFLLDU>PF0R&6O-@V.YNS0U +F4P<W5N2B*T-P4@3LH3#UIVSPE)RV_;Q]
M4DW)RW6U\N1I]BO-K*XZY, 8M*JY8KALF*5?.H]H]8<<TS6!1R2-D??4;B!>
M:G7A$4'ZFB%I*L^83:T5HDMG9U4[XYHNQ7Z>/\@99&G,LJ(06(R]ICLVE<7C
MZ[=62%'*:MEZ%F879 C8K"K9[;R#65\0!3."/1)8=&;"67H)9M8ZC^"&B!1&
MP8J<18*I9:$TKVRYG/EEI3Y79SC955 BY=?3Y'/%#\8^LDCBX(6U@3"1&)TP
M2D8"O@[*V(L0Y5F40YCK> V,YV7#W*R(^N?7=?)Y)$F^SYN16<DF;LT 9GJ;
MOE<Z>OLDLE#XG+"H7'_+! M<M?/G%C7;$IV3-QASH5SA4->ET>*+LRU$7SO7
MTAK.JAGR!X6A98;+$L11O*%<)6M-T^GJ4\(;= 4K/C'%_"%L M;,'[AFWYH[
M!P]1+>C@)$4#8]>.%<QER@[')*XMBP8/*%\%=Y(IEZV&2A^C[^C72B/ADBPU
M8E+6B.-;CSC1(S$^SCOB%Y5(<HYHJ*8LMYQ]_8W%4V=&.#(Z6N4"0O:<U\6Q
MZ&Q"!-9J)22N H9-$QJ#-I(M)!%:,&4(P7J88,0B9K"K&Y>(>WZP)I5]BSJG
MYK;\EIUPM1[CLIDHF][8JSDD(,?AL<<^M$,<8G<TK*%%Q(Y]3DZ/*:C ^X!H
MB@X6;>%[)7MZEH)>+ RLLU)>RC(Q)6^;0R3Q*3/L-F4+E[:C<6U%)8G+(RO;
M7AH<?I+PL1'>PW9"Q L4)5!9J<\TH9);.R)I9Q?3,X#%39,LM1P>(S!Y%6*V
M5!N.RD<PG5;RUR*>9)!;(E"&2)WF:QMR=2 'A)6&B$DWH0$HB"AF%C+RKE(^
M.*68G^"2:$%3RM7:!0FNJU('7%E3>'(Y=7U2^\->1&QFQI>BFV>MT7(//(3'
M.11ZT"54H3_'^ >:6(<KV9A&>;*DB#-2; PL2Y*U\]2)^E56D#?GE0)D>I+%
M9S#'8]8:>L,,>BCH_8SL4$I7LXLL1X1AUH91>PDS?ZNIN3E:HKS?4\FFB:8-
M[[N'NE</CG!+ F=>*IG6KTI&M<J\FYL.>F<4HB)RXTPXI.J]XTAAZCY<96E*
MG1HEL10O\=/+3@SI8SN+S!!#M5_5=:OD*9;/L)CB,UCM(-;:S5,=.6%HD2-'
M*7R#MC0E)3+E.A'G%IB0*1'A()"67E4AS3CVDI[(K*D[^@F 7"U7&!R63%,U
MAS6/HT-A5B7'DT$M>'$,SVB%!K3CK?$FM(6]M(D:PU(@*)-V87LP(R<K'V?N
M3:UD\:@K(^2"W5T@K5Z?7Z%VF*X+ )N!C6RDA0BDZ5/8Z=\*D(F%_;%&TJEJ
M$9ML$241[4X1IDXRARKF1[DZDHISN\\KQZ/O#92C^EGS>[1LJ72@]R6MUH2J
M03*>(#Y4K=E$H.3R5XE3A\SL:L1@R%0R]B]N\&;G/BDF?5-!++0PMOE;-\P1
M7<^A5F0L3>K5LZB/R^ .(%\>7(#VPY*86F^%\5$J3>NTZQM5'I3@#(.,!L2V
M*5<D^/Z"4O6%1H; "[2&PJ_ALL90MB:RYY(JMATFL(M[0V-):SB+RO3,48?)
M6WOJM.>M3($QQ)2Q66GT0!6JT>7;;-Z=E@7OD6B9+"(-7[G'')3%*[HF=<WQ
M-(5*) 2<CJ6QH=&(%+&0Y>0XA5KUZV-0] 26O.&-80,H1A9@1C&+9.5=Y>7-
M=;]"5NPU5/#IFCB4;D\)E[65#9O(X:X;>J\6DN<1VY.#&N3'/3<U.Z5.L^36
M?'2&JTI!PRQ#)+V$2V7+&W#DBMWZO$M=RR4W+,BV>=);+B4YD]PSM?:<#FJ!
MO,:F]Z@]CE.R:41H21M5*D_P"#])STJ]6G.+-(5'E#'*]WZB?-*6M9!2Z:K)
MG(X95U;+;>E4YA(G9\D+S=UAV<47HF7V?-W]W<'Z5JD#J\/;NKVX#5GKGA4D
M4?$+TB  0MSW[OC;O(=;W':D?NAYE=S1*PXO W&MF-YK6WIK R&Z*/+X3(GM
M,D:F1R*:TK@^.2-+\\M*)+5K"$*4DTP92<H 1+9,.+97%E'6XK:U\Y)L!P6E
MU^T53,E+;:=@1P=P5JR'*U:.$W6".R!K)M)A$N<UIII;J$\9GU)<5L7P%RLH
MXLVL[)JDE3P>5RFIYB\-(Q/=)/KY(ZY&B6JVY$RN<B@<DK5S$8W(C2$+@E'$
M)6M3EDG@&42(P)@ Z&6 6B9J$'SB.@)!.7:;.#1,@)))/6>U9=6B"RY^W4M,
M[/8%K.Z-4^EE0HI"1 GN0E.\>0+C]FHMIEZ]$2K6$J%)>C<'*I=J:#2Z$%V,
M9,['=[&<9I;$WG37MQ",AO@T2>5*5)#:XC:$:I7I$SQ2+M:4!H@B %8YFJUG
MPR]J=@"+4LX0P-9GPS_]67\01_J3J+_?N/#K[GX:_#]FS-AR,!@,!@,#69_"
MS?Y+.I_^X1T+_P $KG#K[WY?*-F;#D8'G,]=G.S7U)!JJ97N"6#7<SN]WY_=
MB8E6=Q:=:YFK75<RGIVY#>APE=%O4A;GV#*&UQBQ.DCLB"J"/XIAR8].(UQZ
M9\<(6AWD!O*-U/2=_P![P6KS*[O/GJY;G;8C5_VJ)FT(6T_4*ZZR$+B_2)Y=
M&67H9U#8^X!T60A:SF1>).1LQQ (Q0&97C,V3OEF5;23H60]K\M.=ZHZI(%*
M.*^EYHS@JLR3)TD?<'JQ./3W:#/)$E=G@R4CCA"E-\O(T_TXEQV8=K;:C]H/
MBTZ<;CS8;U_*KUW;/:<(,L*-BHM!XO[$G*:O28D]E/Q#^Y);BCHW=/)_MS]*
M _&+6<(C56VKX8FX!24!)9P!K#(:XQ+XY''M:X^7:P(W=<,KN2FAX\C=VUPU
M5WN9IU+3(D4QJRH=UG.7!5]JE<L(.DMNL!VI T-J(T1!:X(6@8P$;.IQEO3S
M6RY*Z%L.YG6VHI8,=+$HK55!SF:S&&J;AJ"#3Y#-&=S4KFAGBUT(]20F10%\
M8525RV2M7)C4RE I]4YBD:4DEF$+\R53&^J(PZ]'WF[V')[$<[NN=N88XFM6
MQX?&:49JBNF8UO%*]C,.@LLC; @<6AO@Q!SXM5)CG-W=%"K:HX:79"8DMN.D
M[.19_7MWLK;UE<%?12KEE'\7RARCD^C4K%*"[2M(FOH'%K+N-VAT@0N:.+0'
M<=CDJ^784J]M>A/Z] /XIK<0H)-T)K.DO>L(=NR.J375>ZQB%42="W/MF1\7
MPQM>3)V1)A#^=<VUCN:0NR=U^G ;X\N0#"OBY* *IU))$82Z(!F!(##C/GC+
MLT?8'23[.ZXHMBCM*DV>[]%]!T%/9\YH)H. (D%.U6VVVS6-%X(3+$\E/-?&
M60-Z-3'SWP8BEQAVP.?P"M'#IQF,^&'\<.Y;!,J\@K;I4\.Z"CEA]%5M*(0"
ML+TO%'/G/G5^41YXDE9PRI#=6$TP1[,4M2E:ZN(%A,;VZEHSM+%&@;.''^C'
ME/=/1$UB5C6C5<&IYF@=5\3<_=F/#//S9F[2B5:MV$678#S4K4XL#BR-T94M
MK%78@)Y$H2.!8%2@ 1MAH-C&5#C,XO?.$P-?9TR=[ 0U$BBL7'8LBZ:@<*C"
M \;HE)4<US"GR>AE-K+DFUQJC3VU0%H?(\(19NT&Y8A+#[=DF:*%3CTSX8=;
M(9S97(;M1M-K9BV@J!W.DZN1],W?&)S.6YSF\RN I1'Z;=7R)21I;*@7J6:7
MF$,TBDZ@YF6&IDS>25M3O18ATVZ^/DD[OV[FJF:#$WJ9ZU5F_P!WS>(T%$YP
M[NH&1)$55D+3$LLFOU<Q0ETV*(!6J%\?2#O>'T4MI8-;T(>L)K,U3*C^P72(
M\MO,#I"5PZ_YO0O755\=Q>4S.>NDJ;956=O6? VFEYU)YNV'.#X^.S/3=F-Q
M#DN,$I4+WUB7Z,V(W8]Z-77-S>UF4N/_ %QTI'I*;208[2K]<R/KJNN=SYD4
M@FK#6BN$V=SN_P!\M]@EP\Z4/4G02"*)V@Q(J9]O2HEQVE_HEB;YO0D9.,[^
M&&8UGUW:3S;%>4K.(W 128SH;H"AK&DL6+D*)C= U33#;<T2ET)979U<UT?W
M(6>3-I#@WKECI\HH H 4I.#HLW9+K,9<=X[$EJJ":/;9)5\'LETZ,ZBJ.'1Q
MRJ^YKO=9E&.>[2G<!+<(_6-.N(9^YK])&)L/?7$H6VUJ$LWO9?J:G)$7CU^3
MI>&+=.OVY;6NXYI''AVUR+P%8A\;V>J4%,"Z5M_1KFX-1)BQ.C4F%HEAHR@C
M-(3GC  .S2BQ^H Q-IB8]:I<>Z/"OM2QBFUNM^+3UT\G$"@T8Z.<[0=$-&,U
M=Q?GB@;*F_.BN&)+#7'.;U:,012!L:6Q;%$[(<\/(51;D!P))".M_P#CZ861
M2^1>Q'J>R8R,0!(^5PBM#HFHD;0BJF]SY-%-T,SV<A#<DVM8QC24VI@LBL>J
MU+8H:$IA"EK1.B(\3D>IT>A+,\?-VC-WC<]<P2L+6Z,A5:*H?<G&MI=5,3#3
MXI*"2P1WIRL8K;4DK=^<Y.\.C5-4\BB$D-VB>4A#26C<$6TQB906>4KP<9;B
M>%P_5R=F]0<UPM0^6U":/E$CFW--R7963-7I\S;VZ-6'34?CLN=JEG#F^/#G
MN7,+S'Y)Z))8@ R@^;0& -:RPJ2!:$UE[9[I*9Y%U\1VS1D)GUCTZ3#'GF6]
M)U.X!"H#."VU2ZQ^U:.9FTQL?GJS#Q'O[(AF)*9*YG-X2-D[<=[0ZVL(^1)T
MXVSS2G8]NWJ^WX_T!SZBJAK=J^IB*W#-I;<".7/+4Y*+'E$_BM<P..LD/>8X
MX(=+E%7/*EW?3#UQ;65M* IN6F'&:)$DQFJ=-OD"Z"LR!6M<55P"H8_ J5Y-
MJOJ&31RP%,P>I9)W*2-EO.<^J)C>XXXLS,Q"9 U"K*;I0:C<$Z@Q20+;8,H8
MS"HO&3IXY3UY$Y -VY*BSLV-<U>&^8W]Q6C71.$/PHM,Y=%YIU!3*!\@[<\%
M2>()TBF6,+H<W&A.=D*4T"@99QX"A"%E37\OE77QF<3&&/M0<Q<V5$&B)#-H
M?<=UR0CIEP<K)/@D-@4NA4/& EG@5PR84J?I]++!1&)"P3%,G:FM.<<<7LT1
M"49>_P!UZL=J+L;H*Y[=AM9-<(J6&DQN%VV]]!.3DLEDK$BEE#]%2KGJ8QBK
M-HU48"O:YLY18YT:7-P!OZ8DUHM4G4GC^&6+K)/%C%2=4]LVNGY;2@C7,\:<
MNM^<I%T)'5YR*RWM!4**$):N4.$=DK85+&I39JB;ZN%HVD/1*H\%AV4K":%S
M^&2,\6:S/?I5[N?+5<>C.;*QML"8V /=JUFU/YY#4<D>A1%_>&KX:T3.>\-Q
MJ)U)9W;WC2#6(]@/+ #9Q'YPB\,V8N'EQ#G><0SC>UZ^0VI:[@>^^3A[YH<+
M6D4]>'BT6FN+&[<C=82MR(G2Q04O97D^)2%8D1*4.T8&<U67MN ET0G 6;N.
M6?3/T6)K^P85Q_='4E9+G6UG"AH7$>8K"B$=:V*Z>CI# I=<RB[XQ*XTQML9
M;+2M$$7<M4\WO.R1EF-[<K<E!@=DA5:#LEG*2^*J[A:DJMCNB_N>'6PK"J3G
M.[9/SXM!99CA*HF\2M>OYMA<D3\E0 QQTUO= S>T6PQ0].BP\MJ>EJ!.M;VD
M('@2A6W%[:R^*_?D8!,8[P'TZ75KXT1!S9*)G"<E<Z-KT[A3QI+%5R-U0-0V
M>31ER;GHYG]Q2-=M2<%,;Z#&2=Z>W#.GY3*'SKDONMF2]X72,%YN;H9PC XD
MCG$;#&)1 &BSY:.JF:[)##:A9V65N#92,2;*_D;>4WN+IJ4:4.ZLTHP@DE*,
M\XN)<9SU3%SQT?:71%S6CIB9H(P\[5\WU2:S+G-%(3K9F*ZWZ$K"Z6H)Q1;T
M1'(HEBA4[V2JT8F7&+_C%EEZ3"2F&JB623U4C[0EO0)Q'E8C+S.8M(:JA7(%
M/R&NJ[0QM\8'AK?YBINK2;89>HFKNV)5;J?$ME.ZK33L*L 4(B2TORIVE4:U
MD^WSRGVVNTKFYU,MR)VM'*PD\[:8]S,^5:N@#19948"NZ<N>242WQ^;L:;4Y
MFK\77,HC^W$]<RIRU$@;C-E$-R!3H(1U)K+V[+(<GWO-KP8K/(F<?$@=JYL
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M(5H>RR@F&G#,%N6/2WE6C9T7>R2710;X5T>?$'"S2%3T[%F*'2OXXS1B%O\
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MZI14U9+2R3-_9(Y,H<SN3VZ1PQX8T*LM"*1Q=3)G(*!S*"4L))7&E[&,'P]
M$MCN++YBIZW7::/<[87-R<IY X+7;TJ0R:0L*E*S5G.WNS8 Z1U8Q.3<NC,M
MB4]?371 [H32'!.K)(& W6R"_02V=D@5K7B6LHWN.)978$TT-P5.1SY94S>)
MS)#3E0""]D:=G@TP:9O(+3AT4F("407O8A:![QC$(6Y5 J3C6-N*;L)^O2O(
MLB<NT+'12*>P.,RI[>VMDB<-AL<A$)2I)62CBZ]%+#G!B62HY:UE(1-[\\F&
M)C!*"?G#2W;MCP2FY<@5X]Q&.QA_F]XR!UAD^!9<&L=ZN2:K[0A$K!%G.#C/
MB\R-</G&YM60Y\<&U6BV :1<0X*1*2S3C1&X3-9#6/*M,4^ZQ!Y@C&]('"$I
M;N3,JESELFD9YAG15@1FT;<<'=5('1S6/;K*)S$DB[:E48::0/9H2]A :,.Q
MFUWUPT#!+K/ASK(E4PC<NKU<[+H-/ZZF#Y!)Q&/M"A+;)(W(7YA5)S%3%)$!
M!1:]O5@4H5(DY!HBOCIDYI0EL=<=S35RM#:2-R3R5W'<U.12BK&<GB72!T>I
M% 8:SSMC: *'A:N.< R$Q%9#L)4Z:,^=5G'A,-,$,L&]#-11:O /.EQ(9$T2
MIOGJ!@G5;,=465'(?9LWAS!:4-BS4K9HDFL-KCSPA3R9RC*!:84F6F:"J,(]
MJ=0,],662$LVL2<FYEKYLM=?;\=>;*B3Z_NS1(II'(K9<O9*]G\F8H\@BC9)
M9G!4CF&/NSYJ.-*)&I."45]1(0I@K-*/ERO83-QA@#3PQS^RV-#+#;TLZ+55
ME94GM^LX2.RYF=6=<3V=M,T99J]PZNS'@4;9B921/W<9R71 DB<U8;M(6FT8
M8$9>597;/*-=V_93#;3M)[>ALW8H,Z5KMUJJV)G61KO!GB0-LH6L#N?$')M7
M&%[>VHDXM00<G6$^F] -#H6]82;63#Y/''E$K()65?QN/O%9M],.;D\U2_U?
M*I!"II"'5^3NB65+D$M;5_UEV-FQ+XL$_!<S%X'Q0I&H7!/4^TX(Y7.7]EW)
M=;2Y=!9$.16Y')_ (<.O6^THC;,U8+*D$'/5)'%9&)W*T[H-7.VU2[H@+0_5
M0JCDBT1AZ0:<PXX0QF_)V;+R]7$9LB163&'2QXV;,7=VD\O@C+9$L0U7)Y@^
ML7V>>9B[5X!QW'AR!W0Z :K&4440K<"PKCRC%OJHV,W&'>0GG>KZ^/I93&&I
MR2FT!3KI1%:;4/CHMTV5R\%UL4N;7$*I09IZ7C!4[+[5BGXB@'P#/06OC&>X
M6VY]4$*_';S<:EC:=J3V=$C8W2L>YSTX0JX+%B;D_4=&W62/26N).K9) D$\
MM"IQEBTPY2/07+^E_HU)?IA>52:/DJHT<Z9+ ANYO5SHU,<#B[DSU3/I/7\0
MF$9K (B:_8IE$H\X)6)[1Q9O&)"G,^"6I$V"^1--,1A 0$F:EFNZQB-6I)4A
MAZ-4C3S.P9K9S\%6X*W$2B76"^*)#)EA UAIHDJ54Z*AC+3E^TD@._: .@Z]
M,%N41OO)E:2VQ4UAS.06Y-"FZ:,]C,U<2JW9Z\5"R3F.JTKE'9$WULH>OLX(
MR..Z(I>W)#RSVYO<2BU:=.4H*+- .5DQ$JF51##;>1WD-$KW8:"MW*J$SCIR
M6Z0!ACM)VF7K40FC1OT\:LQ\94YFE.P?&" .P:%[1;UL9Z8\&/5'6TRB%.-]
M?679TBLJ:JDTL,EED!/5L+LL<ID^OKXIU&A)U9ZV--<8 ]Z0,A19XC6]"B3!
MT/8R_=L6YN8B&D>(*HH>,EP",RNXY36!<(>:^^ZJS+->I]79\<D7KIZ"X1Q]
M <4ZN3MHU1\TL5C.4JQJU SQF&'&#$6[6]?%F=(\H5)03RND<,^W+W(#XJTU
M\TO5D6+,[+=(A6K J-7,E;PU;-'AX41V&H%IOQ1)R!:-5F%DB5&G[3I]E$NU
MK,8[14!B<>MV-QH#\RH[NET[G4X6H)&[$O'VKL1M2M4C=X^[?,;5QQ1I.B*$
METD$6%(<#0RM!%^7!FL;D='+&ZI:HIBD9<JI>&UK(*81^K !4<ZF5'4[VP.*
MVMFESVM*5-VIFQQLIE6K3!'&[;52G7H(PS0]#/7-9%<=&P:[4\-!*E$G97^O
M92.;5_,8+*G>%S6(2$V/O<1<ES(_,J@A2%.[Q24.#:N3'!.2J4BP83"]BT 0
M!+8QNKN6*9IISB+O &)W;%L(9;F8F(UPE<ED)GRM_P!FL%P6HI=%,@='-8].
MLDL&.)U^U2HPT\D0C0%B" P0=BVWNC1QX"YW61Z,1E"CL&,-T;@3Y5"HV&VC
M.8HXS*K)$]NDC=*[GKFR/*-;*XSM[>UBA.%0/YE")6H"E.) I4A-+RJ8'#G*
MJG/GUIY@4LZ_50,D#A];-K&0].2=Q(B4#2,J&-H?KA2@+J(Y(F8$H1G;,^(;
M[-^[>_=OU)FYSXN%9/,-/VTZ3=[FS([+7:?1*L8@[.+9*)%'G%L34S.)59-8
M/L4<6%R;G")S"&SF8JW)&[(#2%I:@)._B;T2#6A-K.SZ,'.<(9UE7NSH^V/.
M9%4$HETPALFL&P)%+'TEZFT0>8,^?/JG!5\%8VZC3\I)3(_AA2)1BT866$S\
M[8RZ&/<FU9%'J;+(\XV2UQ>>_;X]]JE/9TR^Z,ESM)0M6SYY9:_&ZB9F-=)'
M1S5K1@3!+2$+U:A2G)*/.,,$,U@\)Y!K?G)E"_TI#9'84HKZJ3JGI6 VG<LR
M=(C!X$,#"!37,+<9=J;$02.OVXRVA7J@H5RLQ.W)D_J),020 O*WNS;C7G1O
MY1YIJJB$1J)2JAC(J.D2UN&M-;UTODSNXRJ7*&T]SV)T.: R)Z4EH/F=[/ A
M+) +T]GIHFUY7*#)AX[J>10&9HJQ128$M;JOO^&T4R2VRYLZ5S5"F](6_1^1
M,D4C"QP<6=@BKLO= ;,+^45"1$%A*2Z+(*+(T6;7Q8#+O'+']<D635<2$YOU
MM2_DM1S/'1V59LXET)@\7=(^R)7Z PG;\<[CB4">WIC2F*OETHE*@E"C+'O9
M*-*207E]V?#*T#3Q90J1HLYED;+*+,36W#F^MY:KM:>2^P7@NM&0YT51ZOXX
M]R%W5.L7CD><'I2L2[0G$+?J)FEAJ@Q664< G*OFR\7TPVC<%[P=8T]E#F_T
M\^*IU9%F3&<3;2:A+$06K5<72R%\=%*I!#X[.T&G UO(T64YJ3CC5WS)IHC-
MCE?DS5'S14J!@@,93M#H%HK2Z)-?\3)$_NPS4=ERZ2V#+7QS5*!*=G+VX][L
M]W, B-V),4 X  @T$HO029J.W#BFIW"*2N"H9==T>@4WFT^G#]#XE=,[C\>4
M#M58Y.MB1A$0V.I1S;"Y8]/:Y>8@3&EA2JUQXT@T_O\ 31>5]$G69SM6-HTR
MBH5T0NT:KUE,K4Z,I8"^+X<[1$^H)1%YE7!T8>&DPM8TCB[]#6XPC0-[!L"?
M18]" (0=DELN?%@;CQ]7[U&XLSO\[O%]DD$ECS+X-:SA;DIU;L162-F!'I S
MLL\1'HW($3>F4(B%34=HY =[M&"*V<40847E6/M/!7/L8BL"BL)(LB @K9PM
M15&)+"[:L)BG&FN[IRHLBUXL]3,A_%(9%&9M,CPN"E.N/4&%*TY"A.82I)+.
MT.5?QA\?_+T;@2>LFJ%/!$,0U!#*/:VW4VEX%;+!JZGKM9T"&R/A#R2_-$KA
M\Z=Q.3<])U);HE5$)S 'Z$07O0Y7.5CJSKM+6,<%'$LML*::-<E+F:^69-'B
M<R,PY44F(^6 [/)HQI6X@M*#128@)1 ![&/V_$,,&(EN5>[+X7HNSW&Q5:\Z
MT(>UW,6N*NJ'UE;<_KR#6[IV8B(N]*9Q$HR^(692[/\ &DQ;>XN*,M$Y.*0L
M!:E0;HLOVEFUC/'OE.CI(T77'WR)&N+#T%&XK$[,:37MZ*2N+)"HN"(1@EH&
MG7DJHXJ:6<H&RE*$PA2!26 _0]'!"/1,W^BMEV\-M3A2'0-=U<WNLVL#K"(1
MFG;7LVZ+:F;T]M,-:44N:V2P2%ZHMZ5*Y%5B:7*E3,W-@&KYE?\ !&-22( C
M\+-NLSX+GJZ<KARIL^@'6-)'.I5E:CJ%=$%0S@HEM>FQC[''QXXU*8F4@(.C
MN]I]C*&68'6_4 @BUK>B9N<^*"6GAFBV\3RL=!V5-'^0I:8;GF63VU)Q+I,M
M9^?+1^^&HV7ZD[NY^DS7%)P(:CX9("]K@'&Z5B/$:8(1>59C8')U,62[3V0R
M1I?BI-8+C5KXNE#%+'^/R*.2>F-N^ZVE4&=VE<E5Q"11\3\J#M0C$#YPHX9"
MD)Q!AA0R2V,AHWGBN.>DD_3U\"3G*[2GAMGV"^3"72":R"53U5%(I#%TC<GB
M1KEZO2E<R0M  916RTP!%?T198/0&A;;W3EA# UF?#/_ -67\01_J3J+_?N/
M#K[GX:_#]FS-AR,!@,!@,#69_"S?Y+.I_P#N$="_\$KG#K[WY?*-F;#D8'BQ
MSY=3O3?6W:S]:D^DZVE;*O6ZFYK,E+X]O4?JF9\U4A5-@+&**IERI2BC3'/*
M>=WIV,0I %$?-0]2?H'Q51@AG2S.LQW11SU;%BL-RSIZMTR121UMGMGGB7G1
MB72Z=#24*AM;B"6VP7$H6Q(7<E(G+@<?:$K0H:AD&MBQP^;6C3F*Q@.T+)CI
MY?Y3!?5N=&7)P0LZ!<&&K&B&VKOEVR:6K!C6R@F=H4\LZ/I%_K=#8EFGN)\9
M.-D487D[>"F]A* TJE B2S5Y96S3822;8^*Q;EU;8M?"Z%@=QR"BX?8-5?<6
MOA<[3,]BK('*D=_+I(U1F+AK9"Z.]BR.PFUY@KNC3MS0N--?=B1FE 1[,.))
MK.)TLSA7$CR8S]Y2Q6"-S'"HY:A\GZ5;)-+)54_2"J%GLW/,F@,70*F^I&.,
MFV]$'*RW"TVC6RWLX!4?*3K3=C<__)%JS7#^BPW(MDN5P="V]:+K$Y%7ZZP^
M/^"ILOKZ4D.2)]A+I(W/K!<Z1QT;W9"TKDS@UJ][(,$<D2G&A* ,90/70 F;
M,3YW_"N,'@:J[.*YKVQ*;IMF(=&O<6N:X8]8#1;<Y9HA0JV$/,O41>LVZKTL
MB)JM3 :V218EHD3:ZM*S;\80O-<C#5!_Q"C5Z;<?!--:];WM9TM8X<[I:PHI
MYL&D8;.:@8[)@-F.RVUG^14/%K,E#U"Y:BE,:A#HGK:;/C@T.L.*/-DY+>R'
M.9II"500+"76,+Y@Z%ZXDD%\>E>N2ZIIU+[UY=<+\MFUI*URYM/;XI"57/B,
M:9''4,F4BD-@2U%;1Y1ZS:E$W$N -*])@D%_)'0LG6^KC2SR:&5[+)XJ,!"+
MIK0NK[[G]=.M6Q2U8JA/?:;E\#BK/"#[>FR!95-FES!78*9.L>(V8$AA4I31
M&IU*<6CBZ</ZLMOTWK)%+.'OM*HHASL]VZU<$\=3Q-%8#1 8PVKN/^G_ +3#
ME0WF0+'ZP 1CT&>D^5"P[=A$E@$4@V/9A4)CKY87 YBN"56]#YMJ>M<?;9Y5
MMOV13,P.B.W(,3?7: /6DJ:31Q(\GJW=J;I R+$BD2%2H5&(5!AJ?YA0$L)Y
ME9LQV[(AL:_K\>+8O&N>>8Q5"HOFR PJ5S@ZV%DH3J;$E\\:7Z5,M<PY1'%"
M9-"$">*,19BJ3.!;N4!8Y%DEMI@4R@S"R3$M\75\K]56AU38TM>H]%H1%>=H
MY$*5D;4L>!/BVV),MO3GJL+R9D R$C@5&8Z1#BIYM.M,&!6)?\4L!(2-IS#3
MQMKQ^**4/D#ELAZ&<8%'(,G>ZU;.F'+EQT:&ROKF<K$2JV41T=DUTK)XWQ\=
M0MD$C5@ VC5M1A_S);*6-S&XE&Z"V[+QZ>N%8FBW;TGD/3%DR2(16A)7X:'.
MX!U&VM<U>79AD+S$5;9HYMGDBGK@XN3FVK3@ *7KR%!QC8#9)@1*A;6Y%Q)?
M7DF9B[0MOF"BHDY7E"8$^-97""7H"OVJOE\K^NMKO %-+UZHK.<NSB0]E24U
M\>;F8C /S6@2? "6M#]-/^&08=4NLMZ>;L0=Y]"#97:.-%>U]*[!#=G,U6QF
M>+(7>=3TZ_I^B7.3,#N66W64S))B=(*9=8HH4.@49RPMQ;5* P($1ZSY<@<9
M]%P+?N.W(;(^<Z-AB*NG&\;P3RU6\R^1H9&35D09*JB[.[V1*$440/A<J?SU
MSY(&Y"S,NWA,9\-<,]0N]B,S1Q))UO@H;9=A7#TM/.3:]E372[4=6W?-ATW>
MT(?8K*; @$WF-6<V6C;D/ED:V*81S1\771!8W/2-L=4BM0R2GY00SU/TP6U)
MJ23/P_RMQ;LGOI)V_2$(C\ZA[;1\BYOZ2EDNA2N*/JQ_>'.%RF@FK3D%^32]
M"W$NR$N;Z U&;0#*2$'KPGE*AGIQI3,QQN>^5-N;NN+8YNY)Y3>KNB<)=:R=
M/'[)+>C*&#K)"HL9C(YLHJ&SPQNE;R[J5+#*U%APHPY1HQ&D;ML[B6%,+3@
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M=>[\VYR-4]R2=WESZKL.+O$NAZ.NK('6MC2NOD]J5\W*7=4VP^PD\;<$87I
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M126V*65(7,A2O>H9$JWA+&<VJBS0G-!)3#5+. PLC80&FE&F"U[CA^HY7^C
M))PG0\HG8)ROU8:8DNZ(?T6" --D2ILJ_5Z0J1,TH;;.^PB5<!GV_+W=B).7
MD[U]/6J!FJC$VUIQBD1>5QADK!R+6$65SPB/OEH-<)L)+8I3K4J>R9)NIVI9
M:ZA<OGKI%X6:I,21U2]NKJK6 (3C"@0JUAYJ1.0,T>]DY5^)]R#5ED0"$U+(
MGBS"JHA\(;:V75JRV+(66(6!!6M&TMY$:L="@/*42= >@9RR%(OC$'*DQAQ!
MPQD'FEB+-K+GQ1!=7+);4GC#K2-;2-^F"6Q[KG9\G8^DI)14NCRN^I$5,K*:
MB)(ABTMV[0*<R8HD:YMV6$3;M C4H0"5)B!%"7S97R-Q?$>:Z_JE"L, Y6-"
M*565 \.K*XO?V5TSR">.EH/S6Q('A0>N4(4$N>SRD2];L3B<B*+V>+X@AX-M
MLWT=ZT\35!%S*Y/@;U;%;J:ZK6N:?"H@-HRJ-F3FMZF^-JOHU8X$RL1$LW&@
MK58$Z\P!;H A<I(TI^ >,K8Y5PYUPE0UA3!TE;WJPT:-\M& 7@^0&/V1*V&L
MWFY:T?HI(HK9CA"6Y>2TFR4M?"6W:O6M!1. TP5"E.:KUI1H<K]$XT["9O!X
M](TUAV"OL>22.R;*FH7-26-,W1V.2J9N[I"H#'$)AAQJ)A@<,-0-9?O,&-0>
MF-4BWK9VPA)<7LEG"&!K,^&?_JR_B"/]2=1?[]QX=?<_#7X?LV9L.1@,!@,!
M@:S/X6;_ "6=3_\ <(Z%_P""5SAU][\OE&S-AR,#R1:^E^EJUDW6Y4Q<JVLY
MQ5=K51S-S?$BFV30QGC3_:=540[MHI?(QNTI/)@,<:YBI>G M,A-<ECD4M G
M&$*I(0F-XG3X+BT9<-DO]I7%0MS,T+(L6IF*L9VDE5<">2(9-Z]MLR=-T<<B
MV&1*G-ZB4C:)'6;VA7(#5S@4,DI,K*4;TI$0G,V=,SLA>X>O[&JNU>G='Q"%
M&4+R+SO'+]L=\.5ORFR9D*3Q:YW1%!H2U)/8QMJM.X5>G,.<EHCBM$*_A 3C
M'O9Q)9K+)YVJ]HO(A?1Y!4:;ZUK:7SA[L#EZ,,$E;VF[8+4J'70T^?X#)H>\
M/=AP]J=G.85 :R@<S%#>68!^:E99@$*$W^AV:XSY=4ARKL_H>*JWVG=0&HG[
MH6/=2U!S[MU3N<N9ZC>HK>-8N%D12S@(CS'.6,2J-ID2@EU8Q*5YAHVTSY=7
ML*P@9,3C._AAU<4\A<X>[U1UYJ'QZ11=NZ'.Y9E3?$H7<*B=%RU@+-C<RN=*
M\_0G&MF>KF:T$IJ 36J<#5I#'KZF>XA-U]/W3C,9]'1__C&)\Q562\SILK.-
M77*[CKVFBZ;616X44BYVDDVCDZF[D&[F+:!=,9^ULT-K]R/:'B,MR-FERE*(
M*!06D'M<4.'7T9/">U^AK<>*6KNO:ZKQCFE@._4#'*)U8+-:+- 2V_GI?60&
M2R*_ASNGB<XDT5LA!8J?1:)0H2C0*AF ^>4@1#&J%UDZWLX]>]'=(W/?/$CJ
MV.E?P*O+"K3K,%R5E]+D$D,7SR@[0KJLI4KC\L"\L@5#:4[FJ#(V<>WDB(2J
MU&UI*@PPG2<622_)8GR 2^[H+S^FD=#2Z+PN6AN?G2/N#O)V)U?0&1^;7]6L
M)<FU$2UO3-M.%T#(=)UPA[,$8UF*2R?@J!E*"2:XMZJCJKMOJB+-\@%HI6*N
M)'659WSSVMLPET7RA-)Y,!_YAY:99LEJ]&0J5ML-!%DB_P"J) N>W(+LH.VD
M%\KO0EPHUB62>+/F+R%R.2=&"K]CA+>\UP7TQ)^7%;4SQ.V'*SFMTB"EZC#Y
M<CI)$T8'5*2OT%C,1K:>W;5?,IVH0',Q=HS>VW53CT]<+K="V\[TXRUBYLS0
MVO!LZOZD:A7%.9RHDM"T6E/VB(.CNDVEWH1CDUHW$1R< _Z(9@=:'^;ZX9DS
M_16"S.N;C:[8?Z>K2#5XY/P>MZWYL8'>7NK^F:T+%->/7+I=YG+\F:_14O71
MMQ;3$Q3<F&1I>E"$OXQ!IGQRS4UF,^G^70M79%VR5="Z198?5R+HQ\Z'NJC9
M#)',^5JJ::F.BH>FL&062V,:94DF3D=)(Y(&-*CCXW$D:5Q<%'Q' U.BV8H'
M&=_#"JE7]A6-3C2Z5JJ05_';<M/JCR"R]]=Y81:]D5U%F.F[N:(PL0,R.MHT
M?,'+4RD,_:@MPU 4!+0W;4FJ ''D%(U1;)?AB+(-';'3=D_./%2\YLYR.-<:
M5?U%(ZWFBV4M-MN\WLX%ZM#;1D::%#<T:0NA<EJ<HP+JX) #,1#V6! (]45\
ML3C)WOBZ5_[;1,D=I6X9>I@-JDL/\6S]+7*KB+6KA;"@T;S[)K#?X<\U7.WD
M#XU6-HEG,0+6F5IOC(?C%*2TZ<T0-Z''P^#\SKM+K6EFE\=[6J^B7(*KA3H+
MKV+((+(IH ]JF5-*:?T13$B4O>ADO2 U-:0=&R9*%"!4:3OVMZ4(/4X367MG
MOAE%F]OW'SH5;3->$%K)TE['6](V#6VZ\<9N"-_4;TNPOG]MA,\$J:I'(E(8
M7.7-O5*7EH1&#=6LT\1#6G4$@)/$UE[.MB/=%QSHV/U3%X=!5EP3#H =/Q.S
MWF)V]"Z,?(>WT8ZWY)+*;(M,$+1/G1PC34Q*HZ>PD..RQO?PC=N9:<9@2AQG
M?PPEGQ\.4S=&3JXZP43:W2]/VS>3<\(F-W6/3 68W(82C3J6!8X$)EI3.[)"
M2UI*8XL!J32G9)GN&6(8B;>&/)UG1':3C3%TQZ%L3M6LO8R)]1%>6!!6R-VJ
M_P!DQ99?$Z8H,T/K]-HRUKZLKGZ5]KFYV2M4A&G4/;=HSX2A.(Y+LP37,9?P
MC+[ZFD2O%=>TSB$S7,74?0L'B:B*QQYC^VJ/P>UI7&B6<\+K(7T)[4WE("BF
MP ?:<0C+T%0:I-WLW8VDG;R0/U)-+[+Z'OFORIS%D]!A\<ET3XV%E1YY#* 2
M,HQTCH7TB0ER(M$![)<!@^&;\I\$+=[R=%?'WI5HLDQGQRQ"+=I6KS+0<,=K
MY@L&<V4C@LCH6!-T!>Y,HD2)PK?5*P196L\=71 X)7M;('BY6(P#ZV)"2T_M
M6@VA4:*).4#C+>GFMER-TQ-;P?[6A4Y8V,YQK=)7[RAL."P^UXC7<K2SU/)P
M+8PVI+9C[0\BE5?O$1/*<!$G*"5*%<WJ_8D&I&D))M,(Q\C4;9E,"*41&46T
M@ZOL-%NJ.1&*N+BLJ&?"N-9]1=6B;F0J,R5#"7&.U^68-]F#H]MJU&7%VHXA
M3[RA%ICBZ]__ &^*"K[W-)8'R/6H[6Q8L>GG$$!C0Z%%#)S)X5%([)(CS%&.
MC'B:O,!9']'$9T78\TEIC2YIY$D<TQC*V:0E:+ (_9D6>$\TXS!7-#>[.&9J
M;8EBI&"U:=O\ISIW3[MNK-G-9H+6\B X*(PW)TGVBE>W=V'KY]V-7&H22]$H
MM)@F*?F*STXV>*EP)[81G6I4G,?KK!"==Y*807V;JP)N#FY3!@NHX83Q@&B@
MOPV#ZSJP#-0+[3F1T$8'(B]N '_<@WILV:Q./KC]5[9W/:\4HJH[,N><J@HX
MA5D&D\]D1VS2B1B:XNSJW=2F3C.$$L2U:%+\$@'^TPXP(=:WO>M88DS<1X_<
MB=7;K[71L.=+^B'1D]=>:U?>J$AKM%NLINA]C#:G!'T-2:%4SOKJ9%Z_@DY3
ML![$V$[)*(;WXT)  !)WZ&]IG'3'7"87SN7HVMJM?I]958U"L>)!PO8/9=91
MJ&2"5@+9G&LRZVT_5)/'5Y+&2^&+QVTTB2OK<! 2$1*LL:/80$GG$XS/3SPS
M2<=@7U3#M8D*M6%5.Y31D8.9+ BBF#+Y:7' Q:]^C4-"2F*2,+V,QP526!G&
MB5HW1*(E(\Z.!L:)%\(19D)K+V2=:762V!S?H^%+7>L((14\6YM6PB5S[<J<
MTC_*KV?K):3H\IB\4T9))0\ +@I869J9P_/N2L_97J'7YX:DUSA6.I.BWWHO
MHOD5_?VTMD?X7+N]:EDY;6TS6*,DB<:];*S1HY*BA]@(6N:1Q.[M:Q.HTW.Q
M(U* \PPL)R@O0%!I;,2_)+'D\16:^5]S;%*AL*25I/)7UW6B"/2"./[HP 5/
M;)![2FL9890-K5)MO$&>Y;%6\EY;E'Q$BYOV84:6,._3!ICKGMA7?J+H^3=!
M17D=TJ&2R^O6AML3BJ^;D3QY\=(^Z)E5H]<U71$5H:5KVI2B.5HUSTNF^I V
M':^"<.)? / ,HT0=EFN,Y]?[,^B'DW5/DZ6/"N'H7&D3I'TDP?!B\1MQ38T"
M8^<66SW4ZS)W)7**):J6QRP550.:).@1K"36I4Z-)8U:PU0I+2DNF/B@.PO(
M1TG9'-MX.=>$0R!3#7, >B8;8,?@5RJ6.LTNWR/M[M4TG>YTT0]E?;/*9I<A
M6M#TW;V@7_+./JUEE)2SSXLUDOS6IL/I.U*EG-WM;# X#,K<:'KQZURH6GR6
M=QJ%2N0](6.]5HXK2V5Q=Y:GA#)$!KS%:?:,LY8L+_-5B4# 3[:DF9_5VJKK
MF_FN2N?/JF(5(Y]%&=)0RB8[*T9\O;J=-CLOH!^Z54V,[1Q2K73$E;&('#'E
MO&Q%.@OJ#J4E$!P3D*3/EAQF,^&%AN4+EM2VTE\,]Q1J$1R94CT%):6$;7KB
M\N$<D[0RP.MYFTR\D#\'ZBTJ7Y/._>8WC$=\A[=$;.4;!L\PFTDQCR0A:G6M
MW,F^K;"K*!5L\TUQ8O4-MFM\M>I$AL>T5L4JZ*71:)->JD!08Y# Q.!S)*4U
MC=27$+Z[E'$C^G)M%K#"S6=,]ZZ_CU!,Y+UEWA:,R65O(2-SRJX5!'UGB<E:
MYLT5\LY[I6R([%-.C_*GPEOBVB)C\\M;DR=. ^1J%BS\T)I9)8V_&.U[1B$]
M,GL%LJ11BW[>Y<B<#E[?8]4T)8TRKVS(M,U+LRNC5=)+%!)9!9#=;.Q1IM6(
M!L"5S&YMPSOFVUM<U9OL3C6S&/%"4KZ[L>L;;M^TX[,(A:_*,<XBYNMJFH(U
M)9*3(YJ[7#/K4A5;.(K$?Y"X$IE<W?4#:6[.ZU H"6T?+&?+A4$JC5(X],=M
MLU*-A=E7=SDY2>$WK7M:32>N=61ZPJ<.J-\D,>BDGDS_ '-6'/QE;3$R:E.[
MI&26>RKJBXM2,L)Y*UH6*E'TY,<BVG/$UE[=D2]&W9<-"=$<9/%PI:_F5GSI
MHZ=K6KHO5_VIAE>O,WFQ'.B:%,L[DLU<WPB--21](6A4ORCVA,3_  R42$US
M5)FY26267'9WT_GO35=].]$2N'-=0OKW7_ G-MBV=]HUTS01%W?HI..NW1QA
M]>M2%2I=6'[6Z1JPE/:\Q;IN*3)]&HUHA["23$LGQ9T\=G77,6:Z[*HNNJY5
MUGSA7<$G4X:;*?7UOG%E.LLI**=%N\)@RUA :Q08UAJZ;M8$[LZ$NB=P>U0T
MPDZ1.F&K&.,[7Q1#4?2,W4VA9$'HE!&W*5]/];2Z:1>1VI]?'$X-5<6XNY/L
M!Y=ET=8ER)Z=W]:.7-*%&TD+4!0#EYZHT_VIAE'R+9,9OA/\H_K'K^P*8@K5
M 5S;"8W;MS=;>19W>'>4D699E=0AGIKHEY020MN0UPQ;F<B"]O<W9DS4$P+6
M0B0J#CU OB)0HU-+K+?3$6#KWM?I>X3GYVKSGIA);H+R? N@9+7DJ7RMFM:4
MV-/D_0#*STI#$3LV,1+4%?,::(-2OKNC*^,TKB]_(:-4:VFF4NLGCXK>\J7&
MY7?61\L?)57\F?T$F<H\_HX'&)Y!3H8[MZ)K/70F<P.SCQSV'3MB/6B^:1N1
M20\:8Q.?I.4 X.LK.TQ4 VQU5>30Y=4R>IX'6;U5W%Q:<NRT4U?)$W3JU7ML
MJB+WE.F&O%;83MB@X8[7,R;RV]<[$.9+N]&&IQEHDI/SIA9)TSWK$^.QRR?=
M@=MV_)%L D#*>HI",UJ[HXG(VV>L%<R2D:WL^/Q0+F]RI[2-<=-!*1+G1 E3
M$!62 TU7OV!^&267;\9$KV[+K];>YN48/#II#&JFIC6?0;[.XBYQMZ7/;^L@
M[C3A>E8'=+(D*).L0I9;H#5OY;9281RL2@"KXA&B"3'&WQ4AY2ZRM'GGE#D9
MYNR+Q!93\IY8G\H83(HYO[I:3(&@:;76M\_*5CJ9]GI(&P8'%G [1*4M&:SK
M_ETXS5X33#B35UEVN.^5L..NR9WT#.5\+FL08RBU]21^X&>40*+VVUQ2+&.[
MP!J=JAE;Y9<6CZ2031B*<$2I*YMNR4[PF&J'I C"E"(\SMK).C*N@!O=H]0T
M7S(OF$Q@M62"H[HNZ=!@LI=X')+47US*:AA4>K8J;1E>T3!CBZ#=GJ'AY+:%
MJ18NVG1$&'!1B5DJ!.DRY4W>E?-JVC^;><V8M;-;WET\4L+G<\_LZP(K HQ!
MHN&5SV2+UDBDS_.'_9?N0(6J/)') G&J<1'?'3$$'[$.^;?!"Z/LGHF33F"T
M-':_J)GN@ZZKTH^TI ^N\K=ZTCZNI:GA5R,5@0]N;1-<ED#5-(?83-L3*I4I
M%+>M6FIQK3 HQ'J"\9W\&#-OD#O]#5\.N:;U75+;%K-A_4:.*1:/R24NTDC]
MC\PUY9\S/=)"]K$C:TO4#L<ZG'K29(G2HG%G3J$'Q3U1IB@*8O&9PEJ*]?W!
M%U,.WT<T477K);W+,]Z2A$H:Y3)4L:J]9622N%4O@]OO#V4<0Y-*5):S8I+D
M3:%(4+Y98G^1]VDQQY.,\,]T1M?D-N!S2R2(1^&UQ-;):[ZY>JQDD:B/7)4%
M?OD7Z< [%HI*9&K)9=3M(=!#X\O-,-3;7H7I*45M,82<:82GAQGT3$Q=EV+$
M+!+@U[L59M#-#[QGU#6G9D37R!!&DKR'G"*]15',6IGD!ZY8P,DCA*YT9W9$
MJ5KS$SZG3:(4F%*-:W4XY[>2V_/E@S2VJ(K:T9?'6V&2FQX<CG!,8($M5$1Y
MKE0#7N(-KK\R,E6-X1QE<A"Z ULO6E^CPE^T&@ZT2S%P\\:9Z2ZK;8JV0>5N
MM4V5==U=N=54E6#PJ9Y;%X- 8=3$WNQZE;Q*DH'Y[>)(U1B+5N)#'6A&<A5J
M-')"5:W\U2NT:LGRQ%YN<[CF-DGW)!;-88ZQ6G05H K.:F0Q:XKH7)BW> PB
MTH?,8Q]6+TZM*5^A5@H-JFQ48H/;7$I01\=24$I2<9LQV[*"R:[;VHNV?)O<
M$/BT DM2T=8-3V+8;3*GV0$3251IGY%HMYGK/6XV_P!S'$G2-Q- -Q2&.!*T
MAY<3OE-EH]>Y9LUB62>-_=G*+R'2%[Z+4U_&X4WOM<MW2XN77!H;(G;+E:);
MHB, PR"XSI"AC!U6-D C,\.TB5-IZG:D#.4:Z&+21Z"W"''IZX3;Y"'"4M=+
M5TMA"!(ZRTOK?C$N/M3B\*&!K<W)1U#5B8A&\.Z5,M4(F8S9N]J]@(.&)/H8
M0EC$+0=DU[_*H/G_ 'C952 D]96 RUF"Z&WH^%T,SS)D:+,<JI&SS>B'#HH%
M@.<)9$\EL82J.PN/.C>8RIE9FESH2F'I>E3*#1I"S7/7PPAI[[4?2'J =1R>
M KRWRL>5O(&SJ82E+ED1CMCRJ"=#<?P&&2**BG+$UR%N@5E+G! L0KU[<8<V
MH7 [6_F?EQ#.>*\?#UG^5C:;7WCOR$3%HO(NO-O:3B6N7%"XU6LDY41</J=W
MV,%Q1BC\L-4NK<YQY0C"1\YL\TMS3FEG! E%HQ*42XX]/-8"YKDM!%<U<<[T
M@TP/<_F=?6#;L@F%G_:!5$8C J^>X1$_ETL=C"EK=Y3)Y3*K 1$D%A<$*="C
M3*5!HS!Z(3'DDF,WLJM$NS>F[CEZ6MZPK6EHI-(Y5ERR*SU%@2.92&.-%H41
MT!+.?I%!XL='$C$O>8Q-7^)'K6Y[- 28VM^PC4(U"C?RFB\9.O@]!:)M%/=]
M)5!<R1H.8$ULUC!+()85"H"X]D+FT7:Y(%H.6EDIRUAC;]2^#LX)983=@]V@
MAUOTT9LQ</)3DGHR2T&T=7.UQ2N8S^)RF<]J]$5 &1OSG('4I53O65I4=/:*
MB2UY5K3D:!&)!!CXZTD^A!)DF/)(+"45H.C>TSC'I_9\N:[FMFC:BNJ,3R[H
MN]WDY=S6G&$QMNIK7M]6Z.BVM(!8\SAM2UQ6YRV>/$;B4FD*DIO0-NB6UD9-
M:,V'00@+,%DMZ3IA*L!\C\RGE;D/9%;Q9JL2RXMRB^4'$ECJ_:1RE?T3,W&I
M)4D?=JT+:]@3518<-?W%?O29$I!&0(S#R4Z@PP.B77%_J]29JPHY3$9)'7'4
MA$@>65P;U9<2D3K$9,<G4)C &IV*3L3NP/#"Z* ;V E4F7(S21BT()Q>]>[1
MAYH\?$RAPLWL>KF@R^N<65#$Z@U!*?NB<E6]:5<.,J;K01N?0$+?Y#+[MA!,
M+L-:W$)&QG)?7Q"F>(BN/6(TAJLU,8;V[2]*F_QPG/0N3(PC?Y9,)RXL-L]3
M1(,JG\F=9C,G=LAO55U11B,?Y,]'J7)V6IF-F3D?$,%Z! 4$  @ $( DV[_*
M?V7.D+*GDC"]1Y6L=V]*^M3@T*5\?>'&//J-.Y)349REF?V=0C=F1T(+.V).
MK2G%*4QN@F%C",(1:,O#]=(9-$X7U_)^;K*M1EYDE-C<D<SU?-GZQYG8QJ2R
MY=T"BI?JBY*3F5EOTFD#7%FADL=N:$S@0K-;399'%ZY%K6P"/5'3O9R[]?\
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M>W^YW]_81/XK_@,9K&TF=W6*%;!(85%4$V:T#-]*V(!20M6WV"YDJQ%[T-0
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M3!5EI/\  &66,CJ86-:B?R&;851:D981% <&\Y Z$DF" 6I#K>O02X\F%O\
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MZ;4W3%/V)<[<T,%MF26V'BSDKJ\E0RCVF-Q^7HFN2-L)9-K]J'M684YNRLA
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M5_$C8TBM'[R*\'358W$-NLBR7M5$D=>)HU8"VLUY*8E O >S*U[44-0L.5'
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MXNK+HZ8S^8.<TCL??Y++9)+8XW0= RM6W5S0*I,EC19ISP888G;5&E!ORB@
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MD[ 2E-)QGSQE)W"<UOR<QV_%E[RR&2Q5'.H[Y@D/.B;([LVVJ/PFQ'Y@+9E
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M>A$)W7:68MS0-"-8B4/L2*3)G-,%5\DJ$C)-T26=\49@Y7&/1)C33$382;K
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MJZN8%7BNXI5:%O0T^;OBJP&FCED#I>$UU.7VTHBF<(\VSN0$OH;<C[*0UZT
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M+5JB;:XGJ].,,& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M!K^88]]I9XC/'"J06/$,>TT,BZ=LCC4VEG-BF!-H"W5:G6O2@DGV*U:GVE[
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M>U4T=22%*[(8M%(LQ#2H4T72A0%I4B4"?^DV+1@A[WA,L;!R%6J)#4Z=A?K
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MPMN"2,EQZ!,<7^%3! V.K]&>F[/!<%L0-R4K8\Y_*QEPG*<A2@/0!1/34%.
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M<=C,;F8?\PVRR9/A)@5JLO>C3B2BP"WO0-9"36V7'2VO:_R2V]:M=5CXQ'*
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MYTH<Z^7:.OUVG4]6YMMOD1.1J(N\6.9$&@<R=&%0W:"VJ&I>_B/-),2Z"E,
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MW,\PWX>P[T#0YV2SPKM^@_&U"+COA?T]65^=&<D7U*("VU79<_YNE<1916Q
M&0]2='FJ>QR?0>?QE>]Q32TX#0])TB5W;RS-@+4; $L(!-\3%DL<>,^*CE*%
MUIR75<136$PQWCSHE+U1!%Y,O+<9//KLTFEQ3Y+[ED;XT.KE.U<O6S9<L=!A
M$C..4;+T48224 G0YWK?.83[S;R!5W*LGZ.D%4N4U);NFKM>>@IC"7QY;U\)
MBEE2EN0()BX5RTI65N51MOF"AM)6KTQJE8 :W6S"]EZ%L&R7:[8SX+4X9,#6
M9\,__5E_$$?ZDZB_W[CPZ^Y^&OP_9LS8<C 8# 8# UF?PLW^2SJ?_N$="_\
M!*YPZ^]^7RC9FPY&!KM5JT]3^2BWO(S.".XK[Y2CG*W3-B\E\QUM0;E"XS&&
M%_IV-,:QUMN]&Z2PZ3+K5^VDH?2S=-BU0G;B6HH9100B&$TLZWCI),2YF7F^
M]]_=']6(/#[++ G/;C BOOFOLU;?$%\;9JYJLJR[,H*Q(]6K583%&$83BAQI
M4O9%;F:$&O@I"7'99?H7Z:R-<9+MC'>=VV@TP;4[YM8J\U,;UAVI13K%&=3E
MVD HYTE'M.411HM2!]DHD:H;/<2#XGQERK9 ]E.X3!>S?IZ97'QST:T%5,=\
ML,.\X=A*.[.YI0Z\ O72594"V3&_U;U&RVQ'R*EF#'(9JV"CY&Y#+HQ*948X
M-ZX!B7Y92E3#T#>ROSCM<9UF)UQ_=D+7Y)+QLQ+X)($V1GMRI7>P;HYZ8K[M
M6UZ]<H%6O3+2LYIDBJ2(4<X,>%Q=E()G*BBG\H(B2M+4Y/S?YOM]N3*<).5Z
M,B\25G6;>G1UAR*VK/\ *3.I'%>P>T(DR.PGEP7^/1+"(!-9PQQ"$2E8<G&F
MT\,3,$"9*CT(/L=BDH=;_-UB&\DG3':?%Z.^5WH6\J]'Q=S)SO80:4L3NKJ5
MGH1=?(6-HDCK4M?-\1D4XG;Q#&>0IU4>46(\M;&! RC6EFDDGGB'HO9@2Q K
M&DES;VD5P[6:N@.#J=I:DZ'[+Z5F%B=[]I<_<MM][=,R2(W%(N=6.;)92JGL
MOK40H1'&I._OC0P"*1)G$A:B3+S@F)BBO8$&BZXVN;)B1TDFD?0_ 7<-9\NI
MNK;UZ5H_KWDSK"9,X.B)''9K;=)7-S?"$<Q+FT5L%@BL4<MPR9M3M\L-L5E&
MITCD6$:418?0K1>FVN<266?5Y<\;>0'LUK\;UJT3/[_L6Q.R>E6GB!^XQM:7
MOQKK8VV+R+&(*PVL8W8\.CC2:$FL'EJ[1P="VC^$6(7IK>MZ-[:Z\\R?;,Y^
M3X)NL;QUR=X=RKL[.[-98W9_3/D-KOH&VZ+>II(N@+&CM02:T&JL@Z00N'3V
M32E0U.L=;@%IB6=< I)[_>#1(1C#$Q,[8DSB,DMGLKR)2CD/B+DB8](2KECL
MBVDW6O1SE<UE*H[25O*N:N=R+ #R\T6XTK=1]DCDTZ/DQ["WN*+X2<\TA&>,
MTK0MG^HFNO*[8SKT6)[#[NZTZIH#PO7CP59K_ K5Z-=;4L"25JRN0DD9M.?4
M-1[G8\PYZG+<0,93BROLZKYUCI99GKH!BH!GIZ;UO":ZR7:;=HD*MKVO/RBV
M%Y(V[E+J2UZ@1R+D#Q]79R2>SRU6@2TI<C_'[;D$IB3RTE_"3)")#-8H&-SE
M <6()H4YVA%_$)+WJEDTDS)WK+>,[?[P\K;/T1? )E->.V>LN9K#XHK"ND4A
M5-S"K[^61-:T7QT-+4L;4*USC'Z/L(U(TQ O\X9.R52K1>E0-9$VFNED[]<_
M)&?6-F]%<V=6UZS=]].]PT?Q1'>>.;HC6G4/)"=#]S:WI%&0%HNZ2]?2S[$S
M>7M9,JDZ8CZ6%V2 :!MZ@0S/::(PP-77%GVR7;/9[Z=JS)[BG$G6M@P"1JF2
M21OEB^9E"I='EX2EK2]L]22I[C<C8W-.(02U2!>G)5)CP;WK0P!'K?\ LPY:
M_E)?-J#P_KGN%'Q9U#:E/])=P3JFVCQ%L5M6%>'13'(X^96'D 6O4+,^D<S6
MK+(#"I))HNJC*]T/5!1GN[*G* 4:0M'[RO6._'7E)9,\OHF.L/(KT=0,!\DU
MS4]=/3UWU%R[P93TH50SOI&61;$%[8ME\;RHV_16-R&-1*UE?/XH6ZC=#E#F
M1IL<#20A1'&DZ^)IZI=9;)9);?#R7NLU/UKXYVWQ\=*N/=-^]2F=!=*\^\\=
M6U3<:N#O]7S<OI4HU!N8T+'8Y#8\LJ1PKR2:TJ;DC>K.2JVP'L4A'[1C,K,X
M[VS$G12N#],]E2?ONWX[1M\]HV5<43\RLGIU[HE3&Y%->+8OP"V.C1]X*R9R
M)U@2B$5R]1% L6B;1HI(F>P""G !&,)A1FXUC7C,XQQ^>5@ZW?\ L[M'C/KK
MR=,O>=YT384#FW5#YS-1D%-@:;G"NZ^Y<D\N9F*%7/7+U#'-;9CO/"((H&_+
MU[@4H3Z7 &ET2$OV")>.NTTQTZ91W=7;UZ3^0<E=4=86GVWR-X[+PX9H.RF*
MV>(VE(7"*QZDL [3E9 NI7W4/G\S98$WH5:0MA^.D-9C4P]".T,W:C82S626
M:XNV?'R61\UW7ML'27G'DKC_ *J0<_V5)J;N3M5]MQ).H]%D\C@M.0%Q^Y.M
M=2%S<$38YM70UJ.!2,PDL7_F$B 9@="*T/TK/MZSKMM,^"1G'O.6='V=^'[M
M^HY[)8C6G9#W?+M<$#874Y&PR=;'^87QX70B8(0;$%U*KVSFQ4 H!F_Z)8C]
M_P#MU@XXFTO>(U\C-VV_3??)CKUI>G;_ "YXY#*MJY)2%Y\?(FHNJ(S=JZ1N
M1-B'==R5'"YU)65O/%M"G:@+4GT,2,0A"]#-F#"-9+K]LEV]?\-D(Q[9BF4<
MD&ZM^H^6UB>QO>EA FK3,!)M>)UTO"9M*)OTBU\;XVA;+V7^=Z^GY<.35"\=
M/DRM.RO(-#[,LCHTB:<S^3.3]3P?G:@U4W8'(7-+GS=,$J6BSS8HC5&.T6/Z
M$K!E>%AOS!).EKGLG>O78@:V=MM)-<2=9]4Y<?WS:;!Y$Y/6?D6O_M>G.F)?
MT%>B7F>GW-.SL7COOZC"$[V35L8J1S:88X-DEF3+#1ENJD"]X0OXW5* (Q&B
MV8F'(FTG'.LF,?-?#S+6Y:-,\Z4)(ZFG\IKI^?\ O;BF O;Q$G4YH7NL)FUW
M,#'+XJN4$?GGLDD9U TRPC?YIQ(MAW^3>5G22VY\F*=HV[T'&/)[P-4E,SIU
M;6ZR.8?(2_'UPK=CDE=3JRX) J[55*NG3:#82EQ$;D;H(11@MZV0!0;O7^W!
MKCC<^<4B\8<QD-]AL3E_K[KWR8U-Y&Y%2BU5>]*6N_LU4-C&H+G3&K=KGXK7
ML%?;BQ42:524MI1K&9R5@^DN)GQTHA"TH!&M\3KK)Q_7=6!J6]&P7Q\>9KJ%
M/W9VU([-Y)N7M_FJE036^5CU$V&*5@MAJ&$S-P9_H24Q593(4O.$!W >4$(C
M!"T3K#72[:S$Q9&=V[;5MUGXD.GKEK&W?*Y ;56K^+VO[?=GO[BR/+<=,K<@
MK9*WCFES,3!.3QV0-<H5IG-0'WZ,*$E!O7IK\I))=Y+QQU[+\0YXZ#X9\HW+
MO(ZGJ>W>I>;NTJAOQ\11CHUWCDZM^C[#H)A9Y7N3,ED,L<C+Z[P":-C@) )&
MZ@5:(6ZV(LWUUK65GIMI;C%B8O*I>-Y1Z9<&<C4-9KE0[[W/TDY5=-;VC[>S
M.$RKVL(% 'NQIHCKS<C;W5A;+"F:5L+;VQ<I3*/E-B,&67LSVB 323KM>N(\
M^NC;:Z<X)M#M/D5JZKO*\J\F/B3Z<[,HJP+@?F5_OSGJVJ22KHVYIT=HL,?C
MBY[B<E$X$.#8)P3F*6YR2_#),^'H>AQJ2;2;8Z\L('H_NKJY%%_&GRQ<UYS9
M1T?$^_>3$MDS,IY4(W3J;C+IZB;'MNJIA*3!#$.1M8UX3HO("]ZV$#W&-;-%
MLPW7K6KKKUL[8^K90[.J!;<-%R9 VW1?%&N,,1O-@-\KY]L,5;2UP71R+2#Y
M1A>GD#4["7Q14H5A.4H_8#XIR<D7OU[/39QUN+X5K#1&X^D*8\4OC0[@4]5]
MMW):?4W6W#&[DBBVREUB*W^)*IA8ILUK*HH1I"V'E!M% 44A5M6U9NG4PA*5
ML8/;Z[.UDN]UQ,25-O0OD)OVP^@?)0KK\76_,,6JGPE3RTX!6=X1=PIY^C5U
M,UE3 E)>$4BACDZ;(6B:QIT*=X"9H8A(32M!U\+UW$FLQ,XOW/0OPTNCU,:S
M'8$FD_DVD,HD50TBY29;W<L6'5:_/\BCJM\>))S=\VG+^>9%KB(T2A2$>_5O
M.0?D_.UO*S[G?'3Y*+^9;IN2T[WM!8M)NBNZ*;H=G\=UQW2YMG$OUQR>R;1B
M=I)FR.3B<L;;&I.SDPMJ:#SB7%P>"TS0GUL@*I22 6M[E:TF=>DF<^*L\MZ
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M:)J3M26RYK:I\R5@G7)GZZ.@)')E#7#VY!+HO#&!0B<!&H6\PEW<0DB(*/\
M0&JNL^ZVSMX*PF>0:\;'\5?(TJ;;L?T/1=4^37F+B+I6>0F4)AK)^MA?0+=
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M6!RCQA\PS2U9=:4H0RQZU9O'J;B*X*^6.K2*O+>IQM4C4,#C.6HM@+>#;"C
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M3#"JM4<+U!3O"Z7Q]1=YGZNE$=*36ARGQZ>F=78VX;.VN1-+PM&^I8\A9-R
MA-)E&TY^FS1(!A!L1(]:WH1J[6[<KW1BQ>+KFQ@EO,4Q3++"6+>8N39#Q(B;
M'-\8EC%<O.DCC37'%$(O)LW&"P2XI"8U!<$HD0FH)3@<:/8!%C^%H<[U];E
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MLD<6=XDC1&V$;$RKFYA8-EQEI:HJD*1E* J5( A%\0\S>]>@VVN]S>Z]&&3
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M=8_9W-<8=K6Z3\PB.T+0YN-63*WI>]:BO.(GA9.V((Y#S38+A UC>IG!1#6
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MDY4_@=Y)_4)7_P"C3_ZUC)RI_ [R3^H2O_T:?_6L9.5/X'>2?U"5_P#HT_\
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MDY4_@=Y)_4)7_P"C3_ZUC)RI_ [R3^H2O_T:?_6L9.5/X'>2?U"5_P#HT_\
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M][\OE&S-AR,!@,!@,!@5,Y:_^_G6/^K.<_\ R\JK#6WA\%L\,F P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MOH=RT49(QDG[L$]T/$(HT(R6[W^B ";6@ZT.5_7HZ>!^/;DZK9'7TIK:O9#
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MY,?UI<*_L$O_ /YD<'V>I]"\F/ZTN%?V"7__ ,R.#[/4^A>3']:7"O[!+_\
M^9'!]GJ?0O)C^M+A7]@E_P#_ #(X/L]3Z%Y,?UI<*_L$O_\ YD<'V>I]"\F/
MZTN%?V"7_P#\R.#[/4^A>3']:7"O[!+_ /\ F1P?9ZGT+R8_K2X5_8)?_P#S
M(X/L]3Z%Y,?UI<*_L$O_ /YD<'V>I]"\F/ZTN%?V"7__ ,R.#[/4^A>3']:7
M"O[!+_\ ^9'!]GJ?0O)C^M+A7]@E_P#_ #(X/L]3Z%Y,?UI<*_L$O_\ YD<'
MV>I]"\F/ZTN%?V"7_P#\R.#[/4^A>3']:7"O[!+_ /\ F1P?9ZGT+R8_K2X5
M_8)?_P#S(X/L]3Z%Y,?UI<*_L$O_ /YD<'V>I]"\F/ZTN%?V"7__ ,R.#[/4
M^A>3']:7"O[!+_\ ^9'!]GJ?0O)C^M+A7]@E_P#_ #(X/L]3Z%Y,?UI<*_L$
MO_\ YD<'V>I]"\F/ZTN%?V"7_P#\R.#[/4^A>3']:7"O[!+_ /\ F1P?9ZGT
M+R8_K2X5_8)?_P#S(X/L]3Z%Y,?UI<*_L$O_ /YD<'V>I]"\F/ZTN%?V"7__
M ,R.#[/4^A>3']:7"O[!+_\ ^9'!]GJ?0O)C^M+A7]@E_P#_ #(X/L]3Z%Y,
M?UI<*_L$O_\ YD<'V>JP%+HNBD3>^AZ'DM*R1U,7)11DZEX1.82WI6S286EQ
M3ZGG%@V I7KC%GH(HQ.:F+ 7ZA$ 0OSL)<>":L(JA47^:+K[_P"'G_\ ^7SK
MD\6K^,6ORLF P& P& P-9GPS_P#5E_$$?ZDZB_W[CPZ^Y^&OP_9LS8<C 8#
M8# UF?PLW^2SJ?\ [A'0O_!*YPZ^]^7RC9FPY& P& P& P*F<M?_ '\ZQ_U9
MSG_Y>55AK;P^"V>&3 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8%4*B_S1=??_  \__P#R^=<GBU?QBU^5DP& P& P&!K,^&?_
M *LOX@C_ %)U%_OW'AU]S\-?A^S9FPY& P& P&!K,_A9O\EG4_\ W".A?^"5
MSAU][\OE&S-AR,!@,!@,!@5,Y:_^_G6/^K.<_P#R\JK#6WA\%L\,F P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M# 8# 8&LS^%F_P EG4__ '".A?\ @E<X=?>_+Y1LS8<C 8# 8# 8# 8# 8#
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MQKI+([1YXKNK7FTAV5$7Y"BCLW>V)F02!O3.LH50-J3N3NRH"UHROD5>QN*
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M/"8KULP8GAR0 1G%[_, 3_2!_/UK"2X0G)>"44EF)#^IN*8ACQ-FN5L$P\Q
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M"_\ !*YPZ^]^7RC9FPY& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M[I8BO!5[<IV-Q%;%?\)V+UE3L3XNZ$Y?<.=[FM3F9TMSG^9W)>3I;+4_2ER
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ML!"G N3;]#$^SA(S=!]VORB+%K_:'?H=?>_*7TC9MPY& P& P& P& P& P&
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G,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g563018g83b21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g563018g83b21.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X65^:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM
M<#I#<F5A=&]R5&]O;#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I
M/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR
M,#$X+3 T+3$X5#$S.C$P.C W*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @
M(" @(" @/'AM<#I-971A9&%T841A=&4^,C Q."TP-"TQ.%0Q,SHQ,#HP-RLP
M-3HS,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$
M871E/C(P,3@M,#0M,3A4,3,Z,3 Z,#<K,#4Z,S \+WAM<#I-;V1I9GE$871E
M/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z
M06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V
M/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH
M96EG:'0^,3<V/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%
M05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!
M04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!
M04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#
M=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(
M>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&8O.$%!15%G07-!14%!=T52)B-X03M!04E205%-4D%F
M+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%
M04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!
M0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC6455
M37!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#
M3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT
M+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD
M-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ
M8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!
M341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C13
M3D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG
M6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E7
M5G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A9
M84AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+
M;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E,-F)P=6Y(5')5;3%H2DU-
M9%0V)B-X03MA+WEJ,GA612]O>E1F*U=32"]K5W8Y359D*VI.3B\U6DEF.$%K
M5W8Y359D*VI.3B\U6DEF*U)A+S!X5C,V33 S+VQK:"]W0U)A+S!X)B-X03M6
M3')R579*9'!C=F$S5C%P='9D4FM"-$I:245K57-9,55&5TE)<5HT=U X05A8
M*UE9<6],-6<O3#$V.&13,&AQ2TA.2C=9+T-Z1E90)B-X03LR=6A:4T(W:D96
M<BM:4'DU4C)2.54P9%A65F1L33EQ0T5K45-)>$A,;WE-1T(W9S%X5DPO041&
M9C9.9&%81$YO1W(V4F)G6$9,:35-)B-X03LQ<7%T1VI#1U-/3U8T<G%.6$4X
M,%-M<V)B:TQS5T)X5FA$>&5F=G(K;$903U!L;C9T95A-4RMH+V]O939I6F)A
M57)B2#9S,WAU:VA:)B-X03M".%9%;%1D:E)Y5E%4-FPU-75964Q85%!/9FLR
M-&US-'):.5)U4F-7,W%U.&%Y0S4U>')A>6]I4$Q-:4)H5&%.5#A*9&Q!5D4V
M5F0K)B-X03MA<$=T-#5F4%!L839K*T)*5FEK<VU,4V5L14=50F)C5C500F-L
M96A&461W:%%L561E+S1N9E)R5G)(>F@U9$TY=%DK;G%..#5S,6IA)B-X03LY
M;%<U4TM9,'0U1D-.2W%C9&PO=35"4C8O0W%M56PP,FUV<D5/;RMA3D1-3%%W
M,C%N4%!,6E<P.6Q.0D-9<GEE4F9Q-U)U-75P679G)B-X03MC8U%#0E%D1U93
M:E12-2MT<FTR=4PW>D@U6G9D3W4W;$E35VYT-'AZ:G0R4S=T-V)H67)Y9$QH
M;6M8:S=-06EQ,U9Y5E91>2M:3&)Y)B-X03LW83)/<"MB=DQL=C5K=&]B*S-V
M-V]3,F%+,3=)-T-W6FMK=&%5:3E'5EI)=VE%;&$Q4$9L=TLS95=(-6AJ5D=J
M:3AZ95AO<F52959V)B-X03MA=CA!5FA/2'1P24)E07-B4F<V271T9$1:055:
M=FER>$A%<3%,8RMB-W)4-VAR4'I"-5EJ<S1B9E5N1W)X,U9V231:<$9N<W!:
M06)))B-X03MW2VQV1DQ"2$PO37-N3W9)<&=63&18;3AY4C9->C)F-6IE6$QE
M*VI,<6MT,"MM1TIU8R]Q,FYQ4T,P5VAK<UAB;GA49&M1<CA,3FEQ)B-X03MB
M=&-A;DIQ=')C>&5C9DPV-E1Q33A,,F-(<3)$;5,S9U=&8G=7-V96:#9P.5),
M;&9T9#!.531S<D950TY9,35,5%)$8F5B9DMD-$Q7)B-X03M#2S0X=UA%.3=:
M;V)H=G)C87DK:UER36]K2$-.;U5B:4<U4T=V>$E+:%58<G1L-3185FYV1C@P
M849P;FQZ56)I,6XP;T8W3DIF<5)I)B-X03LT5&E+4V5X;5-1=E!.0U50>&)%
M0W9X1$-Q6$Y(-3=B5%DR<V902&QY-'4T<G4Q9W5:2EAS4%--,S%5+U=,5&Q(
M6F9#-UA%8E!'2V,K)B-X03M',GA8-&Q78F55=%8P2T126EID9CAW84IQ531N
M95%8:T5T;W-35SAZ33%T1U-I>$PO9'%D>5!I;U1G5DYM.'DO;'=S8V-J87)O
M-&IM)B-X03M74U-&>F-7;U8P:4A+4FQ03&-)3C))-F0X5F)0;4PX=7=/4C%0
M4T%V<&UA<&YT<65K23!M3"]A*WHV57%06'!X64AO4FEQ>B]!0E8K)B-X03M7
M9D%Y9G!J4F9457AH;BMS,G1!6E9,>&=N;"LR9S5,-&IC67%N=C9-,#,O;&MH
M+S5&<B]41EAF;WI49BM74T@O04I&<B]41EAF;WI4)B-X03MF*U=32"]K5W8Y
M359D*VI.3B\U6DEF.$%K5W8Y3591,G!A8G!W,#8V271945)$2E$K;78X<#ES
M5E)/;68X8S(P+W=#34UF.$%X15EQ)B-X03MI8U9D:7)S5F1I<D1R=CA!2T@X
M=F)V5T@Q:38P='!T4V4V*W8O5UAU<G1I='E'5B]544=8:6TV2TM+04]+:&9S
M9T1&5C!F-5-F;#-')B-X03MQ<6UJ;W))<V%*2TI:+U9665-H:4-Y*W V9S1E
M:DAX;S)W5E%.9TU65C,O3$AY4$I,2DQ*<'AD-59G4BM6>&-K571V<7AI;T1*
M4E0O)B-X03M!3&HW9FM2=3-!8W$W,5956"]+6#AV,VTY5G1,2E!P6$5"5#9Z
M9&5M579#>'5+>"MR=TIK6BM266ET47!R5E9O<7%1+VQF-4MG,6HY)B-X03M,
M=S)C.&0Y.6%&*T=7.7921TQH4GA$:45496M+2BLW<'AP=RM#;D0T8U95-5!Y
M;CAH4V%O9%9B5&XO4T),15A!=7)S34,Y,F(T;&%3)B-X03MG02]7;4UO239.
M,'A64D@U3F9L<C9T-TQ*;W%Z=G%59VYV:F-4,TTO<7EH,FLU<TI:2$A,;DEX
M<C<T<7%Y9FQ.-4)K16]K,#92>$UR)B-X03M*34=U-W-H=S=4335A<S(W36)U
M64TS56E2=U12:4U68G9F>6XX:%AT>%!C6$=N3UIR;'!(;%I,<3=J*TM7-5,X
M8W%%;%5*5S1J5U0T)B-X03MA8C1Q<C)V-6$K5#=:9E17>F0W9&(S.4IW,CAS
M.#!K8U8S54U:63%:>GA*8V-V;5-E*TMP96XU3&9L<W%U4#!823-Q1FUK6C<R
M*V1M)B-X03LU<DMJ9W,P-4I$<F-Y.&@P8FUX3S5X5E9S9GEJ.&M71C=$9#)6
M=%!#,%144$EJ6$TX=VQA94M72FI),#=Y>5956$UP57%W;WIS97)()B-X03M&
M54YA+VMD*U=&;TI6=&1)94-/84]A1U=+3SAV5FI-9'I'27!L-$-F:BLX4E%'
M,C=!.5%-5E8W6#AN9GDY=$QQ0S9T9%!N9VYT;F=K)B-X03MG6DPK+U5+.7!$
M.5AG8FE**TY5:2M!16IP.#A64G-N-6%E4TI9=$MI;3!W4W@V2D-,8E-K:VUN
M8U%X0FMC04)N3E-':5-J3E5I9S-X)B-X03M63%EF>5(O3$M";F5(4UAJ95<Q
M1FI+-C-L-D=E,490,TQN,7%U;D9&5VIF<VIJ.6YB1E5:9"]L6#5,=FUT;3%+
M,G5.4F$P:&4Q9TXS)B-X03ME6&-W*W)Y4T=1>$]R4VQ:1G%W*S)#9FA7<%!%
M55984F9L6C5%:35C3DY)3%AA86A8-GAC,49X1DI*3$=Y;C%F:$-Y6$5J0D(X
M24Q%)B-X03LP,WA65S O.'502T=N86)A-EI9,FLQ=EI736YR5TU36&0R4%%K
M2U-)>E).-G9*3V%Z>4(K2BM,:V568U91378U3R]L>$Q(1$<K:U93)B-X03LS
M:6UG:$@Q;39(1T\U9U<R;%=O;')V0D=S63A&04%O0FEQ26LO2WIY2DMK:50V
M85HO5E-33C-L=4QM4BM-=&]T:3E(959M571B4G)')B-X03M31%=G.&0X5E%S
M6#5-+VQZ1$ID4U$V8DY$2F5Y4E188G@S,3AJ4WEW171(23578T5U<FYN>38X
M+VHK,79I<DYC5F1I<G-69&EQ1S%0)B-X03LO:FTS9B]'1U0O:4IX5C)M9CAC
M,C O-'=X+SA!15)I<4IX5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R)B-X03M+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+;V)5+RM/8F0O.%E:4"M);D9885HO>'IB5"]J1$@O=T%21TMS3S%(.'8O
M3DXS)B-X03MQ.3-D=RMC8C(P<W)M-$TX9&Q%<FXP;#57>G%I3UIT9T1B3TMC
M94I%:$9/=DI63G1),#-6<E)B3%)P.6%U8F@W1%1R6DIR=W)%6DHU)B-X03MK
M<D<X>FU62FUQ+T1K87-F;6-65%@Y1UAV+U8R=78X06=B6"]!2V]9<3<Y1UAV
M.$$Q9')R+V=B6"]Q:&ER=C!:92\X058R=78K0G1F)B-X03LK<4=+=2]2;#<O
M,61R<B]G8E@O<6AI<G8P6F4O.5AA-B]W0T)T9CA!<6AI<G8P6F4O=T16,G5V
M*T)T9BMQ1TMU+U)L-R]W0EAA-B\T)B-X03M',2\V;UEQ-SE'6'8O5C)U=BM"
M=&8K<4=+=2]2;#<O,61R<B]!24<Q+W=#<4=+=2]2;#<O04Y8838O-$<Q+S9O
M67$W.4=8=B]!1F1R)B-X03MR+V=B6"]Q:&ER=C!:92\Y6&$V+S1',2\V;UEQ
M-SE'6'8O5C)U=CA!9V)8+T%+;UEQ-SE'6'8X03%D<G(O9V)8+W%H:7)V,%IE
M+SA!)B-X03M6,G5V*T)T9BMQ1TMU+U)L-R\Q9')R+V=B6"]Q:&ER=C!:92\Y
M6&$V+W=#0G1F.$%Q:&ER=C!:92]W1%8R=78K0G1F*W%'2W4O4FPW)B-X03LO
M=T)8838O-$<Q+S9O67$W.4=8=B]6,G5V*T)T9BMQ1TMU+U)L-R\Q9')R+T%)
M1S$O=T-Q1TMU+U)L-R]!3EAA-B\T1S$O-F]9<3<Y)B-X03M'6'8O049D<G(O
M9V)8+W%H:7)V,%IE+SE8838O-$<Q+S9O67$W.4=8=B]6,G5V.$%G8E@O04MO
M67$W.4=8=CA!,61R<B]G8E@O<6AI)B-X03MR=C!:92\X058R=78K0G1F*W%'
M2W4P<#=J,4PV0V5D<FHV=&-#3T]344E'-&U#2U-H.4Y56#=4;G1I<71Q9CA!
M>'IB=B]J1$HO=T%2)B-X03M/2W4P>B]J;3)N+T='4#A!-&E-5EE4<D=K9FY.
M3'$X-S94<FUN,BML3F0K<$)(4$5(;%<R-5=X.4TP9R]L5S1(,G$W<CA89%95
M-C!.)B-X03M036-&>&%W-F\P1C5Q,&5L,FEA:F1)-6I34S15=4I84E)%0GA:
M-FMF0U!K3VU+<#4V;7!F-S1H+S5(3B\Q4WA6,W%A;"]V:4@O:V,S)B-X03LO
M5DQ&6&5P<5@K*TEF*U)Z9CE5<U9D-FUP9C<T:"\U2$XO,5-X5C-Q86PO=FE(
M+VMC,R]63$9897!Q6"LK268K4GIF.55S5F0V;7!F)B-X03LW-&@O-4A.+S%3
M>%8S<6%L+W9I2"]K8S,O5DQ&6&5P<5@K*TEF*U)Z9CE5<U9D-FUP9C<T:"\U
M2$XO,5-X5C-Q86PO=FE(+VMC,R]6)B-X03M,1EAE<'%8*RM)9BM2>F8Y57-6
M9#9M<&8W-&@O-4A.+S%3>%8S<6%L+W9I2"]K8S,O5DQ&6&5P<5@K*TEF*U)Z
M9CE5<U9D-FUP9C<T)B-X03MH+S5(3B\Q4WA6,W%A;"]V:4@O:V,S+U9,1EAE
M<'%8*RM)9BM2>F8Y57-69#9M<&8W-&@O-4A.+S%3>%8S<6%L+W9I2"]K8S,O
M5DQ&)B-X03M897!Q6"LK268K4GIF.55S5F0V;7!F-S1H+S5(3B\Q4WA6,W%A
M;"]V:4@O:V,S+U9,1EAE<'%8*RM)9BM2>F8Y57-69#9M<&8W-&@O)B-X03LU
M2$XO,5-X5C-Q86PO=FE(+VMC,R]63$9897!Q6"LK268K4GIF.55S5E$R:T=5
M,U=Q;5965B]R83%65TQ$+V571'51=C9S5E)/<"\X)B-X03MC,C<O04]-36XO
M151I<G1-+W=#3V)A9CA962\K26I&5TDV:#4Y.'DR,G!8=&YB*U5R>3=J=&)G
M=U)816)30EIK1%=W.5)3665/-EA-)B-X03MJ1#1Q9G5Y2SEW<6U7:#8S3&4S
M1G)F,W1J4' Y,65A6&%4>C)$>'EU.$1Y;#-A2GE%2'A)5'A.440T9V1-5E1Z
M.4E19GE49CAI2G8K)B-X03MA359D*VM)4#5*=BM213,O0412:7)V,&A"+TI.
M+W=!:4IV.$%M:D989G!#1"M38B]!2D549C@P67$W.4E19GE49CAI2G8K84U6
M9"MK)B-X03M)4#5*=BM213,O3D=+=2]314@X:S,O26EB+VUJ1EAF<$-$*U-B
M+VM23B]Z4FER=C!H0B]*3B]Y26TO-6]X5C,V46<O:VTO-4549CA!)B-X03M.
M1TMU+U-%2#AK,R]!0TEM+W=#84U69"MK25 U2G8X06M23B]Z4FER=C!H0B]*
M3B]Y26TO-6]X5C,V46<O:VTO-4549C@P67$W.4E1)B-X03MF>51F.&E*=BMA
M359D*VM)4#5*=BM213,O3D=+=2]314@X:S,O26EB+VUJ1EAF<$-$*U-B+VM2
M3B]W03!9<3<Y25%F>51F.$%):6(O)B-X03M!2F]X5C,V46<O:VTO=T-213,O
M3D=+=2]314@X:S,O26EB+VUJ1EAF<$-$*U-B+VM23B]Z4FER=C!H0B]*3B]Y
M26TO-6]X5C,V46<O)B-X03MK;2\U151F.#!9<3<Y25%F>51F.&E*=BMA359D
M*VM)4#5*=BM213,O0412:7)V,&A"+TI.+W=!:4IV.$%M:D953G!%<7E85W%U
M;UE!)B-X03LS83=-<DEF.3593WI!2$955'%F+T%">F)V+VI$2B]X131Q-U10
M*T]B868X04='4"]!26E-5EDO<5@U;BM29$UV2F)/+S%28F$T:&Y.)B-X03MR
M26IX5&=#64=&4V]B:'A.4')5931.2T=V44=I<4DP>E@Y1G8Y4FDQ1S%V23-S
M-S-4<F$T=%I74' X;W!79#!B:2]&:%94,$ER:7%C)B-X03MF<%!49BM7=4@O
M:UEV.6-69"MK.4XO-6$T9CA!:UEV.6-69"MK.4XO-6$T9BM2:2\Q>%8S-E0P
M,R]L<F@O=T-2:2\Q>%8S-E0P,R]L)B-X03MR:"\U1TPO6$989G!05&8K5W5(
M+T%*1TPO6$989G!05&8K5W5(+VM9=CEC5F0K:SE.+S5A-&8X06M9=CEC5F0K
M:SE.+S5A-&8K4FDO)B-X03LQ>%8S-E0P,R]L<F@O=T-2:2\Q>%8S-E0P,R]L
M<F@O-4=,+UA&6&9P4%1F*U=U2"]!2D=,+UA&6&9P4%1F*U=U2"]K678Y8U9D
M*VLY)B-X03M.+S5A-&8X06M9=CEC5F0K:SE.+S5A-&8K4FDO,7A6,S94,#,O
M;')H+W=#4FDO,7A6,S94,#,O;')H+S5'3"]81EAF<%!49BM7=4@O)B-X03M!
M2D=,+UA&6&9P4%1F*U=U2"]K678Y8U9D*VLY3B\U831F.$%K678Y8U9D*VLY
M3B\U831F*U)I+S%X5C,V5# S+VQR:"]W0U)I+S%X)B-X03M6,S94,#,O;')H
M+S5'3"]81EAF<%!49BM7=4@O04I'3"]81EAF<%!49BM7=4@O:UEV.6-69"MK
M.4XO-6$T9CA!:UEV.6-69"MK.4XO)B-X03LU831F*U)I+S%X5D1A4DQ&3&1A
M<3A4<DEH=3%O>6M%8E=S2&-9<6ED5"\T-70S+WAH:R\T:6-69'!N+TA.=% K
M34UF+T%"15EQ:%IF)B-X03M++VQQ8653-&TP;7IL;FUK13!S<C(X5$\P;TM%
M3WI&86QG65EZ6"]*6'='2W),2S%T<E175&$R<U-7.7)B,D5%545%4VA),&I2
M-496)B-X03M%5F%"5E5#9T%X5DYS5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I)B-X03MR
M<U911VUF-S(V="]Z1DPO04Y1<T=+<3)P+SA!2$YU+RM-36XO151I<G1-+S0U
M=' O=T%962\X06E)>%9H=6]F:S<U8W8Y879T56YV)B-X03M,,$YF>F972F)E
M3F]%:E=4;F)Y5E)X1#9W*T]Z:E X065E4&9&53(P4'DU63948U=U:U<X:S=7
M,FTV6&%7:T1V331C<$%8:E5V=TM,)B-X03MY;W4Y04(W67%N;C909R]N;2\U
M2'IF.$%.94MU+U(X2#@X,R]!0U!M+W=#83A69"MJ-% U-78X06MF3B]Z6&ER
M=C!F0B]03B]Y4&TO)B-X03LU<GA6,S909R]N;2\U2'IF.#$T<3<Y2'=F>GIF
M.&HU=BMA.%9D*VHT4#4U=BM2.#,O3F5+=2]2.$@X.#,O22MB+VUV1EAF;RM$
M*V5B)B-X03LO:V9.+W=!,31Q-SE(=V9Z>F8X04DK8B]!2G)X5C,V4&<O;FTO
M=T-2.#,O3F5+=2]2.$@X.#,O22MB+VUV1EAF;RM$*V5B+VMF3B]Z)B-X03M8
M:7)V,&9"+U!.+WE0;2\U<GA6,S909R]N;2\U2'IF.#$T<3<Y2'=F>GIF.&HU
M=BMA.%9D*VHT4#4U=BM2.#,O0418:7)V,&9"+U!.)B-X03LO=T%J-78X06UV
M1EAF;RM$*V5B+T%*2'IF.#$T<3<Y2'=F>GIF.&HU=BMA.%9D*VHT4#4U=BM2
M.#,O3F5+=2]2.$@X.#,O22MB+VUV)B-X03M&6&9O*T0K96(O:V9.+WI8:7)V
M,&9"+U!.+WE0;2\U<GA6,S909R]N;2\U2'IF.$%.94MU+U(X2#@X,R]!0U!M
M+W=#83A69"MJ-% U)B-X03LU=CA!:V9.+WI8:7%',&E*63=R5E55<U%,=&0R
M6FY0*SAS2&1I5&EQ2C%0+T%)-70S+WAH:R\T:6-69'!N+TA.=% X06I$2"]!
M35)')B-X03M+<TDQ9CAU=DXQ.7)6,64R,VY3.'-,3V4U5S1I=$E6;4IJ45!B
M<S!)6G)J,"M"*W)S0E-)9F)05F%Q5E4W,%!43E8P-C1T9%!L,4@V)B-X03LY
M8U=E;#)K13DY8U)S,',W>$8P858O,VQA=5)Y3E-4-VYR:7%E96YQ6"LO-&8K
M4DQF.59C5F0V97!F-R]!268K4DQF.59C5F0V97!F)B-X03LW+V@O-45T+S%6
M>%8S<#9L+W8X06@O-45T+S%6>%8S<#9L+W8K2"]K4S,O5EA&6&5N<5@K+W=#
M2"]K4S,O5EA&6&5N<5@K+S1F*U),)B-X03MF.59C5F0V97!F-R]!268K4DQF
M.59C5F0V97!F-R]H+S5%="\Q5GA6,W V;"]V.$%H+S5%="\Q5GA6,W V;"]V
M*T@O:U,S+U981EAE)B-X03MN<5@K+W=#2"]K4S,O5EA&6&5N<5@K+S1F*U),
M9CE68U9D-F5P9C<O04EF*U),9CE68U9D-F5P9C<O:"\U170O,59X5C-P-FPO
M=CA!)B-X03MH+S5%="\Q5GA64W1P-VDV:3EA,79B865(:WEE<$9'6%AL1WA2
M,7%S<$966E-P.$-+67%Q*VYQ6"LO-&8K4DQF.59C5F0V97!F-R]H)B-X03LO
M=T-23&8X05981EAE;G%8*R\T9BM23&8Y5F-69#9E<&8W+V@O=T-23&8X0598
M1E9+-'5*-V-X:31V<E=%>D])-%)):%AM-3-#<E=5)B-X03M64'--5E<S1C%,
M8D5#-'8W4T5T44M*14MK:S%P4W-O+VQ/2W%1,4M6;4%J=49L1$YX1'A7:SAI
M5C(O8E(R5VYX9&$O<4]+=5<V,7@Q)B-X03M":G0V1FQ*47E2;VEG9T5Q1W!C
M338Q;T(Y:S!R.#9+=&=E6C))0F%Y:4)!2F9J3$I1,3-(0W-D9F@W.'-69$I:
M95E:45%D56EH<4%+)B-X03MW5W1$541C+W9:2FAU9F(K=4MP1C5".'$S3VAA
M<#5Q;6XQ3UA55'%7<4YD0EI&-&E(,4DQ;#1*.%0O0U!6-&HU67%Y:E4O.$%J
M;3-F)B-X03LO1T=4+VE*>%8R;68X8S(P+W=#34UF.$%X15EQ>$\O,5@X,49V
M<BM/>#!E>FQT63=O3' X,')"4DIB8W)C;&YP4'DU1EAN2#)"47%0)B-X03MH
M4%%Q<&AO9#=R:C-&<DQQ.6@V5W)Y85AA4'%-1G4P6FEJ=4=,;59%3%-(6EAQ
M0CA2*UHV-'%N;C%U9B]!2EEP=G9H+S9Q67$W-C-0)B-X03LO=T%S53,S=R]W
M1%941EAF5S4O*U=+8C<T9CA!<7!I<G9R8R\O3$9..3A0+T%&57A64G9.5U-Y
M=$HW>3=T-4E,5S)J86$T;FME0E53)B-X03M/3E-Z=7A-;7=64E4T<6=D4#@V
M84IQ5FA&9C)%9W5B4UI056EK:FMG67-G<E5H4DIY+UI08D969B]%9'1Y2VDS
M;4I7:&%V<$M!1TEO)B-X03M3>E-"84=T4G9V,GA68V1A=4]*-&%89#AG46\U
M0U!J56EV,FMD.79C06I&5W8P=&9U448P*UI+<U9$1E$S46YQ0S!D0E1I83$X
M4C)X)B-X03M6<UAM<DU!2'-R:$$Q86Q"8D)H4VQ0=%A%9S-O93-F=&ER1'9-
M03@K4V5F=DQ5.6I:86A*;U5-5C!U<&<S3G)$1GEM:DMR-G%25EIY)B-X03M#
M1DMK3CA*-EE66FHV=6]G;&AP,'!)-&Q18FM53%9"64@T=6=0,S1&85IR-FA5
M869.>#)52#8Q43AA54HK,W-F.75U2W0K<&5M448Y)B-X03M.:UIE6DHU5&]W
M07)53GA,57)V,#=E3TMT03-.1G)O>3%O45)Z:$Y!04%O2"]!9UEQ-&TU4%A2
M;$I)2DY8:"LQ53=F3#1J=C=N1E=,)B-X03LO;#-:-C5:95A79S%(>61B84AC
M0V52,'-,931H;6I037%X8W5(:V]727(Q-FI#<DIY;'EW86UM2D=+9T%C25I0
M:&]182]V62MV3"]/)B-X03MU=U9S4C-(24@V9T(X9%132T=V1V].2RMT,3(V
M+VAI<3!79$9!*W%Z;6=92#1,3&9K2T-V*W%/;C0Q>%9D.51H2D13869/.&Q+
M1BM5)B-X03M+12]&>7)33U)&<EAV4W5+<$8U;"],+WDS-6EM,#)8571,=6UB
M4W!K=4Q656UJ0S@T=V]8;7!L25E5459R,7A6:VM*5T%U661.94EY)B-X03M'
M<FQ"079)*TIP2G8Q>%96*W1Z+T%03$9..3A0+U941EAF5S4O=T1L:6TK*T@O
M<7!I<G9R8R\X07EX5&9F1"\Q57A6,S%U9B]!2EEP)B-X03MV=F@O-G%9<6AT
M261N=7166F\R:E Q=&9G8FE4+W9,0B]+5T@T-'%I9%0O-#5T,R]!35E:4"M)
M;D9885HO=T%C,C O-'=X+SA21TMS)B-X03M0,6(X-&9,3VPS,3-:6$YT9DY.
M6C-Q-F9*-E534T%Y<S!#:&=&:TQC9CE,5'%!96]!2F]#<6=D3R]/1'E:9&5A
M<F5"<$QI,FQV.4AT)B-X03M,*TE3=W1267 O,WEH>D@V9T1C6E9R*WHW-%9:
M4&$K9'1+=FE6,#5*8G1U2EIF5$,Y44-61$-V3F582"M8=CA!4$=L4F)A;'%,
M2&ES)B-X03M#=VIB.319-VU8=G5/2'!29'4O3$%R:E!D4%536%5S67%/2F=S
M-49.3U!X5CE66F=F:3-&04YT="MU2W4T,G)0>FUL=G!71&-L*T<T)B-X03MJ
M04<Y1C1W<D=P07(K,$1I<6QC-F(U8W4W4V$P=3="<FU#-&IK:&U%.7902WIX
M>6II-FPS5FXK264K2W%M:E=U:#9,<'-/;6%66G9:)B-X03LR1G9543(P5G9-
M15AK>%DP*TAU>D4T<6IF,&A"+TI.+WE);2\U;WA6,S919R]K;2\U151F.#!9
M<3<Y25%F>51F.&E*=BMA359D*VM))B-X03M0-4IV*U)%,R].1TMU+U-%2#AK
M,R]):6(O;6I&6&9P0T0K4V(O:U).+W=!,%EQ-SE)469Y5&8X04EI8B]!2F]X
M5C,V46<O:VTO=T-2)B-X03M%,R].1TMU+U-%2#AK,R]):6(O;6I&6&9P0T0K
M4V(O:U).+WI2:7)V,&A"+TI.+WE);2\U;WA6,S919R]K;2\U151F.#!9<3<Y
M25%F)B-X03MY5&8X:4IV*V%-5F0K:TE0-4IV*U)%,R]!1%)I<G8P:$(O2DXO
M=T%I2G8X06UJ1EAF<$-$*U-B+T%*151F.#!9<3<Y25%F>51F.&E*)B-X03MV
M*V%-5F0K:TE0-4IV*U)%,R].1TMU+U-%2#AK,R]):6(O;6I&6&9P0T0K4V(O
M:U).+WI2:7)V,&A"+TI.+WE);2\U;WA61&%22W-L)B-X03LQ<7)Q1T%.,G5Z
M2WE(+V571'-W0GA6139N+WAZ8G8X031W>68X4D]+=3!Z+T%)-71P+WAH:B\T
M:4U657(W6&1#,#8T:G0W+U5B5WIU)B-X03M*9T1&1E!.2$4W:&Y734968V=M
M<G-Q+TUG67%G-TDV9&1A*V12=$1$3VQX<#A$=UAK6$9X2D4W=7ES:VDQ-4MW
M;U%184A&57IU.5!S)B-X03M,,5%L-6)26$M$;W-Y3$E0=5E(1E5(+VAR4D9.
M64QB-F]E-71(93%R."]184]U2W4O46I2+W=#.'5O,W1U=F1F5D9X6#9B<%IZ
M.7AX)B-X03M6,S%,6&\O:&@Q3T]69C5R<3)%:B]F0DIB3"]W=4MQ9'I0-7)G
M=#57:'1,3R]L4D=A24-E4S%,<T)S=D9O-7=/6'4O.6-654Y(,6YZ)B-X03M2
M8V%883-/<&%!8D\X:VI6<FUZ:G596E=J63E61$AG<"LO1E5:*VQB+W=$-G,Q
M-2]W9&XO04YL1TMU+U-T+SA!.5=A."]W0T1S+SA!)B-X03MS;WA6,S9D44-S
M;&IE>'(K,&916C9F4DAZ62]1359D+VE#=R\S,65F.4E.-2]W0E5S5E%&,34U
M,&TR,65X,'0W6%57;3%!4W1&271H)B-X03MD96UV;TM'8FU41T1V6&%G3TMO
M-SE.=$HO=DYP,3=C1'@Y25%F:&1.06-69"MK3EIK,F<P;WAN>'4U-&]X+WE1
M*W-N.$U68U@X>7E')B-X03MG:7-R568W.#E35S4X4#)/1G0O>$Q&6&964$U$
M:FI*<4U#3"]!1%%7<%8K;FI,3DUV+T,T<3,K:4QT='!.6'9(43E6<&)*-R]!
M1V\T)B-X03M%8C=J:7%884HU4W9D0G-286%B<F0S8THV:VMH+U-P1C=5>758
M8C1H-D5U>$\S-WEN=%AF1E5D*VMT671Q0SDP,'EP,VYS6D)-04(Q)B-X03M,
M4GE#1U%F-G%".%96-U!83DMV2F91:'5&1GI1;C9R24=I;D%(56U'44I)0C@Q
M>%9(67$W1EA9<3=&6%EQ-T97<$I%:E)N:UE):6ER)B-X03M->&]!0C-*3TMP
M669-,FES85<Y=V(Q=31S:VMU<4AW67=,248O=T)L5$950C52,64X,4LX,3@S
M3VU81VUI1%505&@K<SA+>6]T=$-")B-X03M);U9M;T=!<G8T*TY11E4V,5 X
M030U=#,O=T%96E X06E*>%8R;68X8S(P+S1W>"\X4D=+<&)R=FMR>7AR,35$
M96%V6D,W;G0T>D1%)B-X03M795%+16%22E-#:7-&4'AX2V1X-V1#8U959$TP
M1%)B1%59=$]T8D].3$]Y,#8R=#=72F@V;D=+2FY21C50>5DP5613831Q;D@V
M33 S)B-X03LO;&MH+W=#4F$O,'A6,S9-,#,O;&MH+S5&<B]41EAF;WI49BM7
M4T@O04I&<B]41EAF;WI49BM74T@O:U=V.4U69"MJ3DXO-5I)9CA!)B-X03MK
M5W8Y359D*VI.3B\U6DEF*U)A+S!X5C,V33 S+VQK:"]W0U)A+S!X5C,V33 S
M+VQK:"\U1G(O5$989F]Z5&8K5U-(+T%*1G(O5$98)B-X03MF;WI49BM74T@O
M:U=V.4U69"MJ3DXO-5I)9CA!:U=V.4U69"MJ3DXO-5I)9BM282\P>%8S-DTP
M,R]L:V@O=T-282\P>%8S-DTP,R]L)B-X03MK:"\U1G(O5$989F]Z5&8K5U-(
M+T%*1G(O5$989F]Z5&8K5U-(+VM7=CE-5F0K:DY.+S5:268X06M7=CE-5F0K
M:DY.+S5:268K4F$O)B-X03LP>%93=4Y#,$\U:CE/-3 V,FUJ<EAH2D1'-'(X
M:41I<5@O-%!S25185#5(=&%B*VLT5S5I2C=!<D]*1U92-%)S;4MU1G)F,C%"
M8V%4)B-X03MA6#9D-6)-2D9)9D0Y>$]E04@O4%DO3$954&1E6F9)=&DQ=6UP
M=F(V6DQD4T-',VEV-&9Q>E!),S=+97%Q:"]$:W!+*RLT>%9%+UAD)B-X03M(
M:TE&;G!-=#1X,TA#,453165);'5"0D5W*U19<3<V;G%5-'!&<&1H6DLS,EI*
M+S,X:2\V,$UA;VXS5%EQ-R]#-&TO,W-U<6<O8FAT)B-X03M926)E36HR4$=3
M9&9M2F-65EEF2C-L:4DX:G!S33AG3E)*8V<S3&EN9SAX:UEF46-64B\V3# S
M+T%*6DEF*U)A9C!X5D1A4D9&1F1A)B-X03MQ:U-,1V=U,6]Q9T%B,G-(65EQ
M:614+S0U=#,O04U96E K26Y&6&%:+W=!8S(P+S1W>"\X4D=+<$0K66M--S9$
M1DI(<D4R:5)W6&QQ)B-X03LX.3%A=WHS13=Q6FQ26553,UI8+T%(:G5Q;7%U
M=%!T2U)I<58V2G%M9U%A2%E84RMB6DY3;'1R1WES<FTV9T5C.7A+-6M&<W-S
M,$)3)B-X03LU;E9P2C-O,TQD5W)Y3WAX5FMM;GAV<49H8E@Y<')&,CER9'A*
M4$$U:G0P3%)Y2T=5.%AT,5IA9SE#2S1Q:5 P6F4O.5AA-B\T1S$O)B-X03LV
M;UEQ-SE'6'8O5C)U=CA!9V)8+T%+;UEQ-SE'6'8X03%D<G(O9V)8+W%H:7%3
M,W5V-DY9-G8X06]M*SAY6$9P96M21F9R155%54I-)B-X03LU65))<S<R>7=S
M-VQ'-&](-4=N5$96,71R1VY486YB-E1&-6EU6C<K-'1X9%$K;D1!,&-K2EAK
M2E9L5S--6$9H=5!J,S=9<6Y(-DUV)B-X03MF*W)T9&8X04$R=B]!1E%X5C,V
M379F.$%Q-UA8+T$R=B]61$989F]Y.2\V=3$Q+W=.<B\Q47A61#9H1RMN,D9Z
M9C-E<UAA5W1N13@Y)B-X03MW-GA7-VQ9-&Q,=5%I5S=-,49(4E%38U9394AZ
M5#5F;71R:3=I.#%3;$Q/3S1K=3=1>#(T=3!&<4$X=DLQ3G5,9T9&,S0K;E5G
M9VIQ)B-X03M+<7!P<&-K5W$R<'4Y3S$R-75B65-3=VU6571Q97!"25EP1C-T
M>#EL,$EX5D=F;WDY+S9U,3$O=TYR+S%1>%8S-DUV9BMR=&1F.$1A)B-X03LO
M=T161$989F]Y.2\V=3$Q+W=!1&$O.$%61$95;C%R6$Y*,%,V:'1T5SAX6$YK
M,#AB5$Q.3$9#<T-X;WEO>E-82#%B,%EH>6M59D<T)B-X03LS27A68DIR=6MW
M,S%H65-E6EHU3&Y62DI9<D0P;W)E4DI(:4QH,#E33S-E349/0E9U5$1F8G%A
M67%N6#9-=F8K<G1D9CA$82\Y54U6)B-X03MD*VI,,R]Q-UA8+T$R=CA!,5%X
M5C,V379F*W)T9&8X04$R=B]!1E%X5C,V379F.$%Q-UA8+T$R=B]61$973%<R
M=BM53F1&=DEV;4YP)B-X03MP3&533S1T-V$W=#=A2S5$=$4P:U5K3G9C5WE4
M8VU3<%)L5&5H03<T5E1J4G(R>C%Q3U=84SEF=4QQ3T5O<W)O;'5!1$I'<W%I
M<'1X)B-X03MV=VM5;G<V2&9!<5DO;WDY+W=#<G1D9CA$82\Y54U69"MJ3#,O
M<3=86"]!,G8O5D1&6&9O>3DO-G4Q,2]W3G(O04Y53593=EA.4W,Y)B-X03M$
M5S-F5DYC=DE%=6YA3TM145)32T-I1U)I-U(R>FE.5E)#>%HV2T%/=4MQ54AM
M=GEP<'--='=D62]34UAF2SA.>&)O8G5Q4G@R>4AE)B-X03MZ:EI0<U1W<T)3
M<%9U5S1"3TMP+W%F.$%X>F)V+VI$2B]W05)/2W4P>B]J;3)N+T='4#A!-&E-
M5F)V.$%4=% Q1S!E>C%#,6EV3%-1)B-X03MQ6DQE-%):63)+34A5;$A"53A7
M54U08UEQ;#4X;2M51$8V4C!05'I&4VYP;3%G-#!Q>F1/3D]S:D@V5#0T<6UD
M<%HR;&QA>%=L;D)()B-X03MB5W-#:4]#,VA6630P4E)25E)&05910C!!>%96
M>%8R2W5X5DQR<GDU-65U-WAR-C8P=3!N=E=#2S$Q3$)%.'!%5&-O=UA:4S-W
M3G5U)B-X03LK>'A6=7DX=658<D-73V%X,'4P=%IO:TUC56M%16-B2VA.4W%L
M5D)#:VYP:7%967$W1EA9<7 S5G)B6&1T3&$S55-81G)C23!5.$5Q)B-X03MH
M-#-J8V-74C%A;UI70F]18U93=&9*=FQ"54UA-DAP-F]A,5%7<TE(>&-A-V-E
M+W!R.7<X35940W@P-U0W0TIO8D<Q:71);F0U6&IG)B-X03MJ5TY7:VM02C-)
M54%&;4\U4&9&55)I<G-69&EQ03%$>2]O3W!42E!Q3VTR=#=.1VI24GDS145C
M<DQ(2CET07IQ>$-T,TAF1E9S2&QR)B-X03MY-V(S0UA-1VQ78TYX1S=Y>'I2
M,CA3=7-K;7IU1T,Q1$XS4&9&57AX5C)+=7A6,DMP3$8U23AL>$EI4F%"<'-A
M4G1(2D=Q,FM!0W9%)B-X03M363)50DYI;%1X4&)T:7%0<TY),&Y4:$E.4'-O
M3$U41E1+3&5*275:4E%I;'5!1F5+9T%6-UEQ:3A69&ER<U91;6]A4'!'<$=%
M-FI9)B-X03LR.39B6B]5='IC4DI,-F)K535*>D(T;6AP55EQ:')F>70U671P
M4DYB-E):47I+14-Y4C(P4TU"2'@T045+1#A00F%E1D(T67%I.50O)B-X03M!
M3T]B9"\X04='5"]!26EC5F1P;B](3G10*TU-9B]%4FEQ2GA6,DMU>%9!5%$R
M8C,X-S-34G-K8TU2-5-H4T9Q.&QD,C99<6A(,4AY)B-X03M:2&925T0S1VYR
M97I),'-6<U=H16I):$%:9W959U9X5D)A>C5M.&DV3S-'*TU167@K<U!2=%I,
M:7%C=4<S;U)Y5F)L*WHQ.7-647<X)B-X03LY9FQO,70Y65,V=&YI0TY*5DQD
M,E!"5U9#,T99>3%/8VER5VXR:E1R:%9C,VY4.'91>G%H12]P<#9R3F(R3GA/
M=D0Q:F)61%)1=7 O)B-X03MF2U4R4%5(=WA60FHX>69Y=4YR8C-G;4@Q4S9R
M-D9X*VHW<C R2SAE435E:%%-;UE&9V0Q1E-D9V%"561&-7@O3#)A0C4T6DEP
M63!6)B-X03M8<6QP2WA:6$MH5$="151*6#%".6EV-$A#<6AC*V9V>3%T<#-G
M;6Q26D4U,7!9,T1,*S=J37)59%E3<"]D:FM+2&-D3596.5(X,RM1)B-X03M.
M3V%56&A325%C:DTT<W!N4F5!-4Y6;&E:9'%(=C%"2%5(1E=R4'IN*UAD-6,R
M;'1B4W=V4&93=$)B2CE6;%AL26YQ8VQ*84E"4U!1)B-X03ME=DMN-&EQ<6I(
M-3DO3&561FMH8U123V]E3U=+=W58:EI754]'4C%G2W-/2G%A2&)V:7%D-DYD
M958Y87-F<BML<$)C,F9.:T5Y>$)6)B-X03M,26%.5&MQ,49E+U1!<4AV9&(X
M:C)/;U=7;C-C.6Q&939J>2MO=VM*5UAH.7)J454R>%9R53EC.&LV6F17.7)F
M4&)1>EAA;#=91TQK)B-X03MR<411:TUQ;&1U*RLS6$950D@U-2],5B]6275B
M8U)W>$,T:VYE,V1)9E1+3$E'17)2:4YQ<$ER04)Q,"M2=W%R>2MA=DE-55)L
M6C1I)B-X03MG.5-P4S%K9BLU<GHR5TUN86Q2-&IC8EEQ;DYH1F]E;U=.=F97
M;'9&2F$S56%Z44]994):2$A*5S1U<7-+9SEX9U93=7!F2SEO:V(S)B-X03M4
M5U5+4WE*1$<P;G!+1VMK3D515C=T,D=+;V)6=%<X;F%18F-A:6)A1#8Q2C9%
M0CE,;4=K3W=3<4LQ0V4Q8U93>5!Z,2M7:VM2;5,U)B-X03MT>F)I2C5Z8R]6
M<%!216%1<F-->&PY4# O=T,V8T=N3&9P,3)X5EAL.#-F;#5&3$)(3&-7,%IU
M8F\R341007EO,#1!4$5/530P4$EC)B-X03M8<GAB<U1H5D5295EV>3=M36=H
M,5!32D1%=D]8:%!B3GA79U!*<4YS2TU$.4]"6$18+WDO339W3&8V63!R3S!1
M5EI)1V\X8D)'46M%)B-X03MG34A92U%E-7 Q>%9'-F1,<&1X8U<Q,W!Q<#E8
M;6AN<$I';D1L=VMJ53=553=%2$95,7A6,DMU>%9$86XO=T%C,C<O-'=Y9CA2
M3TMU)B-X03LP>B]J;3)N+T%":&HO=T-):D955&ER<U9D:7%!;&YS-#<K9$QQ
M4TY%:V=I2$=5<4%W-5-6,F)R:7%%9E1V2FML.49F=F(V93$W0VI2)B-X03M2
M6$I717E+:FM&;$1D44141E92-V)Y;DI+2G!)<D(U5E0P>$EY=VQG;DE0>'%D
M*U!.43%0159X5E)J,')Y4$9-<SAD;G!I5&]O:E-6)B-X03M9-V-/<4MA<6]9
M0V]!4%%9<38S,&YY4&)!0S)S.4UH055O0DA(8G!20W=C<G-"='I25W T9TA&
M5D)F3&XU9$E62S98<$-L86-324Q9)B-X03M5;U%25#1E>%5(1E979E)V26LW
M1G W2%,U5TDT:W9&8G-32TM+8FIP4D8K-&5'2W):3D(O3"M76G U3D\P;#5N
M3&PU5VAT:7A-9V\U)B-X03M,1590261F2$965S0P>GE48WI'931T3DYM;4I*
M37-K8T1-4U9#;C1I0V0Q540U1$96;S!J>4M%:%%75VQH3&16:F=54E<Y23!J
M<456)B-X03M"5#11=DDP0399<7-':&9L*TE69T=N85-)5EEY3$8V3G1X1'-A
M;&=T2U9*-S1Q;59R4&]6<$8V3G)*83(X24I94GA.1VDQ2G%44F%$)B-X03MF
M1E5*9E=8;$LO,4=Z,4LY4WIU3"]4>7AS8G%1>'1*0U=P>4UB13%7=$\R2W%L
M.4(U5C%"=58O2%DS8F-$1E=C47EN,#(S6E!J<CA*)B-X03LW:D952"MG4'DK
M-'-V-D\P;FDV:$A(;S(Q0VEL4T90=S=G1TYD=EEE1TMR>&\O:V8P9E%A,3 K
M4T5.2S9X4TQ&27%M8S%L-&@K455/)B-X03ME;T<R2V\K>FXP1WET63=3>FMT
M8F$Q:%AH1&)W;4]/3D9(6E57:6=F3$961%9B9GET<3!C15=P:3!V23=A6DQM
M,U-9>'5%;6IR=VM5)B-X03M%-TUV23!/2W%T,C-L,CE#0SA.<&-I36MO2FI&
M2GA*-C U5G!I<5A295AV>3AI6&I&<&UK4G)6,C1R0F)!5FQP-F@R6#EV:4]8
M:FER)B-X03MD=F]0:TLS=&UT66),5%5T0R]Q0S)#42MK<E5287!'9F=4*S94
M-TE(45EQ<VDX=&9L>$-R3$9P5VIX<7<T<W%7.7%O2S=B1VDY3G-6)B-X03M8
M9C1D+TQS5&TT1VUA4C8U6FY-=F]7,U!M-T)M8FQX<E9M545N>$=+;S9X5%-O
M8FTQ=&1-5T-+,6=G;59)3%E)<V%!=D=A0E4R6'9I)B-X03MQ85EQ-T9867%H
M=%0O=T-/8F0O.%E:4"M);D9885HO>'IB5"]!27=X+W=$15)I<4IX5C)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R)B-X03M+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+;V)5+SA!:FTS9B]'1U0O:4IX
M5C)M9CAC,C O=T--)B-X03M-9CA!>$59<6EC5F1I<G-69&ER<U9D:7)S5F1I
M<G-69&EQ4S8S-7HX<S9(8T,R,4\Y149W62]7.45*2DDO<#!K8FYX:E9Z4VM,
M-RLS)B-X03MY>%9+9BM6=69L.$-&8E4R4U4K:V9183%U,6QP36%2<UEZ14A#
M;'9H-55O1RM%-S=9<6DT=GI).&QY349855%P84]'5F5C57E64S59)B-X03MP
M169J469A22MJ<61S859#>F9M,RM8,$5Q=WDV;U5L8TLP84<S=7%U2D5%:49"
M-EAX0F=W030O=&9$.7)B1E9R9FTY-4%%8GEF6'!Z)B-X03M(1W-41U)B0RM:
M5#8V<3!15FA!47I/2$9&6&9&56%F>D<X;4Q.87=(54M3,V]5,GEM1V5R1C%,
M0E!S9D,O1E-3:"M)53-'3DMH6"].)B-X03MJ>4EN4&QF5$%242]76FE,2SE)
M:FER>#5315$P5&-F=%5X5E10-7<O;#$Y5F=U;#%9>7<S55EM=#)I=')Q575H
M2TQS<5)-,655<7)X)B-X03MP5W!P4W5+<')"-30X<UA%0FYH=3)K:D9V.6,R
M9VXU1T%X3%!Z5F5(2G8S8F<P07(R-C1Q<398-78X=39R9'!A5T8P6G U16MK
M4F93)B-X03ML56-96#E.>GE:1EA:='%6,S=9<6Y'2W5X5C)+=7A6,DMU>%8R
M2W5X5C)+=7A61&%N+WAZ8G8X031W>68X4D]+=3!Z+T%)-71P+WAH)B-X03MJ
M+S1I35923TMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5DLY4SAT*U8W,C1.+W%E
M;%=.>F-*1WE.9#--14UJ<D52.%-M4C%*0S V:71-)B-X03M665(U>'102S)P
M5TU).')0-59/;W1*>F%E.2MQ35!3;%(R1%(P:750:DQT-F=*5VAO9D4T5EDS
M9&583F$P>68V>D1R=FQA,&UE4G=O)B-X03MN4W=I<$1#5T-P1S8R84U'='=%
M64TS24)Q9W%10FEQ=D)P;7(R5VYY4&9E679,341)5D=O6$-M=U--4G1!16DU
M.').4G9*15-O8G-O)B-X03LS4$AJ:6A"4S9.3$MX,#9(>DHU5&U764ER449D
M34A.;UI&3'%)0EIY9C-C6'=+4WAP=#A)-C1P5F\W4%9)6E53-#@R959F5V)4
M<$4P)B-X03MY46I4,5E.>%%14$1(.5="5S-I65!2950Y=#A6459V-65U3&TV
M;5IV36YK-DY79%E9259I,'DV16%Z37I15WDO-DIB34$O1VYX37AA)B-X03MH
M2V=5>%9T9DM&.65T<6-6<C5H.')',W0U2&AS8DM'4%-:65E!+T]2235K3VYL
M:U!'3598:V$X5U!Y5EHW-60P-WDQ<'5H;3$X,EA/)B-X03MI4S9L8G1-="LV
M;3!23U!P:%A38FI&84DQ25A8:T1%;S0X86I917%S=71.03!#,G5K=F)45')3
M1S9#1TY,<4M'3DI"1S4U36]D5D(T)B-X03MS,C5&8T-P:&ER<U9D:7)S5F1I
M<G-69&ER<U9D:7)S5E$R<"\X8S(W+W=#34UN+T54:7%H63-K8U9L8GA34GI"
M,&E25TAO5$=H0V=()B-X03MO=4MQ+W=#:TE0-4IV*U)%,R].1TMU+U-%2#AK
M,R]):6(O;6I&6&9P0T0K4V(O:U).+WI2:7)V,&A"+TI.+WE);2\U;WA6,S91
M9R]K)B-X03MM+S5%5&8X04Y'2W4O4T5(.&LS+T%#26TO=T-A359D*VM)4#5*
M=CA!:U).+WI2:7)V,&A"+TI.+WE);2\U;WA6,S919R]K;2\U151F)B-X03LX
M,%EQ-SE)469Y5&8X:4IV*V%-5E=46&1P3D4X56MC>&IK56\T.4=C5D1#:#-#
M,7A6:DME469)16%34G@V6F-2>'EW:3%K:E$S-F]9)B-X03M1:&HY4&ER0F50
M1FIT.5!80W$Y=DDO:UHW1G)#5%0W<5,P6EA4,#5',4(V3$E&5G=P6FEY.&A'
M2S!0.$%(1E5,1"M79C5C45=$5T5/)B-X03ML,U-7<BMM5U%386Q7<TI,4FYN
M>C5!;WI-4G8Q2CAC0W%I9FPS*UA34U<W<G!%,4Q6;&$S:% Q-'=O555+;D=%
M;C O:$$R*TAB0W$K)B-X03MF>4(U0VYM=#5P9%!U,F4P5# T4#-M;VA61D-+
M;%$T5FUO>"M):FQV,7A60GHO;%8K5TYX9E18."MK6$UT-6-C1%!-,&UP1FXY
M3G53)B-X03LX<79V4G0X0V]Y,#AG*U%R5#%F<2MN6%-#6B]5;$)F54=$3E)X
M=4=9:F(Q;DE(66MN<FA65F9Y6C5-;6UK=4QQ>G4W<39M57!08U1')B-X03LK
M9#-$4G)%,TQF:CA3;TMG041V:7)*4#!H0B]*3B]Y26TO-6]W2S<Y25%F>51F
M.$%):6(O04IO>%8S-E%G+VMM+W=#4D4S+TY'2W4O)B-X03M314@X:S,O26EB
M+VUJ1EAF<$-$*U-B+VM23B]Z4FER=C!H0B]*3B]Y26TO-6]X5C,V46<O:VTO
M-4549C@P67$W.4E19GE49CAI2G8K)B-X03MA359D*VM)4#5*=BM213,O0412
M:7)V,&A"+TI.+W=!:4IV.$%M:D989G!#1"M38B]!2D549C@P67%O6#$U2$Q:
M6$558V-X9#1N5E(V)B-X03M%=W%3<$$V<FER+R\R43T]/"]X;7!'26UG.FEM
M86=E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R
M9&8Z06QT/@H@(" @(" @(" \+WAM<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM;&YS.G-T1&EM
M/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1&EM96YS:6]N
M<R,B"B @(" @(" @(" @('AM;&YS.G-T1FYT/2)H='1P.B\O;G,N861O8F4N
M8V]M+WAA<"\Q+C O<U1Y<&4O1F]N=",B"B @(" @(" @(" @('AM;&YS.GAM
M<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+R(^"B @(" @(" @
M(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%109SI.4&%G97,^"B @(" @(" @(#QX
M;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3Y&86QS93PO>&UP5%!G.DAA
M<U9I<VEB;&54<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z2&%S5FES
M:6)L94]V97)P<FEN=#Y4<G5E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN
M=#X*(" @(" @(" @/'AM<%109SI-87A086=E4VEZ92!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(#QS=$1I;3IW/C@N-3 P,# P/"]S
M=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XQ,2XP,# P,# \+W-T1&EM
M.F@^"B @(" @(" @(" @(#QS=$1I;3IU;FET/DEN8VAE<SPO<W1$:6TZ=6YI
M=#X*(" @(" @(" @/"]X;7!44&<Z36%X4&%G95-I>F4^"B @(" @(" @(#QX
M;7!44&<Z1F]N=',^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE/E1I;65S3F5W4F]M86Y04RU"
M;VQD/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT
M.F9O;G1&86UI;'D^5&EM97,@3F5W(%)O;6%N(%!3/"]S=$9N=#IF;VYT1F%M
M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^0F]L9#PO
M<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M5'EP93Y4>7!E(#$\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SXP,#$N,# Q/"]S=$9N=#IV97)S:6]N
M4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A
M;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IF;VYT1FEL94YA;64^351"7U]?7U\N4$9".R!-5$)?7U]?7RY01DT\+W-T
M1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^5&EM97-.97=2
M;VUA;E!3/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F9O;G1&86UI;'D^5&EM97,@3F5W(%)O;6%N(%!3/"]S=$9N=#IF;VYT
M1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^4F]M
M86X\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=%1Y<&4^5'EP92 Q/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^,# Q+C P,3PO<W1&;G0Z=F5R
M<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET
M93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$9I;&5.86UE/DU44E]?7U]?+E!&0CL@35127U]?7U\N4$9-
M/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO>&UP5%!G.D9O
M;G1S/@H@(" @(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z
M4&QA=&5.86UE<SX*(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U<',^"B @
M(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM
M<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P
M3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM
M<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T8VA'<F]U
M<',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T
M<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z
M9F]R;6%T/F%P<&QI8V%T:6]N+W!O<W1S8W)I<'0\+V1C.F9O<FUA=#X*(" @
M(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @
M(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CYG,S!N,S,\
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C
M.G1I=&QE/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP
M34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @
M(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E
M;G0C(CX*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\
M+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \>&UP34TZ1&]C=6UE
M;G1)1#YX;7 N9&ED.D$R0T5#-T0V0S8T,D4X,3%!-T1!0T(T-C@S-T(W-3E"
M/"]X;7!-33I$;V-U;65N=$E$/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)
M1#YX;7 N:6ED.D$R0T5#-T0V0S8T,D4X,3%!-T1!0T(T-C@S-T(W-3E"/"]X
M;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U
M;65N=$E$/GAM<"YD:60Z0CE$0S-%.3-"-D4T130Q,3DU-$-",C0P0T$U049"
M0C$\+WAM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-
M.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#I!,4-%0S=$-D,V-#)%
M.#$Q03=$04-"-#8X,S="-S4Y0CPO<W12968Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#I!,4-%0S=$-D,V-#)%
M.#$Q03=$04-"-#8X,S="-S4Y0CPO<W12968Z9&]C=6UE;G1)1#X*(" @(" @
M(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.D(Y1$,S
M13DS0C9%-$4T,3$Y-31#0C(T,$-!-4%&0D(Q/"]S=%)E9CIO<FEG:6YA;$1O
M8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD
M969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-
M33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @
M(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D(Y1$,S13DS0C9%-$4T,3$Y
M-31#0C(T,$-!-4%&0D(Q/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z=VAE;CXR,#$U+3 T+3$W5#$V.C4Q.C(T*S X.C P
M/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A
M<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V
M=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA
M;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\
M+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A
M;F-E240^>&UP+FEI9#I!,D-%0S=$-D,V-#)%.#$Q03=$04-"-#8X,S="-S4Y
M0CPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T
M.G=H96X^,C Q."TP-"TQ.%0Q,SHQ,#HP-RLP-3HS,#PO<W1%=G0Z=VAE;CX*
M(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@
M26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N
M=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z
M8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" \
M+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z
M86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z<&1F/2)H='1P.B\O;G,N861O
M8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @(" @/'!D9CI0<F]D=6-E<CY!9&]B
M92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F.E!R;V1U8V5R/@H@(" @(" \+W)D
M9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&/@H\+W@Z>&UP;65T83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P !
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M9,^JV(V0B*YZ+V _XKU!Z<=0S+2$Y8=CM:"TX($DE(D \WW.[S+6:ZT01WJ
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MH\=I-@$S)$\P9</BR)I3+B,.0V2K&E]#=Q!0%T^'@R33-O)65VH844$0\\5
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M2-=&J1GRGJT<; E%=>B=%VR%:'(.AK3^L,IB6+2#&6I&+X?<#_CD"X;)3Y(
M=! )]NR0$)<X0[]-B[8R+KH2DV"*HDB"-F+/^S:F9SB=JG:(HN.]M=TJL'7
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MRI ZI6LH&R8'DRYD]:QL8/,>WE*%7HN1G&[G!0R[ECYD.$NV [ ML!<:B"K
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MCQC9.H^HI:P><MVD@7<!U71 A0$54-K-T_?$RHI (XP*6>&,YF2 0PH904+
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M:E08<(^IB(OA@P?E1)H)/H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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ML>0]/;1K[QT7=8 _PZ4G+6/(>GMHU]XZ+NL ?X=*3EK'D/3VT:^\=%W6 /\
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MZ_P7:H/@F_\ _(3=:V/W1S[2DW<X[PMK;[+?U6_NK*O- H% H% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M'SKYD9/Z6ACQ=H'#YU\R,G]+0QXNT#A\Z^9&3^EH8\7:!P^=?,C)_2T,>+M
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M0*!0*!0*!0*!059UQ?P:ZJ/^G^6?DA:JQ?'&.Z3=SCO"RJ/_ #2E_P!G$O\
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M/"4HRCU!..I_R*Q&.UT]2!13[D>#N;[902*P8MCD723BPM*!)/+*0^.>&0)
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MYZY-Z*AKPDH5C".ODX!NKGKDWHJ&O"2A6,(Z^3@&ZN>N3>BH:\)*%8PCKY.
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M<]<F]%0UX24*QA'7R< W5SUR;T5#7A)0K&$=?)P#=7/7)O14->$E"L81U\G
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M+48:C++S5I)#F;&*248A1] &\#1HV="40SAH9V$S*8?2310XFF$ZYD <$S8
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M:GM:3^VZ9^_U XHFI[6D_MNF?O\ 4#BB:GM:3^VZ9^_U XHFI[6D_MNF?O\
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M"NSNV==JO:(>?HZ'DO?O9)V2'9&GN8&^LV A3!&,)I6>5[;66)0M L+QJID
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M^VN->\U ]+W2;[T&G?MKC7O-0/2]TF^]!IW[:XU[S4#TO=)OO0:=^VN->\U
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M^VN->\U ]+W2;[T&G?MKC7O-0/2]TF^]!IW[:XU[S4#TO=)OO0:=^VN->\U
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M0#3,BMSQ.C2BA&R!YE/6$TM[0(T7K<U="5Q16*>_VQ%=:TPF:XK<MQAS2>U
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M8>*P67))O% ]T*3@K DE%S!%(_>T*O;!88QI\CKDR-%\H!<N**]192G7GO\
M,;K'T HC\QL1<@1<0!, A\@\\011 [C8!"WQO8,3,&P@5Q<,,]K+(.PH=\[6
MOC83#;W5@AZ[9G7@602[2VP;/P%?L<4G?>&E*[?/-S<&+70RS+XVK&B"G<3,
MKGO_ )N\\%;$ 7#>2]S&.8!;,Z<?Q]/@]LRS,V:-\ZEM+2AL><8XO.&('7FY
M/)T\3D")H["<4LD3B^W#4>OD%\S$UEQW,[%F"'<3Q0LW4E)-$9"42/GRDHI8
M1E--['PIM?*:3,4BR9YV1?5]S4-&U"J47M?!6D)D-N4S)E.6',?-1.(IHY!-
M-$<QCS+Q;27+XY:RRF'!PB@KJ(O=52S.1 <0HEB@' A@3%GL_CZAI]1<6N65
MX]6V>75W !DK/F(E)J+,>C)S2?T87;K^:RLN/A)=2RO6('E)#*D%!;+E;)=P
MCR>&9:I]NO!/53J4HDB:*F.^-=9RW%RZF$T=!1I=;+[5IQ+N!DN5/;K(F5_1
M%P%#C!J"IXC@+JS<;4^G6XH.!^-EQAFT=F@'LFV>>2[<I99535EF%*<*U[5R
MK-KC)IA346[E34,MLV+G"M$9DB%\%B[<?)Z)B+]8K\-E(I)MIOQ_(Z))^**N
M,IP6:Q@^?:3_ ">8\>.IOKBHT9*#:RX@MQ=$3^W+M69IQZ4YN]<L%ZB'8!J!
M8[""<$%1_++I1EN.1L70WLS,0*+&CM,S%=: FM%X*0+:L_IB+-->),%MW46F
MI)C*?RN^@T%6DXX05!6+-](UMSMNLR<*]".H)8++JW([&<4>37/#@TV&80<0
M*BEN-K:75%NMABG)08+F?#66%I!;))*?K>E!R#']\=X9Y2) ;45EU%R*QT1I
M$!97*VM=]N%>'/5N=6.E.6)H?VI]TM=/<"86%TSH"/$]F^KM!)/2O*=HTU<,
M=78)I6/O,D(@-4065XR47#B[$5&27 M-IFFP'$$"S,ABPB:4XUGI;TE^[[6M
MDC(V<:.PVN\588D6F\LVW.H#:6+AK>(Z;JJ.0BH#E15E&"(+)!;2=,26I6-)
MY9&/HCE,W7$HBJ)[Q5,26;\KJV6Q]5]HZY3(Z^$>1 \$-8?[KCY,?)$'$9="
MTJEAW$R$J0]*!44TH[V)C;5 !G+'BYJQ457%.+H:@ =9K8P1BS?/&4$@[193
M^<)^Z:N?9SHV1H^$?+.1@N%%,CD5!09!]4-:<S1,JY HSAA9*-B9+M]Q"&,V
M28D$_+[7*N&+TL-T;I$N=/E2R68:PZD+/-^L<<^66.KGMD04$I13D1.D$/%W
MM4D*AJ2\F:7FVYX[7#29J%+N)+<]F^^W6A#G$U54X"&;"PVS#A*'"* 9,'0
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MC.?#NE/)[ZC,&](&9?AH=91+5>P&JUWVJ,4!+DO/32HMJ+S<B.4!IAM9+$.
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-PRRMCMWMCE?ZKA__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g563018g95s09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g563018g95s09.jpg
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M$0'_Q "V  $  @(# 0$!            !@<%" 0)"@,! @$! 0$!
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M,:XLSWS^C_U49<34"FO,*QB1%FUJEFR?QV $*LD$G)6MR+"T_<\K6EDDG+8
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M^+6%(I8%V\_+R\W81CSYPNDZ=IJ.D$#RN^.N>5^OFK.N(TQYS]GHXPY& P&
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M>+.(.O'V!Z.G1!U<66B+E0<Z:*.5$GC?KY5>>]ZUO1(F4;X\I^?>&Q(.PC1
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M:S5=X!.0H7"7"C.I(U,H"*\BQ6-R*%H$/Q00#Y\-2)*PG\>>*Q0,J!>VK')
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M=4QNO&6TMB^9IU,_LY^BZMI>"?< E4^B!&GS%-U-[+ZBFK7_ #;SG*:AFT9
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M+<5]W@O(9?$JD%JDVWYS+G3P-%0'6E=M4.7#WC7:FD^>^^21CIC3&<RW,^X
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MCWV4<I--:VNIPGL5.=32<%+5J\'+A]?FK(@0>>%U Z0J$E)A'A\N)JR%*1K
M$Q\;=D4C+SLXC#RW;/2:/6W/(MWM/YM-EOD%3GP0:2>H_,L-.LXM+_15$Q63
M$9$\AX^.R2W*_!'7TM'N1C(A%V8@I(&I!U(F+TVR169<)].4E7:/'7&NE>-=
M"IY/KOTYYLT_GXK?H2C]%*H5Z0M(;^]B!?CZU6Y,HQSI*?L_S_\ $0Y3F0N$
MV&^2/+;>GG?*/_WS>N<%3R6@PEL5*R&01(7)H^2E43;A7<JC+ R.>2"--9(D
M\7CKF0!F[E0B&0/(#G';+MRFGRZX04Z2WUKCK>B*]#^BO/LA1L%P O6G#B%2
MH/75J+A[.A)-&LVPWATH1<6"JR-K\0Q!@FQ7Z6[([;<I:1[WUO6N.O@6IC@^
M3+TAYW)5F0NH=?5+OZ<$/>AI6VF5I0=U68PCP_:BNV!">('5(LR>\E'R#;:2
MCKGO3A;A/X?/WSK8J;JL7*&>@J$-1PC, UW5"6B0>(CK +RD994,?QP7 S#P
MT.$S8B;:FE1C&(E"$;(H-B2JO+)=9@YXX4ZZ05UR*E$7/L+R0RD9V'//4OG-
MI+HOT?XDL5<W=6:$CCO<40<NI3P=!JR?@F(ZC39DLH0TX23VS32[Z6^37/6]
M#;/*4UG5\T;5R1=:S+GJBNT0#*-DCRLZL6(1%((.F3XL,B#\NH?,#^!K*5$@
M#YN-56WQP^79+IH[[Z14UR*E@GWJ'S.+(0$22]$T6.*VLU&/JN&/K;@#0A9+
M$V2_)PSR LG$@3<S%J7+_P#E6J@[ESPX<_Y+C?7?\G!4\DE/7=3$5G\>J>46
M[6$;M.7-V[N*5H>GT4#S^3M';AVT:NH]#2!9O(C3=R[8+I)]MFRO/:B"G.M[
MWQUK0J:O@Q\1]"4'8",T<0.\*@FS>M_Q/[Q%XC9<+DB,"_!?C/QGZT5#&GO$
M6_"?E[CZOX[:'T_H*?-\/DZ^ J7]1WT#0TPCT>EL2NVHY3%)=+T*^BDGCED0
MTW'I//77"ZC6$1\T,,NAIF7.>&RFTQK951YWI/K>D]_+OX"I<QA>-*E7\B%"
M[?J\D3B N2')6.83^*.WT8"0TR[CDO,2!HW+*+AA44D+!=@2<..4T6#U!1!?
MKA7CKG0J7+?W#4@K5==%+2KH9S<#EDRJ79";1IEJT7A$>D6'M*Z_$DTOULZ?
MBEN'**8W\3VJW[Y4YUOC>MX*E\=753G6[,US;-9[W2R>E;CUJ>1;>ZF2V,7-
M:4LS6BOQ@B>P[55W\2GX77X9/I7_ .1SOK0J46G7J+S-5S6+OK,]%457;*<
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MI<<(][WUK7/7P%35\%A80P& P& P& P& P& P& P& P& P& P& P& P& P&
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M&1PP^*/7D?$J$ND6>U^&Y-T15S=7_P#')._;7M.Q_+/@^K)+4'=?670MR/\
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M,!@,!@,!@,!@,!@>:>)?:#],&_:SKTG8@_R9#""?W&3'M+?I*&&K#F/J8M4
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M7$/8]S"NZL>:G? 49"XG#*OF)7L>/,#(VU66Y '"G3%Z\==_#76U6P]M^BG
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M>9Y^H(0+#6#A)LNY7_#+H[6&WFWVPR8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M)>D8T1)-&A%)NY34VBIWRI]-3COX?+USO8F)C"5I80P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M-NM=;-1J]NV>;KPL+[=/M&9>[>K,+DHN>ATEDE;2Z66P">QN#U(2-Q+Q]9M
MD[@+4&Z)2JUA/JZ,S"7-.(@0%'UXHTC;=/3WGIZE\W4:C5IC37'_ '_A4M=_
M;J]IPAS4%R/O/5>E2E$P_P [4F[\PM;7@GY-<;:F_%?I'R\:OM&3.QR4,&]N
M93>+!R+8E.4R^XV,<;6Y0>?09*%G5IF*O/\ +8JTOM\^X1GCWQY48FX&5M.?
M*9?S 895O6@Z+5+8B#BGZ*EM9R%U&+QM(M,H7+"HZP) //!U"T<"\M6HK^1\
M7G+?K59C5IW3/-5,]^V1[/MVS*P=2.7D(U*I77M-V%ZQN]F;JE.MS7I&K?'%
ME^;&SRH8Z"!(78%5($9RCP0:_ 7&-L^7;YMQRNOMAV6->F(\<VROA_QK[/K?
M4XE)0M7?D]23P_RI4IRM6 83=W<LCWF;S]S4AF8Q^21:6P@173V;'W>NA+SM
M$J02"AV.GC)NM\6R1-4Z?-I;5GV\_N!P"@8-#3X6:FCGE\M2#KS9$P]E>7CJ
M7%OBJHOBI?0]I<N9C!QD40\YV3'+)8;'!#2)":BRJKPMPEMSM1!X:G5IOI/F
MG-9?;"]8TI+?/L02!16SXQ7^_MX62=N=*>!QQ*.$?#%&V! 9A1H4$>8,I&\9
MVL?-)M CY+A(4@*/E.R'X7I/2#N).K3-^OW=B_VW* O:I9#ZZL>](J4B[^_K
M<A<NB:%A36M[!N_<?B=4Q>#]CK&DM*@XU4&H^$?AU&\69"6?XMH)U_\ 1!==
MQW\W-9U3$U$.T?#!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,
M!@,!@,!@,!@,!@,!@,!@=;KOT782 >,M \B:R:P-^V?0-9.H*FO&!)H]!:_X
MO:2QJ#N>GK3E*/--Q2. %MEEN$^DF*B+M=;I);KM0U4?9^03W3+IW84*KP%4
M'<B*<<1!*Y5 CJ2L=UX3EUF3FM2@MNC(XL*X6<U,]@CE>2;>*M>%^?Y S;O?
M26UBSIB.*W_4/JQKYX>QEBR$CI63<-VDFE<<WW)$#(^ KS:)P162,GPV.%(R
M/Y3-2KA-/99ZQX<N..4$?GWVHH@2(M2ROODU%$>)79]>Q.,5CWS*Y,^E(N>O
MRSZ*5E!+M_<5*9E*![J)#6_"C0V;"%MH-5UN$!:[W2JNE&?.W V\ET7/<]OQ
MGR2/N:,QR)0VT2;*H";N,3I\3= (GS.YI#!9\.9>M!J#Q1^&#R!9!13Z"::3
MKC??[>./AT(B-U3DJ68>[#D,<F23ZOXB\BGZVN*O8^FRL%;J:,3-%2Q.-3.0
M6!'E(URUBT-)HMG3QFZX<N5&Z*PO;GCG136VI=MK#C/JXU8-V':<AD=@Z&H=
M+9FQDTFDDX=-D"$8A9Z)1@DG"F R/O\ 9V;-B\A7Y?LE54&XK:;/A9;OM_SI
M FVHM!O*WJ2P35>UF#N"$G)#+R]/>;9NVDE<\%[%>%A-U#YJ+:R6Q&K"-!$8
MBY:%ZW>N2CA'3@8BF^2UPKO?'>#5$7@@$>]Q6\&@+XI.(A59F2PN+7S;,[<-
M)J5B8HK7E67K,*M81:M&[^-D5Y#8VFT<VFY3<[:M$G:@])1379/G;:+MB\&;
M?>^YB($D2Q6GQ6DI&4+BZI;BI8:+$'&Q'J85Y<5>V..1AR2\>25+R0<8TB/V
M24Y2[59=;_$<I]J4VPOB>7;;+?Q795[AX0,KRW(S4UCR]A$9ZY<O0@HU"6Y[
MI-\_4'-^'[D,3:A?S%FDJBW<]-W"*;I-NI]7E,E1NK@UPM?V';+YA>T.B\#>
M1U.LA[R*%[@ /W"K&.6"(A==3AP812.!6XU>$2/<W_+12B:[@EUURDY6;<-W
M'SH18B&=X]W6(4>.-!J.9C@!ZZV]*P273F6OXG'^#VK<EM0.VTP77C+APD?6
M>Q7LHS8B^'_"R2FV*KA!WSQM6IMAAH)[(LPU9#R3O(J%=UF^8>=H3(@+*9N"
M*T;G,XOOT=0Y.0U9^&B''$[CL@D<'&/4W+Q<=V[$?0VW1TO\_&RSIBNK+@/=
M%CRI]4\> U?6SJ27T'KN9UWTG:91\"B\.L,/8I9)I9[QE!NW@R;!$X'O6F3%
M%RV)*_C4D7"?Y<HHJ-L>B2U-[@E5NV+!8D I OT"*1^LWE@FVQ==WN($K*AT
MGE'!0:Z5#L@IJ$QU[&^1RKE5RT(/5W*G:#3_ ,DLGV2=-0D?H/TO85(7"\8)
M!H:;K%CY]<3?0Y^6>@I&O8;^Y(+60AZ4.J#7PD%7 ;B:MUS+W?"ZC!G]9SM-
M3Z7"2@B+CK:XZNMR76'%KC;.@<2'V)44QD5=.^@DA(2&O3DE80F,304_&F^@
MXXOP-TC,&K,FW[:[=#R#9VW_ ,K]+A10DQ$>352M?:%EOJYC1J? JP3*?[.G
MF&=DY"(-3=^C+;B]-E3<?A<&B<(CD'/G>F2Y$!_E.^5%%=NWR;=-/Z*:SI,U
MMB\.<OZKOWK,9\]B[Q&I(\RBJI2KXE,G/<]??J-M,K1MVXJ3'(1@,K$DF;H,
M+EU4IN5U'[MDXVQ*?#2>EFO?*HVPQ)?WU9(V,*DFM00A_*H?";-G%O0QY8A\
M 0@CVN9!4(M>L4'3N O&QF8/&%N-G7)-/X 5FZ*3ALNX0=I=\#;'-QYSZ]N%
M!\3#QX!!X]941F4/@<JY,3,P5JM1HY]1U'5)Y^*;\Q0>=_'$XO8Z7:3UQI+\
M"I];C:"VN$U5!&F/3_3;3TIZ'<^>!\0+.(DG)!\V>'80"WP8['N'=Q$!'XJG
MX"FEH:]^*-GGFCD1P\W^UH^4:\_25^OO7!F(MKT^]W'0KY@Y,5[$^8Y)I?.(
MA'M,)^Y5E,=5JR^8;1\Y,6<%<Q=LTBHI963JD6?:3ES^'Z3:LW>TU'FE$36U
M:U=>H9#:%VHUC&X9%]Q@:[OS4JF2DT<.7;9K3-G,JK8-@(1E'EFY,I(3K[I5
MWRL\;)#4VBJ?S+J[XUA)BHM@+N]GJTO,K%@[JO-G3D$B;NV$VR4CX'<DZ39P
M5ZJYL)TNJ+<IAVC&YD$8N\WWI5%FU<:(]J;UQMML1IM3LY]@W&.F).(O 5;,
M!<!CGHGBU'<-FQDGU(W\(\_0NYX3NJI6]B;30DPS:3#Z!5)\R54:=I\N.>54
MND]=%VQ3,D_>,JBB,R(%JL!KQ0)Q9L?A3_FQ%U#IN45:QKE9T^F^EXBW&1:(
MD>IZIT[()*O5AS88JY404X6UPD-K:6AKDDUH#[G9S )#A$BIJURU5DE8!,',
MOCIM8=7M?SO\U:OWP(&]$/.=3K\(X8+(J*-%VG6MJ=_']AF8JFKE:>S[)D4=
MAY(94H8['3*49@4<T_MC75@26RC'C /ZQ$-RCHC# \4:B2*:Z@!P27=H][=]
M\/\ :";?YTN34Z8\>=,$G[;N!8J>,"HO5LB!LZLJS3&%_GTQBAYE=TR]4'/.
M,I R(C((;R_$!X439_1(\?EZRR;QIOZ'UDG":F#;&7C)/)M[Q_03%=,M"@#N
M1LIU=, >"D9OI@V;D*G5B@U"1$'3P'VZ#0U\2F3%R4?+(=:#!U?Q?7+CX\)]
MDC2'_0=UQBT)'&;!95PK%@X7R 08,JIE<A<21:1W-Z5EU6FU4GQF+)<FH[R.
MCJ/*[#E!)9;KC;;E;CIUTJB*BL,T>!^Z;$DRU7!@E85RZD5ZB:PF%<Z0M(D_
M!QJ(6:E->TFMGO6D(V\%34#S$=]:9,4738DKR]01<)[8=JJC:MVE_6!>T)I7
M$?D,+$P(39E9*RF)/'!\D=<RZ91]9TA8D9C+EC'T Z;2"]L_GZ_,UF! BS<)
MNFS;::;CE$3IIR; ]<-X+,);#U(T,=D(Y;X.L&3=63\-"1EJ8\X$K]V>;C>A
MRB_S(]"'([E'CZG/:;=5Q]36T^TM"-+*>5?29V_V1+4EBL3CQ-M7E*VDS6@L
MV4GL<4CEX1<K(P@1R:6 Q[KB4Q_\D6T\XX1[;K,W+)VEW\CGZ? F*5=)/<1!
MEL>%C4$C1B;%35AQ]O'24^Z%:'/HA[3K7R$'='.V\=)D& \QW86S:O7X;I1+
M;/;1/E7??UN1M\>EH*<]=VOT?7V9CT3$0T35T[6E 6+RXFE+.K5K#URS\['G
M48E#Z+_ANH&[Y:]N4]+L>'G23GE-3A/OX=87;'CR;C^8Y1()C3HH]*#"YXTK
M,;;'+DW/*'"JS4!;LZ "D-\MDTDN4V D8@WXUK7QUPEKYM[Z^.]F9S7]A# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8&L.I?2)*U[[9*5(\<V)5=>Q)[/Y8K4
M:+LS/8;.Q\LT/CL/)I#G$JLAGRE!73-=J@BJS[<:3;(]+*<J\)%QJ%?N;8\L
MQ:AJL]#(5=&AP9A7T>L.I88E#JU!6/%(_8!F(B/I1@41*"PL/41D,_&MRZR!
M)L/:N'6MK./AUSUT6ING\63Z(I=LO&C-GT?(#9"(Q#BU) 4?QNIYW^XBNCTI
M=1%C81V0CYJ='<BC[J/NG.N(LZ-$=,!JZZ[=/E#>L$1/!\_0DFH]21,//\XK
MZ7ZCQI"K-3&20P/!F<18QZZ;D7AL5@<O7=E6\R6C%H6;'N6AEN%&N.>DU>57
M:R*7:BG(B\X<J8>S//KBH/4DOE\?DIR(><9A+:KMB#%8B),&):_#JMAG3>+1
M9Z36'2Z.S!V\Z:CE'"B"3I5%PFKRE]%77(VS<=5O6;W3520"S+N-UF (-&]?
MN.IHI'H9%5Y9,X@R&H-T8HZ5?_E:!MFX9))-DF;]WPRUQKGGKKA/GXZ)%S-,
M**1\]L$*UCTRK.KJ@E'1@D<K.L)PRIQI*!)H1WKA4[#1T6-2,*D3VS&I+\N!
M3KMPFCQQI3?':>^.!B^HCT+Y9'2:/16.V74K4J?K22RH$L!,1M(2M65/DVPP
MVIP='J\B&X&&O),IM-OTMRFW3V[43XUPDXZY%2^+N4>.W/Y 8?GO-JVWCF07
M%&2;TA6??2SQJ[[YE5I!G;A7?7XIL_#=<D#:77S\+M=\K+:[3^&A[NK(R634
MT1J*26)%(3$[T@[4/*&Q(97B-8R)L;"=F%"4\&I+R(Z"B3Y#DLS5=DV:S[GI
MPZ0ZWM-1Q\O.QC=9(]";TIE:K KV3@(Y1%8E:^B1@3&[./4_&AJ40GR<A0C0
MAS&([-3XH6Q.!P2_;=NI\J#A/ZJ'&NEF[I)$M3?5R4)5XR18&)LU/>:$QD;$
M :X/2QL_K'EF$ .&Z'<8@I,VBI])@%6:LT]L1JBO+??".OI)_!/^23W98J]]
M#]^/H^[C[6R@L([E,^<2"[ D="!XYP9NUW1D.*RU[P:[_!\M)LU9@2*O2*1%
M;I%;M7G7'?\ APL7P69&;>\KD*_CDZ'2^D \,=*PB-#W:AZOF@H,=##TI/#(
M/VZ;/>A;$_$FQ#\4R'IJ?48?-TJCSQSO?>R5-]7Y:LO\W^8(K)K"E NKX4Z^
MA+;+0&-FD&BTJL"41*.E"11S'4GW8?N139<<^5;<+_4VO\S_ .3M3GE??S"+
ME(@Y+S@_G(ML)5ICJT(5I.(BF+3]$;GT-4,#CAC])L$6_P 3P%1\-8$U^F*/
MT_J)H.NM\;UPKO0Q1>SKG\Y )!5"ME/JX6$V3%K&5A=FRE[!^H:WCS<7&^I*
M,0E9Y]PC^!FX@RAKZ33I5 @W;]_5^*?'/Q$1/!QY[?\ YM\RUK8;EJ=K<$*I
M6,\20W6D)*P@&1#MC3EG^2M4XVF0$#P/4G,'6O""KG\*V[5?)J=J:Y4UUL5,
MRYB$C\I-PDC@9=QY[CZ#2&,)%8]<O"-8Z8 HKSTE)_Q$O#I*_E7Z=&OI3IY^
M)73_  6E"&G'/7_F>>^Q6KJET.,^>)(_ZB4!(TX<)L@D;DO<:B;B&$'K6.I*
M<FHD=V'$]*K(B$%9#R['N/IZ23Z?\JI=:VOKKL8J$B/H;Q*JZC$*B+RF14.D
M;6XP @LBV@48@GYU75I0V!3ZOD47?0WA8P;FAYFZ3:H-^T2"3;EUO?6MM^^R
MU.;8AK^XB?&)U#&?%3S,\/TH/LJ+()Q&0E6NBKE)RLRFH7CEVZ3Y(/1O'?:;
MY/X*K-];WK?2>O@3%#Y,6\_6P;C*#^TX88U34Z<2Q:)BYO$U!C>:P,:^=MUI
M:Q347?\ +BN.^>RG"&EFW#)VUX7<<]?0YUR,8?>!F?,]LR:[6,"8U7,),'*L
M(!>*HL!''SXLN7B@:3#Q$O?<,>^Y2)>QP\A\FU^W+7O>E4=;WVBISR)N,U=R
M+T9Y3IJ+@C4&+4^_1=6-&*0"CZY/UH*:C91.S&E=@WA)(D.#Q]B@B/<%'B:B
MG'2B;'OI--5;7'.RU,YI56]]45;=6*^DEUH1'X"0ZDD*:V!+R\(T@0B#27+Q
MU% A($B+MJ,#R<TVX43$NW/"VE%4N%T.''7T]$F)B:XHK!+/\<'X)%^F3:D(
ME&^"=LE8)$2;:MQ_"K6"2"?P.9SB&@6*BS182;'QDNOI\QYWTY%**_5WK6UN
M.2S&JTM!3_S-<L3AS>$SNN4E+S@1.6UNH#<PQG-C4:F895$M)(R!-,7KE=TN
MQ8J)O=+,%^=],E$727>D%$^28P^=7LO-WFY ]4 *P8(#D/71RSYF%/RF$AI.
MX3[#-ERTM,1H4G'10(*-B@)#6M,QK$<T&,N>N4^$^.N]EG=./!*2DL\R X&$
MDAJ0T<(K*3JZU'#9,E!&,)D*^XJYC&M!'SI5((65_0[)8?\ Y#I3?Y2CVC_^
MS\=<Z)C?&V!9RKQ\, ") P/><1\7B)7JM0)EF0K5J"C)A1ZPE74%#D$5$V 9
M[V_&-BFQR':?6U&Z3KZ?Q3Y4T/=U8RQK/\=UP4GDPL [1HV5#W$3AUE$72,-
M?35OJP"(B!QH/,N4$G$C_+RW1ULTWP\UM'EDI\>]:0YZWH1?!D !SRP%+Q.+
MI-J%A,K3?EXC7L22>54U/J,PUC&.6K:(#0CQ99NT(SJ)JODF3;7"R!9OURLB
MD0;JIIBIZI' 2GF<S*I3'ZO>T<2FHH\XE,T"P5:".I.QDS-V^!NY+)!X'?91
M$VU?NG3)1\YXTOPOVLCOO7>^^<&/%6P>\?(XJRY7^1E*9%$X-78=U*K9$OZX
M:!@(0O-ST9:0(M,&#[EZ+=IR0 NKL<XZ30^?>NN=;4^;6BU-.0?LGQS-C%KO
M)!+J<3DU9)!:TL&>E'<3%'8CQ8<1Y/1P0TGQ+E)=MP5C\I44:;;NND]*J+\<
M_P"4X6YT3W+$8#ZE\P48>.12.,0]<5I7Q*:$^(>*$[(G@\+B&G;LQUMCH:UD
M4D) @7'_ )E93GMVIKCYE-:WK>AC,]4:(S#S5$9S8BDG#US CHH#5T\G,^E8
M:&Q=@8YGYV4)PCHA+7_3=<J=8F:C47WISU\S;MJT43[ZZXUM(8I6;+^<T6Z<
MAD1&E^&P3]>+HFC#B$?2$_1,,']F*HD'G7RL=\GU6JQS?/?/Q>=I=N?\IUQO
M8Q67$WL3)QT85@SJ/OXH614+!B$56'. !% FX6?K$1SD5UT/=)OW;A1;M5/?
M6E5.^NM[WUO>\(D6 P& P& P& P& P& P& P& P& P& P& P& P& P& P& P
M& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&!6HFN^!=N3J
MU=%NUU)K *R@O8/;+E-,=S7!ZTSG!/DAISWVZ[+[LWI+I+:7&D=,M=:Z[^KO
M7!;PI7$=H\_#Z0@U*AI'!#HV$U6(@'XFPZQ6E@L^7C^XPB*-EH\WFX1'87ID
M'=Z<#=+[4[<N$%N'2?X7:;@7C;60W]ND!*8@*@DAD<,ZCY(G.'MC*1VOY+$W
MY,)/K(W9!JMJ_9!+50BD4JY$CUWPT$'!DLY9N%5GZ/?#];MQAK<V=EGG./26
MZGM^=HP]_8 ^L8Q ZZ>3""M98E7QF.26=2+<P&*]EQ9#;HE^L^4%$6RS%;GA
MGK?+C_*;UR9O"FO\O\ "Y4]FSGFSR(MK8(OT2WE0I&*LG \T;MR0V(?JZ1D>
M%#":CA]0RENR7ECSKKC17M^DHITWVT1UA8U4V5N"FREQ4?;=+&90)9,[$C)>
M(!2W$47=H@09$(R'(HGQ"TEXYE:W+Y)PJXVDN,X7;K<H\\)]<;6[)$U-M<I-
MXHD\R>UNF5L^) 89 BL'/:JF$5S*HY5?9B#687L/IP-@R=OK1]5*>(D&XT_H
MXW/=[;LN>QO0[I=Q\Y8U4CIWP47D$"#5^?O'X-D(S9T'8-VL8D"3$!%Y7*JE
ML6%P^ =$;.(2\9&:[D5*LM<M'I@HLX#/7K)!9@EPRZ9C<DB7A6-D8[80YQ*8
M^D7L:M7-<2P@%C!XJSZ+$+<DUKRN0]J3^QY]+7KB4$9#PD19OC#C2KAO^(WW
MK7?*"8W-D =.L@HV_ "4DY55O"5RB:+\\CD$58SJ502,P51%-KP^ZZ*)HJQG
MIU]?KZ'UE%NN-ZUOGY^B7DJEOY &IR:GI$YF>WNJCCGGH"V8N(PV[X,KT")N
MH:P*;5[*J?EK@ZK<6U]:YY5VQ['<_+TIM;?29=RFRWV\A" 6IFX:SD1!.I(5
M5,%CGX@!(0L;-JP,9?4=?N#C&O[*K^3]ZE0N_7OTFS(RTZ:/&G'?7;I)=9OT
M-R^K%\LLY;%*EA\5D0V#!JNKV;U6@-;QIZ9%JPN;52XK'MF%;O)2D0$.@":;
M1PR4<NR6MHH=H+:5Z4TX3):DYQ]OT#-#3(Z-G[!/H4 "0)Y&7H25(PXC$VM3
MH5/*P9H?6]GUN=6<&PK1KTCS^9<-FK;2S19NZ17UM(UN6EZ%\EN;@:OVT-G(
M> <'_/\ /?-4@1D$"YL9@G74Y["N.GD98NI3'-").(<!.-<K.>W[1TEUS]=O
MTH@@IP2-5?5K;;_A6V"BDYEX&YI;,[.ERHV)UW)U4.F;ZHF!"Z&M@\SI\YE=
MB$@7+2O8DH[!I,(P'%:?#N_EVR6<KK+Z+&J,JP;3VUY><RU*G^*PEL<KE*G(
M+8%:@14BKM&Q0*L/G\,"P95JFQ5DT7=L'H 0$2VU4X<=IK?RD7":B':G'1(G
MFHV,_;BC42#3Z*BYZX=@I#&Y&!A9F0,9D=G,(_6KF".YAQTY<V8G79,:85@;
M;X\M8R+?;XX;\*.U.6VOJB=5S;+V5X4:SY*2QT_:(EE7!>Q+:M&/AEJ^'J2A
MO-;H8EVTO'R>7.),DUF$+;M)"6_!C-#F3CZ7;1-PZ71')\*"-7+-:U6^40E>
M7?-;D2D#64-)1(;"FD7;D^)JO(8@9MI:,NYNV&DN['=5ZM'"?<;2TERWBS1_
MI#ALDH\5Y;<[4$ZKBD7(>,.C ^?C"M@L5FTG@GKVO8VNE!N/Q\<#>M++"6F3
M=$7#J3.DS1"&G1RS=/Z"8Y$@T[0^IPDJATHL-R3>?_*H.E9S-9BUD3*7:+/;
M'0C)%YJ<*S"-B[,LXA:,SC!(H3LR00MPSXECE/2>Q4>!+[Y:I[<]++?44[$Z
MK5@X\839>K(/6@&[8JQ;U1'Y_65=R3]TO;]^WK>=0<S7AUC-&;>R&0R2V,*1
M6:.$C+?@8V5?LE>G8Y?\4IRF-T7:UH]Y,#,FTR"26920O&9 ^AIH*WBQN;5L
M<#&X_2,'HXSV8)1"<-!4T"%PM?,GK8<1'J-F;M9?ZFG/.TOI#<KZ)>/7(4]
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MLWY9FAP^4,S7!MIA# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M#1GT+TDLQY><H.7'))B*P=@.&3 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M7Y[$PG$E"]%Y0$^AVZ_.8Z-T]V\-"OPR?2GXAMPJC]/G?7S?#6]X*E+\(8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M+T<"()'U$UUDE=<Q:BNK?3T, M+JYZGC\%L"01V#^BGO=:6JW;$37XZ'C:Z
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MGLN7.)NF7^0TU421X3W_ )37>]_LPDSIG**0FY*,]US"QI!(J<]Z12F*Y?\
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M%T%OE^&QOFJJ+JFT?IKQW#?2<BJ6QN; M&D[LHE_*G54793!B.BYO&AT[%M
M\ZBC\?-(M-X-+89,&0UIMZ-+B'J&UV;==+Z2R7*F$C57DIR!?; \]0!W29-
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MDI! 8,1;C1R+TR264Y0;I\((\]:XXYUSK6L.6J*U3'5LMA# 8# 8# 8# 8#
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M?4-7D^1S?7TF7)$BZN=R_>\M^?@GRY>.%NNU.M:^/776\.W<^&GR>FK#B8#
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M@J^C!J6Q5^&D? ..V%ZLCU<DQ\/_ %9!6P4:V9PPBJR8IN!3K\+^Q7YU5O\
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M^P;=/]H/]M7VS_[1GI;_ -0_B?\ O^P;=/\ :#_;5]L_^T9Z6_\ 4/XG_O\
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M7(W3<FX9:K,QIK"LG<%A@P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MC$EX6I"O.(W83:X.81-)K,!HL58JGFB5(QJ5*6Q\U>%^X,!1Y;O"8)WWV?\
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M!R;!3N$RB#'T2XF3.4U-N1/:B??*2J7::J>N\-;INU%2KPP9DLU+,4WB0NC
MS2Y#<1K-G82;5B6GMM0OF/.B+1N+I88]JALW./GQ3GM,E*FH]XKKI@/11ZZ;
M\#=AU<J%>,[$?VA!+-N.4,9(6#7A)[VD;WF5=%BSITG4==57!*U5X"5E649/
MQ5H;KD5,G"_(T3PR.!&"2#-?>E7NQ.J*J&WD[H*%6!:=97 5=GF4LJII)VH-
M$6[8)A"_4A9:;,74J%O1C[DVXACOI5\$^;OCAB^755^7OYOAHEU%,\8J@))"
M]0R"2E#1TY3A B8"$7OY,GLZ9+08U R)22-&0=J/4<N!QYPYURR28I)N]\]<
M<<IZ^E@M51GR)61WZWXPG,>/K'+9D'7X<H,X^#VY++A=JRGCGYPJGP;-9'!6
M:;+G_P"4DT[5X[Z5[ZY4X&Z5/V5X"AARM)O&H))I,-EIJM9% XX2/&F_(H>L
M;@\M@J1)ZH*CO1!-9J.F+E;A1'G?7#E-+O7&]<;X[-1KF[E:7^R'%'$CCDM,
M6#8AZ1AK;XNHN>()UXU.RN:L@T2C 73\T#@ @E&P Z(0@<'7'1Y0,T+C$U$"
M/#OE=?ZA-S;3#)@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@
M,!@,!@,!@,#S,_9G_P"K+_$$?\R=1?X]QX=>Y\-/E^'IFPY& P& P&!YF?X6
M;_<L]3_]PCT+_F2N<.O>^7I#TS8<C 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M,K3>:LJ&;:UH\4<;:)M+ <?G7TH:Y4=<[2TF1VV[VIKY=:^/[,%2BT\]5T'
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MA3?F^3P^^K%4,>=9M?)H2*> (9JOG5=>B&T&0FM)0Z!(C>!M2UL#6K4.X -
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M_,E<X=>]\O2'IFPY& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P/,S]F?_ *LO\01_S)U%_CW'
MAU[GPT^7X>F;#D8# 8# 8'F9_A9O]RSU/_W"/0O^9*YPZ][Y>D/3-AR,#Y<+
MHJ=K))K)**M^N>5T^%..^T>N^-*<<K<<[WTGUWQO76M;^'QUOXX'UP&!PD"8
MYTKM!J09.5^==]=(H.T%E>>4N_I*=;334Z[UI-3?R];^'[.OV;_;@<W 8# 8
M# ^/#ENJLNW27147:_3TY0X5X[6;[6X^HC]=/GK?:/U4_P"5S\VM?-K]NOV8
M'TZZYXYZ[[ZYXXXYWUUUUO7////.OCUUUUOX:YYYUKX[WO\ P8'S;N&[I'AP
MU71<H*:WM-=NKPLCWK6]\[WPHGUUQUK76MZ_9O\ PZP/M@,!@<+LD.2<Z9J$
M&2;O?27&FO;I#ASOM;6]H\:0Z4TKOI76OY.OA\>O_# Y*RR+=%5PX530003[
M6776[Y21112YWVHJJIWOGA--/CG>^NM[UK6M?'>!_7'?"G'*B?7/?'?//?'?
M'6NN.^.M:WSUSUK>]=<]:W\=;U^S>L#^%UT&J"SETLDV;-TE%W#A=3A%!!%+
MG?:JRRJF^4TDD^.=[ZZZWK6M:^.\#ZX'Q_$M_P 1^$^NC^+VCMSIK]7C\1MO
MKO26U_H?-]3Z.E-ZY^;X?+\W[/C\<#[8'P_$MOQ'X3\0A^*^E]?\-]5/\1]'
MYOD^M]'YOJ?2^?\ 9\WP^'Q_9@?? 8# ^/;ENDL@W4<(IN'7U?PR':O'"SCZ
M'.NUOH)==:[5^CQO6^OEUOY=;^.\#[8'R4712[2356234<=[30X44XX[64YX
MZ4ZX2YZWKI3OE/G?6]:^.]:UO> Y71[[52X62[4;[YTNGRIQUVCOOC2G&E>-
M;WTGOOC?S:^/P^.OVX'YTY;\=(<=KH\=NM[Y;<=*\<].-\\;4WI#G?6MJ[TG
MKYM_+\?V?M_P8'\+/6;=5!!P[;(+NNOD;(K+I)*N._CK7RH)]]\]K=?'>OV<
MZWO Y.!\4W#=91PBDNBJJT4X2=))J\=J-E5$4W'";CCGK?2*G:"W'>M=:UO?
M'6M_X-ZW@?7?6N=?'K>N=?'6OCO>M:^/6]<\Z^.__'KK?PU_\=X'[@,#XN'#
M=H@JZ=KHM6R''2J[APKPB@BGQKX]**JJ=<II\<Z_P[WO6M8'VP/BLY;M]I<K
MKHH=.%>4$-+*\)[66[_^0BEKOKG:BO7P_9SKX[W@$'#=TG]5LNBX2^HLC]1!
M7A9/ZK991NX2^=/KKGZB#A+I/OGX_'GOG?._AO6]8'VP& P& P& P& P& P&
M P& P& P& P& P& P& P& P& P& P& P& P& P& P*/N3TWYP\[:!]7_ '[3
M%(:D_3SF-ZMJSX57?4@V.TET0_).9::$=%-,=.$_K;0UWI+ZG/S?#YM?$L1,
MY0D]57)45ZQ3B=TG:5=V_"5'[P5Q+ZQFD<GD9Z*#]IZ?C?SV+D2@S\P9?5X^
MJC]7ZB?S\_-K7QU\1,3&$YK)PA@?F]ZUK>][UK6M;WO>]_#6M:_;O>][_9K6
MM8&I ;W]X4D4R8UU'_9_E4Y/R9[46&PH1Z"J@C*B,FZ==,>(\Q M)6L3=F^W
MO.T>6J:72_2NODUSOK]F%VZJNIIMQA# 8%,W'Z,\^^=V 4I?UY5#2(V2.W+"
M.OK:LB'UVT//F2*;AZT#+RTP(3*.6:"O':O"&^^D^>^=]:UK>OB6(F<HMDZD
MO.E;^CCF845;U97-$V9)<,\DU5SN+V !9F&R:2S@4Z+10H58MB2"*Z??:':G
M*O/'?/6^?AUK>Q,3&:T\(8'F9^S/_P!67^((_P"9.HO\>X\.O<^&GR_#TS8<
MC 8# 8# \S/\+-_N6>I_^X1Z%_S)7.'7O?+TAZ9L.1@==U1\@=^F;QN5M4$_
MJMF'#EJR'@QU'SX ]N)3]XP]Y*KLEIAK$&L=FCHG).N$XJBD\?$VL?T1)K;3
M2)=H-#4Y4[$<,F!U026K#]77U;,Q@==RFLH/-[8CZ4PLVB:>CDAM!2*)>=PS
MIDA$624'F+UQ&#EP#])G7#46]4Y())?6Y315=.4C=W$)E>-B^PPOF&HEHY"9
MKOT.=KDL?E1"#"V1%@&LZ.07DF A\IC0J!V8CWN>RESRCVERH( M5FRZ:YIL
MGMOIPX$1IOHUTF_H3U$/B%ZSF,S&VM_I>1>H(P:[>57#?T1!6\,O@7!Z;U4!
MA[&&PR<SA5KIZ-49.R13:_TW'1!%JHDS[5+472U'YOV^ZU*"$,.6XZB44CEM
M$:\4D=;PL3.+"'\SRMPH$E+0D@AX-PE-8U$B$Q=1D-TU#=F_P(I8@@K\RG#@
MGM9D1*O9FY@@"B*EGR6L)O.G<5@,ZLZO@D4E\4C4#9P:QB\QLH6O$HL1$"K'
M[YET*%*O13%WO:(EQM#E13;IP*TIMY^_VI9_0%RMK@DTH:SZ2UZD- C=Q$I!
M9I [-)P$@C.&$>/R"O8/'3 )M+G2'Y$Y8(&6+/I-3Y2KY/:?29)VWADH&L(S
MZNA:R5@P).T29LU$?-L1=Q6S8D.&M)F4$>;9>'D4ALIZ5C@F7,B0"RFPEL[=
MHN!R"/:'S*<K<.>U.BSMR6J!:>C; \/>H1MH+2>;3254].1,3BA.OY'&K ;R
M K2_#:2Q';(E *X1DZ3Z=.76A6Q@URUYY7VT1?O^4N%-#"-4<E9S(O8E*/9[
M=/EZK3];5<6>TE6S"H2L#;5FUM:WIXZL:M/US'JQD8\4=BJ$9E5@P1P3>:8"
MW!]D">:VDX3:I+*C/"<U@D3GLFO_ -1R!9W<-L-5#%[0O499Q2#@]LXW&.(X
M/JZQXZX#5\9+-S!)?3\GUWMH=_,&RJJ#46Z739H;'M82O9_[I8+"V\CC5C2X
M$0=6C+&KS]+1X.<3BE&R*QUX_!'CJ2Q2%KM9+Z2$G(2T$.28L<XX;L2RZC=J
MMQWK![6"AUC>XW3R*<NA5L_I5*Z>.)N_)5^DX-)>>"<<I$FY)Q]:15E6!\M8
M8.VBYH1RBI'&O?4-X.NN&JKMD%67$QI]5O\ LFJ9:I8@"Y:7IZ,R>VHS1ES[
M&356"@39<9*_W@^9>8^];D'8<BY>SH) ALE=1A'M-RITZ9]I))*:ZZ14)IGA
M.2LBJ_IJ30N=0^QCMN2 +)*'M)M4/$-IX[PQL&2G5+?$*0J_59#4@*61D\ C
M&HXW&.5QL,8&.G"CGCI1??RIEPX,TB!]BBU6-:"I_<#6*@8X^+-)VA!ZVZ/O
M2#?SX )"(?MTO!EH^B&8VXW6X12X8_C.^NU&*KA1+Y?D'MS0*V2WL*PX+8T:
M(Q^U'<DFT*ED?,5@SK<>A46Z@D/E5V]<EQ,M[CWYIU;_ '=CS\ F*_/5'^GF
M^FFQFQW/+["QMB4MDDX]H,G$GV'[M5 LF_L]"T!RE<1G<*KJOQUP18;74C\X
M'2$6;M;%G[RE'#]ZV8+$)%IV^Y5V_;-G:;9@J3VJP&V?ZRD/,M+UR0LN:0T'
M:4JKQU9<@JX,-M8560.T0C%ZD.;1BIS,G<FQJ.]M^FNHT])<CNG+M8=H@WZZ
M1%:>.;<SS^>]#\6TWCUMF)5/A1"DHP8>R9C71JL:[B,R8#(.@^&+L)7!P[R3
M2>>.B3\IRLP+]*".T7@Y^''_ $6BJI)JL%/Q()+Z^K.VN -+G%_<@]C;Q1:W
MR=4.#^IV[(29X]9'X?<+\5N(F&Y6)N6?<>B[LLWTTVS;BW#-!%KUQR7C_P"4
M4E,V]7B1%L2@'.;G&5%652^G+!K^7V)6L.C<UF9Z'U33Y&$#;%%R" 1IT,!B
M[!+2Q03QT,"O"S<?UI;I5F@FNY$1%P^0V>>KG@WA=W(?3.JF<-C1 !/Q=(1I
M>]B-A[JFO"X:)F8'U7:C5G5*E@O)$D@4T%3;JOVR+94ER(VD[<%]O2WY-9M[
MP!5'-3#H-:3VX9+*3B$9%0D#'7$*K9W"Z9'G @86.$5?8DCE\<L:VGCQER](
M+I#=\MTTUR[!OQKIV2(TWT?-9'UO$7-HO(B.M&1RQW9ET3!NXED,!R1.*A93
M4]7/P#>HBQ<$T%=-QBZAI,2*0?*MUS;'A@0^;72B:A?:RA,W[0>.9R\@LCO%
MQ (/%;3EE//I76$2#3RV3\>ZH):*1:R@1FO0YAF)>G2,W8#VJ8X 6)BD^7'?
M7S-T'2Q/;TM=OL<.%G4QI>NGE52DDY>R,1+BE^ :DFD[=U#&(9-8G(5P,*D\
M*C)\I%;'L<P+:LD'&E&;8:+3>$'*N]MFS9T33S4E4=+&C4G+QZ357,(^8?53
MZFBOJ67+AST1'W/*)]:\?*5CV,G+!04XLO\ %1UH9=L';!RXT!#/_P L54:]
M+],M%F>2CK$HRVB''C3A.M)9TZ@?G#R4$>!$JU?R0I()C$IV"(2V##K21WTC
MX^D%?#A^GA.1J<\?J-D]_ _/I06E\"W&/G+<:Y(M*=>S@DY'00-(.&_GX*'@
MIR44+-;0%)66PGTY),!0NRHT[1#4>^X4?L%GI4HDHBHTZXZUOCZ'76C,95U4
MI5]X>D ]ACV,D(^@YR!B\0H&37#%9)28=I-14BL>">M@\T0B,<BT*#R,[!VM
MQQ")-^7C-%VQ::;;[0?.!OXMQHLQ'3Q3AI _7TQW44I/'+5JV8<$ B!4N)A4
M;;!4YG,O \71ZDEO! \0+)R".QKT'P]8.W;KXL1"_P S?ZJ"*3?I$>WQYKTB
M\EMCT7Y-B]HR&.FD"MJWOY[LB-UZ@R:Z(02J@OH:GG7#-1<;KYB+/F)15Y)7
M;Q15;>D'ZOP[^BFGQR3")I6X4Y[3#Q8!U-#URDALL TC*;4D8:M(>^L*L='Y
M-;8VS@=610%"%_S)P+:C(AP\8J#CI1B-=.WS;A1?K6N2^WA3@DI)[E?&[C0C
MLDG0IBP;)BZW:/ZH?ORI2"D2-0,X38P=^6J@/"F=CH#")YY(Q9$H[><KJ.4>
MP;'ABCWR/:^$X#>H6I<H5</KKF+Z.5;[0K6%C7</ 'XG/7K"PZT,4N9L&-L8
M/U%WAXY"$B:0X@X19,G_ .5\):Y^NX53=C!R9U+?=W")1FQ5FP&/1"T7M1%I
M>Q@21:1RB/B =IRV.WI'0,0K6RS9".2ET:@H0APQ".TTGH\IQ\C9#M9TB(VK
M)])^?+%]"D?+L5D?<:66XK6WAMJV&XK![(0T6D<E@D($*R6#AB,C!+U]/%B_
MXQQ&2#M1XH(61WOMLXZYZYP:9B+E3+0QZPK5Y7\ K: 6NR&C+*MDP>(/A/)F
M.2Z+6'Z$]!O'Q%]SJOB23,Y'8ZD%,\NWTE$.'NRS7IF.>I;=;V/;.;;7S:8O
M2.N5 5W$;(FJ9^$4*7&2*0P@0U7%61+X?,'MM '"D'C806&C$=+1=IU\KQ+?
MY:Z)<M^G/>EF_'))K@W3PR8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8'5J!A4-F_W;/2JLSBD:ERD<\%^0V@#J3@QA_8)L?O'U
MTY.-P_YJV=_EB)IP$9J.^4?DTX[:([4^;:7'RF__ ,17.?X??R1'(]$/N%_<
M] Q,&'C -5GXFD"H2/CF@<1V>*U'.F),UT,')-V6BQ)D%9I.'&N-*KIM$>>^
MNM)\? :OC'J[0\,&!JO[J=.6/B/V,^9.5V3QGY7]".FCQJLHV=-'+>I)<L@Y
M;.$NN%6ZZ"O&N^.^=ZZXZUK>MZWK"Z?E'FZU?5%,4^)^QE8+L75=<#'8+[?(
M$T%>#X5&V#L.9!5("-!2XQVU'(N!Y0089HNVSA+OA5!REPKQUKOG6\-Q,_\
M3U=W8!51<$%664[556$#5555.M]J*J*,T>^U%.^M[Z[[[ZWO>][W\=[WASEE
M\!@=5YJ'Q*:_>%>(3*,1Z6H /ML 7()O)@PX\@%<'?3TJ;FG(I HV=)#G!A
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MP;#PQ2=V=(Y/(?T[$F1%SP.'I+)LVNW2_?">E%E.NB3JG5FVAPA@>9G[,_\
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MO>M?-OX;W\-?'_#OX:PC\^;GX_#YN?C\?E^'QU\?F^7Y_E^'^'X_+^WX?_#
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M#>_GY^&NOEWOYM?#77QUS\N]_']G7QW\/A_\<#@/R: Y48DL@16Z*D>!B'3
M80(IMU^VCQYI<FJQ;.$Q0[2;+KG;ISM)OI7I-/??SJ)\]!S]]\:UOK?7.N=;
M^7?6^M?#6_F^7X;W\?AK?S?L_P#NX#?7.MZUOKG6][^76M[U\=[^'S?#6O\
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M*V$*K4_P<)KEE4A -BL/T.&/77*O7_E&JR2XBNCYQPQ[?6:GR%B'[%&#NK1
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M P&!YF?X6;_<L]3_ /<(]"_YDKG#KWOEZ0],V'(P& P& P& P& P& P& P&
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M9L>'PV.,C+,T8D;0FU%-$7C8](1#4 <+H+)I\]I/RH1DBT74Y^'2C=+GC?\
M)UK6$N44>^?*0)2*52PA5<(>R*;BBX26%7(%DLX/#) Q9C)"W?\ /:>T5.I"
M-'-V[]37.E7J#=)-?I3A/C7);E+IE74%L+@-Q-XJ&D^H\0=% GYLS3<]#'S\
M,3CI!9IWU\.T]$0!EVR<<?'Z:[5PHFISUQUO6$1(]Y^I23LOP!VLH@_;:> "
M"?S"44%T7L6 *Q2/N6SQK]!VV6%Q=PJ-3VFIS_Y!51OOXH]]\;+<I!8%45O:
M@A@"L2& 9:,$O>"0=$LRX57"D4VZK/E^%?)[2?AWNV3A1#I5LJDIT@IVGO>^
M.^N=DB9C)&7OG6BB1IO(B%4PAZ;:QOF(HD70)HLO^GTX\^B*3!7ZG'7#CIO%
M";D8DLIKIPD/<JMN.](J=\=%N7]3.A*OF<6EL8<14.)W+1I1FX-B18Y(R-($
M:S)T^A(1J[AJX13."J[++"FRO:?>DV?7T=ZVGO?.Q<HD/\@>:6,/#096F*_(
MQX-M91-F0C8UPF]7> 149)]$D]H:3?-2H(&R:.&BFNF:C9DW2^E]-NCRF-TL
MU97G>N[#@$F@"0D=$VTK V)%"!D$"!+%FT:N4NW*W&-':+#R#!LI972??YBM
MTCWUTNIIQ\-JI\=:%RE\FIZL)E$@4"E,( G85&M"^ L7(M/KA&: 9AV*',]C
M]]:;NAZ(Q3IOTV6TH@JCUOA3CKG?PP7,8LJ>KF!RAV0?R*(@#3TJ&&1TDZ(C
M&SI=\"#&>Y$)$N5%>.NE6 XZIT[13W_)3<;WWK7S?MPEHC&_/='Q O\ G\8J
MN$ S7)9N<1*#P+)!ZU),]2+3!1BOI/?;!N._5Y7\,W1VFW;?F3GZ7''UE/F+
M<OY+^>://!&<<*U;#'08:)B8(6ST&;-]B1$$[D'4-8"7+72#L4A&M2PIRS_#
MJ)[13(N>.=_(NIST+F'*0H:F6T^86FA6</2L05OA09,.0S7\\'N.(PK"OQS-
MYOC?3<DK#EMB5'7&M.%1NN6W??2/'''(N:K@_M>BZ?<RLM-UZZBRLI/$01@T
M6Z&I_4*F8R1"%P!H@WUO3-T:%DHT-62=]I[<Z['MM[[W]!+Y1<Y."R\\4:-)
MM2["JX4S?,XZ_B*6VX1JDU4BQ+DTF[CSP?SSH>0#;0DA!)-NX25201>KIIZX
M35[YV+EA->5?.GX6,,E*=A#EK"UE%XL@]$\ON G79@?(DTF7XSM??+5D?$M7
MK1#KYD6;MLDJARFHGSUH;I9A_P"=*)*C90'*5-!28B:\25*5BR4?8OQYU"92
M-K,)6V?LW::S=1I()8S3).DM<Z36?\_7ZY^KO?6Q<I6WJZO6<^(6DTB(5I8)
M9@D-*RMJU_#E"C5!JV8H?F7:/7"3YRB/9(MN%U>.U^6R/".N])\<\Z%S5<$;
M5\^4@L;F4D6JN$*F["%F0LT(* &/:LB%R333]2LR''2>T>DY/T/;]$]\\\]$
M>VZ73C:O2?&^1<Y,J6IFIC_9I0Y7,-,=23<FW(/S, .>\&OUH$#1J6Z)IN4%
M$WNI& CS%F\TIKK2[=HEQU\=<<ZT+E'&WFVB6JHYPC6$6VX%QDK#&SA9HJY<
M*Q0TF=1(Q\DNY755,BU4I.2YX2>;7Y1Y?KZ3^3ZO?S"Y?DJ\Y4_+GRI<A$6[
M(ZLTC KN0!'+L0;X 18Y&SK:-M"+-;A8<!+=Q-BT)H-OHZ(CTOPRV^D_AK0N
M4BE]+U-/Y&%ETVKR)RF31[ABF&,FP[1^]9<BBR9\/KE1?CK2VP9Y/3YAM37>
MV+S?2R'TU>NNMBYC)\A=(5$&@QZM!]=Q5*!RI5\XD\85%H.QLB<D46K9V\.<
M/-.%2SU1LQ;I:67Z4532;(\<=<\I)ZY%SFB7'E7SFF"<QI*FX*B$?*/E23%$
M,DCR54*OTR9GHPLEUPY+[.D$M+$/Q/:OX]3>]N/J?-U\1<I&C0=+MY$1EC>L
MH>@>+$11@D]0#-DDWAD&@DT%&5F*?/(_9AFT;IH\N]):<=(I\\==[XYUK0N6
M '>6?.PEDS'#:=@K(>PD ^4-V" 5'AG^=!T6S<*X<-?C]!XV!H,D>&#5;E1J
MQX13Y033UQSK0N7+<>::#=#C8A>J(=V+D4F1F10?H7SPT[E*"Q5?@ZR03[Y3
M$D.U3S_:G;32'U?Q[G7?S:<+:[%RDBU+U*O"HW6ZM<0[J P\4X!Q2&_D _F-
MQT,ZBAB"N!881RAID/8*PV0/A>TDN.>/P+I5'X?)WO6"YS2!S X6\:35@[BP
M)TQLA-5*?LW UJLVF*2\;8PY9.1(*)])E4U8J,;C^N5M=:Z:(\);_D\ZUA$<
M;TI4C80D YKJ)+!DGWYG^7/0S0BU7([KW=3]OGG#_AS^.=K5GUL$HHM]3I47
MO;?O?2>]ZPMRB<K\UU7):4D- - 24:K>2\H)$@X=)!=)1MP8'F'33I$RD4;+
MM".Q_+=9-7COC;;K:?.N=:Y^ N;OBD(BA:7 BGP,55\);"2@*2Q@LPZ ,'*!
M>/S(AR5E@@QR[27V6920CQRL]X<;5_$]\Z^I\WPU\!<L8*\WT;'V6VD>JZ%"
M%>>V+EN_2 LW#]$D)DPR:""O;UURJ]=$1TN!L"":RBG2OXA@VWOKX-T=<"Y?
MW7E#0: 5,M4'X;]0Q\N]F9N8.B#4>-=2^46/*C4YGLC)-XZT#L&;V1RV1/'G
M7+1)'A#:NN$M<\\<_ 3,S-N(Y\Q>?7;1BQ6J*#Z:C0@*.CTD R#7\&(C)@G(
M #=NHU^BHFL),G'[A%?6_P 1RH0=_P OX.E]*"Y?5YYHH%\.4$+5%!4A?<?A
ML7Y'L0348T; J[7=.($Q8H#N6J8[<,[>K:%JH:368IJ=<(]\<;^7!<IFQJRN
M!BS-RPA4<:N6!AE(&;E,8W_$-SHV![JYB7X7WSM7\Q:UUUL+PMO>U-#M_0^/
MR?LP7*)MO.5$LE2*K.J84UT8B8V#%FS8*W08$XH''" PL,_&IZY'NT& :/L&
M:7:B72O#1D@CKKZ27'/(N68+4C49U]V3*U[%W9)0A+"JI#8Q%)\J0G<=0B<R
M<JNT/I.%>Y/'&B#1[KKK?+A)NC\^M[23WR+E9R**3=%)NAQRFB@DFBBGS_\
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MG5,YMG\(8'F9^S/_ -67^((_YDZB_P >X\.O<^&GR_#TS8<C 8# 8# \S/\
M"S?[EGJ?_N$>A?\ ,E<X=>]\O2'IFPY& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P/,S]F?\
MZLO\01_S)U%_CW'AU[GPT^7X>F;#D8# 8# 8'F9_A9O]RSU/_P!PCT+_ )DK
MG#KWOEZ0],V'(P-8*7]&\6Y8MI0)47"HV[KB3SB/)@_WA/R5GD&4,G!"$\2T
MM7CR!@&X6)2)0?\ BF3UJ7*I[3<(<=_+VIK6BS%-G\(8&F;'U>0"V18T)M:#
M@H>-A,H%0T&^@THL"X)G/I";@32T&K:.5I&*48GEFPN#*KNRJR:J^A_353]B
MJ'_F,-5A<+XD%VU9&:J0NXM,6'[K'8R-&6,P&-B1YD2'3%\*&1=<6T!,B10G
MT=(&VB+=-N@HJHHOSKY?C\?@2INN*L;7]>U%4 >3$)(A8KDG&8JUF?47'U19
M',@.Q]<I$0[UW%FY&+L&LC5CSR<C.2R+19583MSKEWRCUSUSH1IF4,D7LV)1
MJS8_""+=MQ&U4;H-3B>I#+-<@H* J,E HZLS,ND:U_*V,L7/V,Q_,&[MVV9"
MFB7:G;I3I5#CLNW!L4]MJ%H0BPI\/=D)""K-2<-)-Q'PI<F2V6KK\:G*PH@<
MBR_%G"0Y\/6:?(TY6Y[=I])<];[XZUHE2U^K/VU6%A3).*NVQV')GH_3,@A+
MN21Z6,NB>KGA128@0TK64CG & 2#OD,Y:M&9)^FL361ZTVUWO?&NBSIE>M77
M?5]SHEUJWD^C_(3@,Y?IK"#P)S^5R1FJ0C$A9,Y$+$NBD5E+!!1866:\+#22
M:2G39=72??RDF)C-!BGK>@ P1>2$)N[3 H2"7QS@JA"I\]9OW->\D>K +AE6
M47<:.0Z!_E#K1H\S^N$%=(=<N7277PUL5+!Q_P!=U<L[=C)F4;Q$HI9TV@ -
M%!,U)&3P7&+#9UJ&F1\P'"*BH4 EDF*LF;1T55;,5'SKENDX54UOX"IX,@\]
M;5+R3KP>%3G\K:V5:O[H8](HY5UB/HBM(-1Z:2!0NWE?<91CYJ'H<05ZW4*C
M7#UEPK\.MJ:1X553&V7X%]=4<[:QC@K.A2!$]&(J?<O@PJ;%8*P<R^&;GH *
MK/'40%!6!N0Q=/;X4,);'FB#3M'OAEKI='CL5*QJJN^LKK8$"-;R%P:;C$@3
MIVF0CTGBS_D;*0Z!^+FT!<M# R;N/28,XY<#R**/;)ZGKOZ*O>T^]<B8F,U&
MVW[;J*O8#:4HC;@M/)%7D=E9<;'!D3G_  QFCR'R<=!9$E$Y&RAI1A+A$1FQ
MAJPD#P%R7T$Z4WMQQSUK7.RQIE8=W7BXI2JHW/R(:-NR)Z65;"UF\FE[NNH@
M')V1)PD7Z*'928BQ4F#"!')?:O?UQ6W76N-)](IJ=;UR2(N6,5]94V%VN*ED
MK9-Y8&$5>^DXR#B9Y9,?8$+D?,1-:AP,NC\&29RM[.RS_A((@W03?DT];5X:
M\\<]_(*E\#/L&D!L6D<I%EI1+N(Q54DN(J&B=>SPN;81&,+R\<\1-LTXYQQ$
MY"Y/P$R,0&F.Q[U0B,=(?3UV@KK@;9328W>$BGGT_P"A$P9U^!#5B[LY".OV
MO<6D3M@B V>;B7;.2<,%@I-;C?*7:;A/2J?>]ZTGWU\..A$7-/V@[D;7A7HR
M;\#1H5P_4(*)L1,D2E0@H Y,E6$7G,7-[& "!B!V&''<E@3]T-'*/QSCA72'
M/.];V)BI4>(]N0Y61*1&41<O%9-$7A !<H;YB4D)5U-GDA2CM8P@*(CD?('K
M)D5U)=*&HTW%L]+.8TCT1532YZ32[+MXKN#^C:6/#?S85.F;EERWA"Z^^A9Y
MLY9=6)8QRHXFR),'0I%\,+/+,C) *X9.$TW@Y^S53>)M_EWO"5*)#?8GG8P+
M+EQ<\=OVHA^!&)HMX18/922/I/*C<'!(0()^E=&;&T1F$:(#>>P*!'CEVR6X
MZZY^GUO0VRDKGT%!7] 3+T3 W"LXAL5AME2MNDDV)QMX7<5=S)&LB *-I$,9
M$PI)N>BSL>KITTYZ073Z^;C>M?M%8U+ECKD;$+(ZKO4?=)K<TJ$N3\UT^143
MVV,GB@/F/\L]-^5-NF_0S:FU_G^3K7>N?DUO7QP5A:KO)7JQMZD %C",6#@.
MAD>K63_B8I/&UE1?IK9T5W*64;=2=M'XQIA8<123VB?#=->MCNEVJG*ZR;GC
MK1=6FD_,^G*9CYHM&C,A.L).(D,>C&XNK7MC;DQDK*^Y3Q'=Q&/)Q/LQ-Q9?
M]#F>D7X=%\QZ3%NN_K:X1[ZT2I2"V;FC-.IUZK)1DL)\V39L2JH)J*Q<Q).F
M)Z8JN4AS\[R*:N.A %MMKUMPZ6^7A/XZU^W>_A@B+4K5_MNGIW7Z4O.D7D3-
MHHL>B,2U'IN8(.W)>?%:U"LX)M&)-G%I+$IB+V.Y_3J!'Y7_ %I#KX=[Y^8L
MZ9]%SDKHA750=W1&Y$ )0M88V*CSY-P9'!>VZY)$7WP2VQ F#PQRU>]]-UV_
M0_IRV=<=(K)I]<]_(2L:0_KUMY_X[E::DY<I;AJQUJ3[6AD\12)OHS8C6HY
M,A:RL8X2L,L(M @UCZ[0#LDXX+/&S;Y/JN4.5!4H7"/:U/R+E[J2$UH<OW:4
M\KH&V?!)BHY[9PF<B:X4D\T;K15DXK <[FIML*[[D'#!NB25Y;;6Z5^.M%G3
M/!*1OL3SJ7:%G@V>NGG MPBT1;IPFP-$I,[7G#NM.6T $J17@I9"Z=@,50ZO
M(!$EM%_SI)3Y=]<_$FV7-$^M?/9T['H\'L-$@]D[.)O1CQO'9=U'D>)XU-.X
M:T.2OH!S%XP6DGZ<?HM&1)XT>*O&:K;27XCC:6#;*NQGNFDR<N.BD2)?<380
M2KI?'Y&G#+&5-S9S:).UDPS2&034)YE,M"+1JJW1AJ7%(OF#L=]9QSWI!MVK
MLNV?5/N/7%!NW[L6%F;N3/6XGDJVZC,1FAT284<58A=HP"!DHV/.(P:EIVJG
M/!Q@(;/%23UA\RB*/?R=ZY)ME)PGH"N2?GX5Z8,/"L+JU]63.V2+^8@2X4M&
MX@X!)R)RY.@E&?95NL.'][Z4Y325TIKGYT=J)]<=]"INN*+K>O?/314RB2GR
MH54 #?G2G)^'SH!M+D2.CY8L ;_G,98_CYV('RL8H[C;?ZI]M^/1Y49\]=ZY
MP;98OCV+1JWXD@G,>6P40XE0"0LB\3LL-8 Z<1R35%%=1!O79&"(2%X67+W.
M$:[;?+P_5=DV2;5LZTJMVV&V7V4]?5 RDUC1<WS/P#RN#5?1UQV3K"POJRT[
M9,.W.00:!AV<;=R"6&6<?276?LFC3MVP3:KJKI<(HJ*<BI?1;V5YPYZ?\M+"
M6.?EZ$.74ZB\+G\K3>;GT)2LJ*- JT;BQ1*0DR==+?GW31ATY=-@_"CQ=-)N
MFHIR-LN"\]?52\L&I:]@I;B=O;.GS2%[-"64BU$AJ3ZDI7>35P.FO,?7A,A.
M]10,/<=B$"7+])@62==\<\:UKLNV:M8$[]$T]6DQ8P*:RWL/)WPP <[:\QR5
M$QX@#*9.K"P$@E$@$ W\>B($C*T=L.7I1TS;<N-ZY[[YUUK>R5,XH):7KFJJ
M[A328,2Z,D_&&@[1$:@U/MW*P)._H#Y]GAIJDD!>O';B%RN>(\:8IH].2*_'
M*3?GKGOZO(C3,N U];P@Q.F,;!+#?TT]80_K4IDJDFB[M&2';+L&LCT&?Q4A
M$MG0,LC1FOW'"K<HFQUPOI1)STUTGKOLNW!>]<6=#[8 ZE$&<F2,>542T/,$
MXG+(NQ.,W+1N^9&HTM*@@7F31LDS=<*M28_\2/=<=?%);O7QPDQ,9J[>^HZ6
M'/# IZ>DJ$B"G1$<5A_59V?N=%"A]K)'X3]+P;F'=2Z8#B@^&EW"+T4R>,NF
MXIVK]7Z;=;K@5+ZN_3M+LDSZRLB.*MHY(6,.=/&5>V,08E)N0*I@TX%$WK&)
MN&LWGS0SWMJ\"!NWQ1@X16X<H)=-U])BI9 #Z.I63,?S +.V3QOPZK\>XUL8
M=:NF)2T)X6J^%!R;%X*;O19HC80%Z(<,W":3H:^:JIO4V^^-X*E6;OV]0?40
M_6L9*3.<B=RBI(WPC$ZRL1\3=MKIG^JXA<N$C7,89NST'<R-N\1Z+,.7+/M8
M>NV2[4=ZX0[+ME)AWJRF^I"*AA:8,DY<9./1#5B!!SLX&9\+6[+*6C/<ADGZ
M.9"(LXD$_B3@*GHBHU;JF^.FC59UKI!9<E3FD-<>DJ9MN4O8; ):N;D#2-[F
M23=:+3 (P,P[\^=1=.718X? "P<OB[@\Q5;(D!;EXU6ZXWTGWUQO76Q,3&:K
M>O7D:83>YQ,J:M(/"*9L=E7!*5RYE80ER==LJ&+WY,RX!LI7O04JR!1AEKI#
M\,06X<-&KEUTJEI0<D^+M2!_[/\ .HUV*'NYC(.")IA#2 X:G5ML."*NK&_/
M/W=#5F#>#JNV<AL#<;?:!BUN$R)7;?>FR"N]\_,3;*V>[CK)*K$[K4EXWBKU
MH^UDZ4LZX>::J"7NDN6?TV/X;\V[)NG*_#9-AIOM_P!O.]-M([<;TG@J;KBI
MH?ZPBDMN:K:DK\89.=30=;128ES42LF+KU_W5"4*1>1@X+*P1+\CF))Y8(UQ
MRS-K"-IC%$W'.U-O1_+D5A;AWU[ AU&G)3%'\;E10_$Z[B-ID7G8(\SA?Z3D
MMJ!JQ<I)S!N'),%Y&-6*=O.1R7"CAQPEI/C7S]?R2QIM,5_6= -402SR>*,?
MS\H9$<MR$2FX]_'G<>E8R"FE)^,?1MN1K,>/F!MD.[=R%(6U_%.T>-*;^IS\
M2;922V;9?0$E7\.BD3U.K'M T4%1&-N3O,5"(,(X(6/2J42F4="CRH6.@!R:
M:?73=@0>.'KQL@DWZTIVHD(B\>#&NO0<)B96/0VSR#*)6,3:1)0^! )2R<1:
M(/)T?7BD-1D-A,8:+!QUG,9,V48AUS? ?9-UQTFBGOOGKG0J>"*QSVAYNEID
M2!C\^?OWYQV :BU.J_LEF+=)2J5N(%&"_P">/X@U"H1J13UJH"8E5'' UV:X
MVQ27Z=?Y+!MEF8EZOHN>CCA.%2@Y*40 UN:6:A*YLM^8,!',C(0_1N'@48AT
M;G05M*1+E@Y>!F[]LT<H]<K]I_L^(F)C-BN?9OFU19LDA8VW23F.AY/R090^
M=O0J R0Q M/(\W?'6L86##CQ^+@7KAD*773)NE&JC=)OTYY^C@VRNR,6'#II
MJ0]10VD?3BSD6S-K#6KYR@W=&HF!G(MNV7X:_2)K/(G*![WGEKM;>DWB>M_#
MOKY<%2U8JSW+5DQ@L<FDY7<UVI,GDC)A@;R,V.X=QROV$^>U_'9E9SA]!1*-
M<"SQ9G]/\<5TV#?B/JI(/7'+=97DLZ9NH;,0*U(/9[24/H*6<FF,/ETG@AL@
MH"D0@;Q+(66> )4*'$#(D>T/: 'ASADZ7'].FR3MNJCM3ZB?7.C-4U]BWMRG
M#;IV*)+25H09"Z77:/PT"L>01N>%KOAQ";1894[IO#4#\^_^@8ATY4^B-1<)
M-$>UE44N4EOI&MLK*]"W9NCX9&Y SC9"4&)G9E:U='AS<7*WK)N6L:6C(VD5
M/J1.,RHN,$"&KQ5QWWMGO2RR:;?77':W/6B1%L,*]64VJ/-.#,S$H*Q>.D9=
M*WH,;-347CD>1ELGB(;HK)E8@-8L3LB*11VW8"UM)$"3M!1-@D[YTFHH*E(C
M'H2O0[2+J/-RX4]G3<IQ#6LJKBR8:@3-CVQQPWC)8C)H@-91.1E_T\Y_!,"G
M31Z]XXUVW15Y43^<5+G1.Z(V6JRF[+E/:413N,56?8@>KV[)MVLGL\0/?@HU
MT3;,$T_G<$'_ "R1<KIMTEE^D^/Y/:O'&Q6-,"!]3T/*#X*-1Z=\F"LE9(O0
M7X&.2Y8<24=QXK,!P= UR!_)M2@Q#@CDPP$=..2CX2GIZW;J-NTU>A4PY$8]
M,TS,)/'H3'Y*7=3&3.)DU915Q!+ %R :K7VX_J8=2P25BS)Y!T OZM$_,J:X
M8)JZ*,_I==_BD/G%2D,LO*K(/-X_7<HE7 R6R78+0YA^4G7C)MN5FG,;B.CY
MU@,= (KN82-FL.$:)NF?YJ_2[;M?JK<[XT*G-7H7V)YXD0-"0!)N3(L""L)3
M MT*]LK9V7)60D=<08A!HQU#^9+.A$E;Q4JHV>!VCUKTD*>][4URT<;3%2@%
M<>Y*LET+"361N^ :4J=-&,7C<8$6#8<P*NWR%FFF*/,;C4!5)]]D8;5Q$NEP
MW3<*I-F[C3GA#I+G2A9TS&"TF_JZ@GLHB<183S9,G-WL0%1E\*B\R*15^:GT
M.4L.& %IP/CSF&#)#(X(GHPV8.WZ#OL<HDO]/2:R6^R5+8C"&!UIW1<WL&=>
MNI)Y9\I2#SU6+6K*!K:[[!G][US8%M.I*\MV=VA#(M$8A%X-:%3(@F8)M4S]
MX0(/'[Q1=1XW11;<<\*J]&HC35ZK3+QY>GH"76GZA\X^F.JGD%F>;BE1OT+)
MI:.RJ#PN=0ZZH60E('E>!3*63TS&)+&7X%^T=_*:?-7B.VZR?T>NE$N1,143
M&4M^L,F!5EYV<C2=)7%<KD2J?;U)5E@V<N"0=<,ES2,"B1>5*B47JB2Z;14E
MP*VCRKUQWI/??S;YWK7PPL1<TZB)MZ#^Z74WDIU[GF,Z\-2N 1FH0GH:5T-'
M*.N^.R9W!780;,#\#CMRD_0!P>C*!T;>JHLB[F*=-73Y'CI5DBDIUI,W6B=6
MW&W> Q=IOV3-\CSWRD]:MW:7*FN=*<IN4N%N.5-<]=\Z[USWKX_#>]?'_P =
MX<W*P&!UN^@[M]82#UJ \C^4R]"UT2&^=U/1D^LN]H'.[5;/1Q2R'-:1B#Q&
M%P>QJJ[8NM/!#Y\0)O"B_/*>FZ*+7>^E%>#<1&W=-YL[Y0N[TB2OOT/Y;]1N
MZ<EL[IN$TA:L;LZCXE+Z]B\HA=UKV:'3 FX'-IO8Q,+)HF?JI[K;E RY:D&;
MQ#OZ3=1-3CHDQ%1,.P7#)@>9G[,__5E_B"/^9.HO\>X\.O<^&GR_#TS8<C 8
M# 8# \S/\+-_N6>I_P#N$>A?\R5SAU[WR](>F;#D8%!J46NZLA_:1&UK#(R=
M '(8M ]+M*Z2'5C%Y?)8G)I<&C#1I V^RWZ@7A QJHZ.=%GB#-KSR@JDKVJJ
MH6\*7YA# ZY5>*$LN\29"+6#<]:6\9MN7,XC/TX,N,BQ.=5I R5+67!8&>L"
MN3=;RO6X_!7:SEBOMVZ67$]OV._I->^N#6,1T;(ZJ&HF]&PBF6!_H;7,7?UJ
M/C1!&2#ER#XI6,SC\J!,US;[AT@4)E)%$T^7_.N?K.-]K\\_3[WKKDES=\5&
M'_$U%&9-;-@$[&DZ).?M;0C!0O\ FM=\.XF\LL]#)-(&R4H<Q!61E5XT;@HS
M80<>?$F(5FGMFBVTUWRER7=+Z3NLJAACMVRX-[ETYML=Z@A T7-)"T%5^;D5
MM (=+[-$S@['(N04B3'3>J6W*&^&_?3?3E9+Z2O:B7TQ$SZ+UJ"IHO5-#13S
MV3E.Y(K&ZW1 S4Z2*\<R.5$#K5TG-)Z:556V\3(S>3OGY!=SW_\ +=N5-_'?
M7QPDS<VUTF%1T/0]>B3DZD=Q2Z(LU:@/F)<&BKF;-&@'SK&^VX$_,>JW@BPX
M)%-1E'6RSOZ+?AQPGM1'I/>N]Z+<S.">>4XC0-,&YSY^J*2Z/2"#16L3AM#<
M$AL?7%00T++#JP'.IK!Z]A@ZPG"(H*Y4_$/G9<PGPORJZ5YVZXZ5$S,XRHCT
M!YK\X0,VZM>WY)9';N0S<[+R4O3IV#S^N82)-L1\<E>YI&DJ6DE61X.9;+C]
MDI(:8?GSK\M067(]MV2_R")F<(?BE?>-G5V&)#N2FFLJK$A;DND3N45B D<"
MDHB+V,RL&R8C$SLZJTZ&=K5)-"^D%?TD[;GANWBK?I=15#6VHN:$9)YJKNO?
M/[CB^+C4KL;J*>D**0U!DS'53U T$OHGI67=I54K(054]QRUOR9RYEV^R@Y'
MM/?#I%=HNOP7&9GFNYMX2K-D%90]I-+,0KU-I 5C$"Y*1KH))9?6%? ZVA4]
M+/>XKU(43XT%% ZZS=F]:B7;\0U66:=?!?A<FZ6P%<4Q%ZP+%S !Z<=.C,,K
M&#.N"SIHX1X$50)+AHZNARV8M.^7[ML95Z=][ZZX44USOCA/6MZV29M1J_B"
MN'C0H$?3"Q'<2_);(C\'B?;Z+)#*Q&VY+14SGB44>H1-(\0[(%0Z2+3HT[*[
M&L-]MFWT^.^OB7=*]+HJ,9=,0910B?.1?L5,83.A!V/MXZ]?L3\"DPZ4A>NF
M$L!22/OV2C\9QPNBX9JZ[2ZZ^7?'?R]\DB:0GGS+$5G3LH6D<K+&B<NH^<%R
MG6XV,_,)!0NQ7<65T-"QT>)'LBR@E/9!LV012ZUUURWTWY^&M"Y0\GXOK@P1
M%+OY',^Q0IK>;;D,W_2#%9]KT&1LHA/6Y&5LXDA-W8+Y[0=]-1'1+\I3=,!S
MQ1LJ\9\+[+NE:<AI 9*J@CU2G9=+'6XOU7I 1.T^8RVEJ4FJZ0@)7#I0NT3C
MGZ+=OV4@C+1PLV5$]#7/R=)J-MI];YPEXVP'GOS5$_.?%@ZB\CEDC5LN5\S6
M0JRM2/=\LSJC/EH\;QAG'H_'Q\8BJO7'UD C-),6P746[:HH].%]J"9M\YAY
MCALL.RR7(R&7QN9R2>U_9HZ4 W03I[$)E6\4W"09 "R+ B@ETT?1E9RT?M23
M=^@Y1>+:USQO?&^!: H^)H0T<"5V%BVDSU^:Q*03[A-]#5>K7D4+O<[Z0$&Y
MDX<PM9R/<KVI*BKAVF"[$-W#%]TS^GRW20X2+NEB97XX!B8W'G59/)(YGL &
MQ(=7[\I-Q,6_)EXU8)^;IGOS?NK["'*E/IR\FS50=A'K%XQ7VAVDEWUIUP-W
M-/ZL\[.8_P"7"'GNQ920D+V: [=93V3C7:71%5[=LEFLHE:@HBZ$,V[A<8YG
M+A%LZ['-TU?H\*[:(\]?0X$S<V_@'YF*!IA'IPK?%I%3HF%MJX,]O0E0(M)=
M!6!I0X.!%VPZLF6AZC-RY<<:>#=L7?:2^_G[ZZY3ZY):[JQKV/U-7<'K**\+
M<QZ!1..P\2J[TU_,';"-AV05H])J,FK)LX*.V['GMPKPDGI17?76N>=;^&B9
MXM-4/MTU0T#6:':SBP^>K8&@0$I,.F56DSR@&.RF<S 9ODR3K9V0?31N<G[M
M=.5OU'DH;K-FBJ#])5OKOHUNEME8E4BK%!1 *[.2(*O!II"IW'S8QTR>%DS4
M'()/&7!!20L#;8HU*M^56SWZZ?2RB2_??"B:^N%>"1-->Y)X0IV3Q>-1=^1E
M?:$-CP<'%W;W])'?RUP LMM:8@VY$2.)EXX;>MSS;;=1!\R<,5QZJB2B'7>]
M*\EW2NPC14/*4IJB5NUV$2Z"L RSB-BHI$G/7+,BV+*O&8B,QP5$!"[\BWVJ
MJFS&H-]=*=_(GS\<)>-J\D'D&NC[$2WZ/S<8^CCZR#<9-#B(71$!)[&OV&>D
MNY(RY> ';!<A%;*@8_H:DX06:=,.5&[M%URIUO!NE#!O@VK6<NC<_*2*33*:
MB)1,)*=/SR/5/,5)?Q-9XRL@B%>L#E;.Q<78"I.SWL8O'T1!%@U6[2Y<[^5'
MI(N[AP5]%?MWQ@A7@@!<$XDDQE8!R_=0]Y\L/.QRM>W%OD+;^A$@TE@*C&1,
M29';)N]1D[4WK;-IRW1VGQK76R[L<%\-O(-7(L5!W2QC3)R0IHF^'C6D2C81
MTYI3IPH$10CL8C 8 ''R)9XMV4;,6S5#O:O7X;EMKX89W2JA_P#;PK0PD'[D
M%B61*B,.#5K&JY>R\?4TI90.,U2-L\#& S*,&ZP>1.2Z<QNW"S(@Z.,2;UWS
MILO];ATWX7PNY>8[S!7(M=@JT5,MVXZR!EG-QC'0$.'3,BO/B/FU 4U$A 0U
M@+CG4$1TOIHS3;<HD-_,CM)OKEOR2Y91+S_'._.J7FHK(Y49AZ5=)U?J0.U
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M3]X<MC1,CUVH;<+?1_EDE^T&GTQ.KD^+7[?$BBJ57=1P;0DN85^'K/@M7T_
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M P& P& P& P& P& P/,S]F?_ *LO\01_S)U%_CW'AU[GPT^7X>F;#D8# 8#
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M.R6BIJEZ>D8MN$D%55P;#-$8ZW:BBL)C3\<V;Q!J08Q-!NS=#56Z*$98EG:
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M7_Y6Y=M>=J)<+_)M7CG>^?CK6_@)B8S7CA# 8# 8# 8# 8# 8# 8# 8# 8#
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M'E\Y',G"B#=5777:27?7'&]<[WK!_P#CU=G>&# 8# 8# 8# 8# 8# 8# 8#
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MNYA&1Y_S_+K@#?E,5;15KJ0(S +#D7KC3HJW<,71M-!'AQPW5[PNW#JR7_\
M$&FC.'C)D;\X&A0M:'V5:A)T[DI\6W=536E1Q:VBIF#MY-6T?.S61J\R7\BY
M:Z9,QG11#:J1%5GWI;D;<:M<R?H^7%_.-HVI+JRE=:E84ZX9-63-^3&;DHYR
MPBI1K)889L"N@9+8SYI'VQ46>Q[GCIZP<Z1TLAM%QV2L:A7VO<<OT]""U:<
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M+'AP[55^EM3O?6$G5,YY-JL(8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M;5^3M/CK7PWSSO0N6?B]?0*#II)0N$Q&()(#_P I02C$<#@4T17YL4/?EJ7
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M_,E<X=>]\O2'IFPY& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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MBGSU]0;G/DG@.0R!E) B<ZB(\61E9N:,G>HJ\<.BY.0TU7M?%14U&\$&C8T
M)R& [[))\N.5"@0FX9]])*?Y?L;@CX")RMW;THDY>L!TGM6OK>CHT+&H6ZW#
M*ND]B-*9&BST)3?NDWW"S?\ <X@4*N^.&3I^9>]K\:0^37S#<N+T/Y9/W)."
MDC#G84S'S2L8[5$A<2N,O#,HKX=')V5FZ<WIXFV?-T0\U(*&=\*;7YXX3>BQ
M+W2G>V'X9<D32"3?RP?B_F*O::K\#"I1(!/I&L;/.]/XXCJ)EMI>BAUIRB12
MH1V_:.B7+=AOOMVMI95UM1+2O'"N^>4>A>-]$*<>#[2>.J[0[M:(#8U%9MW:
M"L: QDJ'#Q66%;CL.UI7'H.R8$6RSV'FV<W:A6O)5PIP*;"E%D&G2A%;E"+N
MA*4_!35D*@T4']UDG$0],^4ZNE8_J$?0[(N?,EW!;:4<CFJ"NV:P6PF_+YJ[
M;.OFZ;N.&RV^E];5YU4W,7O[?ZZ5EL9=^I Q*,_FIYVE&-/)I$F\"X:^B+<O
MN!.X*SBAAJ+=],%;-;CR3!XFFS<?DZ/6M]-^^VFQNPIPC/V_2O<%!UI$#5;P
MN-_[*+7SC83P?%B3GJR.6$%/1<7P0C"SKD& $BI#(%S'#]BHF6=<+.&#KI=!
M?YTR[N,\W'N[Q5*W*Q4[7R4',H%+GC\D#U\0B7'<4#A9+?/B:;'E3(SDJ.9.
M@()#SF7)$D6VDU76R7U$N.UD^N5Q&KAXXMJ?.U:V+4.C,*-LX>K#R;J6V:L7
MC*SH>/8V):%F3.4G(%#HHOSWV)@T-"N&?7+M=32Q)\^55Y21_P HEP9F8EH)
M4WV[[#-4K PDVD<9I\XC4T.KUZ,KJ-+"C3!HP@]YAWLADJS8TLQ?V<.*W7\$
MG#=?IMQID[[Y4WLA\K4U.J+P3TWX LHM7@^"![!B,';%2S\W.T0[BP#S!U+&
MK>J!<4L*/KG3/)UB^$1RLNF6X^F[:!>E'J3M?ITX9ZVX&Z+MR)/]OF5R?23=
MY)X?Q"ATIM1,'3;,C8(>'B8+;\> B9;VE- I-C.%Y/T5"K/6:2^UFPQL4>#V
MBJ*&T%$!&J%Z^@?*\GMF4D2</D46A;&043,Z7EQ@HR-2B0RP&:A]C@8S'B@Y
M\[_)VXN-22=\&>"S91$UU])TQ[[4;/>_IDB:S:D)^,9A/+A[B[V+ &M;04A<
M) A9$PK=)A);&6LCU?1OH#]-F"*DD(=SL>N/K<DRT[X;I-.TOP:Z^DU=[9\Q
MK=4>.3=?OS ]3K9_7P^1!A[=3T[^_L7^&"K(C1(7]]S>W-11J/1=IIMW6N$U
M&_UT_D1_$*;6^G^W?.ZS>-]&$J[Q\RK. RZ"#GL3182SRI3?GQXW$Q;@8,7D
M=9QNSH\7FQ$>FOM)^C(T9TUU]+OXN.4F/R**J:WQ\@F;^JMW7B2=I%8V/"SV
M$-(.T;5J4/-UXJ5W(.I/7'G26>?6K$!ML61$L8R0;&6)372G'3EOTT6;:Y[Y
M<<*H#=":M_()]G24JK+B91U^7)673]FB]EX\\>0LLO4D8I04G#YT T2Y<F8M
M*B%2J?BN4UN.D47J?6N5>T-\*C=C:N9WX>G5A+2_AZ<J2-(6"8%3PN6!1,PO
M+H=* M,?NC0KR#GE7+#7-1D=-^73A-1)!SIF1+,M(]?F'XE NZ$4?>'93([,
MG$;8-877-7)1[RF*#6  C";"RQO5'AI,NY1J$P/(Z0BJ:Y-^DS5Z<-^-LVSI
MWM/3G;K>DANPZXIQ7OA0P%G]63V6DZE2ZJAO! PB,P:O%QL8*<5G5=V0",6*
M_&%B+M%*R%25O<N.>M:43&L!B;5)=?OK2_ G5GU12,^!;-:D/U3+;2B<@F:\
MDK,F1*I@S"6W"D3KJ^*PETT#=].N64/F)X?=^S MH,8HC0[X.V:Z^NC_ .8Y
M&Z/1LWY$\UJ^;H<5!DW DE("*$-#$#H4S-7S21#:_B(Z( 3;P-+2Q-M&S3UB
MRWMPV8;Z1YYTFGTLO]+CO1F9MMQA# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M\_P5)^\RN/[0(1_6L#_/\%2?O,KC^T"$?UK _P _P5)^\RN/[0(1_6L#_/\
M!4G[S*X_M A']:P/\_P5)^\RN/[0(1_6L#_/\%2?O,KC^T"$?UK _P _P5)^
M\RN/[0(1_6L#_/\ !4G[S*X_M A']:P/\_P5)^\RN/[0(1_6L#_/\%2_-V;6
MVO\ #84'U\=_#7QE@'7QW_A^'[7_ /A^&L%2_/WGUK_:'!OZV@/_ *88*D_>
M?6O]H<&_K: _^F&"I/WGUK_:'!OZV@/_ *88*D_>?6O]H<&_K: _^F&"I/WG
MUK_:'!OZV@/_ *88*ED14WA9UYR/"2^+F"'::BO#$4?%$'G226M;55Y;-':R
MW2:6NM?-UKGX<_']N$2C 8# 8# 8# 8# 8# 8# 8# 8$,5L>O$%54%IY#$5D
M%%$5D590#35162[VFJDJGV^UVFHFISOGKG>M;UO7PW^W!4OG^\RN/[0(1_6L
M#_/\+4G[S*X_M A']:P/\_P5)^\RN/[0(1_6L#_/\%2?O,KC^T"$?UK _P _
MP5)^\RN/[0(1_6L#_/\ !4G[S*X_M A']:P/\_P5)^\RN/[0(1_6L#_/\%2?
MO,KC^T"$?UK _P _P5)^\RN/[0(1_6L#_/\ !4G[S*X_M A']:P/\_P5)^\R
MN/[0(1_6L#_/\%2?O,KC^T"$?UK _P _P5)^\RN/[0(1_6L#_/\ !4G[S*X_
MM A']:P/\_P5)^\RN/[0(1_6L#_/\%2?O,KC^T"$?UK _P _P5)^\RN/[0(1
M_6L#_/\ !4G[S*X_M A']:P/\_P5)^\RN/[0(1_6L#_/\%2?O,KC^T"$?UK
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ML.1@,!@,!@>9G^%F_P!RSU/_ -PCT+_F2N<.O>^7I#TS8<C K"DO_J-U3_\
M6ZAG_P#CH["SG*S\(8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# JV>?\ X9TG
M_P#7 /\ _P!B6R<*M+"& P& P*<L/_ZH]!__ ([R_P#^Q-/,+'%<>$,!@,!@
M,!@,!@,!@,!@,!@,"IZ+_P#J05]_^+;/_P#/WA9S6QA# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8%6V'_P#A)2__ -=)S_\ 8IM#"K2PA@,!@,"I;&__  PH
M;_ZZQ?\ ^PG<&%6UA# 8# 8# 8# 8# 8# 8# 8'F9^S/_P!67^((_P"9.HO\
M>X\.O<^&GR_#TS8<C 8# 8# \S/\+-_N6>I_^X1Z%_S)7.'7O?+TAZ9L.1@5
MA27_ -1NJ?\ ZW4,_P#\='86<Y6?A# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8%6SS_\,Z3_ /K@'_\ [$MDX5:6$,!@,!@4Y8?_ -4>@_\ \=Y?_P#8FGF%
MCBN/"& P& P& P& P& P& P& P&!4]%__4@K[_\ %MG_ /G[PLYK8PA@,!@,
M!@,!@,!@,!@,!@,!@,!@,!@,!@,"K;#_ /PDI?\ ^NDY_P#L4VAA5I80P& P
M&!4MC?\ X84-_P#76+__ &$[@PJVL(8# 8# 8# 8# 8# 8# 8# \S/V9_P#J
MR_Q!'_,G47^/<>'7N?#3Y?AZ9L.1@,!@,!@>9G^%F_W+/4__ '"/0O\ F2N<
M.O>^7I#TS8<C Z+ =I?>'C+MY5D*;_9_-(UN]#P5N-)^@/0_4Z'LEU^@T#;3
M8"(@CC8.52-BV2^+;?//"KO??*'S<ZUDQ=*T3C.Y97ZE^_C_ &4?:B_^=OU;
M_=IC%*[?.7\]RC[]R?':BE5_:?333YZ[[[[MWU7SQQQSK?77??75:ZYYYYYU
M\=[W^S6L8E=OG+^M2;[^&_VZJG[4.];_ &ZWJV_5G[?_ /FF,2NWSD_4OW\?
M[*/M1?\ SM^K?[M,8E=OG*K7OI;[PXQWIB35^RP+>]2U_ $VI3TAZ+&+KSH5
MR.[*0UHF0@C;;V3C=%VOXABC]1PCTY3Y[YUUWK6V*UH_]?1E9%?7WH(@!;2J
M6,/LR1>+O"[B/LY)(O1?HP* =GFBA)%T$;&"4%;#UR[94,\Y4;<J;6XZ:+:W
MSK:7?RL2M'_KZ,^WL_[Y+LPUCS6&?:#<GWP'4J9 V]Y^G%C#R+].D6.I(U&)
MUYT]< -O7*:.GG'&V_U5.>/G^;K6ML2NWU5^OZH^[HV%=G7)G[(3<(G(%HDH
M97]2WTD*3E;9DH2<1CLAW#N6G,A;CDNW';+??XGE'G?>^-<ZWO&)MT?^OHF4
MBN+[V\05CZ$MCGV=8NM+2: 6*HR*_O2H163&76T^6HB/IDH V[,DW/2W&DT&
MVE%>]]Z^'._CK&)6CA?T84WZ&^\K&40+F2)_9;C[:4NW0^,.#?I+T.*0D;]D
M[Y'O6(%5_!T."[QH_P"](*I-]J=IK;UQUK76_AEQ*T?^OHSS>W?O>._Q&FL8
M^SRYVTE'<'=Z;WUZ76_"S5/2>U(@X^G7_7T91QI7C>Q_7P=ZUUK_ "?[=9,2
MNWU?KJW/O>,OCI[%_L]--\RAA".M.KZ]+M_EFA733H7$-_5K_CX2@EH@WVW'
M_P#[6MI=/Y$]_/S\6)7;ZHM)O2OWAX5^,_63G[*$2_+GR0LC^I_37H$#^ )N
M/Q>D!SW\UA37\*^7_ +_ "(]_*IU]%3X:_D=?!B5H_\ 7T2(9<WWLS8M$V&C
M_P!G,N%<$ PE N+] >E'XM<K(TQ:T=&(OVL!5:*$#R)QEVR1Y[VHZY>(;2UU
MI5/YF)7;ZOBRN[[UA)L0>C@WV;7[(1^GOS5VR]">D'349^KFS%Y$_P P70@7
M:3+]3M"C54=]3?/XU-RETC\_*G&]L2NWU?A6[_O5@I:&@!L/]FP/.Y&WX=QZ
M$E?0OI ?+CS53MZDFY"QQW T3!1OVH-<<Z[01[YWTW4UK?QXZ^#$K1_ZIP=>
M@OO,[*RP%IO]E[9R CG)>=AO]I#T3^:PH2SY3[=E):._0WXN.#FO"O.U%WG"
M*7&NM;ZZU\=8Q*T?^OHR)*ZOO8ACHJ+EX]]G@;)3CX<+# 'E[>G43!,D88FB
M8A@T']5W^)[=%AT;(KM>-\ZVY28..D_F^BI\K$K1U3+]2_?Q_LH^U%_\[?JW
M^[3&*5V^<GZE^_C_ &4?:B_^=OU;_=IC$KM\Y/U+]_'^RC[47_SM^K?[M,8E
M=OG)^I?OX_V4?:B_^=OU;_=IC$KM\Y/U+]_'^RC[47_SM^K?[M,8E=OG*NK%
MFGWN(XC&YW8$;^T)! 4&D&R?!R47KZ6C\?V0.A#$*9LB)4U7[)FWV[[D^^4.
M?J<]JN?I\<ZWOKX8Q6NWU2F.V1]]*7A1\DB<*^T+*(Z61VX%'X[=7J T%)M^
M5.T=KCRHV!.6+U'2J77.^DU.N?FYWKX_'6\I7;_],OQ)_OXJ:WTG5_VG%.==
M=\;ZXMCU;UK7:??2:G&]\UWO7S)J<[YZU_AUO6];_;@KM]7]_J3[^G]EGVG_
M /YUO5W]W>"NUSD_4GW]/[+/M/\ _P ZWJ[^[O!7:YR?J3[^G]EGVG__ )UO
M5W]W>"NUSE:5#C?NFRJ[8&7]A0_PK&JBA2$M-\._.TYO20V$ZEA*-/HR$9]#
MK$AX:/?I_;8VZ4=*:7TXY432UQSUK?>$G97MNW9SA@P& P& P& P& P& P&
MP& P.C9K9GW>(:?D545VC]HLP,KXXF $"Y/?OH%*RV,;.R/\JK?JP(T$@SK@
M#*),W(L4MH\:_#JOW'TV_7?/7&]S%TK1G[E@?J7[^/\ 91]J+_YV_5O]VF,4
MKM\Y?SW*/OW)\]=]U5]J#CCCG????=N>K.>>.>=;WUUUUNM=:YYYUKX[WO\
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9!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
